










The handle http://hdl.handle.net/1887/21063 holds various files of this Leiden University 
dissertation. 
 
Author: Ewing, Mark McConnell 
Title: Post-interventional atherosclerotic vascular remodeling : preclinical investigation 
into immune-modulatory therapies 

















de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties








Promotor:  Prof. dr. P.H.A. Quax
Co-promotor:  Prof. dr. J.W. Jukema
   
Overige leden:  Prof. dr. R.E. Toes
   Prof. dr. J. Hamming
   Prof. dr. P.J. van den Elsen 
   Prof. dr. J. Kuiper (LACDR, Leiden University)
   
   
The research described in this thesis was performed the departments of Surgery 
and Cardiology in the Leiden University Medical Center, Leiden, The Netherlands. 
Het verschijnen van dit proefschrift werd mede mogelijk gemaakt door steun van de 
Nederlandse Hartstichting.
Financial support for the printing of this thesis was provided by Boehringer Ingelheim 
BV, Boston Scientific, ChipSoft, Daiichi Sankyo Nederland BV, Diabetes Fonds, J.E. 
Jurriaanse Stichting, familie Van Mourik, MSD Nederland BV, Roche Nederland BV 
and Servier Nederland Farma BV.
5
Happiness lies in the joy of achievement and the thrill of creative effort.
Franklin D. Roosevelt
1882-1945
Aan mijn ouders & Hinka
6
Cover design:  M.M. Ewing
  Inspired by the London Underground map and reproduced with the  
  kind permission of Transport for London.
Printing: Wöhrmann Print Service
ISBN:  978-94-6203-331-3
Mark M. Ewing
Post-interventional atherosclerotic vascular remodeling: preclinical investigation into 
immune-modulatory therapies.
Proefschrift Leiden
Met literatuur opgave en Nederlandse samenvatting.
©  2013 M.M. Ewing
No parts of this thesis may be reproduced or transmitted in any form or by any 
























Potential biomarkers for accelerated atherosclerosis and 
other post-interventional remodeling
Biomark Med. 2012;6:53-66
Small animal models to study restenosis and effects of 
(local) drug therapy 
Coronary stent restenosis, Editor: IC Tintoiu. Bucharest: 
The Publishing House of the Romanian Academy. 2011 
Part I Annexin A5 in accelerated atherogenesis
Annexin A5 therapy attenuates vascular inflammation 
and remodeling and improves endothelial function in 
mice
Arterioscler Thromb Vasc Biol. 2011;31:95-101
Annexin A5 prevents post-interventional accelerated 
atherosclerosis development in a dose-dependent fa-
shion
Atherosclerosis 2012;221:333-340
Part II Innate and adaptive immunity in vascular 
remodeling 
Optimizing natural occurring IgM antibodies for thera-
peutic use: inflammatory vascular disease treatment with 
anti-phosphorylcholine IgG 
Submitted for publication
Blocking toll-like receptors 7 and 9 reduces postinterven-
tional remodeling via reduced macrophage activation, 
foam cell formation, and migration
Arterioscler Thromb Vasc Biol. 2012;32:e72-80
T-cell co-stimulation by CD28-CD80/86 and its negative 
regulator CTLA-4 strongly influence accelerated athero-
sclerosis development
Int J Cardiol. 2013; In press 
Part III PCAF in post-interventional vascular remode-
ling
Genetic variation in PCAF, a key mediator in epigenetics, 
is associated with reduced vascular morbidity and morta-














The epigenetic factor PCAF regulates vascular inflamma-
tion and is essential for accelerated atherosclerosis deve-
lopment. Submitted for publication
The lysine acetyltransferase PCAF is a key regulator of 
arteriogenesis. Submitted for publication











Cardiovascular diseases are the leading cause of death worldwide responsible for 
an estimated 16.7 million deaths annually which can be primarily attributed to athe-
rosclerosis, a chronic inflammatory disease of the large and medium-sized arteries1. 
Atherosclerosis lies at the basis of coronary heart disease (CHD) and cerebrovas-
cular pathologies, which both do not become manifest until the development of an 
acute thrombotic vascular occlusion. In the United States alone, atherosclerosis is 
responsible for 610.000 new and 325.000 recurrent cases of myocardial infarction 
every year2. Fortunately, the mortality of CHD has been steadily declining in the past 
20 years, by almost 33% in the Netherlands alone due to improved primary pre-
vention and treatment strategies3. Nevertheless, current incidence rates continue to 
stress the importance of ongoing research into the improvement of prevention and 
treatment of these atherosclerosis-related pathologies.
An atherosclerotic plaque is comprised of a subendothelial accumulation of lipids 
and infiltrated leukocytes such as monocyte-derived macrophages, mast cells and 
B and T lymphocytes, covered by a fibrous cap build up from smooth muscle cells 
(SMC) and extracellular matrix (ECM) deposition. Lesion formation is initiated by a 
qualitative change in the endothelial monolayer by irritating stimuli such as dyslip-
idaemia, hypertension, and pro-inflammatory mediators that lead to the exposure 
of adhesion molecules4. Local leukocyte adhesion and infiltration follows with con-
tinuing cellular activation and pro-inflammatory mediator and enzyme production, 
leading to a localized chronic inflammatory state supported by continuing cholesterol 
accumulation. Over time, apoptosis and necrosis occur which lead to the formation 
of a necrotic core containing cellular debris and free cholesterol crystals. Coronary 
plaque progression causes luminal stenosis and ischemia in distal tissues, evoking 
clinical symptoms of angina pectoris. Eventual plaque rupture and endothelial ero-
sion can trigger local arterial thrombosis due to the exposure of underlying thrombo-
genic material to the circulation causing platelet aggregation and humoral coagula-
tion, resulting in occlusive thrombus formation5. Such atherothrombosis events elicit 
brain or myocardial infarction as life-threatening complications, often requiring lesion 
revascularization through angioplasty, bypass-grafting or thrombolysis.
Target lesion revascularization and post-interventional vascular remodeling 
Revascularization strategies are comprised of percutaneous coronary intervention 
(PCI), coronary artery bypass-grafting (CABG) surgery and thrombolysis. PCI is pri-
mary choice of revascularization strategy in patients presenting with objective myo-
cardial ischemia due to occlusive CHD, diagnosed when presented with two out of 
the following three markers: clinical symptomatic presentation, typical changes on 
electrocardiography (ECG) and of circulating cardiac markers6. 
Transluminal angioplasty was invented by the American Charles Dotter in 1964, who 
applied this technique to re-open blocked arteries in the lower extremities of patients 
and improve blood flow. PCI for the treatment of obstructive coronary artery disease 
was first performed by the cardiologist Andreas Guenztig and colleagues in Zurich 
in 1977, who used Dotter catheters modified by adding an inflatable balloon to allow 







‘restenosis’ developed in 30-60% of all cases due to elastic recoil and negative re-
modeling of the injured artery8. Restenosis following angioplasty has been the major 
problem limiting the success rate of coronary interventions and tremendous efforts 
have been made to target this problem9. 
The introduction of bare-metal stents (BMS), which are deployed in the lesion seg-
ment during balloon inflation, prevented elastic recoil and have reduced the inci-
dence of restenosis to 16-44%10, but also led to the development of neointimal hy-
perplasia and in-stent restenosis (ISR) (figure 1). 
This results from SMC migration and proliferation at the site of injury and extracel-
lular matrix (ECM) formation by these cells. BMS struts serve as scaffolds to keep 
injured intimal and medial flaps from protruding into the lumen. Drug-eluting stents 
(DES) and drug-coated balloons have been developed to counter this phenome-
non11. DES struts are coated with polymers which can release anti-proliferative drugs 
such as sirolimus and paclitaxel to prevent SMC proliferation. These significantly 
reduced ISR incidence, although rates of 5-10% are still reported, responsible for 
over 200.000 revascularizations annually in the United States alone12. Advantages 
of drug-coated balloons over stents are high drug concentration delivery per square 
millimeter of balloon surface and application possibilities in locations anatomically 
unfavorable for stent placement, such as bifurcations, small vessels and coronary 
Figure 1.1 In-stent restenosis development
Stent expansion during therapeutic angioplasty compresses the atherosclerotic plaque into the arterial 
wall, re-esthablishing blood flow (panel A). The inset displays a cross-section of the compressed plaque 
and stent-widened artery. Over time, inflammation and accelerated atherosclerosis support fibrous tissue 
deposition, SMC migration and proliferation and foam cell formation. This can cause renewed (partial) 
blockage of the artery and distal ischemia (panel B). The inset shows a cross-section of the tissue growth 
around the stent. 
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ostia. However, the lack of continued presence of both drug and polymer is the most 
important difference with stents. They reduce the chance of local hypersensitivity 
reactions, but also run the risk of an insufficient sustained period of drug-release to 
be fully effective11. 
Primary PCI has been shown to be clinically superior to thrombolysis with less major 
adverse events and with increased preservation of myocardium, particularly when 
applied in the period 3-12h after onset of symptoms. Thrombolysis however remains 
a viable alternative to primary PCI if it can be delivered within 3h after symptom 
onset6. 
PCI is less invasive and generally preferable above CABG surgery except in cases 
such as chronic total occlusion, three-vessel or left main stem disease with distal 
vessel disease or ostial stenosis, provided patients are presented in a hospital with 
PCI facility and an experienced team. PCI only treats a spot, whereas CABG surgery 
into the distal third or the artery treats the entire vessel13. Nevertheless, PCI and 
CABG surgery both provide good symptom relief and clinical trials have so far been 
unable to show a significant difference in mortality 1-8 years after revasculariza-
tion. The original trend favoring CABG disappeared, despite a reduction in mortality, 
due to the introduction of stenting to PCI. Recommendation of either PCI or CABG 
surgery will be guided by technical improvements in cardiology or surgery, hospital 
expertise and patients’ preference6.
Restenosis risk factors
The underlying causes of post-PCI restenosis can be divided into four general ca-
tegories, namely biological, arterial, stent and implantation factors14, 15. Biological 
factors are comprised of the natural vascular wall resistance to antiproliferative 
drugs, the development of a sustained hypersensitivity reaction directed towards 
the polymer or metallic stent platform and local concentration of proteinases that 
stimulate SMC proliferation and migration. Arterial factors that can influence reste-
nosis development are unfavorable (low) coronary artery wall shear stress levels, 
the progression of primary atherosclerotic lesion growth within a segment treated 
with angioplasty, as well as previous positive vascular remodeling15. Stent factors 
that determine ISR risk are the antiproliferative drug concentration and duration of 
sustained drug release. The stent gap, strut thickness and polymer disruptions, crac-
king and fractures are all major risk factors for ISR10. Above all, carefully-conducted 
technical implantation is highly important for adequate therapeutic effectiveness and 
factors such as barotrauma, inadequate stent expansion and geographical misses, 
where the stent is deployed proximally or distally from the lesion and deployment of 
a DES in a clot-laden arterial segment are all factors that contribute to ISR risk10, 14.
Animal models for restenosis
Over the past decade, positive results have been obtained with sirolimus and pa-
clitaxel-eluting stents (SES and PES respectively), although studies investigating 
other anti-restenotic drug were unable to provide similar results. Animal models that 
mimic the pathophysiology of post-interventional vascular remodeling allow for tes-
ting of new potential anti-restenotic drugs and evaluation of their therapeutic effec-
tiveness, as well as effects of arterial wall integrity, atherosclerotic lesion initiation 







screening of genes of interest concerning their role in lesion development, even in a 
dyslipidemic setting17. One well-defined model is the femoral arterial cuff model for 
post-interventional vascular remodeling and, during hypercholesterolemia, accelera-
ted atherosclerosis development in which a non-constrictive cuff is surgically placed 
around the mouse femoral artery. This model allows for drug-eluting cuff placement 
to mimic DES deployment. This and other animal models to investigate restenosis 
and effects of (local) drug therapy are described in detail in chapter 3.
Arterial thrombosis 
Arterial thrombosis lies at the basis of myocardial infarction in patients and their 
ischemia-related symptoms. In addition, catheter insertion into the thrombotic bloc-
ked coronary artery during PCI, balloon dilatation and stent deployment all favor the 
development of progressive and renewed arterial thrombosis. For this reason, anti-
platelet drugs are the cornerstone of adjunctive medication6. 
Thrombocyte adhesion, activating and aggregation result from contact to tissue 
other than the intact endothelium containing von Willebrand factor, but also from 
thrombin and epinephrine. Upon activation, platelets release prothrombotic media-
tors such as serotonin, tromboxane A2 and ADP which cause vasoconstriction and 
platelet aggregation. Signaling through intracellular transduction pathways leads to 
the extracellular expression of the GPIIb/IIIa-complex which enables fibrinogen bin-
ding and clot formation. Currently often applied anti-platelet therapy consists of ace-
tylsalicylic acid, clopidogrel and abciximab, also used in combination. Acetylsalicylic 
acid irreversibly acetylates cyclo-oxygenase, necessary for the formation of prosta-
glandin thromboxane A2 from arachidonic acid, whilst the thienopyridine clopidogrel 
irreversibly blocks the adenosine phosphate (ADP) receptor on platelets necessary 
for GPIIb/IIIa-complex activation18 and the monoclonal antibody abciximab binds the 
GPIIb/IIIa-complex19. Despite the increased risk for bleeding complications, anticoa-
gulant therapy has been shown to be very effective in reducing myocardial infarction, 
PCI and CABG-surgery-related arterial thrombosis and mortality18, also in combi-
nation with oral anticoagulant therapy (e.g. vitamin K antagonists) when sustained 
for at least 2 weeks following intervention6. Platelet aggregates facilitate leukocyte 
tethering and rolling20, supporting the eventual leukocyte infiltration and local inflam-
matory response responsible for arterial inflammation and remodeling.
Annexin A5
The cellular membrane consists of a phospholipid bilayer that contains positively- 
and negatively charges phospholipids. Viable and healthy (endothelial) cells and pla-
telets actively express the negatively charged phosphatidylserine (PS) on the inner 
cytosolic cellular membrane leaflet. Certain circumstances lead to a loss of mem-
brane symmetry and translocation of PS to the outer membrane side, for example 
platelet activation and collagen adherence, but also erythrocyte aging, microparticle 
shedding and apoptosis21, 22. Platelet-expression of PS enables the assembly of the 
prothrombinase complex comprised of factors Va, Xa and II (prothrombin). This com-
plex promotes the conversion of prothrombin into the proteolytically active thrombin 
which cleaves fibrinogen to form fibrin polymers that lead to thrombus formation23.
Annexin A5 is a member of the annexin family, a group of highly-conserved proteins 
that are able to bind to negatively-charged phospholipid membranes in the presence 
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of Ca2+ ions. Annexin A5 resides intracellularly and is released upon injury and binds 
reversibly, specifically and with high affinity to PS24. For this reason annexin A5 has 
been used diagnostically world-wide for the detection of apoptosis and atheroscle-
rosis both in vitro and in vivo. PS serves as an ‘eat-me’ signal on apoptotic cells for 
circulating phagocytes and annexin A5 binds PS forming two-dimensional crystals 
and may thereby act as a lattice shielding PS from phagocytes and from interacting 
in phospholipid-dependent coagulation reactions22, 25. The binding between annexin 
A5 and PS is uncompromised by circulating heparin, although annexin A5 can bind 
to the heparin oligosaccharide complex26. Annexin A5 was originally discovered as 
an anticoagulant and antithrombotic protein and has been shown to be essential 
in the maintenance of placental integrity, where the pro-coagulant apical surfaces 
of syncytiotrophoblasts possess many binding sites for annexin A5. Its binding is 
crucial for the continuous blood flow and fetal viability27. Annexin A5 has since also 
been shown to associate with the interferon γ receptor and prevent inflammatory cel-
lular responses to secreted interferon γ28. This inflammatory cytokine is produced by 
natural killer (NK) and T-cells and is involved in monocyte recruitment and activation, 
central in pro-atherogenic cellular responses and inflammation29. 
In addition to its strong anti-coagulant properties, annexin A5 binds with high af-
finity to oxidized low-density lipoprotein (oxLDL) cholesterol particles and is there-
fore present in high concentrations in atherosclerotic lesions30, 31. Circulating annexin 
A5 plasma levels are inversely related to the severity of coronary stenosis and are 
indicative of atherosclerotic plaque extent32, but are also elevated in hypertensive 
patients with systolic dysfunction33 and following acute myocardial infarction34. The 
binding of annexin A5 to oxLDL cholesterol particles, to apoptotic cells and the inhibi-
tory effects on inflammation and coagulation have identified annexin A5 as a protein 
with high clinical anti-atherosclerotic and anti-restenotic potential.
The innate immune system in atherosclerosis 
Immune responses against circulating and local immunogenic antigens in the arteri-
al wall play a critical role in the initiation of inflammatory processes that characterize 
accelerated atherosclerosis development. The immune system can be divided into 
the innate and adaptive systems which are closely linked together and are tightly 
regulated. Innate immunity forms the first line of defense and exerts a fast although 
unspecific immune response to invading micro-organisms, whilst adaptive immunity 
reacts more slowly, but targets highly specific antigen-bearing targets on foreign 
intruders35. 
The innate immune system is comprised of the complement system, various toll-
like and scavenger receptors and natural antibodies that target pathogenic anti-
gens. Their activation evokes responses that are comprised of both internalizing 
and signaling pathogen recognition receptors (PRRs) that recognize pathogen- and 
damage-associated molecular patterns (PAMPs and DAMPs respectively) leading to 
inflammation (figure 2)36.
Complement
The complement system consists of a group of liver-synthesized proteins, membra-
ne-bound receptors and regulatory enzymes designed to increase antibody-medi-







central function in this process. C3 cleavage by convertases into C3a and C3b is 
induced by specific substrates through either the classic, alternative or lectin pa-
thways. C3b binds to the surface of pathogenic cells, enabling increased phagocy-
tosis through opsonization37, 38. The classic pathway is activated by binding of the 
C1 complex to antibodies bound to antigen-presenting bacterial cells. The three 
pathways initiate a cascade that results in C5 activation and formation of terminal 
complement component C5b-9, the membrane attack-complex that causes bacterial 
and cell lysis and the chemotactic factor C5a that supports leukocyte recruitment39. 
Many complement triggers reside in the tunica intima in atherosclerotic segments 
and complement inhibition has been shown to result in reduced accelerated athero-
sclerotic lesion formation40.
Toll-like receptors
Toll-like receptors (TLRs) form a major component of innate immunity, innate-adap-
tive crosstalk and reactions towards infectious and immunogenic auto-agents and 
are localized on both the internal and external sides of the cellular membrane. Situ-
ated on the cellular outer membrane leaflet, TLRs 2, 4 and 5 recognize exogenous 
PAMPs that originate from bacteria or viruses such as lipopolysaccharide (LPS) or 
flagellae (TLR5), whilst TLRs 7 and 9 on the inner cellular membrane recognize both 
pathogenic and endogenous ligands released after tissue damage or cell stress41. 
Myd88-dependent signaling is the dominant activation pathway of TLR signaling 
leading to nuclear factor kappa B (NFκB) transcription and expression of pro-in-
flammatory chemokines and cytokines42, 43. Endothelial TLR4 activation by LPS on 
 
Figure 1.2 Innate and adaptive immunity in (accelerated) atherosclerosis development53
Endothelial damage at sites of arterial atherosclerosis or interventional injury can cause platelet adhe-
rence and expression of adhesion molecules that enable recruimtnet and infiltration of leukocytes bearing 
pathogen recognition receptors such as denritic cells. These can ingeste immunigenic antigens such as 
oxLDL particles and TLR-ligands and travel to draining lymph nodes where antigens are presented to na-
ive T-cells in the presence of co-stimulatory factors. Activated effector T-cells enter the blood stream and 
travel to the site of inflammation, where they engage in secondary inflammatory reponses in co-operation 
with residing macrophages. 
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circulating Gram-negative bacteria during bacteremia leads to nitric oxide production 
and vasodilation that can initiate hypotensive septic shock44. DAMPs recognized by 
TLR4 include heat shock proteins45, fibronectin extra-domain A46, tenascin C and 
high mobility group box (HMGB) 147. TLR2 and/or 4 deficiency and inhibition are 
associated with reduced atherosclerosis and vascular remodeling, whilst increased 
signaling aggravates inflammation and atherogenesis, highlighting the importance of 
these receptors in the innate immune response.
Endosomal TLRs like TLRs 3, 7 and 9 recognize viral and bacterial DNA and (dou-
ble-stranded) RNA (TLR3) fragments and possibly also damaged self DNA/RNA that 
might result from during interventional procedures including PCI and CABG-surgery. 
Arterial presence and activation of TLR7 and TLR948 leads to upregulation of in-
terferon γ, interleukin (IL) 6, IL-12 or tumor necrosis factor (TNF) α by innate im-
mune cells such as macrophages49. These TLRs also recognize immune complexes 
containing self nucleic acids in autoimmune diseases and are localized in human 
arteries. Development of atherosclerotic plaques and PCI-induced injury cause a 
release of self RNA/DNA or proteins that enhance the recognition of nucleic acids by 
intracellular TLRs and can activate TLR7 and 9 signaling, by which these important 
parts of the innate immune system contribute strongly to arterial inflammation50, 51. 
Indeed, septic shock can also develop when bacterial unmethylated CpG DNA binds 
TLR9, highlighting TLR7 and 9 as therapeutic targets to prevent restenosis. Surpri-
singly, TLR3 is suggested to have a protective role in atherosclerosis development.
Scavenger receptors
LDL cholesterol is the most important risk factor for cardiovascular disease (CVD) 
and cholesterol lowering therapy alone such as HMG-CoA reductase inhibitors (sta-
tins) can reduce CVD-risk by 30-40%. Once trapped in the arterial wall, LDL oxida-
tion by enzymes such as lipooxygenases occurs. Oxidative modification of phosp-
holipid fatty acids, degradation of apoB-100 into peptide fragments and modification 
of these structures by aldehydes derived from oxidized fatty acids leads to deve-
lopment of immunogenic neo-antigens52. Intramural oxLDL particle accumulation 
stimulates oxLDL-uptake by scavenger receptors such as scavenger receptor (SR)
A-1, SRA-2, SR-B1 and cluster of designation (CD)36 on monocyte-derived macro-
phages. Scavenger receptors are multifunctional PRRs that clear the environment 
of cellular debris and microbes and are responsible for oxLDL particle ingestion by 
macrophages. Cholesterol efflux, termed efferocytosis, is controlled by ABC-type 
cassette transporters that mobilize cholesterol into high-density lipoprotein (HDL) 
particle for transport to the liver53. A defective balance between cholesterol influx and 
efflux in these cells leads to excessive intracellular cholesterol accumulation which 
is stored in lipid droplets and promotes foam cell formation and lesion progression54. 
Continuous influx of monocytes is observed throughout lesion progression and they 
are referred to as being signature cells in atherogenesis that are both central and 
detrimental in lesion progression.
Unfolded protein response
Many exogenous and endogenous sources of cellular stress have been identified, 
including stress that arises from the accumulation of unfolded protein in the en-







three-pronged signal transduction pathway collectively known as the unfolded pro-
tein response (UPR). This is made up of the IRE-1, PERK and ATF-6 axes55. Sus-
tained intracellular UPR is designed to relieve cell stress and reduce amino-acid 
biosynthesis, but UPR itself can lead to cell pathology and tissue dysfunction. In 
the arterial wall, saturated fatty acids, oxidative stress and oxysterols, but above all 
intracellular cholesterol accumulation, all lead to chronic UPR and inflammation in 
intimal macrophages and endothelial cells56. This supports plaque progression and 
CHOP-induced foam cell apoptosis and necrotic core development57, 58, but occurs 
in all stages of atherosclerotic lesion formation59. Overall, it is clear that the UPR is 
fundamental in the pathogenesis of inflammatory diseases and could serve as a 
target of therapy for modulating cellular stress and inflammation60.
Natural (auto-) antibodies
Natural antibodies are immunoglobulines that arise spontaneously without prior im-
mune exposure or infection and even occur in specific-pathogen-free mouse strains. 
Natural antibodies occur predominately of the IgM isotype and are produced by B-1 
cells in the spleen and act as the humoral equivalent of PRRs61. They are suggested 
to aid the homeostasis of the internal milieu by binding to protein determinants of 
dying cells, such as PS and to facilitate C3b deposition on pathogens aiding their 
elimination and that of immunogenic auto-antigens62.
In both mouse and man, natural IgM and IgG antibodies occur towards malondial-
dehyde (MDA) and copper-oxidized LDL cholesterol. To investigate their origin, B 
cell lines were isolated from spleens from non-immunized ApoE-/- mice on high-fat 
diets63. The resulting monoclonal antibodies, termed E0 antibodies were tested for 
their ability to recognize oxLDL. Gene sequence analysis unexpectedly identified 
that the genes encoding for the IgM anti-Cu oxLDL E06 antibody were completely 
similar to a classic B cell clone expressing T15 antibodies directed towards phosp-
horylcholine (PC) present on Streptococcus pneumoniae bacteria64. Of all reported 
anti-PC antibodies, T15 antibodies are most effective in clearance of pneumococci 
pathogen infections65 and they occur frequently in inbred mouse strains66. This dis-
covery identified complete molecular mimicry between oxLDL particles and Strepto-
coccus pneumoniae bacteria that express the same PC moiety (figure 3)67.
Anti-PC IgM T15 and E06 antibodies were found to be functionally equal in their abi-
lity to recognize PC on oxidized phospholipids but not on native LDL68. This was con-
firmed when immunization of hypercholesterolemic LDL-receptor (r)-/- mice against 
Streptococcus pneumoniae raised plasma titers of anti-PC IgM antibodies and 
prevent native atherosclerosis formation69. They are suggested to act by passing 
through the endothelial barrier and binding to PC on oxLDL particles, thus blocking 
their uptake by scavenger receptor bearing macrophages and foam cells, preventing 
their expression of pro-inflammatory cytokines, matrix metalloproteinases (MMPs) 
and co-stimulatory molecules for T cell activation. In addition, anti-PC IgM may bind 
and lead to clearance of circulating oxLDL particles, rendering them unavailable for 
plaque formation and protect endothelial cells from the harmful oxidative properties 
of oxidized phospholipids (figure 4)70. Immunization studies to prevent native athero-
sclerosis formation in mice have thus far been performed through active vaccination 
using Streptococcus pneumoniae69, with PC bound to keyhole limpet hemocyanin 




Figure 1.3 Molecular mimicry of pathogen associated molecular patterns36
The immunogenic phosphorylcholine (PC) epitope is expressed by apototic cells, by oxidized LDL parti-
cles and by Streptococcus pneumoniae bacteria, which share molecular mimicry. These are recognized 
by various parts of the innate immune defenses such as natural antibodies of the T15/E06 type, macro-







passive vaccination with two types of recombinant IgG1 against MDA-modified apoB 
10073 (including regression of existing lesions74), with anti-PC IgM antibodies75 and 
using oxLDL-pulsed mature dendritic cells76. 
Interestingly, recent investigations into the mechanisms of recognition that govern 
T-cell responses to LDL particles yielded surprising results. Research into T-cell hy-
bridomas from human apoB100 transgenic mice immunized with oxLDL revealed 
they no longer recognized oxLDL, but solely LDL particles. Nevertheless, serum 
from these animals did contain anti-oxLDL IgG, indicating that T-cell responses to 
LDL lead to anti-oxLDL antibody production by plasma cells. The hypothesis be-
hind these findings states that ingested and degraded oxLDL particles by scavenger 
receptor-expressing cells are co-expressed with MHC class II on the cell surface 
where they subsequently be recognized by CD4+ (TRBV31+ T-cell receptor bearing) 
T-cells. These CD4+ T-cells can stimulate macrophages, but also plasma cells to 
produce simultaneously anti-LDL and anti-oxLDL and related (PC) atheroprotective 
antibodies77, emphasizing that such an antibody response is not just confined to 
oxLDL, but also extent towards native LDL particles.
Advantages of active vaccination are life-long protection and the need for only re-
lative few immunizations, whilst passive immunization allows the induction of a fast 
and controlled immune response against the desired antigen. Fully human monoclo-
nal antibodies are ideal for such passive immunization strategies and are preferred 
above re-engineered, de-immunized or rodent monoclonal antibodies. They can be 
generated using phage display platforms, which allow for identification of clinical 
candidates selected for their optimal desired functions78. Previously, such recombi-
nant antibody libraries have proven to serve as an excellent source of active and well 
tolerated experimental therapeutics79. 
Natural antibodies in CHD
Over the past twenty years, many basic and epidemiological studies have suggested 
a role for indolent infections such as Chlamydia pneumoniae in atherosclerosis pro-
gression, although clinical trials using antibiotics failed to reduce CHD incidence80. 
Thus far, a clinical study in healthy human volunteers (both smokers and non-smo-
kers) was unable to show an increase in serum anti-PC or anti-oxLDL immunoglo-
bulines following the application of wildly-used adult pneumococcal polysaccharide 
vaccine, despite an increase in antibodies directed towards surface capsular polys-
accharides81. Another study identified that hospital-administered patients suffering 
from myocardial infarction were less likely to have received a pneumococcal polys-
accharide vaccine than patients admitted for other causes, suggesting vaccination 
might protect from myocardial infarction. However, effects are likely to result from 
a reduced incidence of pneumonia, which has been shown to trigger myocardial 
infarction82, and thus acute events triggering infarction rather than through reduced 
Figure 1.4 Proposed role of anti-PC IgM T15/E06 antibodies in preventing atherosclerosis70
Atherosclerosis develops due to scavenger-mediated uptake of LDL cholesterol oxidized by reactive 
oxygen species leading to lipid-laden foam cell formation. These produce proinflammatory cytokines, 
MMPs and myeloperoxidase and express co-stimulatory molecules for T-cell activation. Pneumococcal 
vaccination (in mice) enhances anti-phosphorylcholine (PC) IgM antibodies that cross the endothelium 
where they bind to oxLDL particles to form immune complexes and prevent oxLDL uptake and foam cell 
formation. Additionally, anti-PC IgM can bind circulating oxLDL, facilitating its clearance and rendering it 
unavailable for plaque formation.
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atherogenesis. Indeed, in contrast to chronic infections, prevention and adequate 
treatment of acute infections may prevent abrupt and severe inflammatory changes 
in high-risk patients groups and reduce myocardial infarction incidence83. Neverthe-
less, a save immunization protocol that can elicit a proper and sustained immune 
response or the development of fully human antibodies towards PC, preferably of 
the IgG isotype, could prove very effective in the prevention of both native and post-
interventional accelerated atherosclerosis formation in clinical setting.
The adaptive immune system in atherosclerosis
The adaptive immune system can recognize an almost infinite number of molecular 
structures and depends on the vast variety of B and T cell receptors and immuno-
globulines, generated by somatic rearrangement processes in blast cells. In contrast 
to PRRs, an almost infinite number of receptors exists and is capable of interacting 
with infiltrating pathogens.
Effector T-cells
Most T-cells in the atherosclerotic lesion are CD3+ and CD4+ T-helper (Th) cells 
that express the αβ T-cell antigen receptor (TCR) and have a Th1 phenotype. These 
cells are identified by their production of interferon (IFN) γ and IL-2 and are derived 
from native major histocompatibility complex (MHC) class-II CD4+ T-cells following 
presentation with specific antigens and co-stimulatory signals in the presence of cy-
tokines such as IL-12 and IFN γ84. Cytotoxic MHC class I-recognizing CD8+ T-cells 
are also present in the lesions, although their function remains unclear. CD4+ T-
cells recognize class-II presented peptides by antigen-presenting cells (APCs) such 
as oxLDL particles, heat shock proteins 60 and 65, but also exogenous pathogens 
such as Chlamydia pneumoniae. An extensive body of evidence exists identifying 
the direct role of pro-inflammatory Th1 T-cells in atherosclerosis development77, 85, 
86. IgG2a antibodies in plasma dominate early atherosclerotic lesion progression, 
indicating predominant Th1 involvement. The two most important effector molecules 
produced by Th1 cells are membrane-bound CD40 ligand and the pleiotropic cyto-
kine IFN γ that contribute to monocytes-differentiation and activation. IFN γ is highly 
produced in atherosclerotic lesions by not only Th1 cells, but also macrophages and 
NKT cells87. These molecules in turn stimulate pro-inflammatory IL-1, TNF α and 
MMP expression by macrophages and contribute substantially to local inflammation 
(IL-6 and C-reactive protein), lesion growth and fibrous cap thinning88. Indeed, strong 
atherosclerotic lesion reduction was found in ApoE-/- mice with genetic CD40 ligand 
disruption89 and IFN γ deficiency90 as well as following anti-CD40 ligand antibody 
treatment91. Finally, daily IFN γ administration significantly augmented lesion growth 
in hypercholesterolemic ApoE-/- mice92.
Th2 cells primarily produce IL-4, IL-5, IL-10 and IL-13 and stimulate B-cell antibody 
production, but are not detected in large quantities in atherosclerotic lesions. IL-10 
itself has strong anti-inflammatory and anti-atherosclerotic and restenotic effects93. 
Nevertheless, Th2 specific IgG1 antibodies are only detected in plasma at the ad-
vanced stages of atherosclerotic lesion progression. Studies involving Th2 cells 








Regulatory T-cells (Tregs) have a T-cell suppressive function and contribute effecti-
vely to maintenance of immunological response and auto-reactivity. They comprise 
approximately 5-10% of all peripheral CD4+ T-cells and are defined as the cell po-
pulation expressing CD4+CD25+CD127low markers on their extracellular membrane 
surface and intracellular forkhead box (Fox) P3, vital for their suppressive function94. 
Mice genetically deficient for FoxP3 develop an autoimmune-like lymphoproliferative 
disease, emphasizing the suppressive function of Tregs in maintaining peripheral 
tolerance95, whilst humans lacking FoxP3 suffer from severe autoimmune disease 
that develops in infancy.
Tregs exert suppressive function through inhibition by cytokines, cytolysis, meta-
bolic disruption and intervention in dendritic cell maturation. Thymus-derived Tregs 
express inhibitory cytokines IL-10, IL-35 and transforming growth factor (TGF) β, 
which stimulates collagen synthesis and is fibrogenic96. They migrate towards an 
atherosclerotic lesion similarly to Th1 cells, but the local pro-inflammatory microenvi-
ronment favors Th1 cell survival, causing an imbalance in T-cell adaptive immunity97.
Tregs constitutively express cytotoxic T-lymphocyte antigen 4 (CTLA-4)98, acting as 
physiological dendritic-cell-mediated co-stimulation inhibitor and have been shown 
to control the development of atherosclerotic lesions through regulation of Th1 and 
Th2 responses99 and is vital for their suppressive function100. Indeed, loss of ade-
quate CTLA-4 function with blocking monoclonal antibodies produces auto-immune 
disease in mice similar to CD4+CD25+ Treg depletion and abolishes their protective 
function both in vitro and in vivo, since these cells can no longer block TCR and 
CD28-mediated co-stimulatory signals leading to Th1 activation, even to immunoge-
nic self auto-antigens98. CTLA-4 on Tregs has also been shown to induce the enzyme 
indolamine 2, 3-dioxygenase (IDO) through CD80 and CD86 interaction on dendritic 
cells, which catalyzes the conversion of tryptophan to kynurenine101 that has potent 
immunosuppressive effects on dendritic cells, and thus T-cell activation102. 
T-cell co-stimulation 
T-cell mediated immune responses are initiated in lymphoid tissues where they are 
stimulated by APCs and can then interact with B cells to promote an antibody res-
ponse or migrate to peripheral tissues to engage infiltrated pathogens or immunoge-
nic antigens. A small portion of these cells become memory T-cells, to enable a quick 
response during re-infection. Their activation is described by the two-signal model 
which is composed of the presentation of MHC complex-bound peptides, as well 
as co-stimulatory signals provided by accessory molecules103. Activation of the two 
principal pathways leads to IL-2 regulated T-cell proliferation and their effector func-
tion acquisition. Since T-cell activation leads to TCR internalization, native T-cells 
require prolonged antigen exposure. The dominant co-stimulatory receptor CD28 is 
constitutively expressed on resting T-cells and binds CD80 (B7-1) and CD86 (B7-
2) on dendritic cells, B cells, and monocytes/macrophages. CD80 and CD86 have 
both been shown to strongly contribute to atherosclerotic lesion formation104. Their 
function is required for an adequate T-cell response to atherosclerotic antigens and 
their expression of IFN γ. TCR binding in absence of CD28 ligation leads to T-cell an-




Cytotoxic T-lymphocyte antigen (CTLA)-4 and co-inhibition
CTLA-4 (CD152) is a co-inhibitory receptor expressed on activated T-cells and is 
homologous to CD28 and binds either a CD80 or CD86 mono- or heterodimer on 
APCs with approximately 100 times higher affinity than CD28106. Most CTLA-4 is ex-
pressed intracellularly rather than at the cell surface, thus limiting its engagement to 
CD80/86 and preventing a premature termination of an immune response107. During 
an ongoing immune response, CTLA-4 is upregulated and outcompetes CD28 for 
binding to CD80 and CD86, leading to T-cell proliferation inhibition and termination 
of IL-2 production, IL-2 receptor expression and arresting T-cells in the G1-phase of 
their cell cycle105. 
The importance of the CD28/CTLA-4 pathways has become evident by genera-
ting mice genetically deficient in CTLA-4, which develop fatal lymphoproliferative 
disease with progressive polyclonal T-cell accumulation in peripheral lymphoid and 
solid organs such as the heart, liver and pancreas108.This is prevented by crossing 
CTLA-4-/- mice with Rag-/- and with CD80-/-CD86-/- animals109. CTLA-4 has the maxi-
mal inhibitory effects in primed rather than naïve T-cells and decreases the propor-
tion of cytokine-secreting T-cells in stead of the response magnitude per T-cell, ex-
plaining that more APCs are necessary to generate a detectable cytokine response 
 Figure 1.5 T-cell fate under various T-cell receptor engagements107
Adequate T-cell stimulation requires simultaneous interaction between a specific major histocompatibility 
(MHC)-peptide complex and the T-cell receptor and CD28 ligation by the B7-1 (CD80) or B7-2 (CD86) 
receptors on the antigen-presenting cell (APC). Absence of simultaneous interaction leads to T-cell apop-
tosis or anergy. After successful activation, T-cells upregulate cytotoxic T-lymphocyte antigen 4 (CTLA-4; 







during CTLA-4 ligation107. In contrast to full-length CTLA-4, transgenic expression of 
tailless CTLA-4 mutant protein only reduced lymphocytic infiltration in solid, but not 
lymphoid, organs in CTLA-4-/- mice110, but transfected mutant CTLA-4 constructs into 
Jurkat cells indicated scavenging of CD80/86111. These findings support the balan-
ced view that CTLA-4 receptors act by both scavenging C80/86 away from CD28 on 
APCs as well as through direct intracellular pathways and are vital for maintaining 
T-cell homeostasis and preventing auto-immune reactions.
Unlike activated effector T-cells, Tregs constitutively express CTLA-4 and since bloc-
king CTLA-4 antibodies prevent their inhibitory effects, CTLA-4 is required for their 
suppressive function112. Treg function was shown to be completely inhibited following 
acute CD80 and CD86 inhibition, further confirming the essential role for co-stimula-
tion and inhibition in controlling adequate Treg function99.
A second co-inhibitory receptor expressed by T-cells and shown to be involved in 
atherogenesis is programmed-death (PD)-1. PD-1 is a family member of CD28 
which can bind either PD-1-ligand 1 or 2 (PD-L1 and PD-L2 respectively), expressed 
on either solely hematopoietic cells (PD-L2) or both non- and hematopoietic cells 
(PD-L1)106, 113. PD-1-/- mice also develop lupus-like proliferative arthritis and glomeru-
lonephritis with IgG deposition114. Similarly to CTLA-4, PD-1 signaling inhibits T-cell 
proliferation and activation and their signaling has an important function in downre-
gulating pro-atherogenic T-cell responses115.
Clinical significance of CTLA-4 
Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progres-
sive joint damage and disability and activated T-cells were shown to play a cen-
tral role in inflammation progression116.The potential for CTLA-4 to interrupt T-cell 
co-stimulatory signals was harnessed by fusing the extracellular domain of human 
CTLA-4 to the modified Fc portion of human IgG1, creating the soluble fusion protein 
CTLA-4Ig named abatacept117. Circulating abatacept has been shown to prevent 
CD28-CD80/86 co-stimulation of follicular Th-cells118 and subsequently decreasing 
T-cell production of TNF α, IFN γ and IL-2 and has been approved for the treatment 
of mild to severe RA in patients who respond insufficiently to other disease-modifying 
antirheumatic drugs, including methotrexate, and TNF α inhibitors117. Abatacept dis-
plays little immunogenicity, with <3% of patients developing an antibody response119. 
Interestingly, soluble CTLA-4Ig has also been shown to effectively prevent T-cell 
mediated lymphoproliferative disease in CTLA-4-/- mice120.
B lymphocytes and dendritic cells
Co-stimulatory and -inhibitory receptors are not restricted to T-cells, but are also ex-
pressed on B lymphocytes. These cells are present at the base of early fatty streaks 
and thereafter constitutively in the adventitia of human coronary lesions. At first, they 
were suggested to have a protective function against atherogenesis, since splenec-
tomy increased atherosclerotic lesion size in hypercholesterolemic mice due to loss 
of B-cell produced protective anti-oxLDL antibodies121. However, acute B-cell de-
pletion using anti-CD20 antibodies was since then shown to reduce atherosclerotic 
lesion size by reducing pathogenic T-cell responses whilst preserving the production 
of protective anti-oxLDL IgM, rather than IgG, antibodies. This reduced production 
of IFN γ and enhanced that of IL-17122. Very recently, the important role of CD28 in 
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this process was elucidated. The half-life of antibodies is days to weeks, whereas 
long-term immunity against infection through antibody production by plasma cells 
continues of a life-time. It was shown that CD28-expressing long-lived plasma cells 
(LLPCs) residing in the bone-marrow, but not splenic short-lived plasma cells, re-
quire continuous CD28 signaling through CD80 or CD86 for their function and loss of 
the CD28-CD80/86 pathway strongly reduces LLPCs half-life123, 124. Since these cells 
are the producers of protective natural antibodies (e.g. against oxLDL particles), 
CD28 is suggested to be important in maintaining adequate antibody titers associa-
ted with atherogenesis risk.
Dendritic cells express co-stimulatory molecules such as CD80 and CD86 and ac-
cumulate in the intima of atherosclerotic lesions and two distinctive types have been 
identified, namely classic myeloid dendritic cells (mDC) which mainly recognize en-
dogenous and exogenous bacterial signatures through TLR2 and 4 and can produce 
MMPs and IL-12, leading to recruitment of cytotoxic T-cells125. Plasmacytoid dendri-
tic cells (pDC) specifically recognize viral fragments through TLR9 and can produce 
large amount of IFNγ126, leading to TLR4 upregulation on other APCs and increases 
atherosclerotic lesion development127. pDC presence in the shoulder region of athe-
rosclerotic lesions contributes strongly to plaque instability and rupture29.
Epigenetic regulation of inflammation
Post-interventional atherosclerotic vascular remodeling results from local arterial in-
flammatory processes that are tightly regulated by local gene expression profiles 
immediately after vascular interventions such as PCI and CABG-surgery. Inflam-
mation results from increased transcription of inflammatory genes and is limited by 
the extent of chromatin accessibility to gene-regulatory proteins and transcriptional 
factors. Chromatin consists of DNA wrapped around histones (called nucleosomes) 
and non-histone proteins128 and can display various degrees of compactness. This is 
controlled by the amount of histone modifications exerted by epigenetic factors that 
cause acetylation and methylation of lysine residues129, but also DNA methylation 
at CpG dinucleotides. Since they determine gene expression independently of DNA 
sequence, their actions can even lead to notably different gene expression patterns 
between monozygotic twins130.
Low-density chromatin, termed euchromatin, consists of active genes and is associ-
ated with hypomethylation of CpG dinucleotides in DNA and acetylated histones131, 
132, whilst   compact chromatin (heterochromatin) is a hallmark of silent genes and is 
associated with hypermethylation of CpG dinucleotides in DNA and non-acetylated 
histones. Epigenetic factors have counterbalancing and reversible actions and vital 
epigenetic factors that control the degree of chromatin methylation and acetylation 
are histone methyltransferases and demethylases and lysine histone acetyltrans-
ferases (KATs) and deacetylases (KDACs)133, 134. 
KATs are nuclear enzymes that are recruited to gene promoter regions by gene re-
gulatory proteins such as class II transactivator (CIITA) in leukocytes and can serve 
as master switches by increasing general inflammatory gene accessibility. Examples 
of KAT-regulated genes involved in atherosclerosis development include MHC class 
II and nuclear factor kappa-beta (NFκB), a pivotal transcription factor in inflamma-
tion135. KATs are considered to act dominantly in the nucleus of injured endothelial 







surgery. Intervention in the function of these KATs and their accessory molecules 
could affect the local arterial inflammatory response in the acute setting, affecting the 
degree of post-interventional vascular remodeling and the need for re-intervention 
in the long term136. 
P300/CBP-associated factor (PCAF) 
P300/CBP-associated factor (PCAF/KAT2B) is a transcriptional co-activator with 
KAT-activity and regulates histone acetylation of NFκB-regulated inflammatory ge-
nes137. PCAF can bind the cyclooxygenase (COX)-2 promoter region following cel-
lular exposure to inflammatory mediators and regulates the cellular inflammatory 
response through prostaglandin H2 formation138. Furthermore, PCAF also enhances 
the p65-mediated increase in TNF α promoter activity139 and both TNF α and COX-2 
regulate the cellular inflammatory responses by leukocytes that lead to atheroscle-
rosis (figure 6)140, 141. 
PCAF-/- mice are developmentally normal without a distinct phenotype, although le-
vels of PCAF-B are drastically elevated in lung and liver tissue. In contract, PCAF-
B deficiency is embryonically lethal and PCAF-B-/- mice die between 9-12 days of 
 
Figure 1.6 The role of PCAF in inflammation136
The role of p300/CREB binding protein (CBP)-associated factor (PCAF) in the activation of nuclear fac-
tor kappa B (NFkB)-mediated gene transcription is initiated by NFkB stimulators such reactive oxygen 
species (ROS), tumor necrosis factor (TNF) α and interleukin-1β. PCAF and P300 can act as factor 
acetyltransferases and acetylate NFkB directly, but also enable NFkB-target gene transcription through 




gestation142. However, when PCAF-/- mice reach 6-12 months of age, they develop 
amyloid toxicity143, 144 and short-term memory deficits and exaggerated responses 
to acute stress145, confirming that PCAF histone acetylase activity is involved in life-
long chromatin remodeling processes by post-translational histone modification. 
PCAF in clinical CHD
Recently, association between the -2481G→C SNP in the promoter region of the 
PCAF gene and reduced CHD mortality and restenosis was shown in three inde-
pendent large prospective studies146-148. A meta-analysis of the dataset showed that 
patients heterozygous for the low-risk allele had approximately a 20% reduction in 
risk for cardiovascular events, compared with 40% in patients homozygous for the 
allele149. The SNP might affect binding of a nuclear protein, but could similarly be a 
mere proxy marker for a functional SNP elsewhere in the PCAF locus due to link-
age disequilibrium150. This finding has nonetheless added to the growing body of 
evidence that epigenetic regulation of inflammatory gene expression in activated 
leukocytes is vital for the process of atherosclerosis and restenosis development 
and could serve as a target of therapy or as diagnostic risk marker to improve patient 
screening. 
Aim of the thesis
The aim of this thesis was to investigate the role of the immune system in the pa-
thophysiological process leading to the development of post-interventional athero-
sclerotic vascular remodeling. This research enabled the evaluation of the effec-
tiveness of specific immunomodulatory therapies in the prevention of accelerated 
atherosclerosis development, which could be applied during PCI or CABG-surgery 
in the clinical setting. 
The development of post-interventional atherosclerotic vascular remodeling can be 
divided into specific phases of chronic tissue inflammation elicited by the activated 
immune system. First, intervention for established occlusive atherosclerotic disease 
induces arterial injury which elicits the expression of pro-coagulant factors and ar-
terial thrombosis. This provides the scaffold for cells and mediators from the innate 
immune system to undergo local adhesion, infiltration and activation into the arterial 
wall (phase 1). Innate immune responses are directed towards (self) immunoge-
nic molecular patterns that are present in the subendothelial space such as oxLDL 
particles and TLR ligands and lead to a pathological inflammatory response (phase 
2). These activated cells not only stimulate the process of vascular remodeling and 
ECM deposition through expression of inflammatory mediators such as cytokines, 
but also travel to draining lymphoid tissues to recruit residing naïve cells that belong 
to the adaptive immune system. To this end, intercellular communication through 
specific receptor-ligand interactions and co-stimulatory signals leads to activation of 
naïve lymphocytes that enter the circulation to engage their specific antigen-bearing 
targets (phase 3). Their additive effects at the site of vascular injury to local infiltra-
ted cells, antigen-antibody complexes and pro-inflammatory chemo- and cytokines 
promotes transcription of their inflammatory genes, enabled by tightly-controlled epi-
genetic regulation processes (throughout phases 2-3). This ultimately leads to ac-







Outline of the thesis
Hallmark events of immune system-mediated inflammatory reactions and their de-
rived factors that could serve as future clinical biomarkers of CVD progression are 
described in chapter 2. The underlying factors that are causally related to inflam-
matory vascular remodeling are discussed and investigated for their possible appli-
cation as (additive) biomarkers for adequate risk assessment and patient evaluation 
with the aim of improved patient screening and enabling future tailor-made treat-
ment. Preclinical small animal models to study restenosis and effects of systemic 
and local drug therapy are reviewed in chapter 3, with special focus on the murine 
femoral arterial cuff model that encompasses a pathophysiology highly-resembling 
that of (in-stent) restenosis development. This ensures an ideal intervention model 
for the screening of candidate genes and new (locally applied) anti-restenotic drugs, 
especially when investigated in a hypercholesterolemic mouse strain such as the 
ApoE3*Leiden mouse.
The therapeutic effectiveness of the PS-binding protein annexin A5, which is well-
known for it anti-thrombotic properties and usefulness as apoptotic marker, is eva-
luated in chapter 4 in three different mouse models for vascular inflammation, re-
modeling and dysfunction. It was found that systemic annexin A5 treatment lead to 
annexin A5 accumulation at the site of injury and prevented the initiation of a local 
inflammatory response with major beneficial therapeutic effects. In chapter 5, as-
sociation between polymorphisms in the annexin A5 gene and restenosis risk in 
patients undergoing PCI is investigated in patients enrolled in the GENDER study, 
with further investigations into dose-response effectiveness of annexin A5 at the time 
of revascularization.
Chapter 6 describes the investigations into therapeutic application of optimized 
natural occurring anti-PC IgM antibodies by harnessing the anti-inflammatory PC-
binding properties in a clinically applicable format using recombinant monoclonal 
chimeric antibodies. This strategy was pursued further with fully human IgG antibo-
dies towards PC that were identified and produced using phage display techniques, 
which allowed careful selection for the most optimal anti-inflammatory antibody pro-
perties. In this line, chapter 7 shows the therapeutic efficacy of a newly-synthesized 
dual TLR7/9 antagonist in the prevention of post-interventional atherosclerosis de-
velopment through prevention of inflammatory cytokine expression and oxLDL par-
ticle-uptake by macrophages during TLR7/9 stimulation in vitro. The novel TLR7/9 
antagonist also increased secretion of the anti-inflammatory cytokine IL-10, respon-
sible for reduced oxLDL particle-uptake through scavenger receptors expressed by 
macrophages.
The importance of T-cells and the co-stimulatory and co-inhibitory pathways is dis-
played in chapter 8, where knock-out mouse stains were used to confirm the im-
portance of CD4 T-cells and the CD28-CD80/86 pathway in vascular remodeling. 
Blocking anti-CTLA-4 antibodies and abatacept, a soluble CTLA-4Ig that prevents 
CD28-mediated T-cell activation and is registered for treatment of clinical rheuma-
toid arthritis, were applied to elucidate the role of CTLA-4 signaling in accelerated 
atherosclerosis development. The powerful inhibitory effects on CD4+ T-cell status 




Chapter 9 identifies strong association between genetic variation in PCAF, a key 
mediator in epigenetics, and vascular morbidity and mortality in three independent 
patient cohorts is discussed in, which provides evidence for new concepts in the 
epigenetic regulation of genetics responsible for the processes of inflammation and 
proliferation during atherogenesis. The causal role of PCAF in this process is in-
vestigated in chapter 10, in which PCAF knock-out mice are subjected to surgical 
cuff-induced vascular injury and inhibitory effects of PCAF deficiency on leukocyte 
activation and functional cytokine expression were investigated. Additionally, it is 
shown that perivascular delivery of the only potent natural PCAF inhibitor garcinol 
at the time or surgery can protect against neointimal formation. Finally, chapter 11 
describes the important role of PCAF in inflammation and vascular remodeling in ge-
neral, with significantly impaired arteriogenesis in PCAF knock-out mice compared 
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New circulating and local arterial biomarkers may help the clinician with risk strati-
fication or diagnostic assessment of patients and selecting the proper therapy for a 
patient. Additionally they may be used for follow-up and testing efficacy of therapy, 
which is not provided by current biomarkers. Processes  leading to post-interven-
tional restenosis and accelerated atherosclerosis are complex due to many biolo-
gical variables mediating the specific inflammatory and immunogenic responses 
involved. Adequate assessment of these processes requires different and more spe-
cific biomarkers. Post-interventional remodeling is associated with cell stress and 
tissue damage causing apoptosis, release of damage-associated molecular patterns 
(DAMPs) and upregulation of specific cyto/chemokines that could serve as suitable 
clinical biomarkers. Furthermore, plasma titers of pathophysiological process-rela-
ted (auto)antibodies could aid in the identification of restenosis risk or lesion severity. 
This review provides an overview of a number of potential biomarkers selected on 
the basis of their role in the remodeling process.
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The current concept that inflammation plays a key role in the development of (post-
interventional) atherosclerotic vascular remodeling has led to the investigation of in-
flammatory factors to serve as biomarkers for cardiovascular risk prediction. Multiple 
local arterial and blood-based biomarkers have been identified and selected for their 
association with a more adverse cardiovascular risk profile independently of known 
traditional risk factors such as dyslipidemia, hypertension, diabetes and smoking. 
Many of these markers have been incorporated into risk prediction models to im-
prove risk assessment accuracy in addition to current diagnostic strategies1. Of the-
se, C-reactive protein (CRP) is currently the best-validated inflammatory biomarker. 
Despite the value of plasma lipoprotein profiling and CRP measurements the picture 
is not yet clear. Many patients but not all continue to develop vascular remodeling 
following revascularization procedures and ongoing investigations into newer and 
more accurate or combined biomarker risk profiles remain necessary2. This review 
retracts the underlying pathophysiology of atherosclerosis and post-interventional 
vascular remodeling and the value of recently discovered inflammatory biomarkers3 
in the prediction of cardiovascular events in the biological context that require target 
lesion revascularization, highlighting their potential clinical value. Other biomarkers 
including genetic differences such as polymorphisms are not taken into account in 
this review.
Background of atherosclerosis and restenosis
Native atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the large and medium-sized 
arteries and is initiated by a qualitative change in the endothelial monolayer by ir-
ritative stimuli such as dyslipidemia, hypertension, and pro-inflammatory mediators 
that lead to the exposure of adhesion molecules and infiltration of circulating leuko-
cytes into the arterial wall4. Such mediators could be of high value when measured 
as biomarkers of lesion progression and stage of severity. Changes in endothelial 
permeability provoke the retention of cholesterol-containing low-density lipoprotein 
(LDL) particles that are endocytosed by monocytes-derived macrophages leading 
to foam cell and atheromatous lesion formation in the arterial tree5, 6. Tunica media-
derived smooth muscle cell (SMC) migration and proliferation and extracellular ma-
trix deposition lead to the formation of a fibrous cap overlying a necrotic core due to 
inefficient efferocytosis5, 7. Physical disruption of the plaque exposes the underlying 
thrombogenic material to the circulation triggering thrombosis formation, that may be 
monitored as biomarkers, and luminal occlusion with progressing ischemia in distal 
tissues6, eventually leading to infarction requiring angioplasty or bypass-grafting6, 8.
Post-interventional restenosis
Restenosis following angioplasty and stent implantation has been the major problem 
limiting the success rate of coronary interventions and tremendous efforts have been 
made to target this problem9. Acute and long-term vessel occlusion requiring target 
lesion revascularization following balloon angioplasty occurred in 30-60% of all pa-
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tients due to elastic recoil and negative remodeling. The introduction of bare-metal 
stents (BMS) prevented elastic recoil and has reduced this incidence of restenosis 
to 16-44%, but also led to the development of neointimal hyperplasia10. Drug-eluting 
stents (DES) have been developed to counter this phenomenon, although incidence 
rates of 5-10% of in-stent restenosis (ISR) are still reported, encompassing over 
200.000 revascularizations annually in the United States alone11.Inflammation has 
been shown to be the driving factor behind these remodeling processes, pointing to 
a role as biomarker for this factor in the analysis of disease progression.  DES have 
been successful in the prevention of neointimal hyperplasia, but have not been able 
to completely prevent the process of ISR. These figures support the need for deve-
lopment of new biomarker assays that allow careful screening of patients at risk for 
restenosis.
Restenosis is defined as more than 50% luminal loss at follow-up angiography with 
clinical restenosis defined as recurrence of symptoms such as angina pectoris or 
ischemia at rest, requiring repeat revascularization12. It has been proposed to be the 
result of an overshooting healing response that originally occurred in three distinc-
tive phases: early loss due to elastic recoil, which occurs within minutes and has 
been successfully countered by the application of intracoronary stenting, followed by 
neointimal hyperplasia and eventually accelerated atherosclerosis development13. 
 
Figure 2.1 Post-interventional restenosis development
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Neointimal hyperplasia is evoked by injury to the endothelium and underlying athero-
sclerotic plaque, with exposure of thrombogenic content to flowing blood, supporting 
the adhesion and activation of thrombocytes and thrombosis. Platelets release mi-
togens, which can be traced throughout the plasma to serve as biological markers of 
thrombosis extent, and promote SMC migration and proliferation to the tunica intima 
with local extracellular matrix deposition14. This process is prevented or delayed (e.g. 
by many years) by DES compared to BMS implantation through the release of drugs 
that affect SMC migration and proliferation. This process is ultimately followed by a 
phase of vascular remodeling, in which accelerated atherosclerosis and concentric 
adventitial compression together further comprise lumen patency13. 
Underlying causes of restenosis
The underlying causes of restenosis can be divided into four general causes, namely 
biological, arterial, stent and implantation factors10, 12. Biological factors encompass 
the natural (genetic) vascular wall resistance to anti-proliferative drugs and the 
development of a sustained hypersensitivity reaction directed towards the polymer 
or metallic stent platform. Additionally, the initial levels of proteinases that determine 
SMC proliferation and migration are of great importance to treatment success10. These 
effects of proteinase of SMC proliferation and migration may be direct or indirect 
effects. In vascular remodeling matrix metalloproteinases may regulate migration, 
proliferation, and death of vascular smooth muscle cells by degrading matrix and 
non-matrix substrates15, but also may play a role in activating other factors such 
as growth factor or other pericellular proteases16. Arterial factors that influence the 
vascular response are comprised of factor regulated by local wall shear stress levels, 
the progression of original atherosclerosis lesions growth within a stented segment, 
but also previous positive vascular remodeling. Stent factors that contribute to the 
development of ISR are the specific type of coating used, drug concentration and 
sustained period of release and to a lesser extent the drug of choice17, 18. Differences 
between effectiveness rates of specific drugs are determined by their ability to meet 
the biological threshold that exists and determines the initiation of an inflammatory 
response and the eventual occurrence of neointimal hyperplasia, which could be 
tracked with biomarker levels in plasma10. The stent gap, strut thickness and possible 
polymer disruption or cracking and eventual fractures are all important for proper stent 
effectiveness in the prevention of ISR10. Finally, technical implantation factors can 
limit therapeutic effectiveness that stenting could offer, such as an incomplete stent 
expansion and geographical misses, where the stent is deployed short of or beyond 
the complete lesion area12. During every interventional procedure the eventually of 
barotrauma to unstented segments and the deployment of a DES in a clot-laden 
arterial segment remains, that raise the chance of ISR after discontinuation of anti-
thrombotic drugs. These factors support the search for biomarkers that could offer 
diagnostic insight at the time of procedure. These markers should be an adequate 
reflection of acute vessel injury. 
Inflammation status as biomarker
The overall requirement of a cardiovascular disease biomarker is to enhance the 
ability to optimally manage the patient, identification of patients, to differentiate 
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patients, assess the likelihood of a therapeutic response, the risk of future recurrences 
and progression of disease19. The use of BMS or DES may have different effects on 
the pathophysiological process initiated and thereby on the inflammatory response 
and eventual potential biomarkers related to restenosis or in-stent thrombosis. For 
potential novel biomarkers it would be of major importance to be easily detectable 
and that levels correlate with disease progression. Since inflammation is importantly 
involved in vascular disease many studies focused on CRP as a biomarker. CRP is 
a strong marker of inflammation and upregulated in response to pro-inflammatory 
cytokines. No association was found for major cardiovascular events and high 
sensitivity-CRP, IL6 or TNFα by Sukhija and co-workers20. However, CRP seemed 
to be an excellent marker for post-stenting inflammation since it was produced 
mostly in response to pro-inflammatory cytokines released as a response upon 
the vascular damage initiated by the procedure1. In addition pre-procedural serum 
CRP-level proved to be an independent predictor of adverse outcome after coronary 
stent implantation, suggesting that a systemically detectable inflammatory activity 
is associated with proliferative responses within successfully implanted stents21. 
Higher baseline CRP levels of patients undergoing BMS implantation are a predictor 
of restenosis22. Interactions were also found between CRP levels, statin treatment 
and restenosis-incidence23. No clear association of CRP and restenosis was found 
during application of drug-eluting stents1. A study on first cardiovascular events and 
death based on the Framingham Offspring Study by Wang and co-workers showed 
that the most informative circulating biomarkers for predicting death proved to be 
B-type natriuretic peptide, C-reactive protein, homocysteine, renin, and the urinary 
albumin-to-creatinin ratio2. Other studies focused on CRP levels did not find a direct 
relation with restenosis24. Currently the limitation of existing biomarkers is that even 
in combination, they only add moderately to the prediction of risk in an individual 
person2. This statement is confirmed by Ware who explains that a risk factor must 
have a much stronger association with the disease outcome than we ordinarily 
see in etiologic research if it is to provide a basis for early diagnosis or prediction 
in individual patients. Most studies are of limited value for the risk stratification 
of individual patients as we have discovered new biologic variables that lie on 
the complex pathway leading to chronic disease and death25. Therefore the role 
of experimental research is very important in identifying novel biomarkers since it 
provides the tools to focus more specifically on the pathophysiological process.
Currently a lot of contradicting data is available of using CRP as a biomarker in 
cardiovascular disease, a notion merely worsened by the use of different stents 
types. The approaches thus far may not be specific enough to serve as good 
reflectors of the pathophysiological process that is initiated by the interventional 
procedure. CRP is possibly just an indirect reflection of inflammation which is easily 
become upregulated by other underlying inflammatory processes. The application of 
individual biomarkers only contributes moderately to risk assessment of individual 
patients. The prospect of combining multiple known markers could possibly contribute 
significantly more to the optimization of patient selection and individual tailor-made 
treatment1. The future success of biomarker strategies in this field could possibly 
depend on the discovery of new biomarkers to complement the current markers 
and diagnostic strategies. The identification of patients at elevated risk based upon 
biomarker assessment could be of additive value for the management of patients 
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receiving stent implantation. In this review, we provide an overview of considered 
novel potential biomarkers in post-interventional atherosclerotic vascular remodeling 
with the emphasis on inflammation. 
Future biomarkers
Circulating Factors
Several factors involved in the pathophysiological process of post-interventional 
remodeling may be detected in the circulation soon after the interventional damage, 
thereby forming potential biomarkers that are easily available such as damage-
associated molecular patterns (DAMPs). DAMPs are endogenous structures that 
can be released upon tissue damage and can be recognised by receptors on 
inflammatory cells e.g. Toll Like Receptors. Balloon angioplasty with or without 
stent placement will cause damage to the vessel wall that will cause al release of 
DAMPs and activate toll-like receptors that cause a release of several inflammatory 
cytokines and chemokines26, 27. Also antibodies may be formed upon (auto-) antigens 
that become present after the intervention. Original papers on this subject are 
summarized in the citation overview below.
Annexin A5
Annexin A5 is a member of the annexin family, a group of highly-conserved Ca2+ 
dependent proteins that bind to negatively-charged phospholipid surfaces. Annexin 
A5 is primarily an intracellular protein that is released upon injury and binds specifically 
and with high affinity to phosphatidylserine (PS)28. PS becomes externalized and 
presented upon the outer cellular membrane during the process of apoptosis, but 
also during platelet activation and erythrocyte aging29. For this reason annexin A5, 
alone and bound to contrast agents, has been used world-wide for the detection of 
apoptosis in vitro and in pilot experiments in vivo in patients28. 
PS serves as an ‘eat-me’ signal on apoptotic cells for circulating phagocytes. 
Annexin A5 than binds PS leading to the formation two-dimensional crystals. 
Annexin A5 thereby may act as a lattice shielding PS from phagocytes and from 
interacting in phospholipid-dependent coagulation reactions30, 31. In addition to its 
anti-thrombogenic properties, annexin A5 binds with high affinity to oxLDL cholesterol 
which together with apoptotic cells is present in native atherosclerotic and restenotic 
lesions in high concentrations32. For this reason, annexin A5 is also detectable in 
high concentrations in (accelerated) atherosclerotic lesions33. 
Next to its presence in the vascular wall, annexin A5 has been suggested in the 
prevention of pro-inflammatory microparticle formation. Stimulated platelets and 
Citation overview 
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apoptotic cells expressing PS on their membrane have been shown to shed PS-
containing membrane-derived microparticles. Annexin A5 is able to inhibit the 
formation of microparticles by binding to PS on these cells30.
Annexin A5 is partially removed from the circulation by binding to specific 
components of atherosclerotic tissues, such as oxLDL and activated or damaged 
cells. Measurement of plasma annexin A5 concentration requires only limited 
amounts of venous blood and is therefore an easy-to-perform diagnostic test. 
Although this information does not allow discrimination between a restenotic and a 
de novo atherosclerotic lesion, it could certainly be of much additive value to current 
diagnostic strategies and screening purposes. In addition, it was found that the 
prognostic value of the oxLDL / annexin A5 ratio is even more sensitive than annexin 
A5 alone, stressing the importance of combined biomarkers for disease screening34. 
The presence of high concentrations of annexin A5 in atherosclerotic lesions leads 
to annexin A5 release in the circulation following myocardial infarction35. Increased 
annexin A5 levels are therefore indicative of the extent of myocardial tissue damage. 
Since annexin A5 levels provide both information on plaque severity in the stable 
period of atherosclerosis and on infarction severity during acute episodes of plaque 
rupture, annexin A5 is a highly potential future biomarker of cardiovascular disease 
progress.  
Damage Associated Molecular Patterns (DAMPs)
Restenosis is a late process, although it is believed that events that take place 
within 72 hours after intervention are already triggering the restenosis process. 
The intervention will cause severe damage to the vessel wall leading to a release 
op DAMPs. DAMPs can be seen as endogenous fragments that are recognized 
by the immune system by toll-like receptors (TLR)26.  During the whole process of 
restenosis a continuous process of cell stress, lipid influx, inflammation and matrix 
degradation, the release of DAMPs will continue. The last decade much focus has 
been towards the involvement of TLR in cardiovascular disease where the TLRs 
were predominantly found on circulating cells and in vascular lesions36-38. TLRs are 
membrane-bound receptors located on a variety of immune and non-immune cells 
including macrophages, endothelium, SMCs and platelets. Release of the DAMPS 
as endogenous TLR ligands may have serious consequences due to the activation 
of the TLR signalling pathway on variety of cells carrying TLRs.  These cells may 
than initiate a severe inflammatory response with direct activation of the vessel wall 
but also platelet activation and infiltration of inflammatory cells26, 39, 40. A causal role 
for TLR4 in post-interventional vascular remodeling was previously demonstrated. 
Neointima formation, arterial outward remodeling as well as vein graft remodelling 
were decreased by in TLR4 deficient mice, and TLR4 ligands and TLR4 silencing 
tools could modify these processes41-43. Furthermore TLR4 is importantly involved in 
the sterile inflammatory response upon CD36 activation by oxLDL particles44. Two 
very important DAMPs that can be linked to multiple TLRs are high mobility group box 
1 (HMGB1) and fibronectin-EDA (FN-EDA) that also come available in the circulation 
upon their release. These DAMPS may potentially serve as ideal biomarkers since 
they are only upregulated in response to tissue damage, have direct inflammatory 
effects via multiple TLRs and can also be detected in the plasma27, 49-51. 
Nuclear HMGB1 may become present in the cytoplasm or even outside the cell 
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where it is known to act as TLR2 and TLR4 ligand45, 49. Not only can this release be 
initiated upon cell stress but also activated macrophages are capable of releasing 
HMGB126, 49-51. Previously our group was able to detect intra- and extra-nuclear 
HMGB1 in remodeled vein grafts42. Furthermore presence of HMGB1 was detected 
in atherosclerotic plaques. Although the number of macrophages increased markedly 
in fatty streaks and fibrofatty lesions, the proportion that expressed HMGB1 did not 
alter significantly. However, the proportion of macrophages containing HMGB1 in 
both cytoplasm and nuclei increased markedly52. Others showed that elevation of 
serum HMGB1 level is associated with severe cardiac remodeling complications 
such as pump failure, cardiac rupture, and eventually in-hospital cardiac death. 
This was in association with an increased serum C-reactive protein level in these 
patients. However, in an animal model for myocardial infarction blockade of HMGB1 
caused impaired infarct healing and marked scar thinning thereby worsening left 
ventricular remodelling53. Furthermore, HMGB1 serum levels are markedly increased 
upon surgical thoracic aortic aneurysm repair54. HMGB1 is also of interest in other 
inflammatory disease processes like SLE and kidney ischemia reperfusion55, 56. 
HMGB1 also has pro-thrombogenic features by increasing tissue factor expression 
on monocytes and inhibiting anti-coagulant protein C pathway in vitro. In vivo the 
combined administration of thrombin and HMGB1 caused prolonged plasma clotting 
times57. The effect of HMBG1 on platelets via direct TLR4 activation is still unknown. 
Fibronectin is a part of the extracellular matrix that undergoes severe stress during 
interventional procedures. Fibronectin-EDA (FN-EDA) is an adhesive glycoprotein 
spliced from fibronectin and is important in wound healing and can be produced 
by activated endothelium and fibroblasts. FN-EDA has been implicated in fibroblast 
differentiation, proliferation and migration and is capable of monocytes activation and 
induction of inflammation through upregulation of cytokines like interleukin-1α and β 
and matrix metalloproteinases. Interestingly, FN-EDA is the only spliced variant of FN 
that binds and activates TLR458, 59. FN-EDA targets antigen to TLR4-expressing cells 
and induces cytotoxic T cell responses60. FN-EDA is also considered to be a TLR2 
ligand and therefore has the potential to activate the two most important TLRs in 
vascular disease. We showed that lack of FN-EDA prevents myocardial remodeling 
and preserves pump function after infarction61. FN-EDA was also found in restenotic 
lesions with features of accelerated atherosclerosis and in the myocardium in the 
early phase of the remodeling process following infarction61. Additionally absence 
of FN-EDA reduced atherosclerosis formation. In normal aortas the spliced FN-
EDA could not be found, although FN-EDA was found in atherosclerotic plaques 
and in plasma of atherosclerotic mice. FN-EDA was shown to have effects in both 
plasma lipoprotein metabolism and in macrophage foam cell formation59, 62. Studies 
with atherosclerotic mice that lack FN-EDA indeed showed that cholesterol levels 
were lowered59, 62. In addition, FN-EDA may influence post-interventional remodeling 
directly via inducing an inflammatory reaction but also via effects on lipid metabolism. 
Cytokines and chemokines
Cytokines and chemokines are important mediators of inflammatory responses 
and can be easily measured in serum. Both lowered and elevated concentrations 
of cytokines and chemokines are associated with cardiovascular risk profiles 
and specifically post-interventional vascular remodeling due to accelerated 
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atherosclerosis development. Nevertheless their levels can strongly differ due to 
different pathophysiological processes initiated by different treatment strategies. 
The treatment strategy (BMS vs. DES) therefore may have strong influence on the 
reliability of a selected cytokine or chemokine as biomarker1, 22. Interestingly conditions 
after acute myocardial infarction could exacerbate post-angioplasty restenosis by 
stimulating signaling via TNFα63. This may cause differences for patients that undergo 
scheduled PCI versus patients that had an acute myocardial infarction before PCI. 
It may therefore be important to look for combinations of specific cytokines besides 
a selected biomarker. Activation of innate immune response via TLRs will lead to 
nuclear factor kappa B (NFκB) activation followed by upregulation of cytokines and 
chemokines26, 39. Many different cytokines have been studied in relation to post-
interventional remodeling and may be used in combination with specific biomarkers 
to correlate DAMP presence with remodeling related cytokines. Additionally this may 
provide better insight in the underlying mechanism of the pathophysiological process 
and thereby indications for proper treatment strategies. Cytokines could also be 
interesting to measure the effect of these treatment strategies by checking ratios of 
pro- and anti-inflammatory cytokines. Here we discuss a few cytokines/chemokines 
that have been intensively researched in relation to cardiovascular disease and have 
showed biomarker potential
Tumor necrosis factor α
Tumor necrosis factor (TNF) α is a pro-inflammatory cytokine that is importantly 
involved in inflammatory responses. Multiple cells including endothelial cells, 
vascular smooth muscle cells and monocytes-derived macrophages can secrete it. 
Several studies have shown that blockade of TNF α caused a reduction in neointimal 
formation via acceleration of endothelium repair, found increased mRNA expression 
of TNF α in the neointima of damaged vessels which may be upregulated 4000 
times compared to resting levels. These kinds of studies also showed a relation with 
accelerated atherosclerosis64, 65.
Interestingly, the local delivery of thalidomide as a potent TNF α biosynthesis 
inhibitor demonstrated a powerful reduction of the neointima formation in mice. In 
humans single nucleotide polymorphisms in the TNF α gene were found and showed 
associations with an increased clinical and angiographic risk for restenosis66. 
Angioplasty in peripheral arterial segments gave increased levels of TNF α within 
1 hour, although no statistically significant correlation was found between failed 
angioplasty and the following inflammatory response67. Kubica et al stated that 
the combined analysis of CRP and TNF α might be an effective approach to the 
clinical restenosis prediction and long-term outcome is markedly influenced by the 
periprocedural activation of inflammation68. 
Monocyte chemoattractant protein 1
Monocyte chemoattractant protein (MCP)-1 binds to its receptor CC chemokine 
receptor 2 (CCR2) that belongs to the family of G-coupled receptors and is a 
chemokine that is capable of attracting immune cells like monocytes. Upon vascular 
injury MCP-1 recruits monocytes, memory T cells and dendritic cells to the injured 
site. Attracted monocytes infiltrate the vessel and contribute importantly to neointima 
formation69. MCP-1 is strongly expressed locally in different stages of the remodeling 
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process. Furthermore, it has strong influence on SMC proliferation. Both mouse 
models for arterial restenosis as for vein graft remodeling showed a MCP-1 inhibitor 
showed sufficient reduction in neointima formation. Furthermore studies in which the 
receptor for MCP-1 was targeted gave similar results70-72. No differences in MCP-1 
concentrations between patients with acute MI, patients with stable coronary artery 
disease and healthy individuals were found73. However, an inverse correlation was 
found between MCP-1 concentration at baseline and the time to reperfusion, and 
a significant decrease in MCP-1 concentration immediately after PCI and lower 
MCP-1 concentrations over time in patients who developed restenosis within 6 
months were found73. Elevated baseline level of MCP-1 was associated both with 
traditional risk factors for atherosclerosis as well as an increased risk for death or 
myocardial infarction, independent of baseline variables. Interestingly MCP-1 levels 
are not associated with CRP levels indicating the importance of selecting specific 
inflammatory markers in stead of general markers like CRP74. MCP-1 levels are 
different amongst patients that received a BMS versus a DES75. Furthermore in 
the same study they found increased monocyte CCR-2 expression 24 hr and 48 
hr after stenting in the BMS but not the DES group and changes in plasma MCP-1 
after stenting correlated significantly with in-stent lumen loss. Previously another 
Japanese study already showed a correlation between MCP-1 and the risk for 
restenosis after stenting76.
Interleukin 10
Interleukin 10 (IL-10) is one of the most prominent anti-inflammatory cytokines. It 
may suppress antigen presentation and is capable of inhibiting pro-inflammatory 
cytokine production. Different animal models for restenosis and atherosclerosis 
showed protective effects of IL-10 by the use of recombinant human IL-10 or using 
animals deficient in IL-10. 
In humans three polymorphisms significantly increased the risk of restenosis 
in patients and demonstrate that IL-10 is associated with restenosis77-79. IL-10 is 
however upregulated together with pro-inflammatory cytokines to maintain a balance 
between pro- and anti-inflammatory cytokines. Most of the time upregulation of pro-
inflammatory cytokines exerts the upregulation of IL-10. Peripheral therapeutic 
angioplasty gave no difference in IL-10 levels compared to patients that underwent 
only angiography67. In a study using BMS after PCI a significant low IL-10 levels was 
associated with an increase in restenosis after 6 months80. The use of undergoing 
zotarolimus-eluting (zotarolimus is a semi-synthetic derivative of rapamycin that 
works as immunosupressant) stent implantation combined with pioglitazone 
significantly reduced neointimal hyperplasia within the stented lesion and attenuated 
total plaque burden in the in-segment regions of the stent at the 8-month follow-up. 
These changes were preceded by an elevated IL-10 concentration 10 days after 
implantation81.
RANTES/CCL5
CCL5 (RANTES) deposition was involved in wire-induced intimal hyperplasia and 
blocking of RANTES receptors attenuates neointima formation and macrophage 
infiltration in animal studies82. Two clinical studies focused on the relation of RANTES 
levels and restenosis. While one of these studies found a decrease of RANTES in 
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time in the non-restenosis group another found a significant time-dependent increase 
in the restenosis group83, 84. No association was found between RANTES promoter 
genotype and restenosis85. 
Plasma antibodies
Recent results from murine interventional studies indicate that inflammation and 
(auto)immune mechanisms are both strong contributors to the development of 
post-interventional restenosis development have led to the hypothesis that (auto)
antibodies are both causally related to restenosis development, and titers could 
serve as biological biomarkers for the identification of restenosis risk or lesion 
severity. Longitudinal studies will be required to determine both the diagnostic and 
predictive values of antibody profiles, but promising candidates have emerged over 
the past decade, which will be discussed below. 
The immune system can be divided into the innate and adaptive systems, which are 
closely linked and regulated. The innate immunity forms the first line of defense and 
offers a quick but unspecific response to invading microorganisms, whilst adaptive 
immunity takes longer to develop, but targets highly specific antigen-bearing foreign 
intruders. To this end, the former system is comprised of various toll-like receptors, 
the complement system and cytokines and chemokines, whilst the latter depends 
on the vast variety of B and T cell receptors and antigen-specific immunoglobulines. 
Anti-oxidized LDL and phosphorylcholine antibodies
Immune responses against oxidized forms of cholesterol-containing LDL particles 
play a critical role in activation and regulation of the inflammatory process that 
characterizes all stages of atherosclerosisp86. LDL cholesterol is the most important 
risk factor for cardiovascular disease and cholesterol-lowering therapy (statins) alone 
can reduce CVD-risk by 30-40%. LDL has been found to play a key role in lesion 
development and LDL oxidation by enzymes such as lipoxygenases primarily occurs 
in the extracellular matrix in the arterial wall. Oxidative modification of phospholipid 
fatty acids, degradation of apoB-100 into peptide fragments and modification of these 
structures by aldehydes derived from oxidized fatty acids leads to the development 
of immunogenic neo-antigens87, 88. These contain pathogen-associated molecular 
patterns (PAMPs) that are recognized by the pathogen recognition receptors (PRRs) 
from the immune system, of which TLRs and scavenger receptors are considered to 
be the most important. TLRs occur both intra- and extracellular and are activated by 
lipopolysaccharide (LPS) and various other (viral) micro-biological antigens, but also 
by endogenous ligands such as heat shock proteins and fibronectin extra-domain 
A89.Their activation stimulates MyD88-dependent and independent intracellular 
cascades that eventually all lead to increased NFκB transcription and inflammation.
In both mouse and man, natural anti-oxLDL IgM and IgG antibodies occur, whilst in 
vitro, antibodies are directed towards malondialdehyde (MDA) and copper-oxidized 
LDL87. These antibodies proved to be exactly similar to those produced by natural 
occurring T15 B-1 cell clones and all recognize the phosphorylcholine (PC) antigen 
on oxLDL90, but also on apoptotic cells and Streptococcus pneumoniae, which share 
molecular mimicry91, 92. 
These antibodies are suggested to block the oxLDL-uptake by scavenger receptor-
bearing macrophages and block foam cell and atherosclerotic lesion formation, 
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but could also serve as risk markers for atherosclerotic and restenotic lesion 
development. Several studies have reported increased plasma titers of IgG anti-
oxLDL antibodies in patients with angiographically verified coronary artery disease 
and with acute myocardial infarction93-95.Many studies found that low levels of IgM 
anti-oxLDL antibodies are associated with increased atherosclerosis in hypertensive 
patients and low levels of IgM anti-PC antibodies with acute myocardial infarction, 
ischemic stroke and cardiovascular disease in general in both the general population 
and patients with either hypertension or SLE93-96. Therefore, this could also hold 
true for restenosis due to accelerated atherosclerosis development and the severity 
of lesion development. In general, these studies have identified anti-oxLDL and 
specifically anti-PC antibodies as biomarkers for cardiovascular disease monitoring 
with potentially high additive value to current diagnostic strategies.
Microparticles
Thrombocytes, monocytes and those cellular types lining the arterial wall including 
endothelial cells and SMCs have been shown to vesiculate and release membrane-
shed microparticles in response to cellular activation and apoptosis such as occur 
during the development of atherosclerotic and restenotic lesions97, 98. Membrane 
integrity is largely controlled by intracellular calcium and caspase homeostasis99. 
Disorganization of the cytoskeleton enables blebbing to occur and disruption of 
the membrane phospholipid symmetry supports PS externalization99. These PS-
containing microparticles have been implicated in the development, progression and 
complications of atherosclerotic lesions and patients suffering from atherosclerotic 
or restenotic cardiovascular disease display high levels of circulating microparticles 
and since these microparticles are absent in healthy individuals, their circulating 
levels prove to allow excellent follow-up of lesion progression and serve as surrogate 
markers for vascular function99. 
Specifically endothelium-derived microparticles, but not those originating from other 
cellular types, have been shown to bear high prognostic value in the risk assessment 
of mortality and major adverse cardiovascular events in patients with coronary artery 
disease, but also pulmonary hypertension and end-stage renal failure98. 
What can we learn from the lesion itself for selecting 
novel biomarkers?  
In an ideal situation we would like to extract our biomarkers directly out of the lesion 
since this area previously gave problems and here postinterventional remodeling will 
start again.
Previously detectable CRP levels in the arterial intima were found preceding the 
appearance of monocytes. Furthermore, CRP had actually chemotactic capacities 
by direct influence on monocyte recruitment both in vitro as in vivo100. Another study 
showed that immunoreactivity to CRP was localized to macrophages, SMCs and 
necrotic areas. Moreover, the immunoreactivity to CRP in coronary atheromatous 
plaque increases in culprit lesions of unstable angina and it affects restenosis101. This 
may indicate that local CRP levels are much more specific to study while the role 
of circulating CRP and the relation with post-interventional remodeling may still be 
difficult to assess since it may be upregulated in multiple ways even independently 
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of the interventional procedure. Another factor of which its plaque levels were more 
than 70 times higher in plaques than in plasma is oxLDL in patients undergoing 
carotid endarterectomy102. The same authors also found differences in the oxLDL 
amount in macrophages rich plaques versus macrophage poor plaques. Interestingly 
plasma oxLDL levels were only significantly different between control patients and 
patients with macrophage-rich plaques which may indicate that when studying only 
oxLDL on the plasma level will not discriminate patients without or patients with 
a macrophage-poor plaque and may be more helpful in determination of plaque 
vulnerability than just plaque formation or progression102. Bamberg and co-workers 
showed that different biomarkers of inflammation, vascular remodeling, oxidation, 
and lipoprotein metabolism maybe associated with different patterns of coronary 
atherosclerosis as quantified by coronary CT angiography103. So lesion phenotype 
may be very important for the selection of proper novel biomarkers. Only recently a 
novel study was conducted that uses the knowledge of specific lesions to study the 
disease process and use it as a predictor of future restenosis and or atherosclerosis 
occurrence even at other sites than the initial lesion. This Athero-Express study 
was the first study to provide prospective evidence that plaque composition may 
predict the risk of restenosis after endarterectomy. Here they found associations 
for non-vulnerable plaque phenotype to be more prone to develop restenosis104. 
The Athero-Express biobank was also used for a proteomics search approach 
to identify local biomarkers (selected proteins that have been identified earlier in 
experimental set-ups with any cardiovascular phenotype but not necessarily with 
atherosclerosis, osteopontin (OPN) and Macrophage migration inhibitory factor 
(MIF)) in the atherosclerotic plaque to predict atherosclerotic plaque development in 
other vascular beds. The authors collected plaques from carotids as well as plaques 
from femoral arteries and in both cases they found plaque osteopontin (OPN) levels 
highly predictive for secondary atherosclerotic development. Furthermore, plaque 
MIF levels were strongly associated with secondary cardiovascular events and 
showed that the concept not only applies for OPN105. Although beyond the scope 
of this review, the field of proteomic research is evolving and could contribute 
substantially to the discovery of new biomarkers in post-interventional restenosis 
and accelerated atherosclerosis. 
Most studies are of limited value for the risk stratification of individual patients with 
the current available biomarkers25 and are therefore playing a very little role in the 
prediction of restenosis and decision-making for its exploration and treatment. 
Furthermore, in many clinical centers it is not possible yet to sample and extract tissue 
to select for biomarkers patient specifically however combining results of these kind 
of studies on plaque development and progression together with increased specific 
knowledge on the complex pathways extracted from experimental research may help 
us in understanding not only the pathophysiological process but also to select novel 
biomarkers. They probably will contribute largely to our knowledge and selection of 
novel biomarkers and may find new correlations between local and circulating levels 
of biomarkers and post-interventional remodeling and accelerated atherosclerosis. 
In addition these local studies may even come up with novel biomarkers inside the 
plaque that can not be detected in plasma due to their low plasma levels, incapacity 
of being released outside the plaque or just being plaque specific. 
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Recently published studies have demonstrated that both lowered and elevated 
concentrations of local arterial and circulating biomarkers are associated with 
cardiovascular risk profiles and specifically post-interventional vascular remodeling 
due to accelerated atherosclerosis development. These associations are independent 
of traditional risk factors and could serve as helpful tools for risk stratification or 
diagnostic assessment of patients eligible for intensified treatment for clinicians 
performing target lesion revascularization interventions. Improved assays have 
identified not only circulating biomarkers, but also cellular-expressed receptors, co-
factors and microparticles that all directly causally involved in disease progress, but 
also indirectly as biomarkers of inflammatory status and vascular function. Provided 
these findings are replicated in other studies, the combined power of current 
diagnostic strategies with the latest tools and multiple biological risk markers could 




• Coronary heart disease remains the leading cause of death and is caused by 
atherosclerosis, a chronic inflammatory disease 
Underlying causes of restenosis
• Post-PCI restenosis is determined by biological, arterial, stent and technical 
factors
Inflammation status as biomarker
• Biomarkers can be divided into local, circulating and circulating cell-bound 
markers and are most valuable when causally related to disease progression
Circulating biomarkers
• Circulating markers and ligands of the innate immune system such as 
fibronectin, inflammatory cytokines, annexin A5 and natural antibodies 
towards oxidized LDL cholesterol and HMGB-1 can be highly predictive
• Inflammatory receptors on circulating leukocytes such as TLRs and 
scavenger receptors, but also microparticles are directly implicated in and 
strongly indicative of atherosclerotic vascular remodeling
What can we learn from the lesion itself for selecting novel biomarkers?  
• Biobanks containing mRNA and protein profiles from numerous atherosclerotic 
plaques are highly valuable for local biomarker screening
Conclusion
• Biomarkers of inflammation status possess the highest predictive value for 
accelerated atherosclerosis disease progression, especially when combined 
and in addition to current diagnostic strategies
Future perspective
The insight into the development of atherosclerosis and post-PCI restenosis has 
developed very quickly over the past decade. Ever since, atherosclerosis is primarily 
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viewed as a chronic inflammatory disease due to a dysfunctional immune response 
towards the arterial wall. To this end, the focus on atheroscleroticbiomarkers has shifted 
from traditional markers that serve as risk factors, such as hypercholesterolemia, 
towards markers of systemic inflammation (e.g. C-reactive protein) and arterial 
dysfunction. The important notion remains that causal factors are additionally 
powerful predictors of disease progression and the same would apply for inflammatory 
markers. The field of diagnostic and treatment-evaluation markers will shift in the 
same direction, guided by new insights, and rely heavily on the additional value 
of new biomarkers to the current diagnostic strategies. Epidemiologic assessment 
of additional value from combining biomarkers is a powerful tool to discover new 
biomarkers entities for the development of highly specific assays, specifically for 
genetic biomarkers such as polymorphisms that are associated with disease risk. 
The field of biomarkers for accelerated atherosclerosis and post-interventional 
vascular remodeling has changed due to the introduction of drug-eluting stents. 
These stents have rendered various markers of little use, since they closely followed 
the inflammatory reaction towards BMS placement and are currently prevented by 
adequate local drug release. Their usefulness could be further compromised in future 
due to the ever-increasing application of drug-eluting balloons. Nevertheless, new 
inflammatory factors such as intraplaque and circulating proteins, natural antibodies, 
microparticles and cellular receptor expression could prove to be of highly-specific 
and diagnostic value. Furthermore, application of such screening assays would allow 
for optimal treatment evaluation such as occurred in the past with the introduction of 
cholesterol-lowering statin therapy. 
Development and application of future biomarkers requires clinical validation, which 
remains a time-consuming and expansive entity, and this uncertainty is inherently 
(most notably on safety issues) present at the final stages of drug validation, limiting 
future biomarker development. In spite of this, investigations continue to proceed and 
will improve diagnostic and treatment accuracy of post-interventional atherosclerotic 
vascular remodeling.
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In-stent restenosis remains the major drawback of coronary interventions and is a 
highly complex process, initiated by the induction of vascular injury and stent de-
ployment, ultimately leading to negative vascular remodeling and reoccurrence of 
symptoms. Development, testing and validation of new therapies strongly depends 
on the availability of animal models that closely mimic human restenotic pathophy-
siology. Moreover, for a better understanding of the pathophysiology of the resteno-
sis process adequate animal models mimicking the human restenosis process are 
essential.
Here, we review various animal models, predominately humanized mouse models, 
currently used to study the pathophysiology of restenosis. Larger animal models 
such as pigs and rabbits that are used for testing new therapeutic strategies such as 
new drug-eluting stents, will not be discussed in this chapter. 
We will discuss the involvement of inflammatory and immune modulatory factors 
in the development and progression of restenosis. Furthermore, we will discuss in 
detail several new therapeutic options based on modulation of their anti-proliferative, 
anti-inflammatory or proteinase-interference abilities.
We can conclude highly-reproducible animal models for post-interventional vascular 
remodeling remain essential for the development of future anti-restenotic therapies. 
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Pathophysiology of Restenosis in Humans and Animals
Restenosis is defined angiographically in patients when neointimal tissue compri-
ses over 50% of the luminal surface at the site of intervention of the affected artery. 
Restenosis is characterized by acute elastic recoil, negative remodeling and intimal 
hyperplasia due to inflammation, deposition of granulation tissue and extracellular 
matrix remodeling. Intracoronary stenting has virtually eliminated elastic recoil and 
negative remodeling. However, after balloon angioplasty and stent placement neoin-
timal formation still occurs due to de-endothelization and injury of the vessel wall 
including the atherosclerotic plaque. 
Together, these effects lead to activation of the remaining endothelium, platelet ad-
hesion and subsequent activation, fibrin formation and the expression of adhesion 
molecules, leukocyte adherence and infiltration. Adhered leukocytes release an ar-
ray of inflammatory cytokines, chemokines, proteases such as matrix metallopro-
teinases and growth factors which not only promote inflammation, but also cause 
medial smooth muscle cell migration and proliferation, matrix degradation, local 
proteoglycan deposition and subsequent extracellular matrix remodeling. Under hy-
percholesterolemic conditions this is accompanied by influx and accumulation of 
low-density lipoprotein (LDL) cholesterol in the vessel wall. This will be taken up by 
macrophages, that become foam cells and initiate a process of accelerated athero-
sclerosis in these vessel segments1. Patients receive platelet-inhibitors throughout 
interventional procedures to prevent arterial thrombosis and end-organ ischemia 
due to thrombotic occlusion of the affected vessel. Furthermore, this therapy partly 
prevents the initial pathophysiological events that eventually lead to restenosis de-
velopment. Nonetheless, in patients limited local inflammatory processes are related 
to the healing of the vascular injury triggered by mechanical dilation, stent deploy-
ment and the continuous presence of stent struts against the arterial wall and their 
exposure to flowing blood2, 3. However, uncontrolled inflammatory processes may 
induce intimal hyperplasia.
Intravascular injury to diseased vessels with a hypercholesterolemic background is 
common in patients, but severely difficult to reproduce in healthy vessels of main-
ly young animals with a normocholesterolemic phenotype. Therefore, transgenic 
mouse models with a pro-atherosclerotic or hypercholesterolemic phenotype have 
attracted attention as humanized mouse models for mechanistic and pathophysiolo-
gical restenosis research.
Animal Models for Restenosis and Vascular Remodeling
Various animal models, mainly in mice, are currently available to mimic human res-
tenosis, extensively based on perivascular injury, aimed to induce local coagulation 
and subsequent inflammation, leading to accelerated atherosclerosis formation.
Balloon angioplasty of rat carotid arteries
A model of balloon-induced injury to the carotid artery in rats was described in 1983 
by Clowes et al.4 and used many studies there after, amongst others by Ohlstein et 
al.5, in which an arterial embolectomy catheter is inserted into the common carotid 
artery and a balloon is inflated and drawn along the vessel wall to induce mechanical 
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injury. Afterwards, the external carotid artery is ligated. This leads to severe SMC 
migration and proliferation and intimal thickening. 
Common carotid artery ligation in mice
Neointimal formation can be elicited by completely ligating the common carotid ar-
tery just proximal to the carotid bifurcation to disrupt blood flow as has been descri-
bed by Kumar et al.6 and since then has frequently been used by several groups. 
After 4 weeks, intimal thickening occurs and consists of both SMCs and leukocytes, 
indicating the pivotal role of inflammation in the formation of neointimal tissue. The 
model is hampered by its reproducibility, since morphometric analysis is very critical. 
The degree of the intimal hyperplasia depends on the position the analyzed section 
in regard to the point of ligation.
Mouse model of femoral artery denudation injury
Femoral artery transluminal injury can be induced by passage of a 0.25-mm diame-
ter angioplasty guide wire in mice7. Four weeks after injury, neointima formation can 
be analyzed and consist predominately of migrated and proliferated SMCs, although 
inflammatory cells can already be observed early after injury.
Perivascular electrocoagulation injury
Electrocoagulation-induced injury to the femoral artery of mice was introduced in 
1997 by Carmeliet et al.8, leading to loss of all endothelial and medial smooth mus-
cle cells (SMCs) and formation of a mural non-occlusive platelet-rich thrombus. This 
leads to inflammatory cell recruitment and SMC migration and proliferation, eventu-
ally leading to intimal thickening. 
Photochemical intravascular injury
Photochemical endothelial injury to the femoral artery of mice injected with rose Ben-
gal solution using transluminal green light has been used by Kikuchi et al.9 in 1998 
to induce a local thrombus formation, followed by endothelial denudation and medial 
SMC apoptosis and eventually intimal thickening. Unfortunately, the reproducibility 
of this model remains rather low. 
Perivascular chemical injury
Chemical perivascular injury to the carotid artery of dyslipidemic mice using a filter 
paper saturated with a 10% ferric chloride solution was used by Zhu et al.10 to induce 
formation of an occlusive platelet-rich thrombus due to endothelial cell loss and me-
dial SMC necrosis, triggering inflammatory cell recruitment and SMC migration and 
proliferation. Eventually, this promotes intimal thickening.
Inter-arterial venous engraftment
Accelerated atherosclerosis and vascular remodeling also appear in engrafted vas-
cular segments, which are performed frequently to bypass occluded arterial seg-
ments in patients. Although bypass models do not mimic the pathophysiology of 
restenosis completely, they can be used excellently to study various aspects of res-
tenotic disease.  Models have been developed for several animal species. Only 
relatively recently have mouse models for vein graft disease become available, de-
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veloped by Xu et al.7, most often based on the model described by Lardenoye et 
al.11, in which a venous interposition is made within the carotid artery of a mouse. 
For this, an inferior caval vein is harvested from littermate donor mice and preserved 
in a 0.9% NaCl solution containing 100U of heparin at 4°C, to prevent thrombosis. 
Afterwards, the carotid artery is dissected free from its surroundings, ligated twice 
and cut between the two 8.0 silk ligatures. Clamps are placed proximally and distally 
from the ligatures to allow haemostatic control to the surgeon throughout the proce-
dure, leaving free arterial ends over which a cuff can be placed. Next, the free arterial 
ends are everted over the cuffs and ligated with an 8.0 silk ligature, after which the 
harvested inferior caval vein is interpositioned between the ends of the artery. The 
connections are ligated together with an 8.0 silk suture and visible pulsations confirm 
successful engraftment. 
When performed in hypercholesterolemic mice, concentric lesions are formed within 
4 weeks and are friable, with extracellular lipid deposition and foam cell accumula-
tion, underneath a poorly developed or absent fibrous cap. This morphology highly 
resembles the morphology observed in arterially-engrafted veins in patients. All as-
pects of rapid post-interventional vascular remodeling and accelerated atherosclero-
sis development are present in this very reproducible animal model. 
Intravascular balloon dilatation injury
Intravascular injury models resembling invasive coronary procedures have been de-
veloped recently, but remain technically very demanding. 
Kwak et al.12 described a mouse model in which intravascular carotid balloon disten-
sion injury is performed, which a balloon catheter was introduced through an arterio-
tomy on the proximal external carotid artery and advanced into the common carotid 
artery and subsequently distended to induce controlled vessel wall distension. In this 
elegant model, distention could be matched to the animal’s weight and the balloon 
was expanded using a water-filled inflation device. Vessel wall damage led to en-
dothelial denudation, followed by leukocyte recruitment and medial SMC activation, 
leading to intimal thickening and luminal stenosis. Although this model is technically 
difficult to perform, vascular injury highly resembles the human situation and leads 
to a similar pathophysiological vessel wall response.  
Inter-arterial stented-arterial engraftment
Ali et al.13 have taken intravascular stenting in mouse models a step further, which 
they reported in 2007. Donor mice receiving aspirin underwent stenting using a 
stainless-steel stent crimped onto an angioplasty balloon catheter, which was gui-
ded into place retrograde through the thoracic aorta, leaving the balloon and stent 
in the descending thoracic aorta. The balloon was inflated for 30 seconds until 8 
times atmospheric pressure to induce stent deployment. Next, the stented-aorta was 
removed and kept in heparinised PBS solution, before being engrafted within the 
ligated carotid artery of a hypercholesterolemic recipient mouse, similarly to the vein 
graft procedure. After 28 days, intimal thickening was significantly increased in the 
stented arterial graft, when compared to the aorta and balloon-inflated aortic grafts. 
Lesions consisted predominately of SMCs, macrophages and foam cells, similarly to 
human coronary lesions after interventions.
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Perivascular femoral arterial cuff placement
Already in 1989, it was shown by Booth et al.14 that placement of a perivascular non-
constrictive plastic cuff around the common carotid artery of hypercholesterolemic 
rabbits results in intimal thickening based on SMC migration and proliferation, cho-
lesterol deposition and foam cell formation as seen in human restenotic lesions. This 
is due to mechanical vascular damage and an inflammatory response evoked by the 
cuff. There was no need for endothelial cell damage and the formation of a transient 
occlusive thrombus in this model.
When this attractive model was downscaled to mice15, this offered the unique op-
portunity to employ a mechanically-induced inflammatory-based restenosis model 
in an animal species of which an enormous range of strains with genetic variations 
existed, including atherosclerosis prone transgenic strains. 
Since like the human genome, the murine genome has currently been completely 
mapped and multiple humanized-mouse models have been developed, this has al-
lowed researchers to investigate the role of specific genotypic and general pheno-
typic traits in restenosis development. The aim was to identify pathophysiological 
changes leading to restenosis and accelerated atherosclerosis development, and 
subsequently identify key targets for prevention and treatment of restenosis in pa-
tients in a clinical setting.
The technical procedure of perivascular cuff placement15 is described in detail in the 
next section. Before surgery, mice are anaesthetized with an intraperitoneal injection 
with a combination of 5 mg/kg Midazolam (Roche, Basel, Switzerland), 0.5 mg/kg 
Medetomidine (Orion, Helsinki, Finland) and 0.05 mg/kg Fentanyl (Janssen, Geel, 
Belgium). This combination of anesthetics gives complete narcosis, lasting minimally 
one hour and can be antagonized using Antisedan 2.5 mg/kg (Orion), Anexate 0.5 
mg/kg (Roche) and Buprenorphine 0.08 mg/kg (Schering-Plough, Kenilworth, NJ, 
USA). 
A microscope with 10-15x total magnification is used during the microsurgery proce-
dures (Olympus SZX9 microscope). Basic instruments required are a blunt micro for-
ceps (length: 10.5cm, height: 0.3mm, Medicon Instruments, Tuttlingen, Germany), a 
sharp micro forceps (length: 10.5cm, height: 0.3mm, Medicon Instruments), a micro 
scissor (length: 12.5cm, height: 10mm, Medicon Instruments) and a micro needle 
holder (length: 18.5cm, Medicon Instruments). 
A longitudinal incision is made at the internal side of the thigh and the femoral artery 
is dissected from the femoral nerve and vein. The femoral artery is looped twice with 
a ligature (USP: 6/0, Metric: 0.7., Silkam natural silk, B. Braun, Melsungen, Ger-
many) and a non-constrictive fine bore polyethylene tubing (0.40mm inner diameter, 
0.80mm outer diameter, Portex, Kent, UK) is cut 2.0mm length and longitudinally 
opened and sleeved loosely around the femoral artery. The cuff is closed with two 
6/0 ligature knots in the extremities of the cuff. Finally, the skin incision is closed with 
a running suture (USP: 6/0, Metric: 0.7., Silkam silk, B. Braun). After surgery, animals 
are placed in a clean cage on top of a heating pad for four hours. A schematic re-
presentation and photomicrograph of the femoral arterial cuff placement are shown 
in figure 1.
For histological analysis, animals are typically sacrificed 2-3 weeks after cuff pla-
cement. After anesthesia, the thorax is opened and a mild pressure-perfusion (100 
mmHg) with 4% formaldehyde in 0.9% NaCl is performed for 5 minutes by cardiac 
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Figure 1. Schematic representation of non-constrictive cuff placed loosely around a murine femoral ar-
tery, held in place by two ligatures (A) and a photomicrograph (B) of a positioned cuff in vivo. (C) Photo-
micrograph of the restenosis lesion in the cuffed femoral artery in the mouse. Indicated are the internal 
elastic lamina (IEL) and the neointima (NI) formed within the vessel wall.
puncture. After perfusion, a longitudinal incision is made in the internal side of the 
thigh and the cuffed femoral artery is harvested as a whole and fixed overnight in 
4% formaldehyde. 
Preclinical application of drug-eluting stents and balloons
Intracoronary stenting decreased restenosis rates by preventing elastic recoil and 
negative remodeling, although in-stent restenosis due to neointimal proliferation 
remains the major limiting factor of the success rate for coronary interventions as 
treatment for coronary artery disease. Drug-eluting stents with a polymer coating 
have been developed which are loaded with various types of drugs designed to 
prevent in-stent restenosis. These drugs, some originally used as chemotherapeutic 
agents, against transplant rejection or as
immunosuppressive drugs, tend to prevent the local inflammatory reaction, SMC 
proliferation and migration or promote local healing due to a slow local release. 
Drug-eluting balloons are coated with similar drugs, but are designed to deliver the 








solely the initial local responses to balloon inflation and vessel wall distention. 
Limited (post-mortem) pathological data is available from stented human coronary 
arteries, since histology is usually not readily available. All in vitro and in vivo effects 
of new drug-eluting stents should be evaluated for safety and efficiency before being 
applied in human studies. Preclinical animal studies can also provide insight in the 
method-of-action, dose-response and side-effects of these new stents. Additionally, 
they can be used for investigation into specific genes involved in restenosis deve-
lopment. Genes of interest can be found in large prospective follow up studies, such 
as the GENDER study16, in which the association between gene polymorphisms 
and clinical outcome can be studied. Additionally, these highly-reproducible models 
can be used to screen candidate compounds, without the need for expensive, large, 
long-lasting and time-consuming clinical trials.  
Drug-eluting stents can be mimicked in mice by placement of a perivascular non-
constrictive drug-eluting cuff17, comprised of a poly(ε-caprolactone) (PCL) polymer 
and non-toxic polyethylene glycol, loaded with the candidate drug, shown in figure 
2. This polymer cuff allows encapsulation and local sustained release of compounds 
over a longer period of time. Depending on the ratio between PCL and polyethylene 
glycol, the duration of drug-release can be extended up until 21 days after cuff pla-
cement, to allow local vessel wall drug-exposure throughout the entire study period, 
even in non-hypercholesterolemic mice which develop restenotic lesions relatively 
slowly. 
An alternative for local delivery of active compounds to the mouse vessel wall is the 
use of local administration of the compound dissolved in pluronic gel or gelatin in 
and around the cuff. This allows short period of delivery of compounds locally in the 
murine cuff model as the gelatin or the pluronic gel will degrade in a short period of 
time. The set-up of this local application of pluronic gel in the cuff is shown in figure 3.
In patients, drug-eluting stents release the drug intraluminally, whilst in this model 
drugs are released from the adventitial side of the vessel wall. However, the vessel 
wall in the mouse is smaller, therefore penetration of the compound will be efficient, 
although applied via the adventitia. Nonetheless, this drug-eluting PCL cuff is cer-
tainly an extremely useful and practical tool to evaluate the effects of new candidate 
anti-restenotic drugs on local vessel wall pathology and intimal thickening as part of 
post-interventional vascular remodeling. 
Suitable mouse strains
Contrary to patients, wild-type mouse strains have low levels of pro-atherosclerotic 
low-density-lipoprotein and high plasma levels of anti-atherosclerotic high-density 
lipoprotein and therefore do not readily develop native atherosclerosis. Inbred mice 
used for studies into accelerated atherosclerosis and restenosis tend to respond 
to restenotic stimuli by displaying either a type 1 or type 2 helper T cell (Th1 or 
Th2) response. The Th1 response, typical of the C57BL/6 mouse strain, leads to 
macrophage differentiation into proatherogenic M1 macrophages and production of 
inflammatory cytokines and chemokines, which promote lesion formation18. The Th2 
response, typical of the BALB/C mouse strain, promotes the differentiation of macro-
phages into anti-inflammatory M2 macrophages, which produce anti-inflammatory 
and anti-atherogenic cytokines, eventually leading to a healing response within the 
damaged vessel wall. For this reason, mouse strains with a C57BL/6 background 
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a favored for studying pathophysiological changes leading to restenosis. When the 
perivascular non-constrictive cuff procedure is performed in this mouse strain19, con-
centric lesions develop within 21 days after surgery and typically consist of collagen 
and α-actin positive SMCs.
Dyslipidemic mouse strains
Intravascular injury by balloon inflation and stent placement in diseased human ves-
sels in hypercholesterolemic patients can be mimicked by cuff placement in hyper-
cholesterolemic knock-out or transgenic mouse strains.
Apolipoprotein (Apo) E is an important part of circulating very (V) LDL and LDL cho-
lesterol and acts as a ligand for the LRL-R, thus leading to uptake of proathero-
Femoral Artery
Polymer cuff that allows encapsulation and
local sustained release of compounds
Figure 2. Schematic representation of a drug-eluting femoral arterial cuff and method-of-action.
Figure 3. Schematic representation of non-constrictive cuff around a murine femoral artery, covered by 
hardened pluronic gel (A). Photomicrograph cuff in vivo, with hardened (40%) pluronic gel applied to the 
cuffed vessel segment, loaded with an anti-restenotic drug (yellow) (B).
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sclerotic cholesterol from the circulation. Genetic ApoE deficiency therefore leads to 
hypercholesterolemia due to insufficient LDL-receptor(R)-mediated VLDL and LDL 
clearance, especially when fed a high-cholesterol diet, and spontaneous atheroscle-
rotic and interventional-induced lesion formation. Drawbacks of this mouse strain 
are plasma cholesterol levels that are mainly determined by the VLDL fraction, that 
exceed by far any physiological level and that all other atheroprotective (anti-inflam-
matory, anti-platelet and anti-proliferative) properties of ApoE are lost20.
Patients with familial hypercholesterolemia display mutations in the LDL-R gene, 
leading to insufficient LDL clearance and dyslipidemia. Similarly, LDL-R knockout 
mice develop mild hypercholesterolemia, which increases strongly when fed a high-
cholesterol diet. Since cholesterol elevation is mainly determined by the LDL fraction 
and spontaneous atherosclerotic lesions develop more slowly than in ApoE knockout 
mice, this is classified as a more moderate model. Nonetheless, both mouse strains 
can be used to study post-interventional restenosis development20. 
Mutations in the ApoE3 gene are associated with dysbetaproteinemia in patients. 
One of these mutations is the ApoE3Leiden mutation21. By introducing an ApoE3 and 
ApoC1 gene construct in the C57BL/6 mice, the transgenic ApoE3*Leiden mouse 
strain was generated22. Since the animals still express endogenous ApoE proteins, 
contrary to the ApoE knockout animals, the uptake of ApoE-containing lipoproteins is 
merely reduced and not completely inhibited. Animals have diet-induced increased 
plasma cholesterol concentrations, mainly in VLDL and LDL fractions. They are very 
responsive to high-cholesterol feeding. Desired plasma cholesterol concentrations 
can be obtained by varying dietary cholesterol content. Additionally, since both ApoE 
and LRL-R are still present, plasma cholesterol levels are subject to modulation by 
lipid-lowering drugs that influence endogenous chylomicron and VLDL production 
and indirectly affect LDL-R expression, such as statins. Restenotic lesions after cuff 
placement develop moderately and consist predominately of SMCs, foam cells and 
extracellular matrix formation, very similar to human lesions15. 
New mechanistic and therapeutic insights
Agents currently used or under investigation to prevent and treat restenosis can be 
divided between either drugs with cytotoxic/anti-proliferative and anti-inflammatory 
effects or drugs that target proteolytic systems. Here we give an overview how ani-
mal models may contribute to gain further insight into the mechanism of restenosis 
and to test new therapeutic strategies.
Proliferation
Rapamycin (sirolimus)
Immunosuppressive drugs like rapamycin are currently widely used in drug-eluting 
stents to prevent the development of in-stent restenosis. Rapamycin is a macro-
lide antibiotic drug with anti-proliferative and immunosuppressive effects that targets 
protein translation, resulting in a G1 arrest of the cell cycle which is known to inhibit 
vascular SMC proliferation and migration in vitro by inhibiting DNA synthesis and 
cell growth23-25. Rapamycin has been shown to effectively inhibit the arterial proli-
ferative response after PCTA in a porcine restenosis model, without toxicity in low 
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doses. Local rapamycin application in the murine cuff model was performed using 
a rapamycin-eluting cuff and it was observed that locally released rapamycin led to 
an inhibition of neointima formation by 75±6% for all tested concentrations. Experi-
ments demonstrated that perivascular sustained release was restricted to the cuffed 
vessel segment, with no systemic adverse effects. Moreover, when applying the 
rapamycin eluting cuff to a diseased atherosclerotic vessel segment in ApoE3Leiden 
mice, no progression of the atherosclerotic lesion development could be observed, 
nor any systemic side effects 
Paclitaxel
Paclitaxel belongs to the taxanes, which are potent anti-proliferatives widely used to 
treat patients suffering from cancer. It leads to polymerization of the α- and β-units 
of tubulin and thus stabilizes microtubules, which are necessary for the G2 transition 
of a dividing cell into the M phase. Paclitaxel causes almost complete inhibition of 
cell growth and SMC proliferation and migration by targeting cytoskeleton struc-
ture. SMC proliferation and migration are both induced by balloon inflation and stent 
placement during interventional procedures. In a murine femoral arterial cuff mo-
del, drug-eluting cuffs containing high paclitaxel concentrations (1–5%) have been 
shown to reduce intimal thickening by 76±2%. When placing the paclitaxel eluting 
cuff in hypercholesterolemic mice or even over an existing atherosclerotic lesion in 
mice, dose dependent negative side effects were observed. High dosage of placli-
taxel significantly increased apoptosis (also in the media), disruption of the elastic 
laminas and decrease medial and intimal smooth muscle cell as well as collagen 
content. These findings show elegantly the added value of testing drug eluting de-
vices in atherosclerotic animal model. Many clinical trials26-28 have investigated the 
effectiveness of (non) polymer-based paclitaxel-eluting stents and have shown to be 
very effective in the prevention of restenosis development, however, negative effects 
on the vascular pathology were not detected, emphasizing that the femoral arterial 
cuff model is of high predictive value in the screening for new candidate drugs for 
efficacy and local adverse side effects. 
Inflammation
Although neointima formation is characterized by proliferation and migration of 
smooth muscle cells (SMC) and extracellular matrix turnover it is now broadly ac-
cepted that these processes are triggered by inflammatory activation of the vessel 
wall16. Evidence that inflammation is the initial trigger for vascular remodeling has 
accumulate over the past years and the role of various cytokines and chemokines 
as pro-inflammatory factors as well as immune modulation in general has been the 
focus of many studies on vascular remodeling and restenoses. In the next section 
we would like to illustrate this with a couple of representative examples. Starting with 
the description of the effects of the general anti-inflammatory factor dexamethason, 
we will further zoom in on the effects of specific cytokines (TNF α, IL10), chemokines 
(MCP-1) and the role of the innate immune system (complement, toll-like receptors) 
on restenosis in the mouse models.
Dexamethason
Dexamethason is a corticosteroid with strong glucocortocoid properties and is widely 
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used as a broad anti-inflammatory and immunosuppressant drug. Prolonged syste-
mic delivery is associated with multiple side effects in humans and animals. These 
effect could be abolished by local delivery using a drug-eluting cuff (DEC), mimic-
king the potential effect of drug eluting stents. Local delivery of dexamethason via 
DEC delivery inhibited neointima formation drastically without systemic side effects, 
indicating a beneficial effect of local suppression of inflammation over systemic de-
livery as was tested by applying dexamethason via the drinking water in the same 
model. However pathobiological examination of the murine arteries revealed a dose-
dependent medial atrophy, a reduction in vascular smooth muscle cells and collagen 
content, an increase in apoptotic cell count and disruption of the internal elastic 
lamina29. Short term systemic delivery in a model for vein graft remodeling showed a 
reduction in intimal hyperplasia formation without serious side effects probably due 
to the short period of delivery30. These results not only emphasize the importance of 
the immune system and the role of inflammation in restenosis more specifically and 
systematically, but also show that the use of small (hypercholesterolemic) animal 
models does have predictive value in regard to negative side effects on vascular 
pathology after local drug application.
Innate immunity
Innate immunity is very important in triggering inflammation and can be divided into 
a humoral and a cellular component. It comprises multiple cell types, receptors and 
mechanisms such as the Complement system and Toll like receptors (TLRs) that 
are very important in host defense. The innate immune system is considered to be 
highly involved in regulation of intimal hyperplasia and atherogenesis. This could 
very elegantly be demonstrated using specific mouse models in combination with 
cuff placement or vein grafting as described in the section below.
Complement
The complement system comprises the humoral mechanism of the innate immune 
system. C3 cleavage plays a central role in the complex regulation of complement 
activation and can be initiated via the classical, alternative or the lectin pathway. The 
role of complement was studied in the model of vein graft restenosis combined with 
accelerated atherosclerosis in the ApoE3*Leiden mouse. The expression of com-
plement components C1q, C3, and the regulatory proteins CD59 and complement 
receptor-related gene y (Crry) could be detected on the protein and mRNA level 
in the grafts. A reduction in vein graft thickening and intimal hyperplasia was ac-
complished after interference with C3 activation by systemic administration of either 
Cobra Venom Factor or Crry-Ig protein. The latter was associated with a reduced 
number of inflammatory cells in the vessel wall31, indicating that blocking the central 
factor in the complement activation cascade, C3, results in a profound reduction of 
vascular remodeling. This underscores a role of the innate immune system in reste-
nosis related vascular remoding.
Toll-like Receptors 
TLRs are membrane bound receptors located on a variety of immune and non-im-
mune cells including macrophages, endothelium and SMCs. Cell stress and tissue 
damage may cause a release of Damage Associated Molecular Patterns (DAMPs) 
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that function as endogenous TLR ligands. Balloon inflation and stent placement or 
bypass grafting lead to injury to the vessel wall and may cause up regulation of 
DAMPs such as Heat Shock Protein 60 (HSP60), Fibronectin-EDA, Tenascin C and 
Biglycan. HSP60 binds directly to TLR2 or TLR4 thereby initiating proliferation of 
VSMC32. In response to peri-adventitial cuff induced injury TLR4 expression is up 
regulated in the vessel wall during at least 7 days (unpublished data).  A causal 
role for TLR4 in restenosis was demonstrated by a reduced cuff induced neointima 
formation in TLR4 deficient mice33. Moreover, local adventitial TLR4 activation by 
LPS application strongly augmented neointima formation in both mouse models, so 
with and without involvement of accelerated atherosclerosis34. The same method 
was used to stimulate TLR2 with Pam3Cys and resulted in an increase in neointima 
formation in C57/B6 mice and in APOE-/- mice that develop atherosclerotic lesions35.
We believe that the release upon vascular injury of specific DAMPs as endogenous 
TLR ligands is one of the earliest triggers in vascular remodeling in restenosis and 
there are convinced that the TLR signaling pathway has a crucial function in the 
restenosis process. This is supported by the SNPs found in the TLR4 gene that cor-
relate with in increased risk for cardiovascular event and/or restenosis after an initial 
PCI36-38.
Cytokines
Activation of the immune system results in secretion of multiple pro and anti-inflam-
matory cytokines. These cytokines can be seen as hormones of the immune system 
that communicate, can attract and activate different cell types importantly involved 
in restenosis and atherosclerosis like SMC and macrophages. A disturbance in the 
cytokine balance, locally or systemically, alters the inflammatory status thereby me-
diating inflammatory processes. Since many cytokines have their role in multiple 
inflammatory reactions it is important to know whether they are involved, can be a 
therapeutic target or may function as biomarker for the process of restenosis.
TNFα
Tumor Necrosis Factor alpha (TNFα) is a cytokine that regulates immune cells and 
promotes the inflammatory response. It is produced by many cells including endo-
thelial cells, VSMCs and macrophages. The GENDER project systematically geno-
typed for six polymorphisms in the TNFα gene and found associations with an incre-
ased clinical and angiographic risk for restenosis in humans39. In a rat balloon-injury 
model blockade of the TNFα caused a reduction in neointima formation via accele-
ration of endothelium repair40. In mice, after common carotid artery (CCA) ligation, 
TNFα mRNA expression was found in intimal lesions itself. Application of the same 
model in knockout mice showed a decrease in lesion size41. After peri-adventitial 
cuff placement TNFα mRNA is rapidly up regulated to levels 4000 times to original 
mRNA levels  and deficiency of TNFα in a murine study of restenosis with accelera-
ted atherosclerosis, performed in ApoE*3-Leiden-TNFalpha knockout mice, caused 
a marked reduction in neointima formation. Interestingly, the use of a DEC for local 
delivery of thalidomide as a potent TNFalpha biosynthesis inhibitor demonstrated 
a powerful reduction  of the neointima formation after cuff placement to levels simi-
lar to those observed in the ApoE*3-Leiden-TNFalpha knockout model39. TNFalpha 
is clearly an important cytokine in the inflammatory process that take place in the 
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vessel wall during restenosis and its role can be studied in detail using the specific 
mouse models for restenosis, cuff and drug eluting cuff placement.
CCR2/MCP1
The chemokine Monocyte Chemoattractant Protein1 (MCP1) or CCL2 is a cytokine 
that is capable of attracting immune cell types like monocytes that are known to infil-
trate the vessel wall as a one of the first in neointima formation. Furthermore MCP1 
influences SMC proliferation and is expressed in various stages of vascular remode-
ling. MCP1 binds to its receptor CC chemokine receptor 2 (CCR2) that belongs to 
the family of G-coupled receptors. Femoral artery transluminal injury by passage of 
a 0.25-mm diameter angioplasty guide wire was done in a CCR2-/- mice7.Four weeks 
after injury, CCR2-/- mice showed a 61.4% reduction in neointima formation and a 
62% reduction in intima/media ratio. The effects of MCP1 in vivo were studied in 
the murine vein graft model as well as in the femoral cuff model. Systemic overex-
pression of a dominant negative form of MCP-1, 7ND-MCP, by electroporation of a 
plasmid into the calf muscle resulted in circulating levels of this MCP-1 inhibitor that 
were sufficient to decrease intimal hyperplasia significantly, both in the cuff model42 
as well as in the vein graft model43. 
In addition, in the mouse vein graft restenosis model perivascular local vector ap-
plication for lentiviral shRNA targeting CCR2 reduced intimal hyperplasia in the vein 
grafts by approximately 50%44. These studies demonstrate the role of these models 
in evaluation of experimental therapeutic strategies.
Interleukin-10
Interleukin-10 (IL-10) is one of the most prominent anti-inflammatory cytokines and 
functions pleiotropic. It may suppress antigen presentation and is capable of inhi-
biting pro-inflammatory cytokine production. These capacities make IL-10 a very 
attractive candidate for anti restenotic and anti atherosclerotic therapy. Three poly-
morphisms significantly increased the risk of restenosis in patients and demonstrate 
that IL-10 is associated with restenosis. This set interest for anti-inflammatory ge-
nes to be involved in the development of restenosis45. The functional role of IL-10 
in restenosis was assessed by Feldman et al.46 and showed beneficial effects of 
recombinant human IL-10 after balloon angioplasty or stenting in hypercholesterole-
mic rabbits. Per-adventitial cuff placement in hypercholesterolemic APOE*3-Leiden-
IL-10-/- mice (hypercholesterolemic mice deficient for IL-10) resulted in an increased 
neointima formation indicating a protective role for IL-10 in a murine model for res-
tenosis and accelerated atherosclerosis47. Electroporation of an IL-10 plasmid into 
the calf muscle resulted in IL-10 overexpression in ApoE3*Leiden mice and caused 
a reduction in cholesterol and neointima formation two weeks after cuff placement, 
underscoring the therapeutic potential of IL-10 in restenosis. 
Protease Inhibition in Restenosis
Proteases of the Matrix metalloproteinase (MMP) system and of the plasminogen 
activator system are thought to play an important role in the matrix degradation and 
smooth muscle cell migration during vascular remodeling and are upregulated after 
coronary angioplasty48. Studies in mice showed a decreased neointima formation in 
MMP2-/-, MMP9-/- mice and augmented neointima formation in TIMP1-/- mice49-51. By 
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use of the electrocoagulation vascular injury model Lijnen et al.52 studied whether the 
plasminogen activation system, a system that also may activate the MMP system, 
and the MMP system itself play a role in neointima formation using knockout mice. 
Neointima formation was reduced in urokinase-type plasminogen activator knockout 
(uPA-/-) and Plasminogen (Plg) knockouts (Plg-/-) but no effect was seen in the tissue-
type Plg activator knockout (tPA-/-) mice. 
To study the therapeutic potential of these findings a hybrid protein consisting of the 
receptor-binding amino-terminal fragment of uPA (ATF), linked to the potent prote-
ase inhibitor bovine pancreas trypsin inhibitor (BPTI) was constructed and cloned 
into an adenoviral vector53 Mice were infected with the combined ATF.BPTI vector or 
single vectors for ATF or BPTI and cuffs were placed around the femoral arteries to 
induce neointima formation. Only the ATF.BPT showed a strong inhibition of neoin-
tima formation by selective binding to the uPA receptor and inhibiting plasmin acti-
vity54. Infection with the same vector in a balloon injury model also showed significant 
inhibition of neointima formation in rats55 as well as in mice after cuff placement53. In 
2002 a novel hybrid protein consisting of the tissue inhibitor of metalloproteinase-1 
(TIMP-1) domain, as MMP inhibitor, linked to ATF (TIMP-1.ATF) was constructed. By 
binding to the u-PA receptor this protein blocks binding of u-PA and attaches TIMP-
1 directly to the cell surface. This construct was able to inhibit SMC migration and 
neointima formation in vitro56. In vivo intimal hyperplasia combined with accelerated 
atherosclerosis was studied in murine vein grafts. Plasmids encoding ATF, TIMP-
1, TIMP-1.ATF, were injected and electroporated (non-viral gene transfer) in both 
calf muscles of hypercholesterolemic ApoE*3Leiden mice. Although all constructs 
reduced vein graft thickening compared with the controls, the luminal area was best 
preserved in the TIMP-1.ATF-treated mice57.
Finally a non-viral expression vector encoding the hybrid protein TIMP-1.ATF.BPTI 
(TAB) was constructed and validated. After four weeks, vein graft thickening was 
significantly inhibited in mice treated with the single domains TIMP-1, ATF or BPTI. 
In the TAB treated mice vein graft thickening was reduced and was also significantly 
stronger as compared to the individual domains58. 
Conclusions
For restenosis research animal models are definitely essential for testing new anti-
restenosis devices, such as new drug eluting stent, as well as for unraveling the 
underlying pathophysiological mechanism and identifying new therapeutic targets.
It is important to work with models that mimic the human situation as good as possi-
ble, either in vascular anatomical aspects (size, diameter, wall thickness) or disease 
stage related aspects (hypercholesterolemia, vessel with atherosclerotic lesions).
In the current chapter we have focused on the later group of animal models, those 
humanized models that have the best predictive value for the pathophysiological 
process in the development of restenosis, intimal hyperplasia and accelerated athe-
rosclerosis in the lesions. Various vascular interventions in transgenic mouse mo-
dels have been described, with a strong focus on the mouse femoral artery cuff 
model and these mouse models have proven to be technically suitable for the study 
into restenosis development. 
Next, to study effects of (local) drug therapy, animals should be susceptible to the 
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treatment of interest, have similar metabolic levels, coagulatory phenotype and react 
in a human-like fashion. The use of humanized (transgenic) animal models has ex-
tensively increased the similarity between human and animal lesions and the trans-
lation of new therapies into in the clinical setting.
Mechanistic and pathophysiologal studies have shown that local vessel wall inflam-
mation, proliferation and proteolysis play important roles in the post-interventional 
vascular remodeling, both in humans and in the animal models used. 
In addition, these animal models are extremely suitable to identify new potential 
therapeutic targets to prevent restenosis and test new experimental strategies for 
therapy, e.g. based on systemic or local gene delivery of inhibitory factors (anti-proli-
ferative, anti-inflammatory or anti-proteolytic). These studies clearly demonstrate the 
importance and value of animal models for clinical medicine.
We can conclude that highly-reproducible animal models for post-interventional vas-
cular remodeling remain essential for studying the process of restenosis and the 
development of future anti-restenotic therapies.
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Objective Annexin A5 (AnxA5) has antithrombotic, anti-apoptotic and anti-inflam-
matory properties; we investigated its effectiveness against vascular inflammation, 
remodeling and dysfunction in accelerated atherosclerosis.
Methods and Results AnxA5 (1 mg/kg/d or vehicle) was investigated in vascular 
injury models in hypercholesterolemic ApoE3*Leiden mice. AnxA5 treatment redu-
ced adhesion and infiltration of leucocytes by 71-69% (p=0.015, p=0.031) and ma-
crophages by 51-87% (p=0.014, p=0.018), as well as MCP-1 and TNF-α expression 
in a femoral artery inflammation model (perivascular cuff for 3d), indicating reduced 
vascular inflammation. In a vein graft model, 28d AnxA5 treatment reduced vein graft 
thickening (48%, p=0.006) and leukocyte infiltration (46%, p=0.003). In these mice, 
reduced plasma concentrations of IFNγ (-72%, p=0.040), G-CSF (-41%, p=0.010) 
and MIP1β (-66%, p=0.020) were measured, indicating reduced systemic inflamma-
tion. An in vitro endothelial cell model shows the importance of AnxA5’s anticoagu-
lant properties in reducing vascular inflammation.
Endothelium-mediated dilatation in hypercholesterolemic ApoE-/- mice was improved 
by 3d anxA5 treatment, shown by improved systolic and diastolic blood pressure 
reductions in response to metacholine, which could be abolished by L-NAME, indi-
cating nitric oxide involvement.
Conclusions AnxA5 reduced local vascular and systemic inflammation, vascular re-
modeling and improved vascular function, indicating a therapeutic potential against 
atherosclerotic cardiovascular diseases.
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Accelerated atherosclerosis is one of the key features leading to vein graft failure 
next to acute thrombosis and occlusive vein graft thickening and is initiated by endo-
thelial dysfunction, accompanied by an inflammatory activation of endothelial cells 
and smooth muscle cells (SMCs)1, 2. This activation promotes adhesion of activated 
platelets and leukocytes and increases endothelial permeability, after which low-
density lipoprotein (LDL) cholesterol accumulates in the vessel wall and is taken 
up by macrophages, which become foam cells3, 4. Leukocytes produce pro-inflam-
matory cytokines such as monocyte chemotactic protein (MCP)-1, tumor necrosis 
factor-α (TNFα) and interferon-γ (IFNγ). Leukocytes and cytokine expression are 
also observed in murine vein grafts3, 5. IFNγ can activate macrophages and stimulate 
apoptosis, leading to plaque instability which can result in plaque disruption and 
thrombosis6, 7. 
Viable cells expose phosphatidylcholine and sphingomyelin on their outer cell mem-
brane leaflet and express phosphatidylserine (PS) on their inner membrane leaflet. 
The annexins are a family of phospholipid-binding proteins and annexin A5 (AnxA5) 
binds to PS. AnxA5 was originally identified as an anticoagulant and antithrombotic 
protein8-11, but is now known to have several other additional properties12, 13. PS is 
highly polarised to the inner cell membrane in normal cells, but is externalized in the 
early phase of apoptosis and inflammatory cell activation. AnxA5 binds reversibly, 
specifically and with high affinity to these cells, as well as to aged erythrocytes, en-
dothelial microparticles (EMP), activated platelets and oxidized (ox) LDL cholesterol, 
and is present in high concentrations in atherosclerotic plaques. The annexins are 
thought mainly to act on intracellular mechanisms, but AnxA5 also has extracellular 
functions13-16. 
Plasma levels of AnxA5 are reported to be inversely related to the severity of coro-
nary stenosis and are an indication of the extent of atherosclerotic plaques17, to be 
elevated in hypertensives with systolic dysfunction18 and following acute myocardial 
infarction19. AnxA5 also has anti-inflammatory effects, e.g. by association with the 
IFNγ receptor and prevention of inflammatory cellular responses to secreted IFNγ5. 
Atherosclerosis is associated with a reduced capacity of the endothelium to produce 
vasodilating substances upon stimulation, such as nitric oxide (NO). A reduction in 
endothelium-mediated dilatation (EMD) is a risk factor for premature cardiovascular 
disease and is associated with increased atherosclerosis development20. Binding of 
AnxA5 to PS may prevent PS-mediated platelet and leukocyte adhesion and affect 
the level of systemic inflammation and circulating cytokines, resulting in improved 
local and systemic endothelial function.
The binding to oxLDL cholesterol, to apoptotic cells and the potential inhibitory ef-
fect on inflammation in combination with its antithrombotic effects make AnxA5 a 
promising therapeutic agent against atherosclerosis. By using three mouse models 
for accelerated atherosclerosis development that share a common basis of endothe-
lial cell activation, followed by local vascular wall inflammation, eventually leading 
to vascular remodeling, the aim of the present study was to investigate if AnxA5 is 
therapeutically effective against vascular dysfunction, inflammation and remodeling, 




We performed an in vivo intervention study in which Western-type diet fed 
ApoeE3*Leiden mice were injected intraperitoneally daily with 1 mg/kg AnxA5 or 
vehicle only and underwent femoral arterial cuff placement or vein graft surgery. In 
these vascular segments, inflammatory cell adhesion, infiltration, intimal thickening 
and lesion composition were assessed using histology, morphometry, and immuno-
histochemistry. Plasma AnxA5 and cytokine concentrations were determined using 
ELISA and a multiplex biometric immunoassay. For in vitro studies, TNFα-activated 
HUVEC, incubated with and without AnxA5, underwent whole blood perfusion, allo-
wing assessment of platelet adhesion, aggregation and leukocyte adherence. Wes-
tern-type diet fed ApoE-/- mice, receiving 3d AnxA5 treatment or vehicle only, were 
used for endothelial function assessment, performed by stimulating vasodilatation 
and aortic blood pressure measurements. All materials and methods are detailed in 
the supplement (available online at http://atvb.ahajournals.org). 
Results
Annexin A5 effects
AnxA5 treatment did not affect body weight, total plasma cholesterol or triglyceride 
concentrations. In the ApoE-/- mice, human AnxA5 plasma concentration, measured 
with ELISA, was 35.3±1.5ng/ml 1h after 1mg/kg injection and fell to 3.2±1.1ng/ml 6h 
after injection, which is within the normal range in man (see online figures for plasma 
concentrations). In mice receiving AnxA5 no bleeding complications occurred and 
there was one case of vein graft thrombosis (in n=10 mice) leading to loss of graft 
patency after 28d, compared to three cases of graft thrombosis in mice receiving ve-
hicle only (n=10), this was statistically not significantly different (vehicle: 3/10 cases, 
annexin A5: 1/10 cases, p=0.582). 
Annexin A5 has systemic anti-inflammatory effects
To monitor effects of AnxA5 on systemic inflammation, plasma concentration of a set 
of cytokines and chemokines were defined before surgery, 3d after cuff placement 
and 28d after vein graft surgery, respectively, using a multiplex BioRad Luminex 
analysis. Before surgery, no statistical differences were observed. After 3d, plasma 
concentrations of inflammatory cytokines were increased in all groups due to the 
inflammatory response evoked by cuff placement. However, at 28d after vein graft 
surgery AnxA5 treatment significantly reduced the plasma concentration of G-CSF 
by 40.8% (p=0.010), of IFNγ by 72.2% (p=0.040) and of MIP-1β/CCL4 by 66.1% 
(p=0.020), when compared to vehicle. In addition, AnxA5 treatment gave a trend 
towards reduction of the plasma levels of the cytokines IL-12 (p40) (p=0.120) and 
MIP-1α /CCL3 (p=0.160), shown in table 1. The total dataset is represented in table 
1 in the online data supplement.
Annexin A5 reduces inflammatory cell recruitment after vascular injury
AnxA5 treatment reduced the percentage of femoral arterial endothelial adhesion of 
leukocytes by 71.3% (vehicle: 34.2±3.0%, AnxA5: 9.7±8.9% of the sum of endothe
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lial and intimal cells, p=0.015) and of macrophages by 51.4% (vehicle: 24.5±3.5%, 
AnxA5: 11.9±2.3%, p=0.014) after 3d compared to controls. Furthermore, within the 
media the percentage of leukocytes out of all cells in the media was reduced by 
69.0% (vehicle: 19.6±4.6%, AnxA5: 6.1±2.6%, p=0.031) and that of macrophages by 
87.3% (vehicle: 14.2±5.5%, AnxA5: 1.8±0.9% p=0.018). At this time point foam cells, 
recognisable by positive macrophage staining, intracellular lipid deposition and cell 
swelling, could not be detected.
Although plasma levels of MCP-1 and TNFα were not affected by AnxA5 treatment 
in the femoral artery cuff experiment, the arteries were stained for cells expressing 
MCP-1 and TNFα to investigate if AnxA5 reduced local vascular inflammation. It was 
found that AnxA5 treatment reduced the percentage of adherent and endothelial 
cells expressing MCP-1 by 31.0% (vehicle: 49.1±2.2%, AnxA5: 33.9±3.1%, p=0.003) 
and that of TNFα by 42.7% (vehicle: 39.6±8.0%, AnxA5: 22.7±2.2%, p=0.049) after 
3d. Additionally, the percentage of cells in the media expressing MCP-1 dropped by 
52.7% (vehicle: 31.1±1.8%, AnxA5: 14.7±2.8%, p=0.001), although no relative diffe-
rence was observed for medial cells expressing TNFα (vehicle: 21.2±6.2%, AnxA5: 
12.9±2.9%, p=0. 335) at this time point. The data, including photomicrographs, is 
shown in figure 1. A complete overview of all data is shown in table 2 of the online 
data supplement. 
Annexin A5 reduces vascular remodeling and preserves vein graft patency
To investigate the therapeutic effectiveness of AnxA5 against vascular remodeling, 
vein graft thickening, measured as the area between the lumen and adventitia in 
cross-sections, was quantified after 28d. This revealed that AnxA5 significantly redu-
ced vein graft thickening by 48.0% (vehicle: 0.25±0.05mm2, AnxA5: 0.13±0.01mm2, 
p=0.006), thus preserving graft patency, shown in figure 2. Although in the controls 
AnxA5 could be detected by immunohistochemistry, the staining in the vessel wall of 
the mice injected with human AnxA5 was much more intense. This suggests accu-











Cell type surface (%) area
Annexin A5Vehicle
Table 1. Percentage of cell type area out of total vein graft wall area, total cell numbers per vein graft wall 
cross-section and plasma cytokine concentration (pg/ml) in ApoE3*Leiden mice 28d after surgery and 


































Figure 2. Effect of AnxA5 treatment on vein graft thickening in ApoE3*Leiden mice treated with vehicle or 
AnxA5, 28d after surgery. Panel A: representative cross-sections of vein grafts, (HPS and AnxA5 staining, 
magnification 80x, arrows in insert indicates positive staining). Panel B: quantification of vein graft thicke-
ning, expressed as mm2 thickening in vehicle and AnxA5 treated mice (mean±SEM, n=10).
Figure 1. Panel A: representative cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice treated 
with vehicle or AnxA5, 3d after cuff placement (leukocyte, macrophage, MCP-1 and TNFα staining, mag-
nification 400x, arrows in inserts indicate positive staining). Panels B and C: quantification of cell types in 
cuffed femoral arteries attaching to the endothelium (panel B) or within the media (panel C), expressed 
as the percentage of all cells adhering to the endothelium or in the media, in vehicle and AnxA5 treated 












































































quantification of this immunohistochemistry data.
In order to identify if AnxA5 therapy altered atherosclerotic plaque composition, the 
presence of several important cell types and extracellular matrix was quantified, 
shown in table 1. AnxA5 treatment reduced the number of leukocytes in the vein 
graft wall per cross-section by 46% (vehicle: 53.1±6.1 cells, AnxA5: 28.8±2.3 cells, 
p=0.003). However, despite reduced wall thickening, there was no difference ob-
served in contribution of cell types and collagen to the build-up of the vessel wall, 
observed in macrophage area (from total wall area) (vehicle: 35.6±7.7%, AnxA5: 
32.5±7.4%, p=0.723), SMC area (vehicle: 23.0 ±4.0%, AnxA5: 28.4±3.6%, p=0.289) 
or collagen area (vehicle: 35.8±5.5%, AnxA5: 45.7±5.0%, p=0.289) between mice 
receiving daily AnxA5 or vehicle.
In order to evaluate the therapeutic effects of AnxA5 on plaque stability, apoptotic cell 
numbers and signs of plaque disruptions, characteristic for vein grafts, were quan-
tified. AnxA5 treatment did not affect vein graft apoptotic cells numbers per cross-
section (vehicle: 6.2±2.2 cells, AnxA5: 4.3±0.8 cells, p=0.796) after 28d, shown in 
table 1. Analysis of plaque morphology revealed the presence of disruption features 
and it was found that AnxA5 therapy did reduce the number, length and severity of 
endothelial erosions with fibrinogen lining the vessel wall (vehicle: 3/6 cases, AnxA5: 
2/9 cases) and therefore characteristically distinct from post-mortem artifacts, leaky 
vessel formation with intramural erythrocytes (vehicle: 3/6 cases, AnxA5: 0/9 cases) 
and of severe plaque disruptions with erythrocytes and thrombi in a subendothelial 
space (vehicle: 1/6 cases, AnxA5: 0/9 cases), shown in figure 3. Although no firm 
conclusions about the possible protective functions of anxA5 on plaque stability can 
be drawn from these observations, the reported features are important to the plaque 
and vessel wall morphology and are known to be associated with increased plaque 
instability in human (coronary) atherosclerotic lesions.
Annexin A5 reduced endothelial-platelet and leukocyte-endothelial adhesion
To investigate how AnxA5 led to a reduction of endothelial-leukocyte adhesion in 

































Figure 3. Panel A: representative cross-sections of spontaneous plaque disruption features in vein grafts 
of ApoE3*Leiden mice after 28d (HPS and fibrinogen staining, magnification 80x, arrows in inserts indi-
cate features). Panel B: quantification of length (in μm) and number of plaque instability features (total of 





stimulated with TNFα for 4h to induce endothelial cell activation in the presence 
and absence of AnxA5. AnxA5 (0.75 μg/mL) was added to HUVEC during TNFα-
stimulation (4 hrs) and added to the whole blood prior (5 min) and during the per-
fusion. AnxA5 inhibited leukocyte adhesion by 58.8% (TNFα only: 47.8±16.5 leuko-
cytes / microscopic field, TNFα + AnxA5: 19.7±11.4 leukocytes / microscopic field, 
n=25 frames, p<0.001) and platelet adhesion area by 48.6% (TNFα only: 21.7±7.8% 
coverage, TNFα + AnxA5: 11.1±6.6% coverage, n=25 frames, p<0.001), shown in 
figure 4. 
Non-stimulated HUVEC hardly supported adhesion of platelets and leukocytes, in-
dicating that TNFα-induced tissue factor- and PS-expression was necessary for bin-
ding under flow of both platelets and leukocytes. 
Annexin A5 improves endothelial function
To test the effect of AnxA5 on vascular function, endothelial dysfunction was induced 
by feeding ApoE-/- mice a Western-type diet for 16 to 17 weeks and was quantified by 
measuring the reduction of metacholine-induced NO-mediated vasodilatation. After 
this period, mice were given IP injections with 1mg/kg AnxA5 once daily for 3d. Mice 
were then anaesthetized and blood pressure measurements began. There were no 
differences in heart rate and systolic or diastolic blood pressure between groups 
receiving vehicle or AnxA5 at baseline. 
In normal, non-atherosclerotic mice, 3µg/kg of metacholine lead to a transient reduc-
tion in blood pressure, the response was maximal after 1-3min and then returned to-
wards baseline after approximately 5min. This effect was blunted in ApoE-/- mice on a 
Western-type diet. However, AnxA5 treatment restored EMD, leading to a larger sys-
tolic blood pressure reduction (vehicle: -5.0mmHg, AnxA5: -22.3mmgHg, p=0.027) 
and diastolic blood pressure reduction (vehicle: -0.8mmHg, AnxA5: -11.0mmHg, 


































































Figure 4. Whole blood was perfused over non-stimulated HUVEC or over TNFα-stimulated HUVEC in 
the presence of AnxA5 (0.75μg/mL) with LMWH-anticoagulated whole blood for 10 minutes at 1 dyne/
cm2. After each perfusion, 25 images were made to quantify adhered leukocytes per microscopic field 
(Panel A). Panel B: in the presence of AnxA5, less platelet-adherence (area of microscopic field covered) 
aggregation are observed. 
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Figure 4. Whole blood was perfused over non-stimulated HUVEC or over TNFα-stimulated HUVEC in the 
presence of AnxA5 (0.75μg/mL) with LMWH-anticoagulated whole blood for 10 minutes at 1 dyne/cm2. 
Panel C: three representative micrographs are shown of cell-adhesion to non-stimulated HUVEC (A, B 
and C), TNFα-stimulated HUVEC (D, E and F) and TNFα and AnxA5-stimulated HUVEC. The rectangles 
in panels E, F, H and I are magnified (panel D) and quantified (panel B) to show that platelet morphology is 
changed after AnxA5 treatment. Panel E: significant correlation exists between area of platelet adherence 

















Blood pressures are reported in table 3 in the online data supplement. The reduction 
in systolic pressure was the largest, thus pulse pressure was reduced during EMD. 
Metacholine injection did not lead to changes in heart rate (vehicle: -1.5 beats per 
minute (bpm), AnxA5: -8.5bpm, p=0.379). 
Injection of 50mg/kg L-NAME resulted in similar increases in systolic (vehicle: 
+27.6mmgHg, AnxA5: +29.7mmgHg, p=0.518) and diastolic (vehicle: +15.6mmg-
Hg, AnxA5: +18.0mmHg, p=0.350) blood pressure in both groups, accompanied by 
an equal reduction in heart rate (vehicle: -40.0bpm, AnxA5: -37.8bpm, p=0.833). 
Subsequent IP injection of metacholine following L-NAME injection did not result in 
a significant change in heart rate (vehicle: -17.9bpm, AnxA5: -21.0bpm, p=0.559) 
or systolic (vehicle: -5.1mmHg, AnxA5: +1.0mmHg, p=0.060) and diastolic (vehi-
cle: -1.3mmHg, AnxA5: +2.2mmHg, p=0.071) blood pressure in either group (online 




Our study shows a therapeutic role for AnxA5 against vascular inflammation, remo-
deling and dysfunction, in mouse models for accelerated atherosclerosis develop-
ment. It was demonstrated that injection of human AnxA5 had no adverse effects, 
resulted in a marked reduction in circulating plasma concentrations of IFNγ, G-CSF 
and MIP-1β/CCL4, early inflammatory cell recruitment, adhesion and infiltration in 
the vessel wall after vascular injury, eventually leading to decreased vein graft thic-
kening with less plaque instability features. Furthermore, AnxA5 improved endothe-
lial dysfunction by acting on NO-signaling. This study extends the role of AnxA5 as 
a regulator of inflammatory processes, and demonstrates its potential therapeutic 
use in inflammation-associated vascular disease in addition to its known functions in 
anticoagulation and its use as a marker of apoptosis.
Although these data can be of clinical significance and could potentially lead to new 
therapeutic strategies, at this point we do not have the complete insight in the un-
derlying mechanism of how AnxA5 affects vessel wall pathology. It was previously 
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Figure 5. Effect of 3d AnxA5 treatment on impaired endothelial function in ApoE-/- mice, quantified as 
change in aortic systolic (panel A) and diastolic (panel B) blood pressure (mmHg) in time after IP injection 
of metacholine to induce vasodilatation (mean±SEM, n=10).
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shown that AnxA5 could affect immune reactions on a systemic level. The injec-
tion of PS-exposing cells induced a delayed-type hypersensitivity reaction, which 
was critically affected by AnxA521. This suggested that the PS receptor can act as 
a switch for immune reactions and AnxA5 will interfere with this function22. In vitro 
investigation using TNFα-stimulated HUVEC clearly indicated the importance of the 
anti-coagulant effects of AnxA5 in its ability to reduce leukocyte adhesion to activa-
ted endothelium, since platelet adherence is known to be essential for subsequent 
leukocyte adhesion.
A multiplex analysis of plasma cytokine levels revealed that the raise in levels of 
circulating cytokines observed 3d after femoral cuff implantation was not affected by 
AnxA5. However, prolonged exposure to AnxA5 reduced plasma levels of G-CSF, 
MIP-1β/CCL4 and IFNγ and certainly did have a systemic immunomodulatory effect. 
IFNγ production by inflammatory cells leads to improved antigen presentation and 
increases atherogenesis. In ApoE-/- mice lacking IFNγ or its receptor, atherogenesis 
was inhibited3, 23. In vitro research has shown that AnxA5 can prevent cellular re-
sponses to secreted IFNγ and these data suggest that AnxA5 influences the IFNγ 
production by circulating cells involved in the early inflammatory processes during 
atherosclerotic lesion formation and vascular remodeling3-5.
Leukocyte, and specifically monocyte, adhesion, differentiation and activation is a 
key component in the onset and progression of atherosclerosis and post-interventi-
onal accelerated atherosclerosis3. To investigate effects of AnxA5 on local vascular 
inflammation, the ApoE3*Leiden femoral artery cuff model24, characterized by in-
flammatory cell adhesion and infiltration in the vessel wall early after surgery, was 
used. Not only did AnxA5 reduce endothelial-adhesion and medial infiltration of both 
leukocytes and macrophages, it was also found that early local expression of the 
key inflammatory cytokines MCP-1 and TNFα was reduced25, 26. However, this local 
reduction of MCP-1 and TNFα levels was not reflected by an alteration of plasma 
levels after 3d, nor after prolonged AnxA5 exposure. Taken together, these findings 
suggest that AnxA5 can be used therapeutically to reduce local inflammatory re-
sponses after vascular injury. The exact mechanism by which AnxA5 led to these 
effects was not elucidated, but it has been shown that this is probably due to local 
AnxA5 binding to activated cells. AnxA5 reduces local adherence of platelets, espe-
cially their activation and subsequently adherence of leukocytes (figure 4), ultimately 
preventing their deleterious inflammatory effects.
To investigate if the reduced early vascular inflammation by AnxA5 could be ex-
tended to a beneficial clinical therapeutic effect on accelerated atherosclerosis in 
general, AnxA5 was studied additionally in an model for vein graft pathology27. Here, 
accelerated atherosclerosis forms due to vascular damage, endothelial cell loss and 
a pulsatile arterial pressure, similarly to human venous bypass graft disease in which 
rapid foam cells formation, intimal thickening, apoptotic cell exposure and plaque 
instability features are observed, processes that lead to loss of graft patency. AnxA5 
treatment significantly reduced vein graft thickening after 28d by 48%, as well as leu-
kocyte infiltration in the vein graft wall by 46%. Although AnxA5 did not alter plaque 
content, it nonetheless preserved graft patency greatly.
Complications of atherosclerosis are either the result of reduced blood flow due to lu-
minal narrowing or from acute vessel occlusion due to rupture of the atherosclerotic 
plaque. Apoptosis is associated with decreased plaque stability and although AnxA5 
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can affect apoptosis13, no differences in apoptotic cell numbers detected with TUNEL 
staining were observed at 28d after surgery. Since apoptosis is known to occur pre-
dominately within 14d after surgery in this model28, effects on apoptosis by AnxA5 on 
earlier time points cannot be ruled out. Despite no change in apoptotic cells numbers 
after 28d by AnxA5 treatment, it did reduce vessel plaque instability features such as 
endothelial erosion, leaky vessel formation and severe plaque disruption in addition 
to vessel wall thickening, indicating that AnxA5 treatment is effective against both 
vascular inflammation and (the complications of) vascular remodeling.
Improvement of endothelial function is an important therapeutic goal in vascular 
diseases. In our study, short-term AnxA5 treatment improved EMD in response to 
metacholine injection to induce vasodilatation, displayed by a larger and longer-las-
ting reduction of systolic and diastolic blood pressure in ApoE-/- mice with impaired 
endothelial function. This larger blood pressure reduction was blunted by L-NAME 
administration prior to the metacholine injection, indicating this effect was mediated 
via NO. Since this is important for the central arterial compartment compliance29, a 
large reduction of systolic blood pressure after AnxA5 treatment is suggestive for 
a positive effect on the endothelium in conduit arteries, often early affected by na-
tive atherosclerosis in humans3, 4. Both acute and chronic inflammation is known to 
hamper EMD, so the effects of AnxA5 on endothelial function could be a result of 
a reduced inflammatory burden (figures 1 and 2), but also from other mechanisms. 
For example, endothelial cells can release EMP which in turn can trigger endothelial 
cytokine release and leukocyte adhesion. AnxA5 can shield EMP through PS-bin-
ding and prevent their endothelial cell activation. Thus, although effectiveness was 
shown, the exact mechanism by which AnxA5 improved deteriorated endothelial 
function in vivo is not yet clear and awaits further research.
In normal humans, plasma AnxA5 concentration is normally well below 10 ng/ml, 
and is elevated in certain diseases17-19. In our experiments, 1mg AnxA5/kg/d only 
transiently elevated plasma AnxA5 above these levels (figure 1 online supplement). 
In spite of this, profound treatment effects were observed. This is probably explained 
by a rapid and strong binding to its target tissue, acting long after free AnxA5 is 
cleared from plasma. Clearance of AnxA5 is much slower from tissue compartments 
than from plasma, which is why it is useful as an apoptosis marker in vivo30.
AnxA5 is already used safely in patients as a diagnostic tool for atherosclerosis14. 
Since the present study shows pronounced anti-inflammatory and anti-atherogenic 
effects of AnxA5 in vivo on accelerated atherosclerosis associated with post-inter-
ventional vascular remodeling and vein graft disease, as well as atherosclerosis-as-
sociated vascular dysfunction, it also indicates a possible therapeutic role for AnxA5 
in the prevention of accelerated atherosclerosis after vascular surgery and coronary 
interventions.
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All experiments were approved by the Institutional Committees for Animal Welfare. 
Transgenic male ApoE*3-Leiden mice (bred in our own laboratory), backcrossed for 
more than 20 generations on a C57BL/6J background and male ApoE-/- mice (Ta-
conics, Lille Skensved, Denmark), aged 10-12 weeks at the start of a dietary run-in 
period, were used for this experiment. 
Diets
Transgenic male ApoE*3-Leiden mice were fed a Western-type diet containing 1% 
cholesterol and 0.05% cholate to induce hypercholesterolemia (AB Diets, Woerden, 
The Netherlands). The diet was given three weeks prior to surgery and was con-
tinued throughout the experiment. Male ApoE-/- mice, 8-10 weeks old, received a 
Western-type diet (Harlan Teklad TD.88137) for 16-17 weeks to induce endothelial 
dysfunction. All animals received food and water ad libitum during the entire expe-
riment.
Femoral artery cuff mouse model
To investigate the effect of annexin A5 on vascular inflammation, ApoE*3-Leiden 
mice underwent femoral arterial cuff placement1 after three weeks of diet to induce 
vascular inflammation. Mice were anesthetized before surgery with a combination 
of intraperitoneally (IP) injected Midazolam (5mg/kg, Roche, Woerden, The Nether-
lands), Medetomidine (0.5mg/kg, Orion, Espoo, Finland) and Fentanyl (0.05mg/kg, 
Janssen, Berchem, Belgium). The right femoral artery was isolated and sheathed 
with a rigid non-constrictive polyethylene cuff (Portex, Kent, UK, 0.40mm inner dia-
meter, 0.80mm outer diameter and an approximate length of 2.0mm). 3d after cuff 
placement, mice were anesthetized as before and euthanized. 
The thorax was opened and mild pressure-perfusion (100mm Hg) with 3.7% for-
maldehyde in water (w/v) was performed for 5min by cardiac puncture in the left 
ventricle. After perfusion, the cuffed femoral artery was harvested, fixed overnight 
in 3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial cross-sections 
(5μm thick) were taken from the entire length of the artery for analysis.
Mice received daily IP injections with 1mg/kg human recombinant annexin A5 (Ben-
der Medsystems cat.no. BMS306/50mg. lot no.24926000) in a volume of 150µl, 
using 150µl 0.9% w/v NaCl (vehicle), injected IP daily as control. 
Carotid vein graft model for accelerated atherosclerosis
To study the effect of annexin A5 on vascular remodeling, vein graft surgery2 was 
done in ApoE*3-Leiden mice after three weeks of diet and performed by one sur-
geon, to exclude the possibility of inter-group variation due to different surgical skills. 
Mice were anesthetized and the right common carotid artery was dissected free from 
its surroundings from the bifurcation at the distal end towards the proximal end. The 
vessel was ligated twice with an 8.0 silk ligature and dissected between the middle 
ties. A cuff was placed over both ends after which these were everted over the cuffs 
and ligated with an 8.0 silk ligature. Littermates were used as donor for the inferior 
caval vein. The carefully harvested inferior caval vein was temporarily preserved in a 
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0.9% NaCl solution, containing 100U/ml of heparin and was interpositioned between 
the ends of the artery. The connections were ligated together with an 8.0 silk suture. 
Pulsations confirmed successful engraftment. Mice were sacrificed 28d after vein 
grafting as described before. Daily annexin A5 and vehicle treatments were as des-
cribed above. Blood samples were taken from the tail vein for plasma annexin A5 
analysis at 1, 3 and 6h after administration. 
Biochemical analysis
Total plasma cholesterol (Boehringer Mannheim GmbH, kit 236691) and triglyceride 
(Sigma Diagnostics, kit 337-B) concentrations were measured enzymatically. 
Annexin A5 plasma concentration was determined using a human annexin A5 ELISA 
kit (Bender MedSystems Products, Vienna, Austria). 
To investigate effects of annexin A5 on systemic inflammation, a multiplex biometric 
immunoassay was used for cytokine and chemokine measurements according to the 
manufacturer's instructions (Bio-PlexTM Mouse Cytokine 23-Plex Panel; Bio-Rad., 
Hercules, CA, USA). The plasma concentrations of eotaxin, granulocyte colony sti-
mulating factor (G-CSF), granulocyte-monocyte colony stimulating factor (GM-CSF), 
IFNγ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), 
IL-12(p70), IL-13, IL-17, keratinocyte chemoattractant (KC), MCP-1/CCL2, MIP-1α /
CCL3, MIP-1β/CCL4, RANTES and TNFα were measured. Bio-PlexTM mouse cyto-
kine standard values were provided by Bio-Rad Laboratories. Cytokine levels were 
determined using a Liquichip-200 multiplex array reader with Luminex x MAP™ 
technology (Bio-Rad Laboratories). The analyte concentration was calculated using 
software provided by the manufacturer (Bio-Plex Manager Software). 
Quantification of cuffed femoral artery and vein graft lesions
At time of sacrifice, vessels were harvested after 5min in vivo perfusion-fixation with 
formaldehyde (4%), fixated overnight and embedded in paraffin. Immunohistochemi-
cal (IHC) staining was performed using positive and negative tissue-specific controls 
as indicated by the antibody manufacturer. All samples were stained with hematoxy-
lin-phloxine-saffron (HPS) and specific vessel wall cellular composition was visuali-
zed using antibodies against leukocytes (anti-CD45 antibodies 1:200, Pharmingen, 
San Diego, CA, USA) and monocytes and macrophages (AIA 31240 1:3000, Ac-
curate Chemical, Westbury, NY, USA). To evaluate if annexin A5 could affect the 
degree of inflammation within the arterial wall, cells expressing cytokines known 
to be important in the restenotic process were quantified using antibodies against 
TNFα (anti-TNFα 1:200, BioLegend, San Diego, CA, USA) and MCP-1 (anti-MCP-1 
1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The number of leukocytes, 
macrophages, foam cells and cells expressing MCP-1 and TNFα attached to the 
endothelium or in the media of the femoral arteries was quantified and is displayed 
as a percentage of the total number of present cells. All quantification in this study 
was performed on six equally spaced (150µm distance) serial stained perpendicu-
lar cross-sections throughout the entire length of the vessel and was performed by 
blinded observers.
Vein grafts were stained for collagen (Sirius Red staining) and with antibodies 
against vascular SMCs (α-SM-actin 1:800, Dako, Enschede, The Netherlands), an-
nexin A5 (anti-annexin V 1:100, Biovision, Mountain View, CA, USA), fibrinogen and 
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fibrin (anti-fibrinogen and fibrin, 1:4003) and apoptotic cells (TUNEL staining, Roche, 
Applied Sciences, Almere, The Netherlands). The area containing SMCs, collagen, 
macrophages and foam cells in vein grafts was quantified using computer-assisted 
morphometric analysis (Qwin, Leica) and is expressed as a percentage of the to-
tal cross-sectional vein graft area. Since there are only a few cell layers within the 
media of murine veins and no clear morphological border exists between the media 
and neointima, the region between lumen and adventitia was used to define lesion 
area and vein graft thickening. To determine the therapeutic effect of annexin A5 on 
plaque instability features in vein grafts, the absolute number of apoptotic cells and 
leukocytes and signs of plaque erosion (endothelial disruption and fibrinogen depo-
sition), leaky vessels (erythrocytes within newly formed vessels in the vessel wall) or 
plaque dissection (erythrocytes in a subendothelial space) were counted. 
Effects of annexin A5 on endothelial-platelet and endothelial-leukocyte inter-
action using an ex vivo vascular injury perfusion model
To investigate if annexin A5 affects platelet-endothelium or leukocyte-endothelium 
interactions, human umbilical vein endothelial cells (HUVEC), isolated from umbilical 
cord according to the method of Jaffe et al4, were cultured on gelatin-coated glass 
coverslips in endothelial specific medium (EGM-2, Clonetics, Lonza Verviers, S.p.r.l., 
Verviers, Belgium) supplemented with growth factors and cytokines. At confluence, 
HUVEC from passage 2 or 3 were stimulated for 4 hours with tumor necrosis factor-α 
(TNFα, 10 ng/mL, Boehringer, Ingelheim, Alkmaar, The Netherlands) to activate the 
endothelial cells and thus induce expression of TF and PS, in the presence or absen-
ce of annexin A5 (0.75 μg/ml, AbD Serotec, Düsseldorf, Germany). Non-stimulated 
HUVEC kept in EGM-2 medium were used as negative control. After TNF-stimulati-
on, HUVEC were washed and kept in EGM-2 medium.
To evaluate the effect of annexin A5 on the adhesion of leukocytes, low-molecular 
weight heparin (LMWH-Pfizer, Capelle a/d IIssel, The Netherlands)-anticoagulated 
whole blood perfusions were performed, obtained from aspirin-free donors. Perfu-
sions were performed for 10 minutes at 1 dyne/cm2 according to de Boer et al5. 
When HUVEC were treated with annexin A5 during TNFα-stimulation, whole blood 
was also pre-incubated with annexin A5 for 5 min prior to the perfusion and during 
the perfusion, to inhibit PS, generated during flow. Non-bound blood components 
were removed by washing with HEPES buffer (20 mmol/L HEPES, 132 mmol/L 
NaCl, 6 mmol/L KCl, 1 mmol/L MgSO4, 1.2 mmol/L KH2PO4, 5 mmol/L glucose, 
1.0 mmol/L CaCl2, 0.5% human serum albumin [CeAlb, Sanquin, Amsterdam, The 
Netherlands], pH 7.4). All perfusions were performed in duplicate/ triplicate runs. Af-
terwards, at least 25 photomicrographs were taken (Leica DMI-6000) per perfusion, 
allowing quantification of leukocyte adhesion to the endothelium.
Assessment of vascular function through endothelium-mediated dilatation
The determine therapeutic effects of annexin A5 on vascular function, EMD was eva-
luated in ApoE-/- mice after 16-17 weeks on a Western-type diet. Mice were treated 
with annexin A5 or vehicle as described above once daily for three days. Afterwards, 
mice were anaesthetized with Isofluran (Isoba®vet, Schering-Plough Animal Health, 
Denmark, 4.5% for induction and 1.5-2% for maintenance). A high fidelity pressure 
transducer (Samba Sensor preclin 420LP, Västra Frölunda, Sweden) was introdu-
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ced into the left common carotid artery and transferred into the aortic arch. The 
Samba sensor was connected to a Samba 3200 unit, with 1000Hz as sample rate. 
Data was acquired in Powerlab (AD Instrument, v5) at 2KHz. Mice were allowed to 
stabilize for 15min after surgery.
Blood pressure measurements were performed at basal level and after IP injection 
of 3µg/kg metacholine to stimulate endothelial NO-release and vasodilatation (Ace-
tyl-ß-methylcholine-chloride, 98%, Sigma-Aldrich, Stockholm, Sweden). The blood 
pressure was measured for up to 5min. When baseline pressure was again establis-
hed, IP injection of 50mg/kg (10µl/g) Nw-Nitro-L-Arginine-methyl-ester-hydrochlori-
de 98% (L-NAME), a NO-synthase inhibitor, (Sigma-Aldrich) was given. Blood pres-
sure was then measured until a new plateau was reached (12-15min), after which 
an additional IP injection of 3µg/kg metacholine was given and blood pressure was 
measured again for 5min. 
Statistical analysis
All data are presented as mean±standard error of the mean (SEM), unless otherwise 
indicated. Overall comparisons between data from groups were performed using 
the Kruskal-Wallis test. If a significant difference was found, groups were compared 
using a Mann-Whitney sum test. For the evaluation of cases of vein graft thrombosis, 
the Fisher’s exact test was used (incidences in both groups were n<5). Comparison 
of endothelial-leukocyte adhesion between various groups was performed using a 
2-way ANOVA group analysis with Bonferroni posttest. All statistical analyses were 
performed with SPSS 14.0 software for Windows. P-values ≤ 0.05 were regarded as 
statistically significant and are indicated with an asterisk (*).
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Figure I. Plasma concentration (ng/ml) of circulating human AnxA5 in ApoE3*Leiden mice after IP injec-
tion of 1mg/kg/d AnxA5, detected by ELISA, in time (mean±SEM, n=3).
















































Figure II. Representative photomicrographs of cultured HUVECS, 4h after stimulation with TNFα with and 
without anxA5, taken using confocal laser scanning microscopy (original magnification 40x), in a three-
dimensional area (1 and 8 μm cell height). Note the presence of platelets and fibrin at the endothelial cell 
level, with the presence of adhered leukocytes (n=21 in TNFα group, n=2 in the TNFα + AnxA5 group), 
restricted to the endothelial cell surface in the TNFα only group. 
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Interferon γ 7.9±2.5 2.2±0.7*
IL-10 9.6±2.0 10.0±1.3
IL-12 (p40) 78.7±19.9 53.2±5.8

















Table I. Plasma cytokine concentration (pg/ml), determined using a multiplex biometric immunoassay in 
ApoE3*Leiden mice, 3 and 28 days after (femoral arterial cuff or vein graft) surgery and vehicle only or 














Diastolic pressure (mmHg)Systolic pressure (mmHg)
Table II. Quantification of inflammatory cell recruitment to the site of vascular injury in ApoE3*Leiden mice, 
3d after femoral arterial cuff placement and treatment with vehicle or anxA5. Inflammatory cell types, ex-
pressed as a percentage of all cells present (stained with hematoxylin) in the arterial wall (mean±SEM, 
n=10).
Table III. Systolic and diastolic aortic blood pressure (mmHg) in ApoE-/- mice with endothelial dysfunc-
tion and 3d treatment with vehicle or annexin A5, shown at basal level, 3min after metacholine injec-
tion, after L-NAME injection and after a combination of L-NAME with subsequent metacholine injection 
(mean±SEM, n=10).
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Background Activated cells in atherosclerotic lesions expose phosphatidylserine 
(PS) on their surface. Annexin A5 (AnxA5) binds to PS and is used for imaging 
atherosclerotic lesions. Recently, AnxA5 was shown to inhibit vascular inflamma-
tory processes after vein grafting. Here, we report a therapeutic role for AnxA5 in 
post-interventional vascular remodeling in a mouse model mimicking percutaneous 
coronary intervention (PCI).
Methods and Results Associations between the rs4833229 (OR=1.29 (CI 95%), 
pallelic=0.011) and rs6830321 (OR=1.35 (CI 95%), pallelic=0.003) SNPs in the AnxA5 
gene and increased restenosis-risk in patients undergoing PCI were found in the 
GENDER study. To evaluate AnxA5 effects on post-interventional vascular remo-
deling and accelerated atherosclerosis development in vivo, hypercholesterolemic 
ApoE-/- mice underwent femoral arterial cuff placement to induce intimal thickening. 
Dose-dependent effects were investigated after 3 days (effects on inflammation and 
leukocyte recruitment) or 14 days (effects on remodeling) after cuff placement. Sys-
temically administered AnxA5 in doses of 0.1, 0.3 and 1.0 mg/kg compared to ve-
hicle reduced early leukocyte and macrophage adherence up to 48.3% (p=0.001) 
and diminished atherosclerosis development by 71.2% (p=0.012) with a reduction in 
macrophage/foam cell presence. Moreover, it reduced the expression of the endo-
plasmic reticulum stress marker GRP78/BiP, indicating lower inflammatory activity of 
the cells present. 
Conclusions AnxA5 SNPs could serve as markers for restenosis after PCI and 
AnxA5 therapeutically prevents vascular remodeling in a dose-dependent fashion, 
together indicating clinical potential for AnxA5 against post-interventional remode-
ling.
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Post-interventional vascular remodeling and accelerated atherosclerosis develop-
ment are important complications of revascularization strategies and limit treatment 
success rate1. These features are elicited by endothelial and atherosclerotic plaque 
injury, triggering inflammatory activation and leukocyte recruitment to the injured ar-
terial segment. These cells are the driving factors behind smooth muscle cell (SMC) 
proliferation and extracellular matrix deposition leading to intimal hyperplasia. Su-
bendothelial retention and oxidation of low-density lipoprotein (LDL) cholesterol is 
central to the initial lesion formation in both native atherosclerosis and restenosis 
development2,3. Recently, it was postulated that endoplasmic reticulum (ER) stress, 
leading to the unfolded protein response (UPR), is involved in the regulation of in-
flammation in activated vascular cells and the link between UPR and arterial inflam-
mation is emerging as an important factor in (accelerated) atherosclerosis develop-
ment4-7. 
AnxA5 is a member of the annexin family of proteins that calcium-dependently 
bind to negatively-charged phospholipid surfaces and was originally discovered as 
an anticoagulant and antithrombotic protein8-11 and has been shown to inhibit the 
prothrombinase complex12 and to down-regulate the surface expression of tissue 
factor13. It is now known to have anti-inflammatory and anti-atherosclerotic proper-
ties14,15 and to regulate interferon γ signalling16. Viable cells express phosphatidylse-
rine (PS) on their inner cellular membrane leaflet. When PS is externalized, it serves 
as an ‘eat-me’ signal. Annexin A5 (AnxA5) binds reversibly, specifically and with high 
affinity to PS15. PS becomes externalized during apoptosis, which makes AnxA5 a 
powerful tool to detect apoptosis (and atherosclerosis) both in vitro and in vivo17. PS 
is expressed in native atherosclerosis and after revascularisation procedures, and 
circulating AnxA5 binds with high affinity to these cells, and is therefore present in 
high concentrations in atherosclerotic plaques and injured vascular segments. PS 
externalization is normally thought to be associated to apoptosis, but can also be 
externalized in a controlled and reversible way in non-apoptotic cells18,19. 
Plasma levels of AnxA5 are inversely related to the severity of coronary stenosis 
and are indicative of the extent of atherosclerotic plaques20, but are also elevated 
in subjects with left ventricular hypertrophy and following myocardial infarction21,22. 
It was recently shown that systemically administered AnxA5 can prevent vein graft 
disease and vascular inflammation23 and that the dimer of annexin A5, diannexin, 
can protect against renal ischemia-reperfusion injury and inflammatory cell infiltra-
tion into transplanted islet grafts24,25. Patients with hypercholesterolemia and previ-
ous coronary heart disease (CHD) undergoing PCI for atherosclerosis are most at 
risk for inflammatory-driven post-interventional restenosis development. The risk for 
development of restenosis may partially be determined by genetic factors. It has 
been shown that genetic variations in genes encoding inflammatory factors (SNPs) 
can predict the risk for restenosis after percutaneous coronary intervention (PCI)26. 
The effects of genetic variation in the AnxA5 gene on clinical restenosis after PCI or 
cardiovascular disease progression have thus far not been elucidated.
In the present study we investigated the association between AnxA5 SNPs and res-
tenosis-risk in patients undergoing PCI, followed by in vivo evaluation of the thera-
peutic effectiveness of AnxA5 in a humanized mouse model for post-interventional 
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vascular remodeling using ApoE3*Leiden mice. Our findings point to a potential di-




Association between single nucleotide polymorphisms (SNPs) in the AnxA5 gene, 
extracted from the GENDER genome wide association study (GWAS) dataset27 and 
restenosis-risk following PCI was investigated. 
We performed in vivo intervention studies in which hypercholesterolemic ApoE-/- 
mice on a Western-type diet were subjected to femoral artery cuff placement to in-
duce vascular injury and remodeling28. Cuff placement leads to a localized vascular 
inflammation, which in turn produces concentric intimal lesions that can affect vessel 
patency. The lesions consist of SMCs, connective tissue and infiltrated leukocytes 
such as macrophages / foam cells and are strongly inflammation-dependent29. In 
these vascular segments, inflammatory cell adhesion, infiltration, intimal thickening 
and lesion composition were assessed using histology, morphometry and immuno-
histochemistry (IHC), as described previously29. Treatment with vehicle, 0.1, 0.3 and 
1.0 mg/kg AnxA5 was given to operated ApoE-/- mice. A three day protocol was used 
to evaluate effects on leukocyte recruitment, and a 14 day protocol to evaluate ef-
fects on vascular remodeling. All materials and methods are described in detail in 
the supplemental material. 
Results
Annexin A5 SNP as risk marker for clinical restenosis
AnxA5 plasma levels are linked to the severity of coronary stenosis and AnxA5 is a 
marker of cardiovascular disease progress. These data indicate a potential role of 
AnxA5 in (post-interventional) accelerated atherosclerosis development. Therefore 
we investigated the association between AnxA5 SNPs and restenosis risk in patients 
undergoing PCI enrolled in the GENDER study, composed of 866 patients (295 ca-
ses that developed restenosis following PCI and 571 controls that did not develop 
restenosis). Clinical outcome was linked to genetic data obtained through a genome-
wide association analysis. 
The allelic association test identified two SNPs, rs4833229 and rs6830321, which 
are significantly associated with restenosis risk after PCI (fig 1A). Both SNPs incre-
ased the risk for restenosis (rs4833229, odds ratio (OR) =1.29, (95% confidence 
interval (CI) 1.06-1.58), pallelic=0.011 and rs6830321, OR=1.35 (95% CI 1.10-1.64), 
pallelic=0.003), even after adjustment for clinical risk factors, such as total occlusion, 
diabetes, smoking and residual stenosis (table 1). The minor allele frequencies for 
cases and controls from the GENDER population are 0.481 and 0.418 for rs4833229 
and 0.510 and 0.436 for rs6830321 respectively, indicating they are present in a 
large proportion of the population. The AnxA5 gene linkage disequilibrium (LD) plot 
shows that rs4833229 and rs6830321 are in high LD (r2=0.91, fig 1B). Haplotype 
analysis in the gene showed similar association results with restenosis as found 
in the single SNP analysis (haplotype ACAGTTGTT, frequency: 0.427, OR=1.275, 
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p=0.018). These data link AnxA5 SNPs to restenosis-risk after PCI and suggest that 
AnxA5 genotype functions as risk marker for restenosis. We therefore further explo-
red AnxA5’s therapeutic potential using an in vivo model for restenosis and intimal 
hyperplasia.
Annexin A5 dose-dependently prevents leukocyte recruitment after vascular 
injury 
Effects of AnxA5 on leukocyte recruitment to injured arterial segments was inves-
tigated in the femoral artery cuff model in ApoE-/- mice receiving daily vehicle or 
0.1, 0.3 or 1.0 mg/kg AnxA5 through IP injection. Total plasma cholesterol was not 
affected by annexin A5 treatment (supplementary table I). Three days after cuff pla-
cement there is inflammation in the cuffed arteries, with leukocytes both adherent 
to the endothelial surface and with cells that have migrated into the media layer (fig 
2A). Staining of arterial lesions at this time point revealed that 0.1, 0.3 and 1.0 mg/
p valueOR (95% CI)






0.75640.96 (0.72-1.27)0.139 / 0.145CT122837138rs2306416
0.00341.35 (1.10-1.64)0.510 / 0.436T/C122834205rs6830321
0.06360.79 (0.62-1.01)0.083 / 0.230A/G122830735rs6857766
0.10400.75 (0.53-1.06)0.058 / 0.108C/T122829379rs6534309
0.47050.86 (0.57-1.30)0.181 / 0.067C/T122827178rs17449954
0.09540.81 (0.63-1.04)0.481 / 0.215A/G122821231rs1480287
0.01141.29 (1.06-1.58)0.481 / 0.418A/G122820114rs4833229
0.26220.88 (0.71-1.10)0.283 / 0.309T/C122810925rs2306420
Table 1. Association between restenosis risk and SNPs in the ANXA5 gene.
Allelic association results for 8 SNPs included in the annexin A5 gene in the GENDER study. Positions are 
based on hg18 build. Abbreviations: Chr: Chromosome, MAF: Minor Allele Frequency. ORs are computed 
for the minor allele from the two by two allele contingency table. Significant association was observed for 
SNPs rs4833229 and rs6830321 and restenosis-risk with SNPs displaying high linkage.
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Figure 1. AnxA5 is a genetic risk marker for clinical restenosis after PCI. Association results for the allelic 
test for eight SNPs in the ANXA5 gene (A). LD plot shows that rs4833229 and rs6830321 SNPs are in 
high LD (r2 = 0.91) (B). 
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kg/d AnxA5-treated animals displayed a reduced percentage of endothelial leuko-
cyte adhesion by 26.7% (p=0.014), 34.9% (p=0.010) and 48.3% (p=0.001) respecti-
vely (fig 2B). For monocytes/macrophages, this percentage was reduced by 40.0% 
(p=0.029), 66.9%, (p=0.001) and 45.0% (p=0.037) respectively (fig 2C). 
The percentage leukocyte infiltration into the media was reduced by all AnxA5 treat-
ments by 49.4% (p=0.008), 53.3% (p=0.006) and 49.9% (p=0.011) respectively (fig 
2D). The percentage medial macrophages was reduced by 61.2% (p=0.025) by 1.0 
mg/kg AnxA5, the other dosages did not significantly affect monocyte/macrophage 
extravasation (fig 2E). Together, these data indicate an important role for AnxA5 in 
























































































































Annexin A5 dose-dependently prevents accelerated atherosclerosis develop-
ment
The inflammation caused by cuff placement leads to an inflammation driven intimal 
hyperplasia. Therapeutic effectiveness of AnxA5 on (neo-)intima development was 
evaluated 14 days after cuff placement. Annexin A5 treatment did not affect plasma 
total cholesterol concentration (supplementary table I). Accelerated atherosclerotic 
lesion development was measured on sections stained with HPS and Weigert’s elas-
tin (fig 3A). Vehicle-treated animals developed intimal thickening, resulting in lumi-
nal stenosis. Quantitative analysis displayed reduced intimal thickening (expressed 
as μm2 per cross-section) after 0.1, 0.3 and 1.0 mg/kg AnxA5-treatment by 54.6% 
(p=0.041), 71.2% (p=0.012) and 66.9% (p=0.009) respectively (fig 3B). Intimal thic-
kening was 38.1% more reduced (p=0.031) by 0.3 compared to 0.1 mg/kg AnxA5. 
AnxA5 (0.3 and 1.0 mg/kg) also decreased the absolute medial surface area (μm2) 
by 30.1% (p=0.012) and 24.1% (p=0.025, fig 3C) and intima / media ratio by 62.3% 
(p=0.004) and 60.3% (p=0.007, fig 3D), although the lowest dose was ineffective. 
Furthermore, luminal stenosis (%) was reduced by 58.0% (p=0.001) and 58.8% 
(p=0.0004, fig 3E), identifying a potent role for AnxA5 in the control of inflammatory 
post-interventional vascular remodeling. Compared to 0.1 mg/kg, 0.3 mg/kg AnxA5 
had increased protective effects on both the intima / media ratio (by 38.5%, p=0.016) 
and luminal stenosis percentage (by 33.2%, p=0.042). The total vessel wall diame-
ter and luminal areas were both similar in all AnxA5 dosages, except for 1.0 mg/kg, 
which displayed 27.1% (p=0.043) reduced total vessel area (supplementary fig IA, 
B). 
Figure 2. Annexin A5 dose-dependently prevents leukocyte recruitment after vascular injury. Representa-
tive cross-sections of cuffed-femoral arteries of ApoE-/- mice treated with vehicle or 0.1, 0.3 or 1.0 mg/kg/d 
AnxA5 (leukocyte and macrophage staining, magnification 80x, arrows indicate positive staining) after 
3d (A). Quantification of intimal adhering leukocytes (B) and macrophages (C) as percentage of all cells 
within the internal elastic lamina and medial infiltrated leukocytes (D) and macrophages (E) (%). Results 












IHC showed profound intravascular macrophages/foam cell areas, which co-locali-
zed with AnxA5 (supplementary fig IIA, B) staining at both 3d and 14d after surgery. 
AnxA5 in all dosages strongly reduced the accumulation of the percentage of ma-
crophages/foam cell area (fig 4A) in the tunica media (fig 4B, p=0.0002, p=0.028 
and p=0.0005 respectively) and in the tunica intima (fig 4C, p=0.002, p=0.011 and 
p=0.002 respectively) after 14d. The 78 kDa glucose regulated protein/BiP (GRP78) 
is an ER protein and associates permanently with mutant or defective incorrectly 
folded proteins, preventing their export from the ER lumen. ER stress including up-
regulation of GRP78 is present in unstable atherosclerotic lesions. We investigated if 
annexin A5 affected GRP78 expression in cuffed femoral arteries. AnxA5 in all dosa-
ges strongly reduced GRP78 BiP expressing cells in the media (fig 4D) by 50.2% 












































































Figure 3. Annexin A5 reduces accelerated atherosclerosis development in a dose-dependent fashion. 
Representative cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle or 0.1, 0.3 or 1.0 mg/
kg AnxA5 (A) after 14d (HPS and Weigert’s elastin staining, magnification 40x, arrows indicate internal 
elastic laminae). Quantification of intimal thickening (µm2) (B), medial area (µm2) (C), intima / media ratio 
(D) and luminal stenosis (%) (E). Results indicated as mean±SEM, n=10. * p<0.05, ** p<0.01.
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Figure 4. Annexin A5 leads to a less-inflammatory phenotype with reduced intravascular signs of ER-
stress. Representative cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle or 0.1, 0.3 or 1.0 
mg/kg AnxA5 (A) after 14d (macrophages and GRP78 BiP staining, magnification 40x, arrows indicate 
positive staining) and quantification of medial (B) and intimal (C) macrophage/foam cell area (%) and 





This study demonstrates an important therapeutic role for AnxA5 in post-interventi-
onal intimal hyperplasia and accelerated atherosclerosis development. Association 
between AnxA5 SNPs and increased restenosis-risk in patients undergoing PCI 
was found. Systemic AnxA5 was effective in preventing intimal thickening and could 
dose-dependently reduce leukocyte and macrophage recruitment to injured arterial 
segments in ApoE-/- mice in 0.3 and 0.1 mg/kg dosages. Finally, we demonstrate that 
sustained therapy reduces accelerated atherosclerosis with fewer infiltrated macro-
phages / foam cells and UPR-expressing cells in the injured arterial wall. Together, 
these date indicate high diagnostic and therapeutic potential for AnxA5 against post-
PCI vascular remodeling.
Association between AnxA5 SNPs and restenosis development were investigated 
using a large study population that underwent PCI, the GENDER population. It has 
already been shown in this material that mutations in several genes associated with 
inflammation were associated to restenosis development24. Our results demonstrate 
that SNPs rs4833229 and rs6830321 show significant association with increased 
risk for clinical restenosis (OR 1.29 and 1.35, fig 1A). This genetic variance in ad-
dition to plasma levels19 would allow for excellent stratification of patients that are 
most at risk for restenosis development, enabling individual tailor-made treatment 
strategy. Additionally, our results support the notion that genetic programming of not 
only pro-inflammatory mediators, but also the endogenous anti-inflammatory system 
exerts a significant role in post-interventional remodeling.
In this study, a perivascular cuff-mediated arterial injury model was applied, which 
allows for quick and reproducible lesion formation with continuous blood flow in a pa-
tent vessel segment, although the perivascular approach rather differs from clinical 
endovascular injury through balloon inflation and stent deployment during PCI. This 
perivascular approach could affect the amount of exposure of subendothelial throm-
bogenic material and thrombosis, which are important targets for AnxA5.
Therapeutic effects were shown to most likely result from local AnxA5 binding to 
activated cells in the injured vascular segment. Local AnxA5 can reduce adherence 
of platelets leukocytes and eventually prevent their inflammatory activation, with re-
duced signs of ER-stress and the UPR within these cells. We found reduced GRP78/
BiP expression in the tunica media (fig 4D) but not in the intima (fig 4E) Prolonged 
intracellular cholesterol storage leads to increased ER stress in cells, which is more 
likely to occur in foam cells than in early monocyte/macrophages. In this study, such 
cells should predominantly be found among cells that have migrated towards the 
tunica media, which in turn may explain the difference between GRP78/BiP expres-
sion between the media and intima layers. 
The fact that clearance of AnxA5 is much slower from the arterial wall than from plas-
ma30 and accumulates in the injured vascular wall after systemic injection23, supports 
the hypothesis that AnxA5 could act anti-inflammatory in levels lower than originally 
investigated (<1.0 mg/kg). Current results confirm this, with AnxA5 already effective 
in reducing leukocyte (fig 2B) and macrophage (fig 2C) recruitment and intimal thic-
kening (fig 3B) in dosages 3-10 times lower than previously investigated. This would 
favour clinical application, where undesired side-effects can be kept to a minimum.
In conclusion, this study shows that systemic AnxA5 treatment strongly influences 
117





post-interventional accelerated atherosclerosis development and can dose-depen-
dently prevent vascular remodeling. AnxA5 has previously been successfully ap-
plied to diagnose atherosclerotic patients non-invasively19. These results therefore 
may have important clinical implications. Immune-mediated interventions directed 
towards therapeutically controlling the leukocyte recruitment and vascular remode-
ling process could strongly benefit from systemic AnxA5, which could be applied in 
an early phase following revascularization or bypass grafting to prevent accelerated 
atherosclerosis development. AnxA5 SNPs could function as biomarkers in the as-
sessment of restenosis risk in patients undergoing PCI, improving patient screening. 
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The GENetic DEterminants of Restenosis (GENDER) study was designed to inves-
tigate the association between genetic polymorphisms and clinical restenosis1. In 
brief, it is a large multicenter prospective follow-up study conducted during 1999-
2001 and comprised of patients treated successfully by percutaneous coronary in-
tervention (PCI) for an acute coronary syndrome. Clinical restenosis was established 
during a nine-month follow-up period for death, myocardial infarction and target ves-
sel revascularization (TVR), which occurred in 9.8% of all patients. Eight Single Nu-
cleotide Polymorphisms (SNPs) included in the AnxA5 gene were extracted from the 
GENDER genome wide association study (GWAS) dataset2 composed of 866 pa-
tients (295 cases that developed restenosis following PCI and 571 controls that did 
not develop restenosis after PCI). The GWAS was conducted using Illumina Human 
610-Quad Beadchips (Illumina) and the infinium II assay, following the manufactu-
rer’s instructions. After genotyping, samples and genetic markers were subjected to 
a stringent quality control protocol, described in detail elsewhere2. The open source 
software PLINK3 was used to perform genetic association analysis. All p values were 
corrected for multiple testing. For linkage disequilibrium (LD) analyses in terms of r2 
and haplotype block delineation, we used Haploview software4.
Mice
All experiments were approved by the Institutional Committee for Animal Welfare 
of the Leiden University Medical Center (LUMC). ApoE-/- mice, purchased from the 
Jackson Laboratory (Bar Harbor) on a C57BL/6J background were used for these 
studies. All animals were 10-12 weeks at the start of a dietary run-in period before 
surgery. ApoE-/- mice were fed a Western-type diet containing 0.15% cholesterol 
(Lantmännen Lantbruk, diet R638). The diet was given three weeks prior to surgery 
and was continued throughout the entire experiment. All animals received food and 
water ad libitum during the experiment.
Femoral artery cuff mouse model
Mice were subjected to arterial femoral arterial cuff placement to induce intimal thic-
kening and accelerated atherosclerosis development, as described previously5-7. In 
brief, animals were anesthetized before surgery with a combination of intraperito-
neally (IP)-injected Midazolam (5 mg/kg, Roche), Medetomidine (0.5 mg/kg, Orion) 
and Fentanyl (0.05 mg/kg, Janssen). The right femoral artery was isolated and she-
athed with a rigid non-constrictive polyethylene cuff (Portex, 0.40mm inner diameter, 
0.80mm outer diameter and an approximate length of 2.0mm).  
Animals received vehicle (0.9% sterile NaCl) or AnxA5 (Athera Biotechnologies AB) 
through IP injection. Three and 14 days after cuff placement, mice were anesthe-
tized as before and euthanized. At sacrifice, blood was drawn in EDTA collection 
tubes (Sarstedt B.V.) and centrifuged at 6000 r.p.m. for 10 min at 4°C to obtain 
plasma, which was stored at -20°C. Next, the thorax was opened and mild pressure-
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perfusion (100mm Hg) with phosphate-buffered saline for 5 min by cardiac puncture 
in the left ventricle. After perfusion, the cuffed femoral artery was harvested, fixed in 
3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial cross-sections (5 
μm thick) were made from the entire length of the artery for analysis.
Biochemical analysis
Total plasma cholesterol (Roche Diagnostics, kit 1489437) concentration was mea-
sured enzymatically before randomization at surgery. 
Quantification of cuffed femoral artery lesions
Immunohistochemical (IHC) staining was performed using positive and negative 
tissue-specific controls as indicated by the antibody manufacturer. Samples were 
stained with hematoxylin-phloxine-saffron (HPS) and specific vessel wall composi-
tion was visualized for elastin (Weigert’s elastin staining) and with antibodies against 
GRP78 BiP (1:200, Abcam, to identify cells displaying signs of UPR), CD45 for leu-
kocytes (1:200, Pharmingen), MAC3 for monocytes/macrophages/foam cells (1:200, 
BD Biosciences) and anti-annexin V for injected protein accumulation (1:100, Bio-
Vision). Using image analysis software (Leica Qwin), total cross-sectional medial 
area was measured between the external and internal elastic laminae; total cross-
sectional intimal area was measured between the endothelial cell monolayer and 
the internal elastic lamina, as was GRP78 BiP+ surface area. The luminal stenosis 
is expressed as the percentage of surface area (µm2) within the internal elastic la-
mina (comprised of the luminal and neointimal areas) that is taken up by neointimal 
tissue (in µm2). The number of leukocytes and monocytes/macrophages attached to 
the endothelium, within the neointimal tissue or infiltrated in the medial layer of the 
femoral arteries was quantified and is displayed as a percentage of the total number 
of present cells. All quantification in this study was performed on six equally spaced 
(150 µm distance) serial stained perpendicular cross-sections throughout the entire 
length of the vessel and was performed by blinded observers.
Statistical analysis
All data are presented as mean± standard error of the mean (SEM). Association 
between clinical outcome and individual SNPs was tested using an allelic associa-
tion test. Groups were compared using a Mann-Whitney sum test for non-parametric 
data. Total plasma cholesterol concentrations in time were compared using a Wil-
coxon matched pairs test. All statistical analyses were performed with SPSS 17.0 
software for Windows or using Prism software. P-values <0.05 were regarded as 
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19.8±1.619.3±1.60.1 mg/kg annexin A5
19.2±3.319.9±4.10.3 mg/kg annexin A5
17.1±2.718.0±2.71.0 mg/kg annexin A5
21.1±2.423.7±2.7Vehicle
Late time point (14d)
22.8±2.219.6±1.80.1 mg/kg annexin A5
20.0±1.716.6±0.60.3 mg/kg annexin A5
19.8±1.615.4±0.41.0 mg/kg annexin A5
25.0±0.819.5±1.3Vehicle
Early time point (3d)
SacrificeSurgery
Total plasma cholesterol (mmol/L)Group
Table I. Plasma cholesterol in mice undergoing annexin A5 dose-response investigations.
Plasma total cholesterol (mmol/L) of ApoE-/- mice receiving vehicle or annexin A5 (1.0, 0.3 or 0.1 mg/
















































Figure I. Annexin A5 reduces accelerated atherosclerosis development in a dose-dependent fashion. 
Quantification of total vessel area (µm2) (A) and luminal area (µm2) (B) in ApoE-/- mice receiving vehicle 
























Figure II. Co-localization of injected AnxA5 at macrophage (3d) and macrophage/foam cell (14d) areas 
after 3d (A) and 14d (B). Representative cross-sections of cuffed arteries of ApoE-/- mice receiving vehicle 
or 1.0 mg/kg AnxA5 (MAC3 and annexin A5 staining, magnification 80x, closed arrows indicate positive 
macrophage and AnxA5 staining, open arrows indicate projected macrophages in consecutive slides (5 
μm distance) in annexin A5 stained femoral artery cross-sections to indicate co-localization).  
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Background Phosphorylcholine (PC) is an important pro-inflammatory damage as-
sociated molecular pattern and natural anti-PC T15 IgM antibodies are both clinical 
risk markers for cardiovascular diseases and prevent native atherogenesis in mice. 
For clinical use, however, only IgGs are suitable, but major variability exists in natural 
anti-PCs IgG effects.
Methods and results Chimeric anti-PC T15 IgG was developed and shown to bind 
locally to human atherosclerotic tissues. Following immunization of hyperlipidemic 
ApoE3*Leiden mice undergoing femoral arterial cuff placement to induce vascular 
inflammation and remodeling, 73.6% reduced atherosclerotic lesion size was ob-
served (p=0.0003), with reduced expression of local ER-stress markers and MCP-1 
production. 
Phage display-library screening led to the development of three fully human mono-
clonal anti-PC IgG constructs which specifically bound PC and apoptotic cells and 
prevented both macrophage oxLDL-uptake and their MCP-1 expression in vitro, su-
periorly to natural anti-PC T15 IgM antibodies. Of these, anti-PC M99-B05 IgG was 
most effective in vivo by reducing inflammation and atherosclerotic lesion size with 
61.4% (p=0.014). Germ lining and codon optimization of M99-B05 produced anti-PC 
X19-A05 IgG, which was as effective as M99-B05 in vivo, even in low dosages. 
Conclusions Both chimeric and fully human anti-PC IgGs can prevent post-inter-
ventional atherosclerotic lesion formation by inhibiting injury-induced vascular in-
flammation directly and through reduced macrophage oxLDL-uptake. These could 
represent a novel strategy for prevention of post-inteventional atherosclerotic lesion 
development.  
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Although treatments for atherosclerosis-induced acute coronary syndromes (ACS) 
have improved patient outcome greatly in the last decades, there is still much room 
for improvement, especially for treatment modalities that target increased local vas-
cular inflammatory burden after myocardial infarction1. In this acute phase, cellular 
stress and inflammation can lead to the generation of endogenous ligands. These 
ligands, such as phosphorylcholine (PC), have recently been described as damage 
associated molecular patterns (DAMPs) that are recognized by the innate immu-
ne system2. PC is the polar headgroup of the dominating membrane phospholipid 
phosphatidylcholine. In cellular stress and inflammation as well as during enzymatic 
and oxidative modification of LDL the fatty acids of phosphatidylcholine, especially 
the fatty acids in the sn-2 position, are metabolized. Many of these PC containing 
metabolites (oxPL) have powerful biological effects and are considered important 
mediators of vascular inflammation. A recent review summarized these effects and 
concluded that oxPL is a promising therapeutic target3. There are several receptors 
recognizing PC including proteins, scavenger receptors of phagocytic cells and natu-
ral antibodies2, 4. PC recognition has been reported to stimulate a range of responses 
including endothelial dysfunction, apoptosis, endoplasmatic reticulum (ER)-stress 
and the unfolded protein response (UPR)5, 6. They all lead to vascular inflammation, 
eventually responsible for accelerated atherosclerotic lesion formation, often requi-
ring revascularization7. Interestingly, there is competition between these receptors 
and the prototypic natural anti-PC, the murine T15/E06 IgM, is well known to inhibit 
macrophage binding and uptake of oxLDL through scavenger receptors8.
Uptake of oxLDL by vessel wall macrophages is considered as a pro-atherogenic 
event9, while anti-PC has anti-atherosclerotic effects. Immunization leading to high 
anti-PC levels can prevent native atherosclerosis in mice by inhibition of oxLDL-
uptake and inflammatory foam cell formation10-12. Epidemiological data suggests that 
IgM anti-PC protects against cardiovascular disease (CVD) development, as low 
levels of the IgM anti-PC are associated with increased risks for CV events13-15. Ad-
ditionally, ACS patients with low levels of IgM anti-PC have a worse prognosis than 
patients with higher levels16. The increased risk was particularly present in the semi-
acute phase following ACS, during which there is an elevated systemic inflammatory 
activity17. Experimental data shows that the T15/E06 natural antibodies also have 
profound anti-inflammatory properties unrelated to foam cell formation and enhance 
clearance of apoptotic cells18, 19. This suggests that they could also be therapeutically 
effective in the acute injury phase following ACS, during which there is still a high risk 
for secondary events.
Experimental data has principally been generated using the natural IgM anti-PC. Se-
rum contains anti-PCs of several subclasses20 and not all may be able to block vas-
cular inflammatory processes. Hypertensive patients display an inverse correlation 
between the progression of carotid artery intima media thickness and IgM anti-PC 
titers, but not for IgG anti-PCs21. While T15 IgM was effective against Streptococcus 
infections in mice, there was major variability in IgG anti-PCs effects22-24. These re-
sults indicate that although PC is a chemically defined entity, the presentation of the 
PC (neo)epitope depends on the local environment and that different IgG anti-PCs 
may be more specific for the presentation of PC than the natural IgM anti-PC.
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Chapter 6
IgM antibodies are not suitable for therapeutic use. The aim of this work was to in-
vestigate if anti-PC in an IgG format has the potential to block vascular inflammation, 
and to identify a fully human monoclonal anti-PC that has therapeutic potential. We 
first generated an anti-PC T15 IgG chimeric antibody that prevented inflammatory 
vascular disease both in vitro and vivo, providing support that anti-PC IgGs are at-
tractive as therapeutic antibodies. We then identified multiple, fully human recom-
binant anti-PC IgGs by phage-display library screening. These were selected and 
optimized for their in vitro and in vivo anti-inflammatory and anti-atherosclerotic ef-




The materials and methods sections can be found in the online supplements section. 
Results
Chimeric anti-PC T15 IgG binds to human atherosclerotic lesions and is effec-
tive against vascular inflammation in vivo
A chimeric anti-PC T15 IgG antibody was developed, containing the murine T15/
E06 variable region and human IgG1 in the constant region, highly specific for PC. 
Immunohistochemical (IHC) staining with chimeric anti-PC T15 IgG showed strong 
and specific binding to cells within human aortic atherosclerotic lesions (fig 1a), con-
firmation of antibody affinity for the target tissue. Next, therapeutic effectiveness of 
chimeric anti-PC T15 IgG was tested in a well-established mouse model for post-
interventional inflammatory vascular disease25. Short term leukocyte recruitment and 
long-term vascular remodeling were evaluated. 
Despite similar plasma total cholesterol concentrations (table 2), chimeric anti-PC 
T15 IgG (plasma titer 1208±329 µg/ml) significantly reduced endothelial-adherence 
and extravasation of leukocytes (fig 1c) and macrophages (fig Ic) to the injured ar-
terial segments 3d after injury, prior to foam cell development. Furthermore, anti-PC 
T15 IgG staining displayed strong and specific co-localisation with GRP78 BiP and 
CHOP expressing cells, suggesting specific binding of T15 IgG to PC-expressing 
stressed cells within atherosclerotic plaques. Treatment significantly reduced cells 
displaying ER-stress markers CHOP and GRP78BiP by 73.0% (p=0.021, fig 2b) and 
54.7% (p=0.050, fig 2c) respectively. Together, these results indicate that anti-PC 
T15 IgG prevents early inflammatory responses, well before the generation of local 
foam cells26. 
Chimeric anti-PC T15 IgG is effective against vascular remodeling in vivo
Vascular remodeling was evaluated after 14d treatment (fig 3a) and revealed that 
despite similar plasma cholesterol levels (table 2), anti-PC T15 IgG significantly pre-
vented intimal thickening by 76.3% (p=0.0003, fig 3b) and reduced intima/media 
ratio by 72.2% (p=0.000, fig 3c), luminal stenosis by 60.3% (p=0.000, fig IIa) and 
medial thickening by 20.0% (p=0.050, fig IIb). After 14d, the medial arterial layer dis-
played a less inflamed phenotype, with a higher proportion of stable SMCs (87.0%, 
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Figure 1 Representative cross-sections of (A) human non-diseased and atherosclerotic aortic tissue (chi-
meric anti-PC T15 IgG staining, magnification 20x) and of cuffed arteries of ApoE3*Leiden mice receiving 
vehicle, human anti-streptavidin or anti-PC T15 IgG (B) after 3d (CD45 staining, magnification 80x, arrows 
indicate leukocytes). Quantification of (C) leukocyte and macrophages (% of total cells). Results indicated 
as mean±SEM, n=10. * p<0.05.































































p=0.016, fig 3e) and 72.2% less macrophages (p=0.000, fig 3f). Anti-PC T15 IgG 
also reduced leukocyte infiltration in the intima and media by 66.0% (p=0.001, fig 3h) 
and 74.2% (p=0.002, fig 3i). 































































Figure 2 Representative cross-sections of (A) human atherosclerotic coronary arteries (chimeric anti-
PC T15 IgG, GRP78 BiP and CHOP staining, magnification 10-20x). Quantification of cuffed arteries of 
ApoE3*Leiden mice receiving vehicle, human anti-streptavidin or anti-PC T15 IgG after 3d for cells expres-
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Furthermore, anti-PC T15 IgG significantly reduced cells displaying ER-stress mar-
kers CHOP (absent before injury, fig IIc) and GRP78BiP by 31.4% (p=0.0003) and 
70.4% (p=0.0003, fig 3j), demonstrating that chimeric anti-PC T15 IgG prevents the 
inflammatory UPR, involved in inflammatory vascular remodeling. 








































































































































Figure 3 Representative cross-sections of cuffed arteries of ApoE3*Leiden mice receiving vehicle, hu-
man anti-streptavidin or anti-PC T15 IgG after 14d (A Weigert’s elastin, GRP78 BiP and CHOP staining, 
D SMC-α actin and MAC3 staining; G CD45 staining; magnification 40-80x). Quantification of (B) intimal 
thickening (µm2), (C) intima/media ratio, (E) SMCs in the media (% of total area), (F) macrophages in the 
media (% of total area), (H) leukocytes in the intima (% of total), (I) leukocytes in the media (% of total) and 




Polyclonal IgM and IgG anti-PC obtained from human serum were evaluated to 
block the uptake of oxLDL particles by macrophages, as the murine T15/E06 IgM 
natural antibody is known to block this scavenger receptor-mediated uptake10. As 
expected, polyclonal anti-PC IgMs showed a dose-dependent (fig IIIa-b) inhibition 
of Dil-Labelled Cu-oxLDL uptake (fig 4a), whereas polyclonal anti-PC IgGs did not 
(fig 4b). Previously, low concentrations of polyclonal human anti-PC IgG from serum 
following active immunization was shown to partly inhibit oxLDL-uptake in macro-
phages11. Similar results were obtained with 20 µg/ml anti-PC IgG, but not with hi-
gher concentrations (fig 4c). Cimeric anti-PC T15 IgG also did not prevent Cu-oxLDL 
uptake by human macrophages (fig 4d).
Unlike IgM, the Fc region of IgG1 bears a highly conserved N-glycosylation site that 
is essential for Fc receptor-mediated activity by macrophages and could lead to 
increased antibody-PC complex binding by macrophages and oxLDL-uptake. This 
possibility was excluded by using both a chimeric anti-PC T15 IgG4 antibody, as 
IgG4 antibodies are less prone to bind Fc receptors (fig 4d), as well as Fc-receptor 
blocking anti-CD32 and anti-CD64 antibodies (fig IIIc), through which no blocked 
oxLDL-uptake was observed. Although effective in vivo, at least partly through UPR 
downregulation, the transfer of the T15/E06 variable region from IgM to IgG format 
abolished the scavenger receptor blocking effects of chimeric anti-PC T15 IgG. 
A B
C D
Figure 4 FACS analysis demonstrates that unlike murine anti-PC IgM (A), polyclonal anti-PC IgG does 
not block oxLDL-uptake by macrophages (B), in both low (20μg/ml) and high (80μg/ml) concentrations 
(C). Both IgG1 and IgG4 antibodies fail to display a inhibiting effect (D), excluding the potential enhanced 
Fc-receptor-regulaged uptake of oxLDL.
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Development of monoclonal human anti-PC IgG antibodies
Fully human, monoclonal IgG antibodies against PC were obtained by phage display 
by panning human Fab fragment displayed libraries27 against either BSA- or ferritin-
conjugated PC. Over ten thousand different phage clones were screened by ELISA, 
which yielded over 1500 positive hits, defined as > 3-fold stronger signal for binding 
to BSA- or ferritin-conjugated PC compared to streptavidin-coated controls. After 
DNA sequencing and recombinant reformatting to full length IgG1 51 antibodies with 
unique amino acid sequences were recovered. Binding specificity was assessed 
using a Biacore SPR assay to binding to either PC-BSA or a control BSA containing 
the aminophenol linker that used for the conjugation of PC to BSA, allowing selection 
of antibodies with likely therapeutic effectiveness, also shown by ELISA (fig 5a). Of 
these, 27 antibodies with highest signal for binding PC-BSA were investigated for 
their effects on macrophage oxLDL-uptake. Nine fully human recombinant anti-PC 
IgG antibodies inhibited oxLDL-uptake similarly or better than polyclonal anti-PC IgM 
on a weight basis (fig 5b). 
These 9 monoclonal IgGs displayed approximately 1000-fold higher binding efficacy 
to PC than polyclonal IgG anti-PC, as measured in an ELISA (fig 5c). Antibodies 
M99-B05 and X9-C01, potent inhibitors of oxLDL uptake, were analysed for binding 
to Cu-oxidized LDL and displayed profound increased binding compared to chime-
ric anti-PC T15 IgG (fig 5d). The lack of effect of chimeric anti-PC T15 IgG to block 
oxLDL-uptake is probably explained by the poor binding to oxLDL. The high avidity 
of the murine IgM T15/E06 to PC compared to IgG isotype probably explains the 
effectiveness of the IgM isotype anti-PC18. Antibodies with high apparent affinity for 
PC and oxLDL were tested for binding to apoptotic Jurkat cells using FACS analysis. 
Only marginally increased binding to cells considered as early apoptotic (annexin 
A5+ PI-) compared to normal viable cells was found. Some antibodies, including 
M99-B05, were found to bind strongly to late apoptotic (annexin A5+ PI+) Jurkat cells 
(fig 5e-h), while others did not. Four selected antibodies were finally tested for their 
ability to block oxLDL-induced release of MCP-1 from monocytes and both M99-B05 
and X9-C01 effectively blocked this release in a dose-dependent fashion with an 
IC50 in the 1-3 nM range whilst the other tested antibodies were ineffective (fig 5i). 
M99-B05 displayed strong and specific binding to human atherosclerotic aortic tis-
sue, unlike HRP streptavidin controls (fig IVa).
Monoclonal human anti-PC IgGs are effective against vascular inflammation 
in vivo
The anti-inflammatory properties of X9-C01, M73-G3 and M99-B05 were tested in 
vivo in the femoral artery cuff mouse model, with chimeric anti-PC T15 IgG, Hu 
a-strep A2 IgG and sterile water as controls (fig Va). Despite similar plasma lipid 
concentrations and antibody titers (tables 2, 3), 3d treatment with anti-PC M99-
B05 reduced the endothelial-adherence and extravasation of leukocytes by 60.9% 
(p=0.021), macrophages by 48.9% (p=0.006, fig 6a) and MCP-1 expressing cells by 
81.7% (p=0.003, fig 6c), while other antibodies were less effective. 
Monoclonal human anti-PC IgG is effective against vascular remodeling in vivo
Despite similar plasma lipid concentrations and antibody titers (table 2, 3), twice 
weekly immunization with 10mg/kg M99-B05 significantly prevented vascular remo-
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deling, with reduced intimal thickening by 61.4% (p=0.014, fig 6e), intima/media ratio 
by 58.3% (p=0.008, fig 6f) and outward remodeling by 35.3% (p=0.039, fig VIa) after 
14d. Luminal stenosis was reduced by 20.7%, although not significantly (p=0.160, fig 
VIb). IHC analysis from human aortic atherosclerotic lesions revealed specific M99-




























































































































Figure 5 Antibody binding efficacy by 27 clones to BSA-PC (A), inhibitory effects on macrophage oxLDL-
uptake of nine selected antibody clones compared to anti-PC IgM (B), and their affinity to PC (C) and 
oxLDL (D), measured through ELISA (expressed as OD). Of these, 7 antibodies had approximately 1000-
fold higher affinity to PC than polyclonal IgG anti-PC. FACS analysis of dot plot showing (E) different cell 
populations after staurosporine inducing, including live cells (annexin A5-PI-), (F) early apoptotic cells 
(annexin A5+PI-) and (G) late apoptotic cells (annexin A5+PI+). (H) Mean fluorescent intensity of each cell 
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Optimization of monoclonal human anti-PC M99-B05 into X19-A05
A site-directed mutagenesis study was performed to determine which CDR regions 
were involved in binding PC, providing insight into the paratope of M99-B05. A 3-D 
model of M99-B05 was constructed (fig VIIa) together with an amino acid sequence 
analysis (fig VIIb, c), designed to obtain a full characterization of the antigen-anti-

































































































































Figure 6 Representative cross-sections of cuffed arteries of ApoE3*Leiden mice receiving human anti-
streptavidin, anti-PC T15, M99-B05 or X9-C01 (B) after 3d (MCP-1 staining), (D) 14d (Weigert’s elastin 
staining) or (G) human atherosclerotic coronary artery sections (anti-PC M99-B05 staining, magnification 
10-80x). Quantification of after 3d (A) leukocyte and macrophages (% of total cells), and after 14d (C) 
MCP-1 expressing cells (% of total cells), (E) intimal thickening (µm2) and (F) intima/media ratio. Results 
indicated as mean±SEM, n=10. * p<0.05.
population. (I) MCP-1 release assay of human monocytes stimulated with oxLDL alone or in combination 
with antibody clones (pg/ml) with IC50=1.8 ±0.74 nM for anti-PC M99B05 IgG.
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VIId, e). Codon optimization produced a series of M99-B05 mutants that had some 
replacements for potential de-amidation sites constructed. These were tested for the 
binding to PC (ELISA) and it was observed that some modifications of the M99-B05 
antibody negatively affected binding affinity to PC (fig 7a). The mutant X19-A05 was 
selected as the optimal antibody, as it combines several modifications of M99-B05 
while retaining good binding affinity to PC. 
X19-A05 anti-PC IgG is effective in vivo in low dosages
Despite similar plasma lipid concentrations and antibody titers (tables 2, 3), 14d 
treatment with X19-A05 anti-PC in twice weekly 0.5, 2 and 10mg/kg dosages sig-
nificantly prevented intimal thickening by 40.1% (p=0.024), 46.8% (p=0.014) and 
67.6% (p=0.000) respectively, similarly to M99-B05, when compared to Hu a-strep 
A2 IgG controls (fig 7c), with 10 mg/kg 17.5% more effective (p=0.031) than 0.5mg/
kg. Versus vehicle, 0.5, 2 and 10m/kg X19-A05 anti-PC reduced reduced the intima 
/ media ratio by 38.9% (p=0.042), 39.1% (p=0.018) and 56.1% (p=0.002, fig VIIIa). 
In conclusion, the optimized monoclonal X19-A05 anti-PC IgG antibody retained 
the therapeutic effectiveness of M99-B05 and forms a promising antibody clone for 
clinical use to prevent post-interventional vascular remodeling. 
Titration of PC Binding Activity using ELISA
M99-B05 Mutants
[Antibody] (nM)








 M99-B05 (EC50 = 41 nM)
X19-A01 (EC50 = 62 nM)
X19-A03 (EC50 = 79 nM)
X19-A05 (EC50 = 74 nM)
X19-A07 (EC50 = 91 nM)
X19-A09 (EC50 = 86 nM)
X19-A11 (EC50 = 143 nM)
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Figure 7 PC-affinity by seven M99-B05 clones, measured by ELISA (expressed as OD) (A). Represen-
tative cross-sections (B) of cuffed arteries of ApoE3*Leiden mice receiving human anti-streptavidin, M99-
B05 or X19-A05 (0.5, 2, 10mg/kg) after 14d (Weigert’s elastin staining, magnification 40x). Quantification 




This study demonstrates for the first time natural anti-PC IgM antibody optimization 
and therapeutic efficacy of a phage-library display selected monoclonal human anti-
PC IgG construct against inflammatory atherosclerotic disease. Passive in vivo im-
munization with chimeric anti-PC T15 IgG prevented inflammatory arterial disease 
including UPR and atherosclerotic remodeling. Since natural anti-PC IgM antibodies 
display inhibition of oxLDL-uptake by macrophages and this function was lost by the 
chimeric anti-PC T15 IgG, monoclonal human anti-PC IgGs were screened for this 
function. These proved to be effective in vivo by profoundly reducing inflammation 
and atherosclerotic remodeling. 
Research into new monoclonal recombinant antibodies is a fast-developing and ex-
panding field and atherosclerotic-related CVDs with high incidence, prevalence and 
mortality rates1 are extremely suitable for therapeutic immunization strategies. PC 
plays a key role as DAMP in the inflammatory reaction in both native atherosclerosis 
and following vascular intervention strategies. In the latter setting, it has emerged as 
a promising target for active immunization to prevent vascular remodeling. Until now, 
successful therapeutic immunization against PC has mostly been on an IgM basis in 
mice, whilst for clinical application, IgG-based vaccination is preferred28. 
Specific chimeric anti-PC T15 IgG binding was observed in human atherosclerotic 
lesions with distinctive co-localization with regions displaying signs ER stress (fig 
1-2a), proving antibody binding to the target tissue. In hyperlipidemic mice, chime-
ric anti-PC T15 IgG effectively reduced leukocyte and macrophage adherence and 
extravasation following vascular injury (fig 1c), with notably less MCP-1 expression 
by adhered and infiltrated leukocytes (fig 1d), clearly showing therapeutic efficacy. 
Due to hypercholesterolemia, α-actin SMCs display markers of early ER-stress (fig 
IIb), whilst this progressed to advanced ER-stress and UPR following vascular injury. 
Defective inflammatory resolution is known lead to the progression of atherosclerotic 
lesions29, 30 and by reduction of ER-stress and UPR-induced inflammation, prolonged 
anti-PC T15 IgG treatment led to retarded occlusive vascular remodeling (fig 3b) and 
a less inflammatory arterial wall phenotype (fig 3g). 
Polyclonal anti-PC IgMs showed an inhibition of oxLDL-uptake by macrophages in 
vitro, whereas polyclonal anti-PC IgGs did not. Similarly, chimeric anti-PC T15 IgG 
also did not prevent oxLDL-uptake by macrophages in vitro (fig 4d), an effect unre-
lated to Fc receptor-mediated activity in IgG1 antibodies by macrophages, making 
them unsuitable for clinical use to prevent native atherosclerosis. Post-interventional 
vascular remodeling however does not primarily result from oxLDL-uptake, but from 
local cellular (ER) stress and DAMP expression, followed by leukocyte chemotaxis 
(e.g. through MCP-1) and inflammation. Although this concept supports the chimeric 
anti-PC T15 IgG effectiveness in the murine vascular injury model, vascular remo-
deling can be enhanced through oxLDL-uptake by infiltrated macrophages. Since 
these processes occur simultaneously in the human ACS setting, phage library-dis-
play selection was used to screen for monoclonal human anti-PC IgGs that have 
both anti-inflammatory effects and an ability to block oxLDL-uptake. Recombinant 
antibody libraries provide a solid basis for the discovery of antibody-based biophar-
maceuticals31 and are an excellent source of active and well tolerated experimental 
therapeutics32. IgGs were selected upon their binding capability to PC and apoptotic 
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cells, as well as their ability to block macrophage oxLDL uptake and MCP-1 expres-
sion in vitro (fig 5g). Out of a total 10.660 phage clones, these selection criteria yiel-
ded three promising antibody clones, designated M99-B05, X9-C01 and M73-G3. 
Only anti-PC M99-B05 significantly reduced leukocyte and macrophage adherence 
and infiltration in the injured local arterial wall segments (fig 6a), although both M99-
B05 and M73-G03 reached high plasma titers, whereas X9-C01 did not. It cannot be 
excluded that X9-C01 could be effective in similar concentrations, although M73-G3 
was clearly ineffective. Despite this, effects of prolonged anti-PC M99-B05 treatment 
were investigated and displayed reduced vascular thickening, proving its long-term 
efficacy (fig 6e). In combination with strong local binding to atherosclerotic human 
arterial segments (fig 6g), this makes the anti-PC M99-B05 clone a promising thera-
peutic antibody for clinical use.
To increase production efficacy, reduce immunogenicity and increase antibody sta-
bility in serum, codon optimization of M99-B05 anti-PC was performed. PC-affinity 
assays and in vivo application clearly showed preserved PC-affinity and therapeutic 
efficacy (fig 8b), even in low dosages (2mg/kg/twice weekly). 
The limited time period (14d) of antibody exposure was used to minimize the gene-
ration of murine anti-human IgG antibodies, although their development cannot be 
ruled out. Furthermore, despite in vitro and in vivo therapeutic effectiveness, murine 
results cannot be extrapolated to the human situation automatically. Nevertheless, 
anti-PC X19-A05 IgG has been shown to be a promising therapeutic tool. 
The present findings show that PC is a promising therapeutic target in the preven-
tion of accelerated atherosclerosis development, suitable for passive therapeutic 
immunization with recombinant monoclonal antibodies. By providing direct control of 
the patient’s immune response with restriction to a single immunogenic epitope, this 
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Peripheral blood mononuclear cells (PBMCs) were isolated from citrated human 
blood using Ficoll-Paque PLUS (GE Healthcare) according to the instructions of the 
manufacturer. Monocytes were resuspended in serum free RPMI 1640 medium at 
density of 8x105 cells/ml and 250 µLcell suspension was added into wells of a 96-
well plate (2x 105 cells/well). PBMC cells were treated with 2 µg/mL Ox-LDL (Kalen 
Biomedical) in the presence or absence of up to 40 nM anti-PC IgG for 40 hours at 
37°C, 5% CO2. 
Preparation and characterization of chimeric anti-PC T15 IgG 
Anti-PC T15-IgG was constructed by synthesizing the DNA encoding the mouse 
variable regions and cloning the heavy and light chains into two different IgG expres-
sion vectors. To generate an IgG1 chimera the variable regions were cloned into an 
IgG1 expression vector, pRH1-f-CHO1, such that the final antibody contains a fully 
human IgG1 Fc fragment consisting of human CH1, CH2, and CH3 with a mouse 
variable region. The heavy chain was cloned using the restriction enzymes BstXI 
and NheI and the light chain is cloned using the restriction enzymes ApalI and AscI.
The resulting T15-IgGs are mouse/human chimeras that contains mouse heavy and 
light variable regions and a human Fc region. The T15-IgG1 antibody was transiently 
expressed in 293T (human kidney) cells using FugeneHD (Roche) as the transfec-
tion reagent using Corning® CellStack® chambers (6360 cm2 cell growth area). After 
10 days of expression, the supernatant was harvested and antibody was initially 
purified using using protein A sepharose (MabSelect, GE Healthcare) in which ap-
proximately 2.5 L of clarified cell culture media was applied (2 mL/min) over a 4.2 
mL column equilibrated in PBS, washed with PBS containing an additional 0.4 M 
NaCl, and eluted with 50 mM Sodium Citrate, pH: 3.2. The pH of the eluted protein 
was adjusted to 5.0 and applied to a Poros HS (Applied Biosystems) ion exchange 
column (4.0 mL bed volume) at 2 mL/min equilibrated in 50 mM NaAcetate, pH: 5.0 
and eluted with a linear gradient over 10 column volumes to 50 mM NaAcetate, 0.5 
M NaCl, pH: 5.0. Eluted antibodies were buffer exchanged into Antibody Formulation 
Buffer (0.1 M citrate-phosphate, 50 mM NaCl, 0.01% Tween-80, 2% Trehalose, pH 
6.0). Antibody concentrations were determined on purified samples by absorbance 
at 280 nm (1 mg/mL = 1.4 O.D.).
Mice
All animal experiments were approved by the Institutional Committee for Animal Wel-
fare of the Leiden University Medical Center (LUMC). Transgenic male C57BL/6 
ApoE*3-Leiden mice (bred in our own laboratory), aged 10-12 weeks at the start of 
a dietary run-in period, were used for this experiment. 
Diets
Animals were fed a cholesterol-rich high-fat diet to induce hypercholesterolemia 
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containing 0.05% cholate (to improve intestinal cholesterol uptake and suppress bile 
acid synthesis, both leading to increased plasma cholesterol levels) and 1% choles-
terol (as well as 20% casein, 1% choline chloride, 0.2% methionine, 15% cocoa but-
ter, 40.5% sucrose, 10% cornstarch, 1% corn oil, 5.1% cellulose and 5.1% mineral 
mixture) (AB Diets). They received the diet three weeks prior to surgery and the diet 
was continued throughout the entire experiment. All animals received food and water 
ad libitum during the entire experiment. 
Route of administration and treatment protocol
For all experiments, mice received intraperitoneal injections with antibody solutions 
(Dyax Corporation) in a volume of 100µl, using 100µl sterile 0.9% w/v NaCl (vehicle) 
as control, injected at the time of surgery (3 days) or twice weekly (14 days). 
Vascular injury and accelerated atherosclerosis model2
After three weeks of diet, mice were anesthetized before surgery with a combina-
tion of Midazolam (5 mg/kg, Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl 
(0.05 mg/kg, Janssen) through intraperitoneal injection. The right femoral artery was 
isolated and sheathed with a rigid non-constrictive polyethylene cuff (Portex) with 
0.40 mm inner diameter, 0.80 mm outer diameter and an approximate length of 2.0 
mm). Mice were sacrificed 3 or 14 days after cuff placement. For this, mice were 
anesthetized as before and euthanized. 
The thorax was opened and mild pressure-perfusion (100mm Hg) with 3.7% for-
maldehyde in water (w/v) was performed for 5min by cardiac puncture in the left 
ventricle. After perfusion, the cuffed femoral artery was harvested, fixed overnight 
in 3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial cross-sections 
(5 μm thick) were taken from the entire length of the artery for histological analysis.
Immunoassays 
After three weeks of diet (one day before surgery) and at the time of euthanasia, 
EDTA plasma samples were taken from the tail vein to determine total plasma cho-
lesterol. Total plasma cholesterol (Boehringer Mannheim GmbH, kit 236691) con-
centration was measured enzymatically. Before surgery, mice were randomized in 
groups based on their total plasma cholesterol level. Enzyme-linked immuno sorbent 
assays (ELISA) were used to determine antibody titers. MCP-1 in cell supernatant 
was detected using the MCP-1 ELISA kit (R&D Systems), according to the manufac-
turer’s instructions.
Vascular lesion quantification
The number of leukocytes, macrophages and cells expressing MCP-1, GRP78 BiP 
and CHOP attached to the endothelium or in the media of the femoral arteries was 
quantified and is displayed as a percentage of the total number of present cells. All 
quantification in this study was performed on six equally spaced (150 µm distance) 
serial stained perpendicular cross-sections throughout the entire length of the ves-
sel and was performed by blinded observers. Using image analysis software (Leica 
Qwin), the area containing SMCs and macrophages grafts was quantified morpho-
metrically and is expressed as a percentage of the total cross-sectional vessel wall 
layer area. Additionally, total cross-sectional medial area was measured between 
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the external and internal elastic lamina and total cross-sectional intimal area was 
measured between the lumen and the internal elastic lamina.
Immunohistochemical stainings
Murine samples
All samples were stained with hematoxylin-phloxine-saffron (HPS). Weigert’s elastin 
stain was used to visualize elastic laminae. Vessel wall sections undergoing immu-
nological staining were pre-treated with a peroxidase block to decrease background 
staining due to endogenous peroxidase and with a concentrated solution of bovine 
serum albumin to block the adsorption of other proteins to non-specific binding si-
tes on the vessel wall. Afterwards the primary antibody was added to the sections, 
left overnight and washed before the second antibody, specific to the primary anti-
body, was applied. After rinsing, an Avidin-Biotinylated enzyme complex was added 
to increase the sensitivity of the later to be added peroxidase Nova Red substrate, 
used as chromogen for colour development. Leukocytes were detected with the use 
of anti-CD45 antibodies (dilution 1:200, Pharmingen). Smooth muscle cells were 
stained with the use of anti-smooth muscle α-actin antibodies (dilution 1:800, Dako) 
and macrophages were detected with MAC3 staining (dilution 1:200, Pharmingen). 
MCP-1 expression was determined with the use of anti-mouse MCP-1 antibodies 
(dilution 1:300, Santa Cruz Biotechnology). The presence of ER stress and UPR was 
evaluated with antibodies against GRP78 BiP (GRP78 BiP, dilution 1:200, Abcam) 
and against CHOP (GADD153, dilution 1:200, Abcam).
Human aortic samples 
The Tissue MicroArrays (TMA) included 20 aortic samples with atherosclerotic pla-
ques from different individuals. The classification of the lesions was performed ac-
cording to Stary3. For each lesion three representative areas were selected from 
hematoxylin- and eosin-stained sections of a donor block. Core cylinders (diameter: 
0.6 mm) were punched and deposited into a recipient paraffin block using a specific 
arraying device (Beecher Instruments, Alphelys ring, MD)4. 5 μm TMA sections were 
used for IHC analyses using digital slides (magnification 40) of each TMA spot which 
were acquired using Aperio ScanScope CS-US.
IHC was performed by using standard protocols with the following commercial pri-
mary antibodies directed against: CD68 (Dako; 1:500), alpha AML (Dako; 1:500), 
CD34 (Dako;1:100), GRP78 (Abcam; 1:100) and ATF3 (Santa Cruz Biotechnolo-
gy; 1:200) and noncommercial primary antibodies T15 (1:500) and M99 (1:50000). 
Briefly, IHC was performed on 5-μm sections of TMA blocks. Deparaffinized and 
rehydrated sections were incubated for 30 min at room temperature with primary 
antibodies, washed, and incubated for 30 minutes with a Multilink kit (Biosys) for 
polyclonal antibodies and ABC Vector kit (Biosys) for monoclonal antibodies. After 
washing, the alkaline phosphatase/anti–alkaline phosphatase complexes and Fast 
Red TR substrate (Dako) or Ultravision LP detection System HRP DAB (MICROM) 
were added. Slides were counterstained with aqueous hematoxylin and mounted 
with Immunomount (Shandon).
Phage display selections
Phage display selections were performed using PC conjugated to bovine serum al-
bumin (BSA) and to transferrin (Isosep AB) through a para-aminophenol linker using 
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isothiocyanate reaction chemistry. PC-BSA was produced at molar PC/BSA ratios of 
1.4, 2.9, 5.7, and 22 mol PC/mol BSA. PC-transferrin was similarly prepared to con-
tain 52 mol PC/mol transferrin. BSA was also reacted with just the para-aminophenol 
linker to serve as a reagent to remove antibody binders to the linker group from 
selected antibodies. PC modified BSA, PC modified transferrin, and linker modified 
BSA were biotinylated using EZ Link NHS-PEG4-Biotin (Pierce) to give molar incor-
poration ratios between 2 and 8 mol biotin per mol protein. Free biotinylation reagent 
was removed by dialysis against phosphate buffered saline (137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, pH 7.4). Biotinylation incorporation was 
determined using the 2-(4′-hydroxyazobenzene) benzoic acid (HABA) method ac-
cording to the manufacturer (Pierce).
Phage display selections were performed using previously described antibody pha-
ge display procedures4 and antibody phage display libraries that combine natural 
and synthetic diversity5. Selections were initiated by first depleting the library of an-
tibody binders to BSA, transferrin or the linker by incubating the library with the 
biotinylated depletion proteins immobilized on streptavidin coated magnetic beads 
(Invitrogen). The supernatant from the depletion step was then titered and incuba-
ted with biotinylated PC-protein conjugates that were immobilized on streptavidin 
coated magnetic beads (input titer in first round ~2 x 1012 pfu). Selection strategies 
alternated between panning on biotinylated PC-BSA in one round with panning on 
biotinylated PC-transferrin in the next round. Alternative selection strategies involved 
selecting on the same biotinylated PC-modified protein in each round. Prior to expo-
sing the amplified phage from each selection round the phage were depleted using 
the biotinylated carrier protein in the absence of PC. In the case of selections on PC-
BSA, the phage particles were first depleted with biotinylated BSA that contained the 
para-aminophenol linker molecule used to couple PC to BSA. Phage outputs after 
between 2 to 4 rounds of selection were isolated as individual phage isolates and 
screened for PC binding by phage ELISA.
Individual phage isolates were picked as colonies, grown overnight and the super-
natant used in an ELISA to detect binding to biotinylated PC-BSA or biotinylated PC-
transferrin immobilized on streptavidin coated plates as previously described using 
HRP-labeled anti-M13 and TMB substrate2. ELISA positive hits were identified as 
having a target signal over background ratio greater than 3, where the target signal 
is the absorbance observed with target PC-BSA and PC- transferrin and the back-
ground is the signal observed with linker-BSA or transferrin, respectively. A total of 
10560 phage clones was screened by ELISA to yield 1511 ELISA positive hits, which 
were subsequently found by DNA sequencing (Applied Biosystems 3730) to consist 
of 54 different antibody sequences.
IgG reformatting, expression and purification
The 54 different anti-PC antibodies were converted by batch sub-cloning the Fab 
fragments displayed on gene III of M13 phage into the pBRH1-f vector for the tran-
sient expression of fully human IgG1 (f-allotype) in 293T cells as previously decri-
bed4. A total of 49 out of the 54 unique anti-PC antibodies were successfully reco-
vered after batch sub-cloning and DNA sequencing as full length IgG1 antibodies. 




DNA for each of the 49 IgGs was prepared from E. coli (DH5α) using plasmid purifi-
cation kits (Qiagen) and transfected into human kidney 293T cells to transiently ge-
nerate IgG after a 10 day media harvest in a T175 flask. Purified IgG was recovered 
after a single step protein A sepharose (MabSelect, GE Healthcare) for 41 IgGs; the 
remaining 8 antibodies were either poorly expressed or not well purified and were 
consequently not pursued further. The 41 IgGs purified by protein A sepharose chro-
matography were used for in vitro binding studies (SPR and ELISA analysis). The 
IgGs with superior in vitro binding properties were produced in larger quantities for 
testing in in vivo animal as well as in vitro cell culture experiments and purified using 
both protein A sepharose and ion exchange chromatography as described above for 
the T15-IgG.
SPR analysis
IgGs were screened for binding to PC using a surface plasmon resonance (SPR) 
biosensor (Biacore 3000). Aminophenylphosphorylcholine (Biosearch Technologies) 
was coupled through the free amine group to one flow cell of a CM5 chip to a density 
of 120 RU. To another flow cell of the same CM5 chip the counter screen reagent 
4-aminophenyl phosphate (Gold Biotechnology) was amine coupled to a density of 
approximately 120 RU. PC-KLH (Biosearch Technologies) and PC-BSA were also 
coupled to separate flow cells of a CM5 chip. Using these surfaces with PC immobi-
lized in different contexts, the antibodies were injected at 100 nM at 50 µL/min and 
binding sensorgrams were obtained. Binding was assessed by recording the signal 
at the end of the injection.
Antibody binding assays
Oxidized LDL (5 µg) was coated on the surface of a 384-well ELISA in PBS by 
overnight incubation at 4ºC. The plate was blocked with 2% BSA and washed 5 
times with PBST before 50 µL of the antibody at different concentrations was added. 
Unbound antibody was removed by washing with PBST and bound antibody was 
detected using a 1:5000 dilution of HRP labeled goat anti-human IgG, Fc-γ specific 
secondary antibody with a TMB colorimetric substrate. 
Apoptotic cell binding assays
Jurkat T cells (ATCC) were cultured in RPMI 1640 media supplemented with 10% 
FBS, penicillin (100 U/mL) and streptomycin (100 µg/mL). Cells were harvested by 
centrifugation, washed with ice-cold PBS and aliquoted into wells of a 96-well plate. 
Cells were blocked cells with 5% BSA in PBS at 4°C for 30 minutes prior to incubati-
on with anti-PC antibodies at a concentration of 20 µg/mL in PBS containing 5% BSA 
at 4°C for an additional 30 minutes. A recombinant human IgG1 (A2) with a binding 
specificity towards streptavidin was used as an isotype control. After washing with 
PBS containing 5% BSA, cells were incubated with the secondary antibody (FITC-
conjugated goat anti-human IgA, IgG, or IgM, Thermo) at a dilution of 1:50 in PBS 
containing 5% BSA. Prior to washing the cells, 5 µL of APC- annexin V antibody (BD 
Biosciences) was added. After the cells were washed, they were resuspended cells 
in PBS with 5% BSA and 1 µL of 1 mg/mL propidium iodide per sample. Cells were 
analyzed by flow cytometry using the LSRII instrument from BD Biosciences.
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Construction of germline and stability mutants of anti-PC M99-B05 IgG 
The amino acid sequence of the M99-B05 anti-PC IgG was inspected in order to 
identify potential amino acid substitutions that could reduce potential immunogeni-
city of the antibody in human and avoid susceptible amino acid modification that may 
occur during antibody expression and purification. Substitutions that could make the 
antibody less immunogenic were identified by aligning the amino acid sequence of 
M99-B05 with the most closely related germline antibody sequence from the Kabat 
database. The heavy chain of M99-B03 was compared to the VH3-23, JH3 heavy 
chain and the light chains were compared to the VK4-B3, JK1 light chain germ-
line sequence. The variant X19-A05 incorporates a total of 9 mutations that include 
germline substitutions as well as substitution to remove potential deamidation sites. 
The X19-A05 was transiently expressed and purified as described above for antibo-
dies to be tested in in vivo experiments. 
Statistical analysis
All data are presented as mean ± standard error of the mean (SEM), unless otherwi-
se indicated. Overall comparisons between data from groups were performed using 
the Kruskal-Wallis test. If a significant difference was found, groups were compared 
using a Mann-Whitney sum test. All statistical analyses were performed with SPSS 
16.0 software for Windows. P-values less than 0.05 were regarded as to be statisti-
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Vehicle Hu IgG anti-strep A2 Anti-PC T15 IgGB
Figure I (A) Total plasma antibody IgG concentration (µg/ml) of ApoE3*Leiden mice receiving vehicle, 
human anti-streptavidin or anti-PC T15 IgG after 3d. (B) Representative cross-sections (MAC3 staining, 
magnification 80x). (C) Quantification of macrophages in the intima and media (% of all cells). Results 
indicated as mean±SEM, n=10. * p<0.05.
Figure II Quantification of (A) luminal stenosis (%) and (B) 
medial area (µm2) of cuffed arteries of ApoE3*Leiden mice 
receiving vehicle, human anti-streptavidin or anti-PC T15 
IgG after 14d. (C) Representative cross-sections of un-
cuffed arteries of hypercholesterolemic ApoE3*Leiden mice 
display early ER-stress marker GRP78 BiP, but not the late 
ER-stress marker CHOP, which arises only after injury. Re-




























































C Figure III FACS analysis demonstrates that unlike 
murine anti-PC IgM (A), polyclonal anti-PC IgG (B) 
does not block oxLDL-uptake by macrophages. Ad-
dition of anti-CD32 or CD64 antibodies does not lead 
to an inhibition of oxLDL-uptake by anti-PC T15 IgG 
(C), excluding the potential enhanced Fc-receptor-
regulaged uptake of oxLDL.
A
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Figure IV Representative cross-sections of (A) human non-diseased and atherosclerotic aortic tissue 
(anti-PC M99B05 and HRP streptavidin staining, magnification 20x) and (B) IHC studies on the serial sec-
tions of TMA of human aortic fibroatheromatous plaques (original magnification 100x). The representative 
sections are shown: CD68 staining is specific for monocyte/macrophages and foam cells of monocyte 
origin, alpha AML staining is specific for smooth muscle cells and CD34 staining is specific for endothelial 

















































Figure V (A) Representative cross-sec-
tions of cuffed arteries of ApoE3*Leiden 
mice receiving human anti-streptavidin, 
anti-PC T15 IgG, anti-PC M73-G3, anti-
PC M99-B05 or anti-PC X9-C01 after 3d 
(MAC3 and CD45 staining, magnification 











































Figure VI Quantification of (A) outward remodeling (µm2) and (B) lumen stenosis (%) of ApoE3*Leiden 
mice receiving vehicle, human anti-streptavidin or anti-PC M99-B05 after 14d. Results indicated as 
mean±SEM, n=10. * p<0.05.
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3-D model of M99-B05 A
M99-B05      EVQLLESGGGLVQPGGSLRLSCAASGFT-SGYWMHWVRQAPGKGLEWVSY
M99-B05      ISPSGGGTHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVR
M99-B05      FRSVCSNGVCRPTAYDAFDIWGQGTAVTVSS
M99-B05 Heavy Chain Sequences
M99-B05     QDIQMTQSPDSLAVSLGERATINCKSSQSVFYNSNKKNYLAWYQQKAGQPP
M99-B05      KLLIHWASTRESGVPDRFSGSGSGTDFTLTISNLQAEDVALYYCQQYFNA
M99-B05      PRTFGQGTKVEIK
M99-B05 Light Chain Sequences
B
C
Figure VII (A) A 3-D model of M99-B05 was constructed by grafting the antibody sequence onto existing 
structures of similar antibodies. From the above information on which mutations disrupted PC binding it 
was able to obtain approximations from the model on where the PC antigen may be binding. Analysis sug-
gests that M99-B05 binds PC through an antibody structure that involves multiple CDRs at the interface 
between the light and heavy chains. The light chain is shown in red and the heavy chain is shown in blue. 
(B) Heavy chain sequence optimization of M99-B05. (C) Light chain sequence optimization of M99-B05. 
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Antibody stability in human serum
D E
Figure VII Western blot analysis with HRP-
conjugated goat anti-human IgG (D) or HRP-
conjugated streptavidin (E). Both antibodies 
are stable in serum under the tested conditi-
ons, as evidenced by the lack of degradation 
in the band intensity of the heavy chain (band 
above the 49kDa marker) and the light chain 



















A Figure VIII Quantification of (A) lumen steno-
sis (%) of ApoE3*Leiden mice receiving ve-
hicle, 10mg/kg anti-PC M99-B05 or 0.5, 2 or 
10mg/kg X19-A05 after 14d. Results indicated 
as mean±SEM, n=10. * p<0.05.
61.8±3.8*35.8±3.915.3±3.1*11.3±2.0*6.5±1.8*7.5±1.2*Anti-PC T15 IgG
45.1±2.641.4±3.745.0±3.236.9±4.417.0±2.818.9±2.1Hu IgG1 anti-strep A2
33.1±4.134.0±4.254.9±6.144.3±5.925.4±4.522.3±2.7Vehicle
MediaIntimaMediaIntimaMediaIntima
SMC area (%)Macrophage area (%)Leukocyte area (%)Group
Quantification of arterial wall phenotype 
Table I Quantification of arterial wall phenotype. 
Quantification of leukocyte area (%), macrophage area (%) and SMC area (%) in the tunica intima and 
media of the cuffed femoral artery of ApoE3*Leiden mice receiving vehicle, human anti-streptavidin or 
anti-PC T15 IgG after 14d. Results indicated as mean±SEM, n=10. * p<0.05.
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10.8±2.211.2±1.010 mg/kg Hu IgG1 anti-strep A2
8.4±0.59.5±0.710 mg/kg Anti-PC M99-B05
10.5±0.510.4±0.80.5 mg/kg Anti-PC X19-A05
8.3±0.39.7±0.82 mg/kg Anti-PC X19-A05
9.9±1.011.0±1.010 mg/kg Anti-PC X19-A05
10.6±1.29.9±1.110 mg/kg Anti-PC M99-B05
11.4±2.412.5±1.610 mg/kg Hu IgG1 anti-strep A2
12.4±2.314.4±2.4Vehicle
13.3±2.310.5±2.010 mg/kg Hu IgG1 anti-strep A2
10.6±1.88.3±1.410 mg/kg anti-PC T15 IgG
12.5±2.29.0±1.510 mg/kg Anti-PC X9-C01
9.5±1.89.1±1.810 mg/kg Anti-PC M99-B05
12.4±2.49.9±2.010 mg/kg Anti-PC M73-G3
19.2±1.410.8±1.0Vehicle
13.8±0.611.1±0.910 mg/kg Hu IgG1 anti-strep A2
18.7±1.413.3±2.510 mg/kg Anti-PC IgG
SacrificeSurgeryGroup
Total plasma cholesterol (mmol/L)
No statistical significant differences were observed.
Table 2 Plasma cholesterol concentrations. 
Plasma total cholesterol (mmol/L) of ApoE3*Leiden mice receiving vehicle, human anti-streptavidin, anti-
PC T15 IgG, anti-PC M73-G3, anti-PC M99-B05, anti-PC X9-C01 or X19-A05, measured at surgery or at 




Table 3 Plasma antibody titers.
Plasma total IgG (µg/ml) and anti-PC IgG (µg/ml) antibody concentration in ApoE3*Leiden mice receiving 
vehicle, human anti-streptavidin, anti-PC T15 IgG, anti-PC M73-G3, anti-PC M99-B05, anti-PC X9-C01 
or X19-A05, measured at surgery or at sacrifice (day 3 or 14). Results indicated as mean±SEM, n=10. 
Between groups, no statistical significant differences were observed. n.d. not determined. 
10.8±2.2155±33.510 mg/kg Hu IgG1 anti-strep A2
8.4±0.512.8±15.110 mg/kg Anti-PC M99-B05
10.5±0.52.9±2.50.5 mg/kg Anti-PC X19-A05
8.3±0.33.3±6.62 mg/kg Anti-PC X19-A05
9.9±1.042.2±23.810 mg/kg Anti-PC X19-A05
65.6±47.449.1±99.410 mg/kg Anti-PC M99-B05
0.2±0.0142±76.410 mg/kg Hu IgG1 anti-strep A2
0.3±0.20.4±1.0Vehicle
n.d70.9±14.010 mg/kg Hu IgG1 anti-strep A2
n.d103±25.610 mg/kg anti-PC T15 IgG
n.d3.5±0.610 mg/kg Anti-PC X9-C01
n.d54.6±11.410 mg/kg Anti-PC M99-B05
n.d.58.3±6.310 mg/kg Anti-PC M73-G3
0.5±0.10.4±0.1Vehicle
0.8±0.3200±13110 mg/kg Hu IgG1 anti-strep A2
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Blocking Toll-Like Receptors 7 
and 9 Reduces Postinterventi-
onal Remodeling via Reduced 
Macrophage Activation, Foam 
Cell Formation, and Migration 
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Objective The role of toll-like receptors (TLRs) in vascular remodeling is well es-
tablished. However, the involvement of the endosomal TLRs is unknown. Here, we 
study the effect of combined blocking of TLR7 and TLR9 on postinterventional remo-
deling and accelerated atherosclerosis.
Methods and Results In hypercholesterolemic apolipoprotein E*3-Leiden mice, 
femoral artery cuff placement led to strong increase of TLR7 and TLR9 presence 
demonstrated by immunohistochemistry. Blocking TLR7/9 with a dual antagonist in 
vivo reduced neointimal thickening and foam cell accumulation 14 days after surgery 
by 65.6% (P=0.0079). Intima/media ratio was reduced by 64.5% and luminal steno-
sis by 62.8%. The TLR7/9 antagonist reduced the arterial wall inflammation, with 
reduced macrophage infiltration, decreased cytoplasmic high-mobility group box 1 
expression, and altered serum interleukin-10 levels. Stimulation of cultured macro-
phages with TLR7 and TLR9 ligands enhanced tumor necrosis factor-α expression, 
which is decreased by TLR7/9 antagonist coadministration. Additionally, the antago-
nist abolished the TLR7/9-enhanced low-density lipoprotein uptake. The antagonist 
also reduced oxidized low-density lipoprotein–induced foam cell formation, most li-
kely not via decreased influx but via increased efflux, because CD36 expression 
was unchanged whereas interleukin-10 levels were higher (36.1±22.3 pg/mL versus 
128.9±6.6 pg/mL; P=0.008).
Conclusion Blocking TLR7 and TLR9 reduced postinterventional vascular remo-
deling and foam cell accumulation indicating TLR7 and TLR9 as novel therapeutic 
targets.
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Postinterventional remodeling is a critical determinant of long-term efficacy of per-
cutaneous coronary interventions. Restenosis is characterized by acute elastic re-
coil and intimal hyperplasia attributable to inflammation, smooth muscle cell (SMC) 
proliferation, and extracellular matrix turnover.1 Under hypercholesterolemic conditi-
ons, this is accompanied by influx and accumulation of low-density lipoprotein (LDL)
cholesterol in the vessel wall that becomes oxidized and taken up by macrophages. 
Thereby these macrophages become foam cells and initiate a process of accelera-
ted atherosclerosis.2 Previously, we and others described an important causal role 
for extracellular toll-like receptors (TLRs) in postinterventional remodeling. It has 
been shown that TLR4 and the MyD88-dependent pathway play an important role in 
restenosis and postinterventional accelerated atherosclerosis.3–6 Similarly, a crucial 
role for TLR2 has been described.7
TLRs, as part of the innate immune system, are pattern recognition receptors known 
to recognize exogenous ligands that originate from bacteria or viruses as well as 
endogenous ligands. These endogenous ligands may be released after tissue da-
mage or cell stress, processes that may be initiated by percutaneous coronary in-
terventions. MyD88-dependent signaling is the dominant activation pathway of TLR 
signaling leading to nuclear factor-kappaB activation and upregulation of several 
proinflammatory cytokines. Because TLR2 and TLR4 are known to be expressed 
on the cell surface of vascular cells and activated in vascular disease processes via 
damage-associated molecular patterns as endogenous ligands, such as heat shock 
proteins, fibronectin containing extradomain A, tenascin-C, and high-mobility group 
box 1 (HMGB1),8–11 research in the cardiovascular field mainly focused on TLR2 and 
TLR4. Little is known about the role of endosomal TLRs that are mostly studied for 
their recognition of viral/bacterial DNA and RNA fragments, and were originally con-
sidered absent in the healthy arterial vessel wall.12 Activation of endosomal TLRs like 
TLR7 and TLR9 may lead to upregulation of interferon-α (IFN-α), interleukin-6 (IL-6), 
IL-12, or tumor necrosis factor-α (TNF-α) by innate immune cells (eg, macrophages). 
Recently, increased TLR7 mRNA was found in atheroma of human carotids.13 Mo-
reover, TLR9 was also found in human atherosclerotic plaques,14 and arterial cells 
were responsive to TLR9 ligand.15 Interestingly, it has been suggested that these 
receptors may also recognize self-DNA/RNA that is exposed after cell stress and 
damage causing a sterile inflammatory reaction.16–19 TLR7 and TLR9 have also been 
shown to recognize immune complexes containing selfnucleic
acids in autoimmune diseases.16,20 Percutaneous coronary interventions are con-
sidered to cause severe damage to the endothelium allowing influx of lipids and 
inflammatory cells into the vessel wall. Concurrently, deeper layers in the vessel wall 
experience severe stress, and cellular death at the place of intervention may cause 
a release of self-RNA/DNA or proteins that enhance the direct recognition of nucleic
acids by intracellular TLRs or binding of these nucleic acids to intracellular TLR sig-
naling regulators such as HMGB1.21 Most interestingly, activation of TLR9 is also 
reported to increase the secretion of HMGB1, the endogenous ligand for TLR4.22
Recently, we have identified a novel class of oligonucleotidebased compounds that 
act as dual antagonists of TLR7 and TLR9, and inhibit immune responses mediated 
through these receptors.23,24 In the present study, we focus on the therapeutic poten-
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tial of targeting TLR7 and TLR9 to reduce postinterventional remodeling by preven-
ting neointima formation and accelerated atherosclerosis. We illustrate the presence 
and upregulation of TLR7 and TLR9 and their colocalization with macrophages/foam 
cells in a murine model for neointima formation and accelerated atherosclerosis. A 
causal role of the TLR7/9 was studied in a murine model for postinterventional
vascular remodeling in hypercholesterolemic apolipoprotein E*3-Leiden (apoE*3-
Leiden) mice by the use of the TLR7/9 antagonist. Furthermore, we studied activa-
tion and antagonism of TLR7 and TLR9 on cultured macrophages and on foam cell 
formation using a novel TLR7/9 dual antagonist.
Materials and Methods
A detailed description of all materials and methods used is available in the online-on-
ly Data Supplement. In brief, nonconstricted polyethylene cuffs were placed around
the femoral arteries as a well-established model for neointima formation and ac-
celerated atherosclerosis in hypercholesterolemic apoE3-Leiden mice. Immunohis-
tochemistry for TLR7 and TLR9 was performed on paraffin-embedded sections of 
cuffed arteries of hypercholesterolemic apoE3-Leiden mice at t=0 and t=14. A TLR7/
TLR9 dual antagonist was synthesized, and specificity was determined. We studied 
its effect on neointima formation and accelerated atherosclerosis in hypercholes-
terolemic apoE*3-Leiden mice after femoral arterial cuff placement by injecting the 
antagonist biweekly to get sufficient TLR7/9 blockade. Intimal lesions were analyzed 
for CD45, MAC3, and HMGB1 by immunohistochemistry. The antagonist was used 
to study the effect of blocking of TLR7/9 on macrophage activation and lipid accu-
mulation in macrophages. Cytokine levels of TNF-α, IFN-γ–induced protein 10, IL-6, 
IL-12, and IL-10 were quantified by ELISA.
Results
Arterial Injury Leads to TLR7 and TLR9 Presence in the Vessel Wall 
Little is known about the presence of TLR7 and TLR9 in the vessel wall after surgical 
intervention. Using immunohistochemical analysis, we explored whether TLR7 and 
TLR9 are expressed in cuffed remodeled arteries with neointimal lesions after 14 
days and in noncuffed arteries of hypercholesterolemic apoE*3-Leiden mice, be-
cause TLR expression may differ among different arterial segments and also in res-
ponse to vessel damage.12,13 Cuff placement for 14 days provoked severe neointimal 
thickening, and showed the presence of TLR7/9 profoundly in the tunica media of 
these arterial segments. Presence of either TLR7 or TLR9 could not be observed in 
noncuffed femoral arteries (Figure 1A–1D). Lesions in cuffed arteries of wild-type 
mice on a chow diet that consist dominantly of vascular SMCs were also negative 
for TLR7 and TLR9 (Figure IA and IB in the online-only Data Supplement). Negative 
controls showed no staining (Figure IC in the online-only Data Supplement). The 
area with positive staining for both TLRs contained many macrophages, whereas in 
mice with normal cholesterol these lesions hardly show any of these cells. (Figure ID 
and IE in the online-only Data Supplement).
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Inhibition of TLR7- and TLR9-Mediated Immune Responses by Antagonist
Splenocytes were cultured with 0.01 to 10 μg/mL of the dual TLR7/9 antagonist in 
combination with TLR3, TLR4, TLR7, or TLR9 agonist. The antagonist showed a 
dose-dependent reduced production of TNF, IL-6, and IFN-γ–induced protein 10 on 
either TLR7 or TLR9 activation. Activation of TLR4, the most robust signaling TLR, 
was not affected. Also cytokine production via activation of intracellular TLR3, which 
recognizes double-stranded RNA, was not affected by the antagonist (Figure IIA–IID 
in the online-only Data Supplement). Culturing of splenocytes with the antagonist 
alone did not induce cytokine production (not shown). Administration of either TLR7 
or TLR9 agonists alone to mice resulted in elevated inflammation indicated by incre-
ased levels of serum IL-12. Mice administered with antagonist before TLR7 or TLR9 
agonist administration displayed lower levels of serum IL-12. TLR7/9 antagonist al-
one did not induce IL-12 expression, suggesting it does not induce immune respon-
ses. At the dose used, antagonist showed ≈64% and 85% inhibition of TLR9 and 
TLR7 agonist-induced IL-12 in mice, respectively. (Figure III in the online-only Data 
Supplement). Control oligo showed no inhibition of either TLR7- or TLR9-mediated
immune response in mice (Figure 2). 
TLR7/9 Antagonist Reduced Neointima Formation and Accelerated Athero-
sclerosis
After detecting TLR7 and TLR9 presence in remodeled arteries, we focused on vas-
cular remodeling. By in vivo administration of the antagonist, the causal involvement 
of TLR7/9 activation in intimal hyperplasia and accelerated atherosclerosis was as-
sessed in hypercholesterolemic apoE*3-Leiden mice that underwent femoral arterial 
cuff placement, a widely applied model for restenosis. These mice were fed a Wes
Figure 1. Toll-like receptor (TLR) expression in injured femoral artery lesions of hypercholesterolemic 
apolipoprotein E*3-Leiden (apoE3*-Leiden) mice. TLR7 expression (A) and TLR9 expression on femoral 
arteries with neoinitma 14 days after cuff placement (B). Noncuffed femoral arteries stained for TLR7 (C) 
and TLR9 (D). EEL indicates external elastic lamina; IEL, internal elastic lamina.
166
Chapter 7
tern-type diet, starting 3 weeks before surgery to induce hypercholesterolemia, and 
are well known to develop intimal lesions attributable to neointima formation and ac-
celerated atherosclerosis. No significant difference in plasma total cholesterol levels 
was detected before surgery (control 9.3±0.60 mmol/L; TLR7/9 antagonist 9.0±0.46
mmol/L), nor had antagonist-treated mice significant altered cholesterol levels com-
pared with control mice after 14 days at euthanizing (control 8.4±0.4 mmol/L; TLR7/9 
antagonist 7.7±0.8 mmol/L). Hematoxylin-phloxine-saffron–stained sections were 
used to study vessel wall composition and showed a profound neointima formation 
with foam cell formation, which was clearly reduced in the antagonist-treated group. 
After quantification, we observed reduction in neointima formation of 66% (n=9 ver-
sus n=7; 5838±1158 μm2 versus 2008±223 μm2; P=0.0079), a beneficial intima/
media ratio (0.473±0.09 μm2 versus 0.168±0.018 μm2; P=0.0021), and a reduction 
in percentage of lumen stenosis of 64% (33.9±6.6% versus 12.5±2.9%; P=0.0021) 
after administration of antagonist biweekly. No differences in total vessel wall area or 
media area were found (Figure 3A–3G). In addition, we found a difference in IL-10 
serum levels that were significantly higher in the antagonist-treated mice 14 days af-
ter cuff placement (0.43 versus 15.46 pg/mL; P=0.0003; Figure IV in the online only
Data Supplement). At euthanizing, the antagonisttreated mice had a higher number 
of circulating Ly6Clow monocytes compared with PBS-treated controls (Figure V in 
the online-only Data Supplement). In the lesions of the antagonist-treated mice, a re-
duced number of macrophages (MAC3-positive cells) was observed (Figure 3). This
difference may be attributable to reduced infiltration of the vessel wall by the circu-
lating monocytes because the expression of adhesion molecule CD11b was decre-
ased on the cells of the antagonist-treated mice (Figure 3H). Nonspecific oligonu-
cleotide administration not only had no effect on the number of circulating (Ly6Clow) 
monocytes or CD11b expression compared with PBS treatment, it also did not affect 
neointima formation (Figure 3I and 3J). 
Figure 2. Antagonist or control oligo was injected at 5 mg/kg, s.c. in the left flank of 6- to 8-week-old 
female C57BL/6 mice (n=2/group). RNA-based toll-like receptor 7 (TLR7) agonist at 10 mg/kg, s.c. or 
TLR9 agonist at 0.25 mg/kg, s.c. was injected 48 hours later in the right flank. Two hours post-TLR agonist
administration, blood was collected, and serum interleukin-12 (IL-12) level was determined by ELISA. 
TLR7 or TLR9 agonist alone was used as a positive control. Data shown are representative of at least 2 
independent experiments.
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Figure 3. Restenosis with accelerated 
atherosclerosis was initiated via cuff pla-
cement around the femoral artery in hy-
percholesterolemic apolipoprotein E*3-
Leiden (apoE*3-Leiden) mice. Areas of 
femoral arteries were quantified by using 
6 sections
per vessel of each mouse. A mean of 
these 6 sections was used as the out-
come of arterial remodeling per mouse. 
Outcomes of
analysis are expressed in μm2 
(mean±SEM). Mice treated with the an-
tagonist showed a significant reduction 
in neointima formation compared with 
controls (A). Antagonist-treated mice 
also showed a decrease in percentage 
of lumen stenosis (B) and a beneficial in-
tima/media ratio (C). Neither total vessel 
wall area nor media area were altered 
(D and E). Representative hematoxy-
linphloxine-saffron (HPS; F) and Wei-
gert elastin (G) stained cross sections of 
control mice and antagonist-treated mice 
14 days after cuff placement. Number of 
circulating Ly6clow monocytes (correc-
ted for total white blood cell count; H). 
Expression of adhesion molecule CD11b 
on Ly6clow monocytes (I). Neointima for-
mation of cuffed mice treated with PBS, 
control oligo, and toll-like receptors 7 
and 9 (TLR7/9) antagonist (J). *P<0.05. 
Statistical analysis was performed by 
use of a nonparametric Mann-Whitney 




Figure 4. Lesion composition after treatment with toll-like receptors 7 and 9 (TLR7/9) antagonist in hy-
percholesterolemic apolipoprotein E*3-Leiden (apoE*3-Leiden) mice. Sections were stained for MAC3 
and CD45. Positive staining in areas of femoral arteries was quantified by using 6 sequential sections per 
artery of each mouse. A mean of positive staining of these 6 sections was used as the outcome of positive 
immunostaining per mouse. Outcomes of analysis are expressed in μm2 (mean±SEM) and percentage 
of area of either media or neointima. Macrophage infiltration was significantly reduced in the antagonist-
treated group compared with the controls in both neointima (A) as well as media (B). Percentage of 
positive staining for MAC3 was reduced in this group in both media (C) and neointima (D). Resentative 
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TLR7/9 Blockade Reduced Macrophage/Foam Cell-Positive Area
As stated above, we observed a significant reduced MAC3-positive area. This was 
the case in both media (2445±327 μm2 versus 661±199 μm2; P=0.002) as well as 
neointima (268±59 μm2 versus 26±9 μm2; P=0.003), indicating less infiltration of ma-
crophages that are importantly involved in the remodeling process. The percentage 
of positive area was also significantly reduced indicating a reduction of positive cells 
per μm2 in both media as well as in the formed neointima. We also checked whether 
the effects observed in vivo could be related to the accumulation of total leukocytes 
in the lesions. Therefore, we quantified the area of the vessel segments that was 
positive of CD45, a pan-leukocyte marker. Vessels of the antagonist-treated mice 
showed a trend toward a reduced CD45-positive area which was significant in the 
neointima (Figure 4A–4J). 
TLR7/9 Blockade Reduced Cytoplasmic HMGB1
Layers in the vessel wall undergo severe stress on intervention. Together with our 
finding of a significant decrease in macrophages, we searched for the presence 
of cytoplasmic or extracellular HMGB1 that is a marker of cell stress and macro-
phage activation. HMGB1 can be directly upregulated by TLR9 activation and is an 
important TLR7/9 signaling regulator and an endogenous TLR2/4 ligand. Kalinina 
et al previously showed that HMGB1 could be detected in atherosclerotic plaques. 
Furthermore, the authors showed that this was dominant in macrophages, and that 
in these macrophages there was a marked increase of HMGB1 in the cytoplasm.25
Therefore, we performed analysis for the presence of cytoplasmic HMGB1 in the ar-
terial wall. Because TLR7/9 was predominately expressed in the tunica media, where 
most macrophages/foam cells were present, the media area of the vessel segments 
that was positive for HMGB1 outside the nucleus was quantified. We found a signi-
ficant decrease in the percentage of positive cytoplasmic HMGB1 in the media area 
of mice treated with antagonist (12.97±1.03% versus 7.80±1.28%; P=0.011; Figure 
5A–5C). This is of special interest, because HMGB1 release is increased on TLR7/9 
activation, regulates TLR7/9 signaling, and is known to function as an endogenous
ligand for TLR2 and TLR4 (Figure 5A–5C).
TLR7/9 Blockade Reduced Macrophage Proinflammatory Cytokine Production 
on TLR7/9 Activation
Macrophage activation and foam cell accumulation play a crucial role in lesion for-
mation and accelerated atherosclerosis development after cuff placement. Because 
we found less macrophages and HMGB1 after blocking TLR7/9, we studied the ef-
fects of modulation of the TLR7/9 signaling in cultured bone marrow–derived ma-
crophages. Bone marrow–derived macrophages were cultured for 7 days, and then
stimulated with either TLR7 ligand imiquimod, TLR9 ligand C-phosphate-G (CpG)-
oligodeoxynucleotide, or a combination of both for 24 hours. Activation was monito-
red by analysis of TNF-α expression, a key proinflammatory cytokine also known to 
pictures of control mice and antagonist-treated mice (E). Leukocyte infiltration in the antagonist-treated 
group compared with the controls in media (F) as well as neointima (G). Percentage of positive staining 
for CD45 in the media (H) and neointima (I). Representative pictures of CD45 stained sections of control 




be regulated in vivo after cuff placement.26 Coadministration of TLR7/9 ligands with 
the antagonist caused a significant reduction in the production of TNF-α, whereas 
lipopolysaccharide-induced production of TNF-α was not altered by the antagonist 
(Figure 6A). 
Figure 5. Presence of cytoplasmic highmobility group box 1 (HMGB1) in the injured vessel wall of hy-
percholesterolemic apolipoprotein E*3-Leiden (apoE3*Leiden) mice 14 days after surgery. Sections were 
stained for HMGB1. Positive staining in areas of femoral arteries was quantified by using 6 sequential 
sections per artery of each mouse. A mean of positive staining of these 6 sections was used as the out-
come of positive immunostaining per mouse. Outcome of cytoplasmic HMGB1 analysis in percentage
(mean±SEM) of area of media (A). Representative pictures of HMGB1 staining in control mice (B) and 
antagonisttreated mice (C). Statistical analysis was performed with a nonparametric Mann-Whitney test, 
*P<0.05. TLR7/9 indicates toll-like receptors 7 and 9.
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TLR7/9 Blockade Reduced Foam Cell Formation by Macrophages
Additionally to the direct effect of proinflammatory cytokine excretion by macropha-
ges, we looked into the effect on lipid accumulation by macrophages because both 
processes are important in postinterventional remodeling. Because macrophage-
induced cytokine production and foam cell formation are major contributors to neoin-
tima formation and accelerated atherosclerosis, we studied whether TLR7 activation
in combination with native LDL could induce lipid uptake by macrophages as was 
shown previously for TLR9. Reduced TLR9 activation was previously described to be 
important in foam cell formation via oxidation of native LDL-cholesterol that normally 
is not capable of causing foam cell formation.27 Furthermore, we were interested in 
whether our antagonist could block this process efficiently like it did on inflammation
with only the agonists. Presence of native LDL with TLR7 stimulation alone caused 
lipid accumulation shown by positive Oil Red O staining in the macrophages whereas 
native LDL-cholesterol alone showed no staining at all (Figure 6A and 6B). The use 
of antagonist showed a clear reduction in lipid uptake, and thus foam cell formation 
indicated less intracellular Oil Red O staining in the fixed macrophages (Figure 6B–
6E). TLR9 activation and blockade in the presence of LDL gave the same results, 
and was described previously27,28 (data not shown). Foam cells, formed by oxidized 
LDL (oxLDL) uptake of macrophages, die of releasing lipids, intracellular molecules, 
and necrotic debris which can further activate the
remaining macrophages via endosomal receptors like TLR7/TLR9.29 Therefore, we 
cultured macrophages in the presence of oxLDL cholesterol (Figure 6F) to check 
whether the antagonist also could influence this lipid accumulation if we combined 
oxLDL administration with the antagonist. Oil Red O staining was found in the ox-
LDL-treated macrophages, whereas in combination with the antagonist showed only 
a few slightly positive cells (Figure 6F and 6G). To see whether this effect was de-
pendent on influx or efflux of lipids, we analyzed expression of scavenger receptor 
CD36 and IL-10 production. CD36 scavenger receptor expression was not different 
(positive CD36 macrophages; control 41.48% versus antagonist 41.32%; Figure V 
in the online-only Data Supplement), however we noticed significant change in IL-
10 levels (Figure 6G) indicating effects on lipid efflux whereas IL-10 enhances lipid 
efflux via the peroxisome proliferator-activated receptor-γ-liver X receptor- ATP-bin-
ding cassette subfamily A member 1/ATP-binding cassette subfamily G member 1 
pathway.30
Figure 6. Bone marrow–derived macrophages cultured with imiquimod (IQ) as a ligand for toll-like receptor 
7 (TLR7), C-phosphate-G–oligodeoxynucleotide (CpG-ODN) as a ligand for TLR9 or TLR7/9 antagonist 
for 24 hours. IQ and CpG induced macrophage activation. Use of the TLR7/9 antagonist caused a decre-
ase in tumor necrosis factor-α (TNF-α) production. TLR4- (lipopolysaccharide, [LPS]) induced activation 
was not altered by the antagonist. A, Foam cell formation was studied on cultured macrophages in the 
presence of empty medium, native low-density lipoprotein (LDL), IQ, IQ+LDL, and IQ+LDL+antagonist. 
All wells were screened for positive Oil Red O (ORO) staining, and representative pictures are shown. 
Macrophages with native LDL showed no lipid uptake after staining with ORO (B). Positive staining in the 
presence IQ with native LDL (C), IQ+LDL+antagonist (D), and IQ (E). Foam cell formation independent of
direct TLR activation was studied on cultured macrophages in the presence of oxidized LDL (oxLDL) or 
oxLDL+antagonist. All wells were screened for positive ORO staining, and representative pictures are 
shown. Macrophages with oxLDL showed lipid uptake after staining with ORO (F) but only a few positive 
spots in the presence of TLR7/9 antagonist (G). Analysis by ELISA showed a significant difference in in-
terleukin-10 (IL-10) levels in the presence of TLR7/9 antagonist (H). Student t test was used for statistical 




The present study describes the role of a novel TLR7/9 dual antagonist in resteno-
sis and accelerated atherosclerosis in mice. Individual presence of both TLR7 and 
TLR9 was noticed in femoral arteries of hypercholesterolemic apoE*3-Leiden mice 
with neointimal lesions and accelerated atherosclerosis after 14 days. These have 
to be infiltrating cells (eg, macrophages), whereas normal arteries or arterial lesion 
from normal mice that consist dominantly of vascular SMC stained negative for both 
TLRs and macrophages. In vivo administration of antagonist showed a significant 
reduction in neointima formation with a beneficial intima/media ratio in hypercholes-
terolemic apoE*3-Leiden mice. Moreover, blockade of TLR7/9 signaling led to a re-
duction in CD45- and MAC3-positive cells in both media as well as in the neointimal 
lesions, and we notice a decrease in cytoplasmic HMGB1 indicating a decrease in 
cellular stress and a difference in serum IL-10. In vitro, macrophages showed a sig-
nificant increase in TNF-α production on TLR7 or TLR9 activation that was reduced 
after receiving TLR7/9 dual antagonist. Administration with TLR7 ligand imiquimod 
or TLR9 agonist CpG caused lipid accumulation in macrophages that could be suffi-
ciently blocked by the antagonist. Moreover, oxLDL-induced foam cell formation was 
inhibited by antagonist, possibly via upregulation of IL-10.
Previously, we and others described involvement of TLR2 and TLR4 in postinter-
ventional neointima formation.3,6,7 Recently, a protective role for intracellular recep-
tor TLR3, important in recognition of double-stranded RNA, was found in vascular 
remodeling.31 Neointima formation attributable to postinterventional remodeling is 
strongly mediated by local activation and physiological changes, such as increased 
wall stress, cell damage, and inflammation. In the present study, we were able to 
notice the presence of TLR7 and TLR9 in the postinterventional remodeled arteries 
whereas noncuffed vessels show no presence of these TLRs at all. This can proba-
bly be related to leukocytes that express these TLRs and infiltrate the vessel wall as 
a result of the damage of the intervention such as macrophages, and start to clear 
apoptotic cells and infiltrated lipids. The level of TLR expression may vary among dif-
ferent vessel specimens and may be influenced by these changes.12 Other studies in 
addition to the present showed TLR7 expression in atheroma of carotids13 and TLR9 
presence in human atherosclerotic plaques14 that may be activated via unmethylated 
CpG motifs from bacteria.32 Furthermore, DNA from 17 different bacterial genera 
that can activate TLR9 was found in atherosclerotic carotids,15 together indicating 
a possibly important contribution of these pattern recognition receptors to vascular 
remodeling.
Blocking TLR7/9 signaling by antagonist strongly inhibited neointima formation the-
reby reducing the percentage of lumen stenosis. Neointima formation is strongly 
mediated by SMC proliferation/migration and macrophage activation and lipid up-
take. Because TLR7/9 presence could not be detected in undamaged arteries, it is 
unlikely that there is a direct activation of SMC. However, indirect activation of SMC 
is still possible via cytokines produced by leukocytes which express these TLRs. Our 
results may be explained, at least in part, by the difference in IL-10 production. On 
the other hand, TLR7 and TLR9 stimulation by their ligands causes a strong increase
in the upregulation of TNF-α, which is important in postinterventional vascular re-
modeling, indicating a direct influence of TLR7/9 activation on inflammation. This 
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response was nicely blocked by the antagonist in macrophages. Furthermore, we 
observed lower levels of HMGB1 in the cytoplasm after cuff placement in the anta-
gonist-treated mice, thereby reducing its effect via direct activation of TLR2/4 and 
activation of intracellular TLRs via its binding to their nucleic acid ligands.21,33 More-
over, there were significantly fewer numbers of macrophages/foam cells present in 
media as well as neointima.
Activation of TLR7/9 leads to nuclear factor-kappaB–mediated upregulation of proin-
flammatory cytokines. Furthermore, it is known that TLR9 activation causes release 
of nuclear HMGB1 that may become available in the cytoplasm or even outside the 
cell, where it is known to act as TLR2 and TLR4 ligand and was seen in macropha-
ges in atherosclerotic plaques.22,25,33,34 Not only can this release be initiated on cell 
stress but also on activated macrophages that are capable of releasing HMGB1.34,35 
Previously, we were able to detect HMGB1 in remodeled vein grafts in and outside 
the nucleus.4 On cuff placement, we noticed the presence of HMGB1 in the cyto-
plasm as well. Others previously showed that CpG-oligodeoxynucleotide stimulates 
macrophages to secrete HMGB1, and extracellular HMGB1 is known to accelerate 
the delivery of CpG-oligodeoxynucleotides to its receptor, leading to a TLR9-depen-
dent enhancement of IL-6, IL-12, and TNF-α.22 Interestingly, HMGB1 is also known 
as a regulator of TLR7/9 signaling itself because the absence of HMGBs also seve-
rely impairs the activation of TLR3, TLR7, and TLR9 by their cognate nucleic acids.21 
Therefore, these intracellular TLRs are thought to play a very important role in autoi-
mmune and other inflammatory diseases.20,21 Our data confirm causal involvement 
of TLR7 and TLR9 in vascularrelated diseases, and development of a novel TLR7/9 
dual antagonist may have important implications for understanding and treatment 
of exacerbation periods of other inflammatory diseases such as rheumatoid arthritis 
and after vascular interventions that cause direct vessel damage.
Blocking TLR7/9 signaling leads to a reduction in inflammation and reduced lipid 
accumulation. The role for TLR7/9 may therefore indicate regulation of cell stress 
and thereby providing activation of macrophages to start scavenging lipids, dying 
cells, and attracting more leukocytes to the inflammatory hazard. Our results confirm 
macrophage activation via TLR7/9 ligands and show a decrease of the presence 
of macrophages in the vessel wall after cuff placement in the TLR7/9 antagonist-
treated mice.
Several studies have demonstrated the effect of intracellular TLR activation on lipid 
uptake.27,28,36,37 Both TLR7 and TLR9 agonists cause upregulation of adipocyte diffe-
rentiationrelated protein that is involved in lipid droplet formation in macrophages.38 
TLR9 was previously described to be involved in foam cell formation via upregulation 
of nicotinamide adenine dinucleotide phosphate oxidase 1, lectin-type oxLDL recep-
tor 1, and perilipin 3.27,28 This foam cell formation was nuclear factor-kappaB– and 
IFN regulatory factor 7–dependent, and can be countered via liver X receptor acti-
vation.37 Both nuclear factor-kappaB and IFN regulatory factor 7 are also important 
mediators of TLR7 signaling, and additionally we show that TLR7 stimulation in the 
presence of LDL leads to lipid uptake in macrophages. Our data show that blocking 
of TLR7 receptor results in no lipid uptake in macrophages that receive only LDL. 
Interestingly, the antagonist was capable of decreasing lipid accumulation of oxLDL 
in macrophages probably via IL-10. This might be attributable to altered efflux of 
lipids rather than decreased influx because CD36 expression is not altered whereas 
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IL-10, like in vivo, is upregulated. Macrophage IL-10 is known to enhance the ef-
flux of cholesterol.30 Different mechanisms, directly related to TLR signaling, can 
be involved in changing IL-10 levels. Martin et al.39 showed that glycogen synthase 
kinase 3 can differentially regulate TLR-mediated cytokine production. In the nor-
mal TLR activation situation, there is little phosphatidylinositol 3-kinase stimulation, 
and glycogen synthase kinase 3 primarily remains constitutively active promoting 
the expression of IL-12. Alternative situations, with different pathogenic stimuli or 
blocking antagonists (small molecule inhibitors, RNA inhibitors), can lead to TLR-
dependent activation of phosphatidylinositol 3-kinase and thereby inhibition of glyco-
gen synthase kinase 3 that causes a decrease in IL-12 production and an increase 
in IL-10 production. Woodgett and Ohashi40 have provided a nice overview about 
this glycogen synthase kinase 3 in TLR signaling. Alternatively, it was previously 
described that TLR4 activation can cause an increase of HMGB1 in macrophages, 
and that this HMGB1 is capable of reducing IL-10 levels.41 OxLDL triggers inflam-
matory signaling through a heterodimer of TLR 4 and TLR6. Assembly of this newly 
identified heterodimer is regulated by signals from the scavenger receptor CD36.42 
Foam cells die of releasing lipids, intracellular molecules, and necrotic debris which 
can further activate the remaining macrophages via endosomal receptors like TLR7/
TLR9.29 Although HMGB1 can also be upregulated via TLR9 activation and it further 
enhances TLR7/9 activation, this might be a mechanism that causes the differences 
seen in IL-10 levels. Previously, it was already shown on regulatory T cells that ad-
ditional TLR9 activation could inhibit IL-10 synthesis.43 Further studies are needed to 
fully elucidate the mechanisms causing differences in IL-10 levels in relation to TLR 
signaling and blockade.
In summary, we observed upregulation of TLR7/9 expression during arterial resteno-
sis and reduced macrophage activation and foam cell formation after TLR7/9 bloc-
kade, which was accompanied with increase in IL-10 production. Additional blocking 
of TLR7/9 leads to a reduction in neointima formation, increased IL-10 production, 
reduced macrophage presence in the lesions as well as less HMGB1 release, in-
dicating the important role of TLR7 and TLR9 in postinterventional remodeling via 
reducing inflammation as well as lipid accumulation, thereby making it an interesting 
therapeutic target to reduce restenosis and accelerated atherosclerosis after vascu-
lar intervention.
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All animal experiments were approved by the animal welfare committee of our insti-
tute and are performed according to the regulatory guidelines. Ten week old male hy-
percholesterolemic APOE*3Leiden mice bred in our laboratory were used as previ-
ously described elsewhere.1 Mice were fed a Western-type diet starting three weeks 
before surgery that was continued throughout the entire experiment. Mice were al-
located randomly to different treatment groups. Cholesterol levels were measured 
one day before surgery and at sacrifice. All mice received water and food ad libitum.
Murine model for neointima formation
Non-constricted polyethelene cuffs were placed around the femoral arteries as a 
well-established model for neointima formation and accelerated atherosclerosis.1 
Mice were sacrificed 14 days after cuff placement. All mice received a subcutaneous 
(s.c) injection with either 200μl sterile water (n=9) or 200μl TLR7/9 antagonist (n=7) 
(15mg/kg dissolved in sterile water) for sufficient blocking of TLR7/9 continuously 
without infectious complications. The first injection was administrated directly after 
cuff placement and injections were repeated 4 times (schedule of two injection per 
week) until sacrifice of the mice.
Antagonist activity for TLR7 and TLR9 was assessed in six-to-eight-week-old female 
C57BL/6 mice obtained from Charles River Labs, (Wilmington, MA). Experimental 
procedures were performed according to the approved protocols and guidelines of 
the Institutional Animal Care and Use Committee of Idera Pharmaceuticals. Mice 
(n=2) were injected subcutaneously (s.c.) with 5 mg/kg antagonist. This was follo-
wed twenty/four hours later by 0.25 mg/kg TLR9 agonist 2 or 10 mg/kg of an RNA-
based TLR7 agonist.3 Two hours post agonist administration, blood was collected by 
retro-orbital bleeding.
Morphological Quantification
At sacrifice blood was taken for cholesterol measurement and perfusion/fixation 
was done at 100mmHg with 4% formaldehyde via the left ventricle. Paraffin-embed-
ded cross-sections were stained with either Weigert’s Elastin stain or Hematoxilin-
Phloxine-Saphrane (HPS) to visualize overall morphology. Six sections (5 μm thick) 
equally spaced throughout the cuffed segment were used to quantify intimal lesions, 
media and total vessel size using image analysis software for morphometric analysis 
(Qwin, Leica, Germany).
Cell cultures and reagents
Macrophages were derived from bone marrow from tibia and femur and seeded at a 
density of 250.000 cells/well in 6-wells plates and cultured for 7 days in RPMI Gluta-
Max (Gibco) supplemented with 100U/ml penicillin/streptavidin, 25% Fetal Calf Se-
rum (FCS) and 20μg/ml M-CSF (Myltec Biotechnologies) as described previously.4 
Cells were cultured in the presence of the TLR7 agonist imiquimod (5μg/ml, Invivo-
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gen), the TLR9 agonist ODN-CpG (10μg/ml, Invivogen), oxLDL 50μg/ml or native 
LDL 50μg/ml (Myltec Biotechnologies) and TLR7/9 antagonist (10μg/ml antagonist, 
Idera Pharmaceuticals). All analysis was done on triplicate wells each in three inde-
pendent experiments.
C57BL/6 spleen cells (1x106 cells/ml) were cultured with 0.01 to 10 μg/ml of a TLR7/9 
antagonist in combination with 1 μg/ml of a TLR9 agonist (DNA), 200μg/ml of a TLR7 
(sRNA) agonist or 50 μg/ml of a TLR4 agonist (LPS) or 1μg/ml TLR3 agonist (Poly 
I:C). As controls, spleen cells were cultured with medium alone, TLR9, 7, 4 or 3 
agonist alone, or highest dose (10 μg/ml) of the TLR7/9 antagonist alone. After 24 
hours, culture supernatants were collected and induction of selected cytokines and 
chemokines was assessed. All analysis was done on triplicate wells each in three 
independent experiments.
FACS analysis
Circulating monocytes were stained with anti-mouse CD11b (Biolegend 101224) and 
Ly6C (Bioconnect MCA2389A488). BMD Macrophages (non-stimulated, antagonist, 
oxLDL or oxLDL+antagonist, 24h) were stained anti-mouse CD36-PE, clone 72-1, 
isotype Rat IgG2a (Ebioscience) and analyzed by FACS (BDcalibur).
TLR7/9 antagonist
TLR7 and TLR9 antagonist (5’-TGUCG*TTCT-X-TCTTG*CUGT-5’; wherein, G/U 
are 2’-O-methyl-ribonucleotides, G* is 7-deaza-dG, and X is glycerol linker) was 
synthesized at Idera Pharmaceuticals on solid support on an automated DNA/RNA 
synthesizer with phosphorothioate backbone, purified by HPLC, and analyzed. The 
purity of full-length antagonist was over 93% with the material balance comprised of 
oligonucleotides shorter than the full-length product (n-1 and n-2) as determined by 
anion-exchange HPLC, capillary gel electrophoresis and/or denaturing polyacryla-
mide gel electrophoresis. Sequence integrity was confirmed by MALDI-TOF mass 
spectral analysis. Antagonist contained less than 0.2 EU/ml of endotoxin, as de-
termined by the Limulus assay (Bio-Whittaker). A novel control oligo was created 
with similar chemical modulations in the backbone as in our antagonist since these 
modifications are crucial to the functional activities of the antagonist. The following 
sequence was used as a control oligo=: 5’-CACCCAAGACAGCAGAAAG-3’; It is 
a phosphorothioate oligodeoxynucleotide with 2’-O-methyl-ribonucleotides at each 
end (nucleotides shown in bold).
Assessment of foam cell formation
Foam cell formation was assessed in macrophages that were either stimulated with 
native LDL 50μg/ml or oxLDL 50μg/ml (Myltec Biotechnologies). Incubation with na-
tive LDL was used to study the effect of TLR7 and TLR9 agonists (IQ, and ODN 
CpG) on lipid accumulation in macrophages, whereas oxLDL was used under con-
ditions where effects the antagonist are studied. Oil-red-O staining of macrophages 
was used to identify foam cells. Cells were washed with PBS, fixed in 4%formalde-
hyde and pretreated with 60% isopropanol followed by staining with 1% Oil-Red-O 
solution (Sigma Aldrich). Cells were washed with 60% isopropanol followed by three 
times washing with PBS and examined by light microscopy. Foam cell designation 




ELISA assays were performed with cell free supernatant using commercial available 
kits following the instructions of the manufacturer for TNFα, IL6, IL-10 (BD Bioscien-
ces) and IP-10 (Ebioscience).
Immunohistochemistry
Paraffin-embedded sections (5 μm thick) were stained with antibodies against TLR7 
(AbD serotec), TLR9 (AbD serotec), CD45 (BD Biosciences), Mac3 (BD Bioscien-
ces), HMGB1 (Abcam, Cambridge, United Kingdom) followed by the appropriate 
secondary antibody (Donkey anti Rabbit, GE Healthcare) (Goat anti Rat, Jackson 
labs) and incubated with AB complex (Vector laboratories) and were visualized with 
Novared (Vector laboratories). Slides were counterstained with haematoxylin.
To confirm the specificity of the IHC staining, parallel sections were incubated with 
1% PBS/BSA alone without adding the primary antibody or with Rabbit IgG or Rat 
IgG controls or staining without 1st antibody or staining without the 2nd antibody. Sec-
tions were incubated with the secondary antibody, AB complex and were visualized 
with Novared. Controls were all negative.
Statistics
For to the animal experiments, values are presented as mean ± standard error of the 
mean (SEM). Statistical significance was calculated in SPSS for Windows 17.0. Dif-
ferences between groups were determined using a non-parametric Mann-Whitney 
test. In vitro assays are presented as mean ± standard error of the mean (SEM) and 
were statistically analyzed with a students T test.
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Supplemental figure I: TLR7 staining on arterial lesion of wild type mice (A). TLR9 staining on arterial 
lesion of wild type mice (B). Example of negative control (C), Macrophage staining in lesions of hypercho-
lesterolemic mice (D) and in wild type mice (E). N= 4 mice per staining; at least 6 sections per mouse were 
stained for either TLR7 or TLR9. IEL= Internal Elastic Lamina. EEL= External Elastic Lamina
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Supplemental figure I: TLR7 staining on arterial lesion of wild type mice (A). TLR9 staining on arterial 
lesion of wild type mice (B). Example of negative control (C), Macrophage staining in lesions of hypercho-
lesterolemic mice (D) and in wild type mice (E). N= 4 mice per staining; at least 6 sections per mouse were 
stained for either TLR7 or TLR9. IEL= Internal Elastic Lamina. EEL= External Elastic Lamina
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Supplemental figure II: Effect of antagonist on different TLR stimuli. Cytokine production of TNFα, IL6 
and IP-10 upon TLR activation in the presence of 0.01 to 10 μg/ml of the TLR7/9 antagonist. TLR7 ago-
nist IQ+ TLR7/9 antagonist (A), TLR9 agonist ODN-CpG + TLR7/9 antagonist (B), TLR3 agonist PolyI:C 
+ TLR7/9 antagonist (C), TLR4 agonist LPS + TLR7/9 antagonist (D). Data shown is 1 representative 
experiment out of 3 independent experiments.
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Supplemental figure II: Effect of antagonist on different TLR stimuli. Cytokine production of TNFα, IL6 
and IP-10 upon TLR activation in the presence of 0.01 to 10 μg/ml of the TLR7/9 antagonist. TLR7 ago-
nist IQ+ TLR7/9 antagonist (A), TLR9 agonist ODN-CpG + TLR7/9 antagonist (B), TLR3 agonist PolyI:C 
+ TLR7/9 antagonist (C), TLR4 agonist LPS + TLR7/9 antagonist (D). Data shown is 1 representative 
experiment out of 3 independent experiments.
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Supplemental figure III: Inhibition of TLR9 and TLR7 agonist induced IL-12 by dual antagonist of TLR7/9 
in C57BL/6 mice. Mice (n=2/group) were injected s.c. with 5 mg/kg of antagonist in the left flank and 24 
hr later 0.25 mg/kg of TLR9 agonist or 10 mg/kg of TLR7 agonist s.c. in the right flank. Two hours after 
agonist administration, blood was collected and serum IL-12 levels were measured by ELISA.
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Supplemental figure IV: Plasma IL10 levels in hypercho-
lesterolemic ApoE3Leiden mice treated with or without 
TLR7/9 antagonist 14days after cuff placement. Statisti-
cal analysis was performed by use of a non-parametric 
Mann-Whitney test, * = P<0.05.
Supplemental figure V: FACS analysis of CD36 expression on oxLDL stimulated macrophages.
CD36 expression on macrophages stimulated for 24h with either oxLDL (A) and or with oxLDL in the 
presence of TLR7/9 antagonist (B) Isotype Control (C).
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Objective T-cells are central to the immune response responsible for native athe-
rosclerosis. The objective of this study is to investigate T-cell contribution to post-
interventional accelerated atherosclerosis development, as well as the role of the 
CD28-CD80/86 co-stimulatory and Cytotoxic T-Lymphocyte Antigen (CTLA)-4 co-
inhibitory pathways controlling T-cell activation status in this process.
Methods and Results The role of T-cells and the CD28-CD80/86 co-stimulatory 
and CTLA-4 co-inhibitory pathways were investigated in a femoral artery cuff mouse 
model for post-interventional remodeling, with notable intravascular CTLA-4+ T-cell 
infiltration. Reduced intimal lesions developed in CD4-/- and CD80-/-CD86-/- mice 
compared to normal C57Bl/6J controls. Systemic abatacept-treatment, a soluble 
CTLA-4Ig fusion protein that prevents CD28-CD80/86 co-stimulatory T-cell activa-
tion, prevented intimal thickening by 58.5% (p=0.029).
Next, hypercholesterolemic ApoE3*Leiden mice received abatacept-treatment 
which reduced accelerated atherosclerosis development by 78.1% (p=0.040) and 
prevented CD4 T-cell activation, indicated by reduced splenic fractions of activated 
KLRG1+, PD1+, CD69+ and CTLA-4+ T-cells. This correlated with reduced plasma 
interferon-γ and elevated interleukin-10 levels. The role of CTLA-4 was confirmed 
using CTLA-4 blocking antibodies, which strongly increased vascular lesion size by 
66.7% (p=0.008), compared to isotype-treated controls.
Conclusions T-cell CD28-CD80/86 co-stimulation is vital for post-interventional ac-
celerated atherosclerosis development and is regulated by CTLA-4 co-inhibition, in-
dicating promising clinical potential for prevention of post-interventional remodeling 
by abatacept.
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Atherosclerosis is a chronic inflammatory disease in which endothelial dysfunction 
leads to retention of oxidized low-density lipoprotein (oxLDL) cholesterol particles, 
attracting leukocytes and leading to a local inflammatory response1-3. T-cell subsets 
have been shown to play a vital role in this process4, 5. Unlike native atherosclerosis, 
their contribution to post-interventional remodeling and accelerated atherosclerosis 
development remains uninvestigated. Although local intimal hyperplasia consist pre-
dominately of smooth muscle cells (SMCs) and connective tissue6, platelet and leu-
kocyte (e.g. T-cells) adherence and activation have been shown to be driving factors 
behind this overshooting inflammatory healing response, leading to re-occlusion7.
T-cell responses to immunogenic (neo) antigens such as oxLDL cholesterol are 
regulated by antigen recognition signals provided by peptide-MHC antigen com-
plexes on antigen-presenting cells (APCs) that bind to the T-cell antigen receptor 
(TCR), which operates in concert with co-stimulatory signals. The dominant co-
stimulatory receptor CD28 is constitutively expressed on resting T-cells, whereas 
Cytotoxic T-lymphocyte antigen (CTLA)-4 is a co-inhibitory receptor expressed on 
activated T-cells8, 9. Their ligands CD80 and CD86 are upregulated upon activation 
and predominantly expressed on dendritic cells, B cells, and monocytes/macropha-
ges. CTLA-4 is homologous to CD28 and binds CD80-CD86 with much higher af-
finity than CD2810. During an ongoing immune response, CTLA-4 is upregulated 
and outcompetes CD28 leading to inhibition of T-cell proliferation and reduction of 
interleukin (IL)-2 production11. The importance of the CD28/CTLA-4 pathways has 
become evident by generating mice genetically deficient in CTLA-4, which develop 
fatal lymphoproliferative disease with progressive T-cell accumulation in peripheral 
lymphoid and solid organs12, 13.
Upon stimulation, CD4+ T helper 1 (Th1) effector cells upregulate CD40 ligand and 
produce interferon (IFN)-γ, responsible for pro-atherogenic cellular chemotaxis and 
macrophage activation3, leading to inflammation. Blocking of CD28-CD80/86 me-
diated co-stimulation by CTLA-4 domain-containing Ig fusion proteins (abatacept), 
capable of binding CD80/86 with high-affinity can downregulate T-cell proliferation14 
and production of tumor necrosis factor (TNF)-α, IL-2 and IFN-γ in vitro15. Abata-
cept displays little immunogenicity, with <3% of patients developing an antibody res-
ponse towards abatacept16 and is used to treat rheumatoid arthritis (RA) patients17-19. 
Although the T-cell20, 21 and CD28-CD80/CD86 co-stimulation5, 22 roles have been 
demonstrated in native atherosclerosis, their contribution to post-interventional re-
modeling and accelerated atherosclerosis development is unknown, as is the role 
of CTLA-4. We hypothesized that the CD28-CD80/86 pathway is instrumental in 
post-interventional T-cell-regulated arterial inflammation and that the co-inhibitory 
CTLA-4 pathway downregulates these T-cell responses limiting inflammatory-indu-
ced intimal thickening.
In the present study, we studied the role of CD4 T-cells and co-stimulatory cellular 
activation in post-interventional remodeling in both CD4-/- and CD80-/-CD86-/- mice 
using a well-established mouse model7, 23. CTLA-4 contribution to this process is 
investigated by treating operated C57Bl/6 mice with abatacept. Next, CTLA-4 co-
inhibition effects are investigated by studying post-interventional accelerated athero-
sclerosis development in hypercholesterolemic ApoE3*Leiden mice after both aba-
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tacept treatment and systemic CTLA-4 antibody blockade. Our results demonstrate 
that CD4 T-cells promote post-interventional atherosclerosis in a CD28-CD80/CD86-
dependent fashion and that CD4 T-cell CTLA-4 co-inhibition regulates accelerated 




The authors of this manuscript have certified that they comply with the Principles of 
Ethical Publishing in the International Journal of Cardiology24.
Femoral arterial cuff mouse model
All experiments were approved by the Institutional Committee for Animal Welfare 
of the Leiden University Medical Center and the investigations are in conformation 
with the Guide for the Care and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication No. 85-23, revised 1996). We performed 
multiple in vivo studies in which wildtype (C57Bl/6) control, CD4-/- and CD80-/-CD86-/- 
mice were subjected to femoral artery cuff placement to induce vascular injury and 
remodeling7, 23. Both during surgery and sacrifice, mice were anesthetized with a 
combination of IP injected Midazolam (5 mg/kg, Roche), Medetomidine (0.5 mg/
kg, Orion) and Fentanyl (0.05 mg/kg, Janssen). This surgery produces concentric 
intimal lesions that affect vessel patency and consist predominately of SMCs and 
connective tissue and is strongly inflammation-dependent6.
 
Abatacept treatment
Treatment with 10 mg/kg abatacept at the time of surgery through intraperitoneal in-
jection, similarly to that used in clinical treatment of RA and in earlier murine studies 
was given to evaluate the role of the CD28-CD80/CD86 co-stimulatory pathway in 
this process. 
Vascular wall lesion analysis
In these vascular segments, inflammatory cell adhesion, infiltration, intimal thicke-
ning and lesion composition were assessed using histology, morphometry and im-
munohistochemistry (IHC), as described previously23. Samples were stained with 
hematoxylin-phloxine-saffron and specific vessel wall composition was visualized 
for elastin, collagen and with antibodies against leukocytes, macrophages, vascular 
SMCs, CD3 and CD4 T-cells, matrix metalloproteinase-9 and CTLA-4. This analysis 
was repeated in operated hypercholesterolemic ApoE3*Leiden mice to assess ac-
celerated atherosclerotic lesion phenotype. 
Flow cytometry 
Leukocyte subsets were characterized using flow cytometry in spleen and draining 
inguinal lymph nodes25. These were harvested and single-cell suspensions were pre-
pared by mincing the tissue through a 70-µm cell strainer. For cell surface staining, 
cells were resuspended in staining buffer and incubated with fluorescent conjugated 
antibodies. After washing and resuspension in staining buffer, cells were acquired 
using a BD LSRII flow cytometer and data was analyzed using FlowJo software. 
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Cells were stained with fluorochrome-conjugated monoclonal antibodies specific for 
CD3, CD4, CD44, CD25, CD62L CD69, CD127, CTLA-4, and KLRG1 and staining 
for intracellular FoxP3 was performed using the FoxP3 staining set. 7-AAD was used 
to exclude dead cells.
Biochemical analysis 
Plasma IFN-γ and IL-10 levels were determined using ELISA were performed accor-
ding to the manufacturer's instructions and total plasma cholesterol was measured 
enzymatically. 
Functional CTLA-blockade
CTLA-4 co-inhibition effects on accelerated atherosclerosis development was con-
firmed using anti-CTLA-4 blocking antibodies11. Anti-murine CTLA-4 IgG antibodies 
used in this study were isolated from supernatants from the 9H10 hybridoma line. 
Antibody concentration was performed using an artificial kidney and the concen-
trated antibodies were protein G-purified. CTLA-4 blockade in ApoE3*Leiden mice 
was induced by injecting animals IP with 200 μg of anti-mouse CTLA-4 or control 
IgG once every 2 days, starting at the time of surgery. All materials and methods are 
described in detail in the supplemental material.
 
Results
CD4 T-cells and CD80/86 mediated-co-stimulation are critically involved in 
post-interventional vascular remodeling 
To investigate the contribution of CD4 T-cells and the CD28/CTLA-4-CD80/86 pa-
thways to vascular remodeling, we placed femoral artery cuffs in control, CD4-/- 
and CD80-/-CD86-/- mice and animals receiving abatacept-treatment. Murine body 
weights were similar at surgery and sacrifice (table 1). 21d after surgery lesions 
were stained with hematoxylin-phloxine-saffron (HPS) to visualize overall vascular 
wall morphology (fig 1A), and revealed that untreated animals, compared to CD4-/-, 
CD80-/-CD86-/- and abatacept-treated mice, developed concentric intimal thickening 
leading to luminal stenosis. Weigert’s elastin staining was performed to allow mor-
phometric analysis using the elastic laminae to assess vessel layer surface area 
and remodeling. Analysis showed that intimal thickening was reduced by 72.1% 
(p=0.006) in CD4-/- mice, by 64.2% (p=0.015) in CD80-/-CD86-/- mice and by 58.5% 
(p=0.029) in abatacept-treated animals compared to controls (fig 1B). 
Since the total surface area (μm2) of the media was similar in all groups (fig IB), 
absence of CD4 T-cells and CD80/86 co-stimulatory molecules and abatacept-tre-
atment led to reduced intima / media ratio with respectively 70.0% (p=0.011), 66.4% 
(p=0.005) and 55.3% (p=0.047, fig 1C). Additionally, the percentage luminal steno-
sis was reduced in these groups by 48.7% (p=0.042), 47.7% (p=0.031) and 49.9% 
(p=0.036) respectively (fig 1D). These results indicate a reduced inflammatory-dri-
ven remodeling process the injured arterial segments. The total vessel and luminal 
areas (μm2) were not different between all groups (fig IA,C). These data indicate an 
important role of CD4 T-cells and the CD28/CTLA-4-CD80/CD86 co-stimulatory axis 
in post-interventional vascular remodeling.
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CD4-/-, CD80-/-CD86-/- and abatacept-treated mice display an altered lesion com-
position during post-interventional vascular remodeling 
Lesion composition was analyzed using IHC, which showed larger relative areas (to 
the total vessel layer surface area) of α-SMC actin in the media by 15.8% (p=0.028) 
in CD4-/- and 16.1% (p=0.028) in abatacept-treated mice (fig 1E), whilst α-SMC ac-
tin+ relative area in the intima was significantly decreased compared to controls 
by 31.6% (p=0.001) and 29.3% (p=0.019) respectively (fig 1G). Both medial (fig 
1H) and intimal (fig 1I) relative collagen areas (%) were similar between groups, 
reflecting absolute α-SMC actin+ and collagen areas (μm2) in the media (fig IIA,C). 
Total α-actin+ SMC area (μm2) in the intima was only reduced in CD4-/- mice by 
59.7% (p=0.008) whilst collagen area (μm2) remained unchanged (fig IIB,D) with 
limited CD45 leukocyte and CD4 T-cell infiltration in the vascular layers in control 
sections (fig IIE), indicating an indirect but clear effect of CD4 T-cells upon vascular 
SMC proliferation and migration.
Abatacept prevents accelerated atherosclerosis 
The contribution of the CD28-CD80/CD86 co-stimulatory pathway to accelerated 





























































Figure 1. Reduced vascular remodeling in CD4-/- and CD80-/-CD86-/- and abatacept-treated mice. Repre-
sentative cross-sections of cuffed-femoral arteries of CD4-/-CD80-/-CD86-/- and abatacept-treated mice (A) 
after 21d (hematoxylin-phloxine-saffron (HPS) and Weigert’s elastin staining, 80x, arrows indicate internal 
elastic laminae). Quantification of intimal thickening (µm2) (B), intima / media ratio (C) and luminal steno-
sis (%) (D). Horizontal bars indicate median values, n=10. * p<0.05, ** p<0.01.
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sclerosis development in Western-type diet-fed hypercholesterolemic ApoE3*Leiden 
mice using abatacept as therapeutic intervention strategy. Plasma cholesterol con-
centrations (12.1±3.1 mmol/L) were similar in all groups throughout this study (table 
2). Vehicle and abatacept-treated ApoE3*Leiden mice were sacrificed 14d after ar-
terial cuff placement and accelerated atherosclerotic lesions were stained with HPS 
to visualize overall vascular morphology (fig 2A). This revealed that vehicle-treated 
animals developed concentric intimal thickening and luminal stenosis, consisting of 
connective tissue with profound cellular infiltration which was absent in abatacept-
treated mice. Quantitative analysis of cuffed arteries stained with Weigert’s elastin 
identified reduced intimal thickening after abatacept treatment with 78.1% (p=0.040, 














Figure 1. Reduced vascular remodeling in CD4-/- and CD80-/-CD86-/- 
and abatacept-treated mice. Representative cross-sections of cuffed-
femoral arteries of CD4-/-CD80-/-CD86-/- and abatacept-treated mice 
(E) after 21d (α-SMC actin and Sirius Red collagen staining, 80x). 
Quantification of relative medial SMC (F) and collagen (G) areas (%) 
and intimal SMC (H) and collagen (I) areas (%). Horizontal bars indi-














































































(p=0.040, fig 2C), and intima / media ratio by 69.5% (p=0.037, fig 2D). Furthermore, 
luminal stenosis percentage was reduced by 48.2% (p=0.021, fig 2E), identifying a 
potent role for CTLA-4 co-inhibition controlling inflammatory post-interventional vas-
cular remodeling. The total vessel and luminal areas (μm2) were similar in the aba-
tacept-treated group, although a trend towards reduced total vessel area by 34.6% 
was observed (p=0.094) (fig IIIA, B). 
Abatacept positively affects accelerated atherosclerotic lesion composition
Lesion composition was analyzed using IHC to allow arterial wall inflammatory phe-
notype assessment (fig 3A). Abatacept-treatment produced an altered lesion com-
position with a reduced inflammatory phenotype. Abatacept reduced leukocyte and 
macrophage/foam cell fractions (% of all cells) in the media by 64.0% (p=0.043, fig 
3B) and 72.1% respectively (p=0.003, fig 3D) and intima by 73.9% (p=0.009, fig 3C) 
and 30.5% (p=0.048, fig 3E), respectively. Abatacept-treatment also led to a compa-
rable medial (p=0.602, fig 3F) and 29.8% (p=0.042, fig 3G) increased intimal α-SMC 
actin surface area (%), although absolute intimal SMC area (µm2) was not increased 
(p=0.743, fig IVA), similarly to the tunica media (p=0.888, fig IVB). Whereas limited 
CD3 T-cells and matrix metalloproteinase-9 expressing cells could be detected in the 
tunica intima (fig 3H, I), corresponding with a similar collagen quantity in the intima, 
abatacept reduced these cells in the tunica adventitia by 65.9% (p<0.0001, fig 3J) 
and 64.7% (p<0.0001, fig 3K) respectively. 













































































Figure 2. Abatacept prevents accelerated atherosclerosis in hypercholesterolemic mice. Representative 
cross-sections of cuffed-femoral arteries of hypercholesterolemic ApoE3*Leiden mice following vehicle or 
abatacept-treatment (A) after 14d (HPS and Weigert’s elastin staining, 80x, arrows in inserts indicate in-
ternal elastic laminae). Quantification of intimal thickening (µm2) (B), medial area (µm2) (C), intima / media 
ratio (D) and luminal stenosis (%) (E). Horizontal bars indicate median values, n=10. * p<0.05.
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jured arterial segments of vehicle-treated ApoE3*Leiden mice and was absent in 
uninjured arteries, but occurred 3d after surgery and could still be observed 14d after 
injury, indicating continuing local arterial T-cell activation throughout the remodeling 


















































































































































































































































Figure 3. Abatacept positively affects accelerated atherosclerotic lesion composition. Representative 
cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice following vehicle or abatacept-treatment 
(A) after 14d (leukocyte, macrophage and α-SMC actin staining, 80x). Quantification of relative medial 
leukocyte (B), macrophage (D) and SMC (F) areas (%) and intimal leukocyte (C), macrophage (E) and 
SMC (G) areas (%) and intimal CD3 (n) (H) and MMP-9 (n) (I), as well as adventitial CD3 (n) (J) and MMP-
9 cells (n) (K). Horizontal bars indicate median values, n=10. * p<0.05, ** p<0.01. 
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Abatacept prevents systemic CD4 T-cell activation during accelerated athero-
sclerosis 
To examine the role of CTLA-4 co-inhibition upon T-cell activation involved in ac-
celerated atherosclerosis development, CD4 T-cell numbers and T-cell activation 
status were assessed. The markers Killer cell lectin-like receptor subfamily G mem-
ber (KLRG)-1, Programmed Death (PD)-1, CD69 and CTLA-4 were used to analyze 
T-cell activation in the splenic reservoir and draining inguinal lymph nodes of mice 
14d after surgery. 
Absolute CD4 (p=0.557, fig 4A) splenic T-cell numbers were similar in vehicle and 
abatacept-treated mice, as were total splenic cell contents (absolute cells) and per-
centages CD4 T-cell fractions (fig VA,B). Abatacept reduced splenic CD4 T-cells 
fractions expressing CD69 by 61.9% (p=0.008, fig 4B), PD1 by 49.4% (p=0.041, fig 
4C), KLRG1 by 47.4% (p=0.032, fig 4E), and CTLA-4 by 47.0% (p=0.016, fig 4F). 
These data indicate that abatacept strongly and consistently prevented systemic 
CD4 T-cell activation, thereby reducing accelerated atherosclerotic lesion formation. 
In contrast to the reduced severity of inflammatory vascular remodeling, co-inhibition 
with abatacept treatment also reduced fractions of CD4+CD25+FoxP3+ regulatory 
T-cells by 33.3% (p=0.016, fig 4H) in the spleen. No significant differences in the per-
centages of naive (CD62L+ CD44-), central-memory (CD62L+ CD44+) or effector-
memory (CD62L- CD44+) CD4 T-cell populations were observed (p>0.05, fig VC-F).
Contrary to significant reduction of activated CD4 T-cells in the spleen after aba-
tacept-treatment, no evidence of T-cell activation in draining inguinal lymph nodes 
could be found (fig VIA-G), despite adequate cell number isolation for analysis. 
Abatacept affects systemic cytokine levels during accelerated atherosclerosis 
Contribution of activated T-cell fractions to vascular remodeling severity is supported 











Figure 3. Abatacept positively affects accelerated atherosclerotic lesion composition. (L) T-cell CTLA-4 
and CD4 expression throughout the vessel wall of ApoE3*Leiden mice in time before and 3d and 14d after 
surgery (CTLA-4 and CD4 staining, 80x, arrows in inserts indicate positive staining). 
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Figure 4. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Abatacept did not 
affect total CD4 splenic T-cell count (absolute cells) 14d after surgery (A). T-cells were analyzed using 
multiparametric flow cytometry and gated for 7AAD-, CD3+ and CD4+ markers and subsequently for 
either KLRG1+, PD1+, CD69+, CTLA-4+ or CD25+ and FoxP3+ expression and are displayed in dot 
plots (D and G). Abatacept reduced CD69+ (B), PD1+ (C), KLRG1+ (E) and CTLA-4+ (F) activated CD4 
T-cell fractions (%), together with CD25+FoxP3+ regulatory (H) CD4 T-cell fractions (%). Horizontal bars 
indicate median values, n=5. * p<0.05, ** p<0.01.
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and intimal thickening (μm2) (fig 5A). Interestingly, the ratio between regulatory and 
effector helper T-cells remained unchanged in treated animals (fig 5B). Affected sys-
temic CD4 T-cell activation in abatacept-treated mice was investigated by IFN-γ and 
IL-10 measurements in plasma at 14d. Hypercholesterolemic control animals con-
tained an elevated plasma concentration IFN-γ of 43.2±12.1 pg/ml, while abatacept-
treatment reduced the IFN-γ concentration to non-detectable levels (p=0.00023, fig 
5C) after vascular injury. In contrast, plasma IL-10 was significantly elevated from 
4.5±2.0 pg/ml in controls to 23.7±7.1 pg/ml (p=0.012, fig 5D) in abatacept-treated 
mice. Together, these cytokines indicate that abatacept reduced systemic inflam-
mation.
CTLA-4 blockade exacerbates accelerated atherosclerosis development 
To confirm the anti-inflammatory role of CTLA-4 co-inhibition in accelerated athe-
rosclerotic lesion development, we analyzed injured femoral lesions of mice un-
dergoing CTLA-4 blockade using antibodies. HPS staining (fig 6A) revealed that 
CTLA-4 blocking provoked increased accelerated atherosclerosis development and 
decreased luminal patency. Weigert’s elastin staining and morphometric vessel wall 
analysis confirmed increased intimal thickening by 66.7% compared to control mice 
receiving non-specific anti-β gal IgG (p=0.008, fig 6B). Due to a comparable medial 
area between groups, the intima / media ratio was increased by 69.3% (p=0.010, 
fig 6C). Finally, CTLA-4 blockade increased relative luminal stenosis by 86.3% 
(p=0.004, fig 6D) and compromised absolute luminal area by 56.9% (p=0.010, fig 
6E). Total vessel and medial areas (μm2) were both not different between groups (fig 
VIIA,B). Together, these results indicate a strong increase of inflammatory induced 
post-interventional vascular remodeling during functional blockade of CTLA-4 func-




































































































Figure 5. Profound CD4 T-cell contribution to post-interventional accelerated atherosclerosis develop-
ment. (A) Positive correlation between KLRG1+ CD4 T-cell fractions (%) and intimal thickening (µm2) 
(n=6). Abatacept did not affect CD4 regulatory T-cell: effector T-cell ratio (B). Plasma IFNγ (pg/ml) was 
reduced after 14d following abatacept-treatment (C), whilst plasma IL-10 (pg/ml) was upregulated (D). 
Horizontal bars indicate median values, n=10. n.d. non-detectable. * p<0.05, ** p<0.01.
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Accelerated atherosclerotic lesion phenotype is preserved during CTLA-4 
blockade
Lesion composition was analyzed using IHC to assess arterial wall inflammatory 































































































































Figure 6. CTLA-4 blockade exacerbates accelerated atherosclerosis development. Representative 
cross-sections of cuffed-femoral arteries of hypercholesterolemic ApoE3*Leiden mice following isotype 
antibody or anti-CTLA-4 IgG-treatment (A) after 14d (HPS, Weigert’s elastin and CD3 staining, 80-160x, 
arrows in inserts indicate internal elastic laminae and CD3+ T-cells). Quantification of intimal thickening 
(µm2) (B), intima / media ratio (C), luminal stenosis (%) (D) and luminal area (µm2) (E). Quantification 




phenotype (fig VIIIA). Although CTLA-4 blockade enhanced accelerated atheroscle-
rosis development, no lesion composition differences were observed compared to 
controls. There were similar leukocyte and macrophage/foam cell fractions (% of all 
cells) in the media (p=0.414, fig VIIIB; p=0.097, fig VIIID, respectively) and intima 
(p=0.142, fig VIIIC; p=0.769, fig VIIIE, respectively). CTLA-4 blockade also led to a 
comparable medial (p=0.728, fig VIIIF) and intimal (p=0.258, fig VIIIG) α-SMC actin 
surface areas (%). IHC revealed that functional CTLA-4 blockade led to a significant 
increase of CD3+ T-cells (n) in both the tunica intima by 200.0% (p=0.0001, fig 6F) 
and in the tunica adventitia by 241.4% (p=0.0003, fig 6G) compared to controls.
 
Discussion
This study demonstrates an important role for T-cell co-stimulation by CD28-CD80/
CD86 and the negative regulator CTLA-4 in post-interventional intimal hyperplasia 
and accelerated atherosclerosis development. We show that CD4-/- and CD80-/-
CD86-/- mice develop significantly smaller SMC-rich lesions following vascular injury 
and that infiltrated T-cells express CTLA-4 early after surgery. Therapeutic inhibition 
of CD28-CD80/86 function by abatacept significantly prevented accelerated athe-
rosclerosis development in hypercholesterolemic ApoE3*Leiden mice together with 
reduced IFN-γ plasma concentration (fig 5C), probably due to reduced CD4 T-cell 
activation. The role of CTLA-4 co-inhibition was confirmed using blocking antibodies 
which led to profound increased vascular lesion size. 
The role of CD4 T-cells and CD80/86-mediated co-stimulation during native athe-
rosclerosis development26, 27 has been investigated, but their contribution to post-
interventional vascular remodeling remained until this study unknown. In ApoE-/- 
mice, T-cells have been shown to be important in early native atherosclerotic lesion 
progression, but not its initiation27, 28. We provide evidence for activated CD4 T-cell 
involvement in the early stage of vascular remodeling following intervention. As of 
yet, it remains to be investigated towards which antigen the T-cell response is raised. 
Nevertheless, this form of accelerated atherosclerosis develops within months and 
in a localized area, opening the perspective for (local) T-cell-directed treatment di-
rectly after percutaneous coronary interventions. 
CTLA-4 is expressed on activated effector T-cells and constitutively on regulatory 
T-cells, while both CD80 and CD86 are primarily expressed on activated dendritic 
cells, B cells, monocytes/macrophages, which play an important role in native athe-
rosclerosis development4. T-cell-mediated immune responses are initiated in lymp-
hoid tissues where they are activated by APCs presenting two concomitant signals: 
an antigenic signal provoked by specific MHC-antigen peptide complexes that bind 
to the TCR and a co-stimulatory signal induced by CD80 and CD86 molecules that 
interact with CD28 expressed on all T-cells. Together, TCR and CD28 signals lead to 
an inflammatory and pro-atherogenic response. We show that abatacept-treatment 
was able to prevent this systemic activation by reducing the number of activated 
CD4 T-cells fractions in the spleen as evidenced by the activation markers KLRG1, 
PD1, CD69 and CTLA-4. Since vascular injury occurs locally, profound T-cell activa-
tion was expected to occur in draining lymph nodes. However, only low fractions of 
activated T-cells were identified in these lymph nodes (fig VIA-G) whilst analysis of 
splenic T-cell fractions revealed significant activation (fig 4A-F). We cannot exclude 
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effects of abatacept in other lymph nodes, but these are unlikely to supersede the 
effects in the analyzed primary draining lymph nodes. 
Although abatacept effects on accelerated atherosclerosis are mediated through 
systemically reduced T-cell activation, it is not clear to which extent effects on speci-
fic T-cell subsets contributed to the lesion development. Buono et al.22 showed that 
CD80-/-CD86-/-LDL-receptor (r)-/- mice developed decreased atherosclerotic lesions 
compared to LDL-r-/- mice through reduced CD4 Th1 cell activation by CD80/86 on 
APCs. Unlike activated effector T-cells, regulatory CD25+ FoxP3+ T-cells constitu-
tively express CTLA-429 and this is essential for their suppressive function30, 31. Ait-
Oufella et al.5 demonstrated the vital role of regulatory T-cells in native atherosclero-
sis development , using irradiated LDL-r-/- mice receiving reconstituted bone-marrow 
from CD80-/-CD86-/- mice which developed increased atherosclerotic lesions through 
strongly reduced splenic fractions of regulatory CD25+FoxP3+ T-cells. Therefore, 
it is possible that abatacept, may have inhibitory effects on accelerated atheroscle-
rosis development through regulatory T-cell activation status modulation. However, 
Platt et al. showed that abatacept prevented effector T-cell activation, although ef-
fects on regulatory T-cell status in this murine arthritis model were not studied14. 
This study shows reduced fractions of both activated Th1 and regulatory T-cells in 
hypercholesterolemic ApoE3*Leiden mice receiving abatacept. Since the Th1: re-
gulatory T-cell ratio remained unchanged (fig 5B), this strongly suggests that thera-
peutic effects of abatacept can primarily be attributed to directly reduced activation 
of Th1 T-cells and not to Th1 suppression through regulatory T-cells, reflected by an 
elevated concentration of IL-10 (fig 5D) in plasma (baseline 14.4±2.3 pg/ml)23 and 
reduced concentration of IFN-γ (fig 5C) (baseline 9.8±4.6 pg/ml)23, similarly to that 
observed following IL-12 vaccination by Hauer et al. which downregulated the Th1 
immune response and led to attenuation of native atherosclerosis development32. 
These findings are based upon results from animal studies and cannot be automa-
tically extrapolated to the clinical situation. However, they do provide further insight 
into the role of T-cell co-stimulatory pathways when viewed in the light of recent 
exiting data by Dumitriu et al.33 concerning the role of CD28-/- activated T-cells and 
regulatory T-cells during acute coronary syndromes (ACS) in humans, as well as 
carotid stenosis34, unstable angina35, 36 and atherosclerosis development in both hu-
mans37 and animals in general38. The function relevance of CTLA-4 expression for 
human peripheral T-cell has previously been shown by Hoff et al.39 and Yi-qun et 
al.40, in which CTLA-4 blockade was found to both determine CD28null T-cell and 
memory T-cell longevity and responsiveness (e.g. IL-2 production). The potential of 
co-stimulatory-based T-cell-directed intervention strategies in the clinical situation 
is further enhanced by the findings of Bluestone et al.41 and Körmendy et al.42, in 
which functional CTLA-4 blockade functionally affected circulating regulatory T-cells 
in patients undergoing kidney transplantation and peripheral Th cells in rheumatoid 
arthritis patients. This study demonstrated the effectiveness of modulation of co-
stimulatory receptors against post-interventional atherosclerotic vascular remode-
ling in mice, thus greatly enhancing the potential of a similar therapeutic approach to 
improve the survival of ACS patients.
In conclusion, this study shows that T-cell co-stimulation through the CD28-CD80/86 
pathway plays a vital role in post-interventional accelerated atherosclerosis deve-
lopment and is strongly negatively regulated by CTLA-4 co-inhibition. These results 
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may have important clinical implications. Immune-mediated interventions directed 
towards therapeutically controlling the inflammatory T-cell response such as aba-
tacept are widely applied in other immune (e.g. rheumatoid) disorders and could 
now be used in an early phase following interventions such as revascularization or 
bypass grafting procedures in patients to prevent subsequent vascular remodeling. 
This application could be accelerated by the availability of abatacept as a currently 
clinically approved T-cell specific therapeutic agent.
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All experiments were approved by the Institutional Committee for Animal Welfare of 
the Leiden University Medical Center (LUMC). Male C57Bl/6J controls, CD4-/- and 
CD80-/-CD86-/- mice on a C57Bl/6J background were purchased from the Jackson 
Laboratory (Bar Harbor) and transgenic male ApoE*3-Leiden mice, backcrossed for 
more than 20 g enerations on a C57BL/6J background, were bred in our own labora-
tory. All animals used for this experiment were 10-12 weeks at the start of a dietary 
run-in period or surgery and were weighed before and at the end of the experimental 
period.
Diets
C57Bl/6J controls, CD4-/- and CD80-/-CD86-/- mice received chow diet and transge-
nic male ApoE*3-Leiden mice were fed a Western-type diet containing 1% choles-
terol and 0.05% cholate to induce hypercholesterolemia to desired levels in male 
ApoE3*Leiden mice (AB Diets). The Western-type diet was given three weeks prior 
to surgery and was continued throughout the experiment. All animals received food 
and water ad libitum during the entire experiment.
Treatment protocol
To investigate the role of CTLA-4 co-inhibition, C57Bl/6J control and ApoE3*Leiden 
animals were injected intraperitoneally (IP) with abatacept (Bristol-Myers Squibb 
B.V.) in a concentration of 10 mg/kg twice monthly (200 μl) or vehicle, starting at the 
time of surgery. CTLA-4 blockade in ApoE3*Leiden mice was induced by injecting 
animals IP with 200 μg of anti-mouse CTLA-4 IgG (clone 9H101) or control IgG dilu-
ted in 200 μl sterile phosphate-buffered saline (PBS) once every 2 days, starting at 
the time of surgery. 
Blocking CTLA-4 IgG antibody generation
Anti-murine CTLA-4 IgG antibodies used in this study were isolated from superna-
tants from the 9H10 hybridoma line1, first using Iscove's Modified Dulbecco's Me-
dium (IMDM) (Invitrogen) with 8% FCS and 1% glutamine, followed by GIBCO™ 
protein-free hybridoma medium (PFHM)-II (Invitrogen) throughout T75, T175 and 
roller bottle culture systems (Sigma-Aldrich Chemie B.V), maintained at 37°C with 
5% CO2. Antibody concentration was performed using an artificial kidney (Fresenius 
Medical Care). The concentrated antibodies were protein G-purified (GE Healthcare 
Bio-Sciences AB) and antibody concentrations were determined using a Nanodrop 
spectrophotometer and stored at 2 mg/ml in sterile PBS at -20°C for further use.
Femoral artery cuff mouse model
To investigate the role of CD4 T lymphocytes, CD28-CD80/CD86 co-stimulation and 
CTLA-4 co-inhibition, mice were subjected to arterial femoral arterial cuff placement 
to induce intimal thickening and accelerated atherosclerosis development2-4. In brief, 
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mice were anesthetized before surgery with a combination of IP injected Midazolam 
(5 mg/kg, Roche), Medetomidine (0.5 mg/kg, Orion) and Fentanyl (0.05 mg/kg, Jans-
sen). The right femoral artery was isolated and sheathed with a rigid non-constrictive 
polyethylene cuff (Portex, 0.40mm inner diameter, 0.80mm outer diameter and an 
approximate length of 2.0mm). Using two ligatures, the polyethylene cuff was held in 
place, after which the wound was closed using continuous sutures.
Either 14 days (ApoE3*Leiden mice) or 21 days (normocholesterolemic mice) af-
ter cuff placement, mice were anesthetized as before and euthanized. At sacrifice, 
venous blood was drawn in EDTA collection tubes (Sarstedt B.V.) and subjected to 
centrifugation (6000 r.p.m. for 10 min at 4°C) to obtain plasma, which was stored at 
-20°C for further research. The spleen and draining inguinal lymph nodes were iso-
lated and either snap frozen in liquid nitrogen for further analysis (stored at -80°C) 
or minced through a 70-mm cell strainer (BD Biosciences) to create single-cell sus-
pensions and stored in 3% fetal calf serum-rich GIBCO™ RMPI 1640 medium (Invi-
trogen) on ice. 
Next, the thorax was opened and mild pressure-perfusion (100mm Hg) with PBS 
for 4min by cardiac puncture in the left ventricle. After perfusion, the cuffed femo-
ral artery was harvested, fixed overnight in 3.7% formaldehyde in water (w/v) and 
paraffin-embedded. Serial cross-sections (5 μm thick) were made from the entire 
length of the artery for analysis.
Biochemical analysis
Total plasma cholesterol (Roche Diagnostics, kit 1489437) concentration was mea-
sured enzymatically before randomization and at sacrifice. Plasma cholesterol 
concentrations (12.1±3.1 mmol/L) were similar in all groups throughout this study 
(p>0.15, table 2). To investigate effects of abatacept on systemic CD4 T-cell specific 
activation after surgery, interferon (IFN)-γ and interleukin-10 enzyme-linked immuno 
sorbent assays (ELISAs) were performed (BD Biosciences) according to the manu-
facturer's instructions. 
Quantification of cuffed femoral artery lesions
Immunohistochemical (IHC) staining was performed using positive and negative 
tissue-specific controls as indicated by the antibody manufacturer. Samples were 
stained with hematoxylin-phloxine-saffron (HPS) and specific vessel wall composi-
tion was visualized for elastin (Weigert’s elastin staining), collagen (Sirius Red stai-
ning) and with antibodies against leukocytes (anti-CD45 antibodies 1:200, Pharmin-
gen), macrophages (MAC3, 1:200, BD Biosciences), vascular SMCs (α-SMC actin 
1:800, Dako), T-cells (anti-CD3, 1:100, AbD Serotec and anti-CD4, 1:250, Abcam), 
matrix metalloproteinase-9 (anti-MMP-9, 1:100, Santa Cruz), and CTLA-4 (anti-mou-
se CTLA-4, 1:200, Abbiotec), using hematoxylin for counterstaining to visualize all 
cells. The anti-CD4 antibody specificity for CD4 was confirmed on cuffed sections of 
CD4 knock-out mice (21d) (fig IIF).
Sections were deparaffinized by placement in xylene for 5 minutes, followed by etha-
nol 100% for 2 minutes, ethanol 70% for 2 minutes and ethanol 50% for 2 minutes 
and distilled water for 2 minutes. Sections underwent citrate buffer antigen retrieval 
(10mM sodium citrate, pH 6.0) for 10 minutes at 100°C, followed by 30 minutes coo-
ling. PBS (1%) was used as a wash solution and for diluting antibodies. Novared 
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(Vector laboratories) was used as staining vector according to the manufacturer’s 
instructions. Sections were dehydrated by placement in ethanol 50% for 2 minutes, 
ethanol 70% for 2 minutes and ethanol 100% for 2 minutes, followed by xylene for 
5 minutes. The slides were mounted with xylene-based pertex and 24x60 mm co-
verslips.
The number of leukocytes, macrophages and cells expressing CTLA-4 attached to 
the endothelium, within the neointimal tissue or infiltrated in the medial layer of the 
femoral arteries was quantified and is displayed as a percentage of the total num-
ber of present cells. The area containing vascular SMCs, collagen or macrophages 
was quantified using computer-assisted morphometric analysis (Qwin, Leica) and 
is expressed as a percentage of the total cross-sectional arterial wall layer area. All 
quantification in this study was performed on six equally spaced (150µm distance) 
serial stained perpendicular cross-sections throughout the entire length of the vessel 
and was performed by blinded observers.
Flow cytometry 
Spleens and draining inguinal lymph nodes were harvested and single-cell suspen-
sions were prepared by mincing the tissue through a 70-µm cell strainer (BD Biosci-
ences). Erythrocytes were lysed using hypotonic (0.82%) ammonium chloride buffer. 
For cell surface staining, cells were resuspended in staining buffer (PBS + 3%P 
PFCS + 0.05% sodium azide) and incubated with fluorescent conjugated antibodies 
at 4C° for 30 minutes in 96-well plates. After washing and resuspension in staining 
buffer, cells were acquired using a BD LSRII flow cytometer and data was analyzed 
using FlowJo software (version 7.4.6., Tree Star). 
Cells were stained with fluorochrome-conjugated monoclonal antibodies specific for 
CD3, CD4, CD44, CD25, CD62L CD69, CD127, CTLA-4, and KLRG1. All antibo-
dies were purchased from eBioscience or BD Biosciences. Staining for intracellular 
FoxP3 was performed using the FoxP3 staining set from eBioscience (1:200, APC). 
7-AAD was used to exclude dead cells. 
Statistical analysis
All data are presented as mean± standard error of the mean (SEM). Groups were 
compared using a Mann-Whitney sum test for non-parametric data. All statistical 
analyses were performed with SPSS 17.0 software for Windows or using Prism soft-
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Table 1. Murine body weights at surgery and sacrifice. Body weight (gram) of control, CD4-/-, CD80-/-
CD86-/- and abatacept-treated (10 mg/kg/twice monthly) C57Bl/6J mice at surgery and sacrifice at day 21 


















































25.9±0.3 23.7±0.4 Abatacept 
26.0±1.0 24.1±1.1 CD80-/-CD86-/- 
29.0±0.4 26.7±0.4 CD4-/- 
24.8±0.4 22.6±0.4 C57Bl/6J 
Sacrifice Surgery   
Body weight (gram) Group 
        
Figure I. Reduced vascular remodeling in CD4-/- and CD80-/-CD86-/- and abatacept-treated mice. Quan-
tification of total vessel area (µm2) (A), medial area (µm2) (B) and luminal area (µm2) (C) after 21 days. 





































































































































Figure II. CD4-/-, CD80-/-CD86-/- and abatacept-treated mice display an altered lesion composition. Quan-
tification of medial (A) and intimal (B) vascular α-SMC actin area (µm2) and medial (C) and intimal (D) col-
lagen area (µm2) after 21 days. Horizontal bars indicate median values, n=10. ** p<0.01. Representative 
cross-sections of cuffed-femoral arteries of vehicle-treated C57Bl/6J mice (E) after 21d (CD45 leukocyte 
and CD4 T-cell staining, 80-160x). (F) Representative cross-sections of cuffed-femoral arteries of CD4 
knock-out mice after 21d (HPS and CD4 staining, 80x). 
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8.1±1.5 12.3±0.9 30.1±0.8 30.4±0.7 Anti-CTLA-4 IgG 
8.9±0.9 13.4±1.4 29.0±0.6 28.8±0.6 Anti-β gal IgG 
10.4±2.4 11.5±1.0 29.9±0.7 29.4±0.7 Abatacept 
7.9±0.6 11.3±0.4 29.4±0.7 29.0±0.6 Vehicle 
Sacrifice Surgery Sacrifice Surgery   
Total cholesterol (mmol/L) Body weight (gram) Group 
           
Table 2. Murine body weights and plasma total cholesterol at surgery and sacrifice. Body weight (gram) 
and plasma total cholesterol (mmol/L) of vehicle, abatacept (10 mg/kg/twice monthly), isotype control 
antibody (anti-β gal IgG 200 μg every 2 days) or anti-mouse CTLA-4 IgG (200 μg every 2 days)-treated 
ApoE3*Leiden mice measured at surgery and sacrifice (14 days) (mean±SEM, n=10). No significant dif-






































Figure III. Abatacept prevents accelerated atherosclerosis in hypercholesterolemic ApoE3*Leiden mice. 
Quantification of total vessel area (µm2) (A) and luminal area (µm2) (B) after day 14. Horizontal bars indi-
cate median values, n=10.
Figure IV. Abatacept positively affects accelerated atherosclerotic lesion composition. Quantification of 








































Figure V. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Quantification of 
splenic total cell count (*106 cells) (A) and CD4 T-cell fractions (%) (B) 14 days after surgery. Horizontal 








































































































Figure V. Abatacept prevents systemic CD4 T-cell activation in ApoE3*Leiden mice. Quantification of sp-
lenic naïve (CD62L+CD44-) (C) and activated central-memory (CD62L+CD44+) (D) and effector-memory 




























































































Figure VI. Abatacept does not affect draining inguinal lymph node T-cell activation status in hypercho-
lesterolemic ApoE3*Leiden mice. Quantification of total cell count (*106 cells) (A), total CD4 T-cells (*106 
cells) (B), CD4 T-cell fraction (%) (C) and regulatory CD4+CD25+FoxP3+ T-cells (%) (D) in draining 
inguinal lymph nodes, 14 days after surgery. Horizontal bars indicate median values, n=5.
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Figure VI. Abatacept does not affect draining inguinal lymph node T-cell activation status in hypercholes-
terolemic ApoE3*Leiden mice. Quantification of activated PD1+ (E), CD69+ (F) and CTLA-4+ (G) CD4 




























































































































Figure VII. CTLA-4 blockade exacerbates accelerated atherosclerosis development in hypercholestero-
lemic ApoE3*Leiden mice. Quantification of total vessel area (µm2) (A) and medial area (µm2) (B), 14 days 





















































































































































Figure VIII. Accelerated atherosclerotic lesion phenotype is preserved during CTLA-4 blockade. Repre-
sentative cross-sections of cuffed-femoral arteries of ApoE3*Leiden mice following isotype antibody or 
anti-CTLA-4 IgG-treatment (A) after 14d (leukocyte, macrophage and α-SMC actin staining, 80x). Quan-
tification of relative medial leukocyte (B), macrophage (D) and SMC (F) areas (%) and intimal leukocyte 
(C), macrophage (E) and SMC (G) areas (%) showed no significant differences. Horizontal bars indicate 
median values, n=10.
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Aims A major influence on gene expression is attributed to the counterbalancing ac-
tion of lysine acetyltransferases (KATs) and lysine deacetylases (KDACs). This study 
was designed to investigate the influence of genetic variation in the promoter of 
the gene encoding P300/CBP associated factor (PCAF), a lysine acetyltransferase 
(KAT) on coronary heart disease (CHD) and mortality.
Methods and results We investigated the association of genetic variation in the pro-
moter region of the PCAF-gene on CHD and mortality in two statin trials (PROSPER 
and WOSCOPS) and on restenosis risk in a third study of percutaneous coronary 
intervention (GENDER). We combined the results from these cohorts to examine 
1) overall effects on CHD mortality and on 2) restenosis risk and determined the 
contribution of PCAF in an animal model of reactive stenosis. Compared with the 
homozygous -2481G allele in the PCAF promoter, we observed a significant re-
duction in CHD mortality risk with the homozygous -2481C PCAF promoter allele in 
PROSPER (risk reduction 22%; 2% to 37%), a non-significant trend towards reduc-
tion in WOSCOPS (risk reduction 17%; -14% to 39%), and a significant reduction 
of restenosis in GENDER (20%; 3% to 33%). A combined risk reduction for CHD 
death/ restenosis for the three studies was 21% (15%-26%; p= 8.1 x 10-4). In elderly 
patients (>58 years) the effects were stronger and significant in all three studies. 
Furthermore, this PCAF allele was significantly associated with all cause mortality 
in PROSPER (p=0.001). Functional analysis showed that nuclear factors interact 
in vitro with the oligonucleotides encompassing this -2481 G/C polymorphism and 
that this interaction might be influenced in some cell types by this polymorphism in 
the PCAF promoter, and modulation of PCAF gene expression was detectable upon 
cuff-placement in an animal model of reactive stenosis. 
Conclusion: We showed in three large prospective studies that the -2481C allele 
in the PCAF promoter is associated with a significant survival advantage in elderly 
patients while also protecting against clinical and angiographic restenosis after PCI. 
Our observations promote the concept that epigenetic processes are under genetic 
control and that, other than environment, genetic variation in genes encoding KATs 
may also determine susceptibility to CHD outcomes and mortality.
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Investigations into the pathogenetic mechanisms of human complex disease, such 
as cardiovascular disease and cancer, may lead to better risk prediction, treatment 
and new targets for future therapy. Cell proliferation regulatory pathways and pro-in-
flammatory transcription factors, such as NFκB, have been associated with progres-
sion of these diseases1. In the past decade, research into cardiovascular diseases 
such as atherosclerosis and restenosis, has been focused on the identification of 
genetic factors that determine disease risk. Several genes involved in inflammation 
and cell proliferation appeared to be common denominators of these diseases2-4. It 
has become clear, however, that part of the gene-environmental interactions rele-
vant for complex diseases is regulated by epigenetic mechanisms such as histone 
acetylation and DNA methylation5. Epigenetic processes modulate gene expression 
patterns without modifying the actual DNA sequence and have profound effects on 
the cellular repertoire of expressed genes6. Evidence is growing that epigenetic me-
chanisms also regulate the expression of genes in the inflammatory and cell prolife-
ration pathways7;8 and may therefore also play a role in cardiovascular disease9-11. 
A major influence on gene expression is attributed to the counterbalancing action of 
lysine acetyltransferases (KATs) and lysine deacetylases (KDACs)12. KATs acetylate 
histones by transfer of an acetyl-group to the ε-portion of lysine residues, which 
results in an open modification of chromatin structure and in accessibility of DNA to 
transcription factors and recruitment of the basal transcription initiation machinery. 
Conversely, gene repression is mediated via KDACs, which remove acetyl groups 
and counteract the activity of KATs resulting in a closed chromatin structure. Thus 
far, the main focus has been to investigate the environmental influence on epigenetic 
processes. Research in this field has shown that epigenetic differences arise during 
the lifetime of monozygotic twins6. Furthermore, oxidative stress has been shown 
to influence the balance between KATs and KDACs in favour of KATs, leading to an 
increase in inflammation13. Notably, genetic variations in the genes encoding KATs 
and KDACs, which affect the activities of the enzymes they encode, have a bearing 
on the global and gene-specific levels of histone acetylation. As such, these genetic 
variations in the genes encoding KATs and KDACs could also be important determi-
nants contributing to susceptibility to major human diseases.
P300/CBP associated factor (PCAF) is a transcriptional co-activator with intrinsic 
KAT-activity. Besides its role in lysine acetylation of histones at the site of  NFκB-
regulated genes and the resultant inflammatory gene activation14;15, PCAF is also 
found to act as a factor acetyltransferase (FAT) that acetylates non-histone proteins, 
including several tumor-suppressor proteins, such as p5316;17 and the phosphatase 
and tensin homolog (PTEN)18. Because PCAF is involved in proliferation and inflam-
mation, common denominators of the major diseases determining human mortality, 
with clear evidence for inflammatory factors predicting incident CVD events19;20, inci-
dent cancers21 and mortality, we hypothesized that the PCAF-gene could be of major 
importance in the development of cardiovascular disease and cancer, and death 
from such disease. 
We investigated the impact of genetic variation in the promoter region of the PCAF-
gene on all-cause mortality and mortality due to coronary heart disease and cancer 
in the PROSPER-study, a randomized controlled trial in which 5804 elderly patients 
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(age 70-82) at risk for vascular disease were randomized to pravastatin or placebo22. 
In order to validate the observed effects and to be able to extrapolate our findings 
to a younger population, we investigated the PCAF gene in the WOSCOPS study, 
a randomized controlled trial similar to the PROSPER-study, designed to determine 
the effect of pravastatin in middle-aged men with hypercholesterolemia without a 
history of cardiovascular disease. Finally, in order to further test the validity of results 
in the two statin trials, and to get insights in the mode of action, we investigated 
these variants in another large prospective study, the GENDER-study, a prospective 
follow-up study that included 3104 patients undergoing percutaneous coronary inter-
vention (PCI)23. The primary endpoint in this study was clinical restenosis, a process 
that is known to be mainly determined by inflammation and proliferation2. 
All participants in these three study groups were analyzed for 2 polymorphisms 
(SNPs) in the promoter region of the PCAF-gene. Of these polymorphisms, the 
-2481G/C SNP was found significantly associated with CHD mortality in elderly pa-
tients in PROSPER and WOSCOPS, and, in addition, with differential risk for reste-
nosis in the GENDER study. 
 
Methods
Study Design and Follow-up of the PROSPER Study
The protocol of PROSPER has been described elsewhere24. PROSPER is a pros-
pective multicenter randomized placebo-controlled trial to assess whether treatment 
with pravastatin diminishes the risk of major vascular events in elderly individuals. 
Between December 1997 and May 1999, we screened and enrolled subjects in Scot-
land (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and women aged 
70-82 years were recruited if they had pre-existing vascular disease or increased 
risk of such disease because of smoking, hypertension, or diabetes. A total number 
of 5804 subjects were randomly assigned to pravastatin or placebo. In this genetic 
sub-study, we evaluated the predefined endpoints all-cause mortality and mortality 
due to vascular events and cancer. Mean follow-up was 3.2 years (range 2.8-4.0) 
and 604 (10.4%) patients died during the study22. Of these patients, 292 (48%) died 
from vascular disease and 206 (31%) from cancer.
Study Design and Follow-up of the WOSCOPS Study
The WOSCOPS study (the West of Scotland Coronary Prevention Study), a primary 
prevention trial, included 6595 men, aged between 45 and 64 years old, who had 
LDL cholesterol levels between 174 and 232 mg/dL (4.5 and 6.0 mmol/L), who had 
no history of myocardial infarction, but were considered to be at enhanced risk for 
developing CHD25. The first patient was enrolled on February 1, 1989, and the study 
ended on May 15, 1995. Mean follow up duration was 4.9 years. All participants were 
randomly assigned to receive 40 mg of pravastatin or placebo daily.
The present genetic study was performed in a previously described nested case-
control cohort26. In brief, the prospective nested case-control study included all of 
the 580 on-trial CHD events (death from CHD, nonfatal MI, or revascularization pro-
cedures) from the WOSCOPS cohort as case subjects and 1,160 control subjects 
matched to case subjects by age and smoking. In the present genetic study we used 
death from coronary heart disease as our primary endpoint.
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Study Design and Follow-up of the GENDER Study
The present study sample has been described previously23. In brief, the GENetic 
DEterminants of Restenosis project (GENDER) was a multicenter follow-up study 
designed to study the association between various gene polymorphisms and clinical 
restenosis. Patients eligible for inclusion in the GENDER-study were treated suc-
cessfully for stable angina, non-ST-elevation acute coronary syndromes or silent 
ischemia by PCI in four out of 13-referral centers for interventional cardiology in 
the Netherlands. Patients treated for acute ST-elevation myocardial infarction were 
excluded. Experienced operators, using a radial or femoral approach, performed 
standard angioplasty and stent placement. During the study, no drug-eluting stents 
were used. Follow-up lasted for at least nine months, except when a coronary event 
occurred. Clinical restenosis, defined as TVR, either by PCI or coronary artery by-
pass grafting (CABG), was the primary endpoint. Median follow-up duration was 
9.6 months (interquartile range 3.9) and 304 (9.8%) patients underwent TVR during 
follow-up. A prespecified subpopulation of 478 patients was scheduled for re-angio-
graphy at 6 months, according to standard procedures as described previously27. 
Identical projections were used before, during and 6 months after the PCI for all 
assessed angiograms. Quantitative Computer Analyses (QCA) were independently 
performed by Heartcore (Leiden, the Netherlands).  
For all three studies, all endpoints were adjudicated by independent clinical events 
committees. The protocols meet the criteria of the Declaration of Helsinki and were 
approved by the Medical Ethics Committees of each participating institution. Written 
informed consent was obtained from all participating patients.
Genotyping
Blood was collected in EDTA tubes at baseline and genomic DNA was extracted 
following standard procedures. As a first step to investigate this gene, we selected 
2 validated polymorphisms in the PCAF-promoter. The -4556 C/T (rs2623074) and 
the -2481 G/C (rs2948080) polymorphisms were selected on the basis of their high 
minor allele frequency (>5%) and measured using the Sequenom Massarray ge-
notyping platform. A multiplex assay was designed using Assay designer software 
(Sequenom). As quality controls, 5-10% of the samples were genotyped in duplo. 
No inconsistencies were observed. Cluster plots of the signals from the low and 
the high mass allele were drawn. Two independent researchers carried out scoring. 
Disagreements or vaguely positioned dots produced by Genotyper 4.0 (Sequenom 
Inc.) were left out of the results.
Cells and Cell Culture
The cell lines (HeLa, U251, Raji) used in this study were obtained through the ATCC 
(Rockville, MD, USA) and were cultured in Iscove’s modified Dulbecco’s medium 
(IMDM; BioWhittaker Europe, Verviers, Belgium) supplemented with 10% (v/v) heat-
inactivated fetal calf serum (FCS; Greiner, Alphen a/d Rijn, The Netherlands), 100 
IU/mL streptomycin and 100 IU/mL penicillin. For interferon-γ (IFN-γ) induction, cells 
were treated with 500U/mL of IFN-γ (Boehringer-Ingelheim, Alkmaar, The Nether-
lands) for 4 hours, hereafter nuclear extracts were prepared (see below). HUVECs 
were cultured in Medium 199 with Earl’s salt and L-glutamine (Life Technologies, 
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Breda, The Netherlands), supplemented with 20% (v/v) FCS (PAA, Pasching, Aus-
tria), 100 IU/mL streptomycin and 100 IU/mL penicillin, 10 IU/mL heparine (Leo 
Pharma, Breda, The Netherlands) and 25 mg bovine pituitary extract (BPE; Life 
Technologies). 
Transcription Factor Binding Site Search
Potential transcription factor binding sites were identified using the TFSEARCH 
program (http://www.cbrc.jp/research/db/TFSEARCH.html), which searches the 
TRANSFAC database28. Cutoff was set at 75% of the consensus TF binding site.
Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts and EMSAs were performed as described previously29. In brief, 2 µL 
of nuclear extracts (HeLa, HUVEC, U251, Raji) in binding buffer were incubated for 
30 min on ice, with 2 ng of a [33P]-labeled dsDNA probe. The probe sequences were 
similar to either the C or G promoter variants of the PCAF-gene (PCAF-C: 5’-GCAAT-
AAGCCTCCTCAATCCTTTGCCCTTG-3’; PCAF-G: 5’-GCAATAAGCCTCCTGAAT-
CCTTTGCCCTTG-3’). Probe sequences for transcription factors MZF1 and GATA1-
3 were similar to their previously described consensus sequence (MZF1 (zinc fingers 
1-4): 5’- GATCTAAAAGTGGGGAGAAAA-3’; MZF1 (zinc fingers 5-13): 5’- GATC-
CGGCTGGTGAGGGGGAATCG-3’; GATA: 5’- GGACCTTGATCTTATCTT-3’)30;31. 
For competition assays, nuclear extracts from IFN-γ stimulated HeLa cells were in-
cubated with unlabelled oligonucleotides in 100- and 200-fold excess for 30 min on 
ice, prior to incubation with the labeled probe. In case of IFN-γ treated samples, 
cells from five different cell types were stimulated with IFN γ (500U/mL; Boehringer-
Ingelheim) for 4-hours prior to preparing nuclear extracts. Samples were run on a 
6% polyacrylamide gel in 0.25x TBE-buffer. Gels were densitometrically analyzed 
using the ImageJ software32. 
Mouse Model for Reactive Stenosis
The institutional committee on animal welfare approved all animal experiments. For 
all experiments hyperlipidemic male ApoE*3-Leiden mice33 were fed a high-choleste-
rol diet (ArieBlok, Woerden, The Netherlands). Blood samples to determine plasma 
cholesterol were collected at time of surgery. After 3 weeks on diet, a non-constric-
tive polyethylene cuff was placed loosely around one femoral artery and mice were 
sacrificed at several time points after surgery. After sacrifice, at t=0 hours (control, 
no cuff placement), 6 hours, 24 hours, 2 days, 3 days, 7 days and 14 days, both 
femoral arteries were isolated and snap-frozen in liquid nitrogen (n=6 mice for each 
timepoint). 
RNA Isolation and cDNA Synthesis from Femoral Artery Tissue 
Per time point, cuffed segments of three femoral arteries were pooled to enable iso-
lation of suitable amout of RNA, resulting in 4 pooled RNA samples obtained from 
n=6 mice, cuffed at two limbs. After RNA isolation, cDNA was synthesized and RT-
PCR analysis was performed as previously described34. 
PCAF mRNA Quantification
Expression levels of PCAF were measured by virtue of quantitative RT-PCR using 
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TaqMan® gene expression assay (Mm00451387_m1). PCR runs were carried out in 
the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, 
CA, USA). HPRT was assayed as control gene and its cycle threshold (Ct) was sub-
stracted from the Ct of the gene of interest, yielding ΔCt. For each timepoint, ΔΔCt 
was determined by substracting the average ΔCt at timepoint 0 hours from the ΔCt 
at each other timepoint. This ΔΔCt was used to calculate the displayed fold increase 
for each gene35. 
Statistical Analysis
Allele frequencies were determined by gene counting. The Chi-squared test was 
used to test the consistency of the genotype frequencies at the SNP locus with Har-
dy-Weinberg equilibrium. Hazard ratios (HR) with 95% confidence intervals (CI) were 
calculated using a Cox-proportional hazards model. All analyses with PROSPER 
and WOSCOPS data were adjusted for sex, age and pravastatin use. The analyses 
with PROSPER data were additionally adjusted for country. In the GENDER-study, 
polymorphisms were included in a multivariable model containing clinical and proce-
dural risk factors for restenosis, such as diabetes, smoking, hypertension, stenting, 
total occlusion and residual stenosis >20%. 
To reach statistical significance with an alpha of 0.05 and a beta of 0.8 in the as-
sociation between the -2481 polymorphism and coronary heart disease death in this 
population, we need 168 cases of coronary heart disease death, for the -4556 we 
need 379 cases of coronary heart disease death. A combined-effect analysis was 
performed to pool the results of the effect of the -2481G/C polymorphism on study 
endpoints (all-cause mortality, CHD death and clinical restenosis) and coronary end-
points (CHD death in two studies and clinical restenosis in the third study) in the 
three separate studies at old age. The random-effects model was used to consider 
both the between-study and within-study variability. The pooled hazard ratio over 
the genotypes was assessed with ordinary logistic regression. The SPSS software 




Participant characteristics are presented in table 1. Genotyping success rates were 
higher than 96% for all polymorphisms and there were no significant deviations from 
Hardy-Weinberg equilibrium.
Using a Cox proportional hazards model, which included several clinical variables 
such as sex, age, pravastatin use, and country, we found a significant association 
of the -2481 G/C promoter polymorphism with all-cause mortality in PROSPER. As 
presented in table 2 and figure 1, heterozygotes had a reduced mortality risk by 17% 
(2% to 30%, p=0.03), whereas individuals homozygous for the -2481C allele had a 
39% lower mortality (16% to 56%, p=0.003). The effect of PCAF is more profound 
in the association with coronary heart disease (CHD) death (risk reduction 22% (2% 
to 37%), p=0.03) compared to the association with cancer mortality (risk reduction 
13% (9% to 30%), p=0.22). Due to its proximity to the -2481 G/C polymorphism, we 
also present the data of the -4556 C/T polymorphism (table 2). It shows a small and 
non-significant trend towards a decrease in all-cause mortality. The linkage disequi-
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librium (LD)-coefficient between these promoter polymorphisms was 0.79.
WOSCOPS study 
To validate the association of the -2481 G/C polymorphism with CHD mortality, and 
to investigate whether its effect is also present in a population largely without esta-
blished vascular disease, we aimed to replicate our findings in a previously descri-
bed26 nested case-control cohort of the WOSCOPS study. Baseline characteristics 







Continuous variates (mean, SD)
Age (years) 75.3 (3.4) 56.8 (5.2) 62.1 (10.7)
Body mass index, (kg/m2) 26.8 (4.2) 26.0 (3.2) 27.0 (3.9)
Categorical variates (%)
Male sex 48 100 71
Current smoker 27 54 25
History of diabetes 11 2 15
History of hypertension 62 18 40
History of myocardial infarction 13 0 40
History of stable angina 27 8 67 
Statins 50 48 55
Genotype, minor allele frequency (%)
PCAF -4556 C/T 9 9 11
PCAF -2481 G/C 33 33 33
Table 1. Baseline characteristics of the PROSPER, the GENDER and the WOSCOPS study. All data are 
presented in % unless otherwise stated.  
All cause mortality in PROSPER CHD death in PROSPER CHD death in WOSCOPS
N (%)* HR 
(95%CI)
p-value N (%)* HR 
(95%CI)
















































































Table 2. Results of the association between two promoter polymorphisms in the PCAF gene and mortality 
endpoints within the PROSPER and WOSCOPS studies. HR=Hazard ratio. CI=Confidence interval. All 
hazard ratios and p-values were assessed with a Cox-proportional hazards model and adjusted for sex, 
age, country, and use of pravastatin. *Calculated for 5595 subjects in the PROSPER study and for 1092 
in the WOSCOPS study.
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In this case, the -2481 G/C polymorphism was associated with a non-significant trend 
towards protection against death from coronary heart disease (CHD) (risk reduction 
17% (-14% to 39%), p=0.26) at all ages. Heterozygotes (risk reduction 11% (-39% 
to 42%), p=0.62) and homozygotes (risk reduction 37% (-36% to 71%), p=0.24) had 
a non-significantly lower mortality risk. Although these data did not reach statistical 
significance, the point estimate for CHD mortality in WOSCOPS was similar to that 
observed in the PROSPER study (figure 1). The -4556 C/T polymorphism was not 
significantly associated with the risk of CHD death (risk reduction 20% (-36% to 
53%), p=0.40). 
GENDER study
To extent the observed results in the PROSPER study, we tested the relevance of 
the gene to clinical conditions in which cell proliferation and inflammation play a role 
in a large patient population included in the GENDER-study. In this study patients 
were followed for at least 9 months after a PCI to determine absence or presence of 
clinical restenosis, as defined by the need for target vessel revascularization (TVR). 
We considered TVR a suitable intermediate endpoint as it is a direct consequence of 
mainly proliferative and inflammatory processes2.
In agreement with the results from the PROSPER and WOSCOPS-study, the -4556 
C/T polymorphism was not associated with the risk for TVR in the GENDER-study, 
whereas the -2481 G/C polymorphism showed a significant association with TVR (p-
trend = 0.02) (table 3 and figure 1). Heterozygous patients were at lower risk for TVR 
(risk reduction 20% (-2% to 38%), p=0.07), and patients carrying two -2481C alleles 
had a greater protection against the development of restenosis (risk reduction 36% 
(0% to 59%), p=0.05). 
In analogy of the clinical restenosis (TVR) results, carriers of the -2481C allele also 
Figure 1. Hazard ratios for all-cause mortality in PROSPER, for coronary heart disease death in WO-
SCOPS, and for clinical restenosis in GENDER by PCAF -2481 G/C genotype at all ages. The PCAF 
-2481 G/C polymorphism is associated with mortality in the PROSPER study, with coronary heart disease 
death in the WOSCOPS study, and with clinical restenosis in the GENDER study in all age groups.
228
Chapter 9
had less angiographic restenosis in a subpopulation of 478 patients undergoing an-
giography six months after the PCI (risk reduction 44% (4% to 67%), p=0.03) (table 
3). 
Combined Effect Analysis
Hazard ratios were almost remarkably equal in all three studies (figure 1). We for-
mally test for homogeneity using a standard Olkin-type Q-test and found p-values 
of 0.91 and 0.77 for heterozygotic and homozygotic carriers of the minor allele of 
-2481G/C SNP between the three studies. Therefore and since all three studies 
have comparable endpoints, we conducted a combined effect analysis to show the 
effect of the -2481C on the study endpoints (CHD death in PROSPER and WO-
SCOPS, and clinical restenosis in GENDER) at all ages (figure 2, top panel). The 
pooled hazard ratio for the- 2481C allele was 0.79 ((95%CI: 0.74-0.85), p =8.1 x 
10-4). Heterozygotes had a reduced risk (HR: 0.82, 95%CI: 0.68-0.98, p=0.03), and 
this risk was lower in subjects homozygous for the -2481C allele (HR: 0.61 95%CI: 
0.44-0.84, p= 0.002).
Clinical restenosis Angiographic restenosis a Clinical restenosis in the stented 
subpopulationb
N (%) HR 
(95%CI)
p-value N (%) HR 
(95%CI)













































































Table 3. Results of the association between two promoter polymorphisms in the PCAF gene and clinical 
and angiographic restenosis within the GENDER study. a measured in a subgroup of 478 subjects. b 
measured in a subgroup of 2309 subjects. HR=Hazard ratio. CI=Confidence interval. All hazard ratios and 
p-values were assessed with a Cox-proportional hazards model and adjusted for sex, age, and clinical 
and procedural risk factors for restenosis. 
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Examining for an Age Effect
We investigated an effect of the -2481C variant allele on vascular mortality in two 
age strata, older and younger than 58 years old. We could however not perform this 
analysis in the PROSPER cohort since all subjects were older than 70 years. In the 
WOSCOPS study, among participants ≥58 years old (median age), we found that the 
-2481C allele significantly reduced the risk of CHD death (risk reduction 39% (3% to 
62%), p= 0.035), whereas there was no significant effect in the lower age group. We 
found similar results in the GENDER study. We again observed a strong protective 
effect of the C-allele in old patients (≥58 years, n=1800) (risk reduction 30% (12% 
to 45%), p=0.003) whereas there was no significant effect present in young patients 
(<58 years, n=1052).
We also conducted a combined effect analysis to show the effect of the -2481C allele 
at a high age only (median age >58), shown in figure 2 bottom panel. The pooled ha-
zard ratio for the -2481C allele on coronary events (CHD death or TVR) in this high 
age group was 0.72 ((95%CI: 0.61-0.84), p=4.9 x 10-5), which is somewhat stronger 
than the effect at all ages. 
Functional Involvement: The -2481 Region Encompassing the C/G PCAF Vari-
ants
Using the EMSA technique we tested whether the observed polymorphism would 
lead to differential protein binding in vitro. Using nuclear extracts of different cell 
types, we studied complex formation at the -2481 region of PCAF. We could detect 
constitutive protein binding to both PCAF-C and G-variants (figure 3). In both hu-
man umbilical vein endothelial cells (HUVECs) and U251 cells nuclear factor binding 
is slightly enhanced by IFN-γ stimulation. Densitometric analysis revealed that the 
PCAF G-variant exhibits slightly stronger protein binding in some cell types than the 
C-variant, although these differences are not statistically significant. Competition as-
says also suggest a modest difference in binding affinity (figure 3B).
Using the TFSearch program, we identified possible binding sites for MZF1 and 
GATA1-3 in the PCAF C-variant promoter. However, ds-oligonucleotides represen-
ting binding sites for MZF1 and GATA1-3 did not compete with factor binding to the 
PCAF C-promoter variant (data not shown).
PCAF mRNA Expression in a Mouse Model of Reactive Stenosis
Placement of a small non-constrictive cuff around the femoral artery in hyper-cho-
lesterolemic (13.9 ± 3.6 mmol/L) ApoE3Leiden mice results in induction of neointima 
formation. In the developing neointima a rapid upregulation of the PCAF expression 
was observed after cuff placement in a time dependent manner (figure 4). PCAF 
expression showed a peak two days after vascular injury (~1.5 fold increase) and 
reduces to baseline levels of expression after 7 days. PCAF expression at day 3, 7 
and 14 differed significantly from the 24h measurement (p<0.05).
Figure 2. Combined effect estimate of the hazard ratios of the PROSPER, WOSCOPS, and GENDER 
studies for the PCAF -2481 G/C polymorphism. This figure represents the hazard ratios for the addi-
tive model of the PCAF -2481 G/C polymorphism. Coronary endpoints consist of CHD death for the 
PROSPER and WOSCOPS study, and clinical restenosis for the GENDER study. The top panel is the 





Our data indicate that the -2481C allele in the gene encoding PCAF, a protein which 
has been shown to be a key mediator in epigenetics by acetylating histones and 
several non-histone proteins, such as the p53 tumor-suppressor proteins, is asso-
ciated with a significant survival advantage in three independent studies. We found 
in the PROSPER-study an advantage in survival mainly due to a significant risk re-
duction in CHD death. In line with this observation we also observed that the -2481C 
allele was associated with a lower death by CHD in the WOSCOPS study in an 
age dependent manner. Furthermore, this allele also protects against clinical and 
Figure 3. Protein binding to the C- and G-variant of the -2481 region. (A) EMSA showing binding of protein 
to the C- and G-variant of the -2481 region using nuclear extracts of various cell-lines. EMSA suggests 
slightly stronger binding of protein to the G-variant of the -2481 region, most pronounced in HUVECs and 
U251 cells. (B) Competition assay with nuclear extracts from HeLa cells stimulated with IFN-γ also sug-
gests slightly increased binding affinity for the -2481 G-variant at high concentrations. The difference is 
best observed when unlabelled probe is added in 200-fold excess, indicating that the observed difference 
in affinity is weak. Shown are representatives of multiple independent experiments.
Figure 4. Expression of PCAF mRNA in a cuff-induced reactive stenosis mouse model. The figure shows 
PCAF differentially expressed upon activation of the vessel wall in a time dependent manner, with an 
expression peak 48 hours after vascular injury. The data is presented as fold increase compared to the 
control arteries, using HPRT as an internal control for cDNA input.
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angiographic restenosis in the GENDER-study. The effects of the -2481C allele on 
mortality, CHD death and clinical restenosis were more profound at older age (>58 
years). The -2481G/C polymorphism in the PCAF promoter affects transcription fac-
tor binding, as was demonstrated by an EMSA band shift analysis. A role for PCAF 
in vascular disease was further confirmed in a mouse model for reactive stenosis, 
in which modulation of PCAF expression was detected during vascular remodeling.
Our observation in the PROSPER-study that this promoter variant associates to lo-
wer mortality from cardiovascular disease and cancer as well as clinical restenosis 
after PCI in GENDER, may indicate a role of PCAF in inhibiting cell proliferation also 
in more general terms. PCAF has been shown, for example, to activate p53-respon-
sive enhancer elements within the p21waf1 promoter17 and activity of p21waf1 is 
known to induce cell-cycle arrest in vascular smooth muscle cells36-39. Furthermore, 
A20, a NFκB-dependent gene that has been shown to inhibit proliferation of VSMCs 
via increased expression of p21waf1, was able to prevent neointima formation after 
balloon angioplasty in a rat model of carotid artery stenosis40. 
Apart from its well-described role in cell-cycle regulation, PCAF is also known to be 
required to co-activate p65-dependent transcription and has been shown to directly 
activate the transcription of several NFκB-regulated genes known to be involved in 
cardiovascular disease41. Miao et al. has shown that PCAF could enhance the p65 
mediated increase in TNF-α promoter activity and that high glucose increased the 
recruitment of PCAF to the TNF-α and COX-2 promoters14. Furthermore, they de-
monstrated concomitant acetylation of specific lysine residues of histone H3 and H4 
at these promoters. Since TNF-α and COX-2 have been implicated in the develop-
ment of atherosclerosis42;43, and restenosis27;44,  and also cancer45;46, our data sug-
gest that PCAF may also play a role in the development of these diseases.
Our finding in the WOSCOPS and GENDER-study that the strong protective effect 
of the -2481C allele was more profound in patients older than 58 years old, whereas 
it seemed not present in young patients (<58 years old) is of particular interest47. It 
could reveal the combined effect of a life-time dysregulation of expression of the 
lysine acetyltransferase -2481C PCAF variant, which affects global levels of histone 
acetylation, in addition to the accumulating effect of exposure to environmental fac-
tors which also affects histone acetylation profiles during life as observed by Fraga 
et al 6. In the PROSPER population such an age dependent effect was not observed 
as this trial included only patients >70 years old. As expected, here the effects on 
cardiovascular and cancer mortality associated with the PCAF -2481 G/C polymor-
phism were evident for the entire population. After observing an age-dependent ef-
fect in the WOSCOPS and GENDER study, we suggest that this polymorphism in 
PCAF is associated with an altered tendency to acetylate histones and non-histone 
proteins (such as the tumor-suppressor p53 whose function relies on acetylation, re-
viewed in Spange et al.36) and may therefore become important especially in elderly 
patients, who may have been under the influence of altered PCAF activity for many 
years. This hypothesis needs however further investigation.
Although our findings in the GENDER-study do not directly replicate the effect of the 
-2481 G/C polymorphism on CHD mortality in the elderly, they are of much value as 
this study has a mechanistically linked and better defined concise endpoint. Thus in 
this way patho-physiologic insights would be obtained and not just replication only. 
Restenosis after a PCI is very well investigated and is now known to be mainly the 
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consequence of inflammatory and proliferative processes, which is underscored by 
the fact that stents eluting drugs that suppress these processes are highly efficacious 
in the prevention of restenosis. Therefore, we believe that our finding that the -2481C 
allele protects against restenosis in the GENDER-study could possibly confirm its 
functional significance, but could also provide mechanistic insights in its beneficial 
role in survival in the PROSPER and WOSCOPS studies. However this could only 
explain part of the causes by which CHD death risk is decreased in PROSPER and 
WOSCOPS studies, the exact mechanism is not known. We did not find any associ-
ation between the strongly linked -4556C/T polymorphism and survival in any of the 
three studies. The estimated hazard ratio’s were quite similar as expected, however, 
due to small numbers since the minor allele frequency of -4556C/T is three to four 
times smaller than of -2481G/C, no significant results were yielded. This could sim-
ply be due to lack of power.
Here we show a strong association between the PCAF locus involved in epigenetic 
control and clinical conditions in three large follow-up studies with a mechanistically 
linked endpoint, however our studies warrant further investigation into the influence 
of the -2481 G/C polymorphism on the activity of the PCAF promoter or expression 
levels of NFκB-regulated genes. Here we hypothesize a new concept that differential 
transcription of the PCAF gene leads to differences in gene expression in various 
pathways mechanistically linked to CHD events, such as inflammatory regulatory 
pathways or pathways involved in proliferation. Hence, further research has to be 
performed to test this hypothesis. 
In a first analysis we were able to demonstrate binding of nuclear factors to the 
specific region flanking the -2481 G/C polymorphism in the PCAF promoter. EMSA 
analysis showed that the G-variant possibly exhibits a slightly higher affinity for nu-
clear factor binding than the C-variant in some cell types tested (e.g. HUVECS and 
U251), albeit that this was not significant. It should also be noted that IFN-γ stimula-
tion slightly increases nuclear factor binding in HUVECs and U251 cells, suggesting 
a role for IFN-γ induced nuclear factors. It remains to be established whether these 
interacting factors play a role in the transcriptional regulation of PCAF. However, pro-
vided that this SNP influences PCAF transcription and resulting protein levels, this 
could have a bearing on the cellular portrait of expressed genes and might lead to a 
dramatic different outcome if the effects accumulate over years. The fact that nuclear 
extracts do bind to the same region of the promoter in which the polymorphism is 
situated does strongly suggest that the SNP might affect the binding of transcription 
complexes and thus influences gene transcription, however this needs to be confir-
med in future studies.
To further illustrate a possible role of PCAF in vascular disease, we quantified PCAF-
transcripts in the stenotic vessel wall in a mouse model of cuff induced reactive ste-
nosis in the femoral artery. During the stenotic process, the PCAF gene expression 
was rapidly upregulated, indicating that PCAF gene expression is activated upon 
vascular injury and suggesting that this transcriptional coactivator is involved in the 
development of reactive stenosis, at least in the early stages. Unfortunately it is 
not possible to measure the PCAF protein levels directly, however the rapid up and 
down regulation of the mRNA levels suggests that PCAF is not stable. The changes 
in mRNA levels are likely to reflect the changes in protein levels.
In conclusion, we showed in three large prospective studies that the -2481C allele 
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in the PCAF promoter is associated with a significant survival advantage in elderly 
patients while also protecting against clinical and angiographic restenosis after PCI. 
Although the exact mechanisms of these actions are thus far unknown, we sug-
gest that the effect of this allele on these endpoints may be due to the well-known 
involvement of PCAF in inflammatory and proliferative processes. Our observations 
promote the concept that epigenetic processes are under genetic control and that, 
other than environment, genetic variation in genes encoding KATs may also deter-
mine susceptibility to CHD outcomes and mortality. Therefore epigenetic histone 
modification, when our results are confirmed in our studies, might become a target 
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Objective Genetic P300/CBP-associated factor (PCAF) variation affects resteno-
sis-risk in patients. PCAF has lysine acetylase activity and promotes inflammation, 
which drives post-interventional vascular remodeling and accelerated atheroscle-
rosis development. We studied the contributing role of PCAF in post-interventional 
vascular remodeling.
Methods and Results PCAF contribution to inflammation and vascular remodeling 
was assessed in macrophages in vitro and in a mouse model for vascular remode-
ling and accelerated atherosclerosis. PCAF regulates MHC class-II, but not MHC 
class-I expression in macrophages through CIITA, inducing a pro-inflammatory reac-
tion. PCAF-/- mice are used to show that PCAF deficiency is associated with 73.2% 
(p=0.001) reduction of intimal hyperplasia, intima/media ratio and luminal stenosis 
by preventing smooth muscle cell (SMC) accumulation. This was confirmed using 
the potent natural PCAF inhibitor garcinol in vivo which reduced arterial leukocyte 
and macrophage adherence and infiltration following injury and accelerated athe-
rosclerosis development by 71.9% (p=0.004) in operated hypercholesterolemic 
ApoE3*Leiden mice. This occurred due to downregulation of MCP-1 and TNFα ex-
pression by garcinol, similarly to PCAF siRNA, as demonstrated on cultured spleno-
cytes, SMCs and macrophages and in vivo. 
Conclusions These results identify a vital role for the epigenetic factor PCAF in the 
regulation of local inflammation after arterial injury, responsible for vascular remode-
ling and accelerated atherosclerosis development. 
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Percutaneous coronary intervention (PCI) remains the main choice of revasculariza-
tion therapy for coronary artery disease. However, restenosis is a common complica-
tion and inflammation plays a pivotal role in its development1-3. Endothelial injury and 
underlying plaque exposure during PCI, together with sub-endothelial LDL choles-
terol retention evoke thrombocyte adhesion and activation, promoting leukocyte at-
tachment and extravasation2, 4. Macrophages and T-cells play a central role and their 
pro-atherogenic cytokine expression is responsible for further chemotaxis. T-cells 
secrete interferon (IFN)γ, which enhances class II transactivator (CIITA) and MHC 
class II-molecule expression in macrophages. Although it can both stimulate SMC 
proliferation and lead to SMC apoptosis in vitro5, it has been shown to function as an 
important pro-atherogenic cytokine in (accelerated) atherosclerosis development6.
Gene-environmental interactions that stimulate nuclear factor kappa-beta (NFκB) 
expression are regulated by epigenetic factors that strongly modulate gene expres-
sion patterns without DNA sequence modification, mainly by regulating histone ace-
tylation and de-acetylation7. Inflammatory gene expression is the result of the coun-
terbalancing and reversible actions of lysine acetyltransferases (KATs) and lysine 
deacetylases (KDACs), which together determine chromatin structure modification 
and accessibility to transcription factors8, 9. P300/CBP associated factor (PCAF/
KAT2B) is a transcriptional co-activator with intrinsic KAT-activity and is involved in 
lysine acetylation of histones at the site of NFκB-regulated genes9, 10. PCAF binds 
the cyclooxygenase (COX)-2 promoter region following cellular exposure to inflam-
matory mediators and thereby regulates the general inflammatory response through 
prostaglandin H2 formation11. PCAF also enhances the p65-mediated increase in 
tumor necrosis factor (TNF)α promoter activity and both TNFα and COX-2 regulate 
the inflammatory response that lead to atherosclerosis12, 13. 
Few natural inhibitors of PCAF have been described, of which only the natural inhi-
bitor garcinol, derived from the Garcinia Indica fruit rind, has been shown to be ex-
tremely potent14. It inactivates PCAF activity within 3min15 and has strong apoptosis-
inducing effect on leukemia cell lines16 and prostate and pancreatic cancer cells17 
through NFκB downregulation. These properties make garcinol an extremely potent 
inhibitor of PCAF-regulated inflammation in vascular remodeling and accelerated 
atherosclerosis development.
Previously, association between the -2481C variant allele of the PCAF gene and 
reduced vascular mortality was shown in three independent large prospective stu-
dies18-20, identifying PCAF as possible diagnostic marker for CHD mortality and res-
tenosis21. Increased intravascular PCAF mRNA levels after injury suggested PCAF 
involvement in inflammatory-mediated remodeling, although the nature of this eleva-
tion remained unexplored21. 
In the present study, PCAF knock-out mice22, 23 were used to investigate the PCAF 
contribution to the inflammatory response following vascular injury in a reactive ste-
nosis mouse model24, 25. Mice lacking PCAF are developmentally normal without a 
distinct phenotype, although they have been shown to be resistant to amyloid toxi-
city22 and display an altered memory capacity in response to stress22. Furthermore, 
PCAF inhibition with siRNA and garcinol is shown to functionally affect the cellular 
inflammation reaction after stimulation, resulting in reduced inflammatory cell re-
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cruitment to the site of vascular injury and eventually attenuated accelerated athero-
sclerosis development in vivo. This highlights inflammation-regulation by PCAF as a 
contributing factor in post-interventional vascular remodeling.
 
Materials and methods
PCAF-/- and control macrophages were used to study expression of MHC-I, II and 
CIITA, the master regulator of class II MHC transcription, at RNA and protein le-
vel using quantitative real-time PCR and flow cytometry in resting conditions and 
following INFγ stimulation. We performed multiple in vivo studies in which control, 
PCAF-/- and garcinol-treated hypercholesterolemic ApoE3*Leiden mice were sub-
jected to femoral artery cuff placement to induce vascular remodeling. This evokes 
rapid leukocyte recruitment and infiltration (3d) and inflammation-dependent con-
centric intimal lesions (21d) that consists predominately of SMCs and connective 
tissue. In these vascular segments, inflammatory cell adhesion, infiltration, intimal 
thickening and lesion composition were assessed using histology, morphometry and 
immunohistochemistry (IHC). Cultured splenocytes, SMCs and macrophages were 
used to study the effects of PCAF inhibition by siRNA and garcinol on the expression 
of MCP-1 and TNFα by ELISA. A detailed description of materials and methods can 
be found in the supplemental material section.
 
Results
PCAF is essential for CTIIA and MHCII, but not MHCI, expression in macropha-
ges
We analyzed the expression of MHC-I and II at the RNA and protein levels and the 
expression of the master regulator of class II MHC transcription, CIITA, at the RNA 
level. First we confirmed by quantitative real-time PCR (QPCR) analysis that PCAF 
is not expressed in PCAF-/- mice (fig 1A) and we observed that PCAF expression is 
not induced by INFγ. 
We compared IFNγ-induced MHC-II expression in WT and PCAF-/- macrophages. 
Constitutive MHC-II and IFNγ expression was inhibited in PCAF-/- macrophages, 
compared to the WT macrophages at the mRNA level measured by QPCR (fig 1B) 
and at the protein level at the cell surface, both constitutively and following IFNγ 
induction, measured by flow cytometry (fig 1C). The mRNA level of CIITA was as-
sessed by QPCR and we observed that WT and PCAF-/- macrophages displayed the 
same level (fig 1D), indicating that the levels of IFNγ-induced CIITA transcription are 
not modulated in theses macrophages, but its activity is impaired due to the lack of 
PCAF. As CIITA also contributes to MHC-I gene transcription, the cell surface ex-
pression of MHC-I in macrophages incubated or untreated with IFNγ was measured 
in WT and PCAF-/- cells (fig 1E). We observed that the MHC-I expression was not 
altered in PCAF-/- macrophages. 
Intimal thickening is significantly reduced in PCAF-/- mice
Quantitative analysis of cuffed femoral artery segments of C57Bl/6 control and PCAF-
/- mice stained with Weigert’s elastin revealed, despite similar plasma total choleste
241





rol concentrations (supplemental table I), 73.2% reduced intimal thickening in PCAF-
/- mice when compared to controls (WT: 9777±1608 μm2, PCAF-/-: 2623±368 μm2, 
n=10, p=0.001, fig 2A). Since the media area was similar, this was accompanied by 
a reduced intima/media ratio by 73.7% (WT: 0.94±0.18, PCAF-/-: 0.25±0.03, n=10, 























































































































































































Figure 1. PCAF is necessary for MHC-II expression in macrophages. The loss of PCAF inhibits IFNγ-induced MHC-
II expression in peritoneal macrophages at RNA and protein level. A, B and D: Analysis of mRNA levels by semi-
quantitative Q-PCR of PCAF, MHCII and CIITA respectively. Constitutive and IFNγ-induced levels of transcripts were 
analyzed at times 0, 6 and 24h following IFNγ exposure respectively. C and E: Analysis of protein expression at the 
cell surface by flow cytometry of MHCI and MHCII respectively. Endogenous and IFNγ-treated cells during 24h were 
analyzed and displayed against untreated cells (ct: consecutively, n.d.: non-detectable, n.s.: not-significant). Results 
are representative of three separate experiments (mean±SEM, n=3, * p<0.05).
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PCAF-/-: 20.5±2.5%, n=10, p=0.001, fig 2C). IHC was performed to assess lesion 
composition (fig 2D) and it was observed that PCAF-/- mice displayed a significantly 
smaller area of α-SMC actin expressing cells (positively-stained area per cross sec-
tion in μm2) by 61.8% (p=0.028) within the intimal layer (fig 2E). 
PCAF regulates the functional leukocyte and SMC inflammatory response
Vascular injury leads to inflammatory cytokine expression by recruited leukocytes 
and resident VSMCs which drives subsequent vascular remodeling. The anti-inflam-





















































































Figure 2. Reduced vascular remodeling in PCAF-/- mice. A: intimal thickening (μm2), (B) intima / media 
ratio and (C) luminal stenosis (%) in wildtype and PCAF-/- mice, 21d after femoral arterial cuff placement 
(mean±SEM, n=10, * p<0.05). D: representative cross-sections of cuffed arterial segments, stained with 
HPS (200x), Weigert’s elastin 200x (arrows in inserts (400x) indicate internal elastic lamina) and for SMC 
α-actin (200x). E: quantification of SMC area (μm2) in the intimal and medial layers of wildtype and PCAF-
/- mice (mean±SEM, n=10, * p<0.05).
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tent natural PCAF inhibitor described, was first tested in vitro. Analysis of garcinol-
treated wildtype and PCAF-/- cultured splenocytes showed reduced expression of 
TNFα by 25.7% (p=0.037) and 42.3% (p=0.030) respectively (fig 3A) and of MCP-1 
by 41.3% (p=0.057) and 71.4% (p=0.029) respectively (fig 3B) after overnight li-
popolysaccharide (LPS) stimulation. Next, splenocytes were subjected to siRNA-
mediated knock-down of PCAF, incorporation assessed with siRNA luciferase (fig 
3C) and control siRNA as controls and were again exposed to LPS. When compared 
to vehicle-treated splenocytes (which responded similarly to control siRNA-exposed 
cells, p=0.240), knockdown of PCAF led to reduced TNFα expression by 41.2% 
(p=0.029) as did PCAF-/- splenocytes by 55.5% (p=0.004). No differences in TNFα 
expression were measured between PCAF deficient splenocytes and wildtype sple-



































































Figure 3. PCAF inhibition prevents inflammatory cytokine expression in vitro. Compared to overnight 
LPS-stimulated (100 ng/ml) wildtype splenocytes, garcinol-incubated (15 μM) and PCAF-/- splenocytes 
display a reduced expression of TNFα (pg/ml) (A) and MCP-1 (pg/ml) (B). Luciferase siRNA controls 
display effective splenocyte tranfection after 24h (C). TNFα expression (pg/ml) is also reduced after siR-
NA-mediated PCAF knockdown in wildtype splenocytes following overnight LPS-stimulation (300 ng/ml) 
as effectively as in PCAF-/- splenocytes (D). Results are representative of three separate experiments 
(mean±SEM, n=3, * p<0.05, † 0.05<p<0.10, n.s. not significant, n.d. not detectable).
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PCAF was shown to regulate macrophage MHCII expression through CTIIA. Functi-
onal macrophage dampening was investigated and it was found that TNFα expressi-
on after overnight LPS stimulation was profoundly reduced by simultaneous garcinol 
incubation (fig 3E) (p=0.0*10-6) in vitro. Finally, MCP-1 expression by LPS-stimulated 
SMCs was reduced by 24.5% (p=0.043, fig 3F) in the presence of garcinol (15 μM), 
although this could not be demonstrated at the lowest garcinol concentration (5.0 
μM). Next, analysis to which extent PCAF contributes to MCP-1 expression by VS-
MCs was performed in a dose-response experiment using (0.1-10.0 ng/ml) LPS. It is 
shown that VSMC-secreted level of MCP-1 (pg/ml) is reduced by garcinol by 19.2-
26.0% at LPS concentrations of 0.1, 1.0 and 10 ng/ml respectively (fig 3G, p=0.049, 
p=0.021 and p=0.043 respectively), measured by ELISA. 
PCAF inhibition prevents injury-induced leukocyte recruitment in vivo
PCAF inhibition to prevent post-interventional remodeling and accelerated athero-
sclerosis development was investigated by garcinol in the femoral artery cuff mo-
del in hypercholesterolemic ApoE3*Leiden mice. Viability of circulating leukocytes 
in the presence of garcinol (0-250 μM) was investigated using the redox indicator 
Alamar blue. Fluorescence intensity (FI) remained constant at ~5700 AU (615 nm) 
at garcinol concentrations 0-20 μM, indicating complete cellular viability compared 
to positive controls (100%) (p=0.448, fig 4A), with cytotoxicity at concentrations ≥30 
μM (FI: ~900 AU). 
























































































Figure 3. PCAF inhibition prevents inflammatory cytokine expression in vitro. Macrophage TNFα (ng/
ml) expression following overnight inflammatory mediator (LPS) stimulation is significantly reduced by 
garcinol (15 μM) to non-detectable levels (E). Garcinol (15 μM) downregulates MCP-1 (pg/ml) expression 
by cultured vascular SMCs (F) and reduces vascular SMC MCP-1 (pg/ml) expression following a dose-
dependent increase of LPS (0.1-10 ng/ml) (G). Results are representative of three separate experiments 
(mean±SEM, n=3, * p<0.05, † 0.05<p<0.10, n.s. not significant, n.d. not detectable).
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table I), garcinol in pluronic gel (10 μl of 41.5 mmol/L lubricated around operated 
arterial segment) reduced the percentage of endothelial leukocyte adhesion out of 
all cells within the internal elastic lamina by 62.1% (p=0.028) and of macrophages by 
54.6% (p=0.010) after 3d compared to vehicle only. Medial leukocyte infiltration was 
reduced by garcinol by 61.7% (p=0.005) and macrophages by 84.5% (p=0.004) (fig 
4C, D). Garcinol reduced the percentage of cells in the tunica intima (predominately 
endothelial cells) that expressed MCP-1 by 65.0% (p=0.003) and of cells in the tu-
nica media by 57.1% (p=0.010) (fig 4E), suggesting that garcinol reduced leukocyte 



























































































































Figure 4. Garcinol-mediated PCAF inhibition reduces the leukocyte inflammatory response. A: 
ApoE3*Leiden-derived whole blood viability assay after overnight 0-250 μM garcinol incubation using 
Alamar blue conversion (emission 615 nm), expressed as percentage fluorescence intensity (of positive 
controls) (mean±SEM, n=10, * p<0.05). B: representative cross-sections of cuffed arterial segments of 
ApoE3*Leiden mice, 3d after surgery (CD45+ leukocytes, macrophages and MCP-1 expressing cells, 
400x, arrows indicate positive staining). Quantification of (endothelial)-adhered or medial infiltrated leu-
kocytes (C), macrophages (D) and MCP-1 expressing cells (E), expressed as the percentage of all cells 
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PCAF inhibition prevents accelerated atherosclerosis development 
IHC showed that PCAF expression is absent in non-injured hypercholesterolemic 
arteries (fig 5A). Negative staining was confirmed in PCAF-/- arteries (fig 5B). PCAF 
presence was increased 3d after surgery in ApoE3*Leiden mice (fig 5C). Staining 
was observed in both endothelial-adhering leukocytes and in the SMC-rich tunica 
media. Garcinol reduced PCAF staining (fig 5C) after 3d. 
Early anti-inflammatory effects of PCAF-inhibition were substantiated by garcinol 
application during femoral artery cuff placement. Despite similarly elevated total 
plasma cholesterol concentrations (supplementary table I), garcinol (10 μl of 41.5 
mmol/L concentration lubricated around operated arterial segment) significantly re-
duced intimal thickening by 71.9% (p=0.004) in ApoE3*Leiden mice when compared 
to vehicle only (fig 5D, G). Since medial surface was similar, this was accompanied 
by a reduced intima / media ratio by 72.5% (p=0.002) (fig 5E) and reduced luminal 
stenosis by 63.3% (p=0.001) after 14d (fig 5F).
adhering to the endothelium or in the media. The entire length of the cuffed femoral artery segment was 









































































Figure 5. PCAF inhibition prevents vascular remodeling. Representative cross-sections of (un)cuffed-fe-
moral arterial segments, stained for the presence of PCAF (200x). A: non-cuffed artery from ApoE3*Leiden 
mouse. B: cuffed femoral artery of PCAF-/- mouse (negative control). C: PCAF expression in cuffed fe-
moral arteries of ApoE3*Leiden mice ± garcinol treatment, 3d and 14d after surgery. Arrow in insert in-
dicates positive medial staining. Garcinol-treatment in ApoE3*Leiden mice reduced intimal thickening 
(μm2) (D), intima / media ratio (E) and luminal stenosis (%) (F), 14d after femoral arterial cuff placement 
(mean±SEM, n=10, * p<0.05). G: representative cross-sections of cuffed femoral arteries (HPS and Wei-
gert’s elastin staining, 200x, arrow in inserts (400x) indicate internal elastic lamina).
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PCAF inhibition affects vessel wall composition
IHC was performed to assess lesion composition in vehicle and garcinol-treated 
animals (fig 6A), revealing a reduced inflammatory phenotype following garcinol 
treatment. This led to reduced relative macrophage presence (in %) by 75.7% in 
the intimal layer (p=0.023) and by 74.7% in the medial layer (p=0.004) (fig 6B). In 
garcinol-treated arteries, the relative α SMC actin+ area (%) was 14.6% (p=0.042) 
higher in the tunica media, although there were no relative differences measured in 
the tunica intima (fig 6C). However, absolute α SMC actin intimal thickening was pre-
vented by garcinol, indicated by 40.0% (p=0.042) reduced SMC surface area (μm2) 
(fig 6D). Cellular proliferation in the arterial wall was assessed using BrdU staining, 
injected once daily for 3d after surgery. Control arteries displayed more elaborate 
BrdU staining, suggesting PCAF inhibition could affect injury-induced cellular proli-
feration in vivo (fig 6A). Together, these data identify clear effects of PCAF inhibition 






























































































Figure 6. PCAF inhibition affects accelerated atherosclerotic lesion morphology. A: cross-sections of 
cuffed arterial segments of ApoE3*Leiden mice, 14d after surgery, treated with vehicle only or garcinol-
containing pluronic gel, 200x. Arteries are stained with HPS, Weigert’s elastin (arrows indicate internal 
elastic lamina) and for SMC α-actin, macrophages and BrdU-incorporation (arrows indicate positive stai-
ning). Quantification of macrophages (B) and relative SMC α-actin+ surface area (C) in the intimal and 
medial layers, expressed as the positively-stained area as percentage of the total area. D: quantification 




Here we demonstrate that compared to controls, post-interventional vascular re-
modeling is reduced in PCAF-/- mice, as is post-interventional accelerated athero-
sclerosis development in hypercholesterolemic mice treated with a PCAF inhibitor. 
Furthermore, we demonstrate that this reduced remodeling is due to an attenuated 
inflammatory response, shown by reduced MCP-1 and TNFα-expression in vivo and 
in cultured cells. It was shown that PCAF regulates MHC class II, but not I, expressi-
on in macrophages through CIITA and becomes upregulated in the early period follo-
wing vascular injury. To our knowledge, this is the first paper to show that PCAF has 
a contributing role in vascular remodeling by regulating the inflammatory response.
PCAF-/- mice were used to demonstrate clear effects of PCAF deficiency on inflam-
matory-regulated vascular remodeling. Animals developed significantly smaller 
SMC-rich neointimal lesions with reduced luminal stenosis. The only described na-
tural potent PCAF inhibitor garcinol, was used next to siRNA-mediated PCAF knock-
down and PCAF-/- cells to demonstrate its essential contribution in the production 
of pro-inflammatory cytokines (MCP-1 and TNFα) by various cell types including 
splenocytes, macrophages and vascular SMCs. This contribution was confirmed in 
vivo where garcinol prevented post-interventional leukocyte recruitment to the site of 
arterial injury and accelerated atherosclerosis development in operated hypercho-
lesterolemic mice. These results demonstrate an important role for the epigenetic 
factor PCAF in the post-interventional arterial inflammatory response26.
The role of PCAF was further investigated in macrophages, which play a vital role 
in the progression of accelerated atherosclerotic lesions. MHC class II, but not class 
I, expression was found to be inhibited in PCAF-/- macrophages at both mRNA and 
protein level, whilst CIITA mRNA was normalized. This indicates that IFNγ-induced 
CIITA transcription is not affected by PCAF deficiency, but its activity is impaired due 
to the lack of PCAF27, 28, suggesting PCAF-requirement for adequate adaptive im-
mune responses in this leukocyte subset. Although PCAF is important for MHC class 
II expression, it cannot be fully excluded that other inflammatory genes are also af-
fected by PCAF inhibition (e.g. COX-2), albeit not MHC class I. 
Previously, mouse PCAF mRNA levels were demonstrated to be reactively incre-
ased within 48h after vascular injury, after which levels were reduced below resting 
values21. Using IHC, we show abundant PCAF protein expression 72h after surgery 
in endothelial-adhering cells (e.g. macrophages) and in the SMC-rich tunica media. 
Since vascular injury in known to elicit inflammation and provoke SMC proliferation, 
regulation of inflammation by PCAF could strongly contribute to vascular remode-
ling. Indeed, short-term PCAF inhibition early after surgery led to reduced PCAF 
expression after 14 days, indicative of a reduced inflammatory phenotype of arterial 
wall. Consistent with PCAF expression by SMC, SMC-rich intimal lesions which oc-
curred in wildtype mice were significantly less present in PCAF-/- mice (fig 2E), indi-
cating that PCAF-regulated inflammation contributes strongly to lesion formation in 
these animals.
An ex vivo LPS stimulation experiment in splenocytes, macrophages and vascu-
lar SMCs from either wildtype or PCAF-/- mice was performed to test if PCAF was 
involved in inflammatory cytokine expression by these various cell types. Indeed, 
TNFα expression by splenocytes and macrophages was severely compromised in 
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PCAF deficient animals and similarly in wildtype cells subjected to siRNA-mediated 
PCAF knockdown or garcinol-treatment, indicating a vital role for PCAF in inflamma-
tory gene transcription. Since cytokine levels were differently affected in different cell 
types such as VSMCs and macrophages, this might differences in PCAF expression 
concentrations in different cell types or altered histone acetylation status between 
cells.
Garcinol was used successfully in preclinical cancer studies in rats, where oral gar-
cinol application reduced the severity of tongue carcinoma by inhibiting tumor cell 
proliferation29, 30. Anti-proliferative drugs, originally applied as cytostatic anti-cancer 
agents such as sirolimus and paclitaxel, have been extensively used against reste-
nosis in drug-eluting stents31, 32. However, they affect cellular proliferation non-speci-
fically, whereas PCAF inhibition could be a potent promising anti-restenotic therapy. 
It is speculated that the protective function of garcinol is primarily through PCAF 
inactivation in macrophages, affecting their MHCII expression. However, garcinol 
also downregulates KDAC-induced tissue-type plasminogen activator in endothelial 
cells33. Unlike the quiescent state in an uninjured artery, the fibrinolytic system beco-
mes activated after vascular trauma with strong t-PA expression in SMC, endothelial 
cells and platelets34 and can increase SMC migration. Inhibition of plasmin activity at 
the cell surface inhibits intimal thickening in our mouse model for reactive stenosis35 
and it can therefore not be ruled out that garcinol affects intimal thickening by influ-
encing plasmin activity, provided this is KDAC-induced.
It is also conceivable that PCAF itself influences post-interventional vascular re-
modeling through indirect effects on macrophages. High mobility group 1 protein 
(HMGB1) is a chromatin component that can be secreted by activated monocytes 
and macrophages and functions as a late mediator of inflammation. These cells can 
tilt the acetylation / deacetylation balance in favor of acetylation upon activation and 
PCAF is known to acetylate HMGB18, which occurs extensively upon activation with 
LPS36. LPS also provokes significant intimal thickening, which could indicate that 
PCAF may not directly affect inflammatory gene transcription, but indirectly through 
LPS-induced HMGB1 acetylation in stimulated monocytes and macrophages. Mo-
reover, HMGB1 may act as an endogenous ligand for TLR4 and TLR4 signaling 
is also a key regulatory process in vascular remodeling37. A significantly impaired 
inflammatory response by LPS-stimulated PCAF-/- whole blood ex vivo is supportive 
of this possibility. 
In conclusion, using PCAF-/- mice, evidence is provided that PCAF contributes to 
post-interventional vascular remodeling. Further, local delivery of the PCAF-inhibitor 
garcinol inhibited reactive stenosis and accelerated atherosclerosis development in 
hypercholesterolemic ApoE*3-Leiden transgenic mice. This could be explained by 
an as yet unrecognized direct or indirect effect of PCAF on inflammation and SMC 
proliferation, leading to reduced post-interventional remodeling. These results might 
therefore shed light on the possible contribution of PCAF as an important epigenetic 
factor in vascular remodeling and accelerated atherosclerosis development in sten-
ted human coronary lesions and identify it as a possible new clinical target against 
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All experiments were approved by the Institutional Committee for Animal Welfare 
at the LUMC. The generation of PCAF knockout (KO) mice has been described 
previously1. Male C57Bl/6 PCAF KO mice2 and wildtype (WT) C57Bl/6 controls 
were used, as were transgenic male ApoE*3-Leiden mice (both bred in our own 
laboratory), backcrossed for more than 20 generations on a C57BL/6 background. 
ApoE3*Leiden (at the start of a dietary run-in period) and WT and PCAF KO mice 
aged 10-12 weeks, were used for femoral artery cuff experiments. 
Peritoneal macrophage culture 
Peritoneal macrophages (PM) were elicited by intraperitoneal (IP) injection with thio-
glycollate broth. 2 ml of thioglycollate was administered IP to 4-6 week old control or 
PCAF KO mice and PM were harvested 3d later under anesthesia, as described in 
the section below. Thioglycollate elicited PM were plated at 5*106 cells/dish in 100 
mm tissue culture dish in RPMI 5% fetal calf serum (FCS) overnight. The PM were 
then washed with RPMI 5% FCS and were either treated or untreated with IFNγ (100 
U/ml) for 24 or 48 hours.
Peritoneal macrophage RNA isolation and real time (RT) PCR
Real time PCR analysis was done with an ABI PRISM 7700 sequence detection 
system (Applied Biosystems). Real-time PCR was used in analysis of RNA samples 
from macrophages-like cells isolated from PCAF WT and KO mice. RT-PCR reacti-
ons were done with a kit from Perkin Elmer (SYBR Green PCR master kit). Primer 
sets for CIITA, MHC-II and HPRT cDNAs were (forward and reverse) 5'-TGCAGG-
CGACCAGGAGAGACA–3' and 5'–GAAGCTGGGCACCTCAAAGAT–3'; 5'–TATG-
TGGACTTGGATAAGAAG–3' and 5'–ACAAAGCAGATAAGGGTGTTG–3'; 5'– 
GGGAGGCCATCACATTGTG –3' and 5'–TCCAGCAGGTCAGCAAAGAAC–3', 
respectively. Real time PCR values were determined by reference to a standard 
curve generated by real time PCR amplification of serial dilution of cDNA using CI-
ITA, MHC-II and HPRT primers. Values obtained for levels of CIITA and MHC-II 
mRNAs were normalized to the levels of HPRT mRNA expression as determined 
by real time PCR. Data are representative of at least three separate experiments on 
different RNA.
Flow cytometry analysis
Macrophages-like cells were plated at a concentration of 0.5-1*106/ml and were 
either treated or untreated by IFNγ for 48h. Cells were removed from the plates, 
washed in PBS and resuspended in medium. For surface marker analysis, cells were 
first blocked with anti-mouse FcγR antibody (CD16/CD32 2.4G2, BD Pharmingen) 
followed by incubation with specific antibodies or isotype control for 30 min at 4ºC. 
FITC-conjugated antibodies against H-2Kb (AF6-88.5), PE-conjugated anti-mouse 
I-A/I-E (M5/114.15.21), were purchased from BD Pharmingen. PE-conjugated anti-
254
Chapter 10
F4/80 (Ly-71) antibody was obtained from Caltag. Cells were collected on FACS 
Caliber and analyzed using Cell Quest software (Becton Dickinson).
Diet
PCAF KO and WT mice received chow diet. Transgenic male ApoE*3-Leiden mice 
were fed a Western-type diet containing 1% cholesterol and 0.05% cholate to induce 
hypercholesterolemia (AB Diets). The diet was given three weeks prior to surgery 
and was continued throughout the experiment. All animals received food and water 
ad libitum during the entire experiment.
Femoral artery cuff mouse model
To investigate the role of PCAF in restenosis development, mice underwent a non-
constrictive cuff placement around the femoral artery after three weeks of diet to in-
duce vascular inflammation and remodeling. Mice were anesthetized before surgery 
with a combination of intraperitoneally (IP) injected Midazolam (5mg/kg, Roche), 
Medetomidine (0.5mg/kg, Orion) and Fentanyl (0.05mg/kg, Janssen). The right fe-
moral artery was isolated and sheathed with a rigid non-constrictive polyethylene 
cuff (Portex, 0.40mm inner diameter, 0.80mm outer diameter and an approximate 
length of 2.0mm). 3d, 14d or 21d after cuff placement, mice were anesthetized as 
before and euthanized. 
The thorax was opened and pressure-perfusion (100mm Hg) with 3.7% formalde-
hyde in water (w/v) was performed for 5 minutes by cardiac puncture in the left 
ventricle. After perfusion, the cuffed femoral artery was harvested, fixed overnight 
in 3.7% formaldehyde in water (w/v) and paraffin-embedded. Serial perpendicular 
cross-sections (5μm thick) were taken from the entire length of the artery for analy-
sis.
In vivo garcinol treatment
During non-constrictive cuff placement, ApoE*3Leiden mice were treated with 10 μl 
pluronic gel (40%, maintained at 0°C, Sigma Aldrich) ± 25 mg/ml garcinol (Enzo Life 
Sciences), which was lubricated around the isolated femoral artery and was allowed 
to harden out and settle around the artery, which occurred within 20 seconds after 
application. 
Biochemical analysis
Total plasma cholesterol concentration (Roche Diagnostics, kit 1489437) was mea-
sured enzymatically. Inflammatory cytokine concentration of monocyte chemotactic 
protein (MCP)-1 and TNFα were determined using ELISA kits (2665KI and 558534, 
both Becton Dickinson), according to the manufacturer's instructions.
Immunohistochemistry (IHC)
To detect the presence of PCAF, inflammatory cells, vessel wall characteristics and 
effects of garcinol therapy, IHC was performed on paraffin-embedded sections of 
cuffs harvested after 3 and 14 days (ApoE3*Leiden) or 21 days respectively (PCAF 
KO and WT mice). All samples were stained with hematoxylin-phloxine-saffron 
(HPS) and Weigert’s elastin staining was used to visualize elastic laminae. Presence 
of PCAF was assessed using an anti-PCAF antibody (1:500, Abcam). Inflammatory 
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cell presence in the vascular wall was visualized using antibodies against leuko-
cytes (anti-CD45 antibodies 1:200, Pharmingen) and macrophages (MAC3, 1:200, 
Pharmingen). To assess vessel wall morphology, smooth muscle cells (SMC) were 
stained using anti-smooth muscle α-actin (1:800, Dako). Since garcinol can alter 
global gene expression and can inhibit proliferation, incorporation of 5-bromo-2’-
deoxyuridine (BrdU) into DNA as a marker of DNA synthesis was used to determine 
the rate of cell proliferation in cuffed vessel segments. Mice (n=5 per group) were 
injected IP with 25 mg/kg (in 100 μl) BrdU (Sigma Aldrich) three times, once daily 
starting at time of surgery or 72, 48 and 24h prior to sacrifice. Sections were incuba-
ted with a rat anti-BrdU antibody (1:200, Abcam). 
Immunohistochemical analysis
All quantification in this study was performed on six equally spaced (150µm distance) 
serial stained perpendicular cross-sections throughout the entire length of the vessel 
and was performed by (at least) two blinded observers. The number of leukocytes, 
macrophages and proliferating cells were counted and expressed as a percentage 
of the total number of cells (stained with hematoxylin). Vessel wall morphology after 
14d is expressed as the percentage of total medial and intimal area stained positive 
for SMC α-actin or MAC3. Using image analysis software, (Qwin, Leica), total cross-
sectional medial area (between both elastic laminae), neointimal area (between in-
ternal elastic lamina and lumen) and luminal area was measured. These values were 
used to calculate the intima / media ratio and percentage luminal stenosis. 
Cell-cultures
Murine aortas were harvested from C57Bl/6 PCAF KO mice and WT controls. The 
aortas were cut longitudinally to expose the luminal side. The endothelial cells were 
removed by gently scraping. The aortas were cut in small pieces and placed on 
gelatin-coated culture dishes. The explants were cultured in DMEM (PAA laborato-
ries) containing 20% FCS heat-inactivated (Lonza), 1% penicillin/streptomycin (Invi-
trogen) and 1% NEAA (PAA laboratories). Cells were cultured and used for experi-
ments at passages 2 to 4. 
Splenocytes were isolated from PCAF-/- and control WT mice and were transfected 
during 24 hours with 100 nmol/L control short-interfering (si) RNA or directed to-
wards murine KAT2B (PCAF) 1, KAT2B 5, KAT2B 6 and KAT2B 7 (all from Qiagen) 
using Lipofectamine 2000 (Invitrogen). 
Bone-barrow derived cells were isolated from PCAF-/- and control mice and sub-
jected to murine macrophage colony-stimulating factor (M-CSF) (20 ng/μl; Miltenyi 
Biotec) to stimulate differentiation into macrophages. To evaluate the effects of in-
flammation on inflammatory cytokine expression, confluent layers of human SMC 
were trypsinized and seeded out in DMEM supplemented with 8% FCS and 1% 
penicillin/streptomycin and cultured for 24h. SMCs, splenocytes and macrophages 
were stimulated by exposure to 8% FCS in the presence and absence of 10-100 
ng/ml lipopolysaccharide (LPS) from Escherichia coli K-235 L2018 (Sigma Aldrich) 
alone or together with a serial dilution of garcinol (0, 5 or 15 μM). The cells were 
incubated overnight at 37°C in 5% CO2 atmosphere. After 24 hr incubation the su-





Since garcinol can affect cellular viability in high concentrations, garcinol-induced 
apoptosis in ex vivo whole blood was assessed in heparinized venous whole blood 
drawn from WT mice. Blood was diluted 1:25 in RPMI together with (0, 2.5, 10, 15, 
20, 30, 50, 100 or 250 μM) garcinol for 24h at 37°C in 5% CO2 atmosphere. After 
24h incubation, the medium of all cells including garcinol treated cells was refreshed 
with RPMI supplemented with 8% FCS and 10% (vol/vol) Alamar blue (Invitrogen). 
The optical density of each well was measured in a Millipore CytoFluor 2300 plate-
reading Fluor meter with excitation at 560 nm and emission at 615 nm when medium 
in untreated samples turned pink (±4h). Cell viability (%) was calculated compared 
with positive (untreated) control cells.
Statistical analysis
All data are presented as mean±standard error of the mean (SEM), unless otherwise 
indicated. Overall comparisons between data from groups were performed using 
the Kruskal-Wallis test. If a significant difference was found, groups were compared 
using a Mann-Whitney sum test. All statistical analyses were performed with SPSS 
14.0 software for Windows. P-values less than 0.05 were regarded as statistically 
significant and are indicated with an asterisk (*).
Supplemental figures
12.4 ± 1.130.8 ± 1.0ApoE3*Leiden + garcinol
13.3 ± 0.930.5 ± 0.5ApoE3*Leiden + vehicle
Vascular remodeling (14d)
11.4 ± 1.226.9 ± 0.9ApoE3*Leiden + garcinol
10.9 ± 0.927.0 ± 0.7ApoE3*Leiden + vehicle
Leukocyte adhesion (3d)
2.4 ± 0.227.0 ± 1.3PCAF-/- mice 





Table I. Mean body weights (gram) and total plasma cholesterol (mmol/L) at surgery. Values are shown as 
mean±SEM (n=10/group). No significant differences were observed between groups.
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Therapeutic arteriogenesis, i.e., expansive remodeling of pre-existing collaterals, 
using single-action factor therapies has not been as successful as anticipated. 
Transcriptional co-activator P300/CBP-associated factor (PCAF) has histone ace-
tylating activity and promotes transcription of multiple inflammatory genes. Because 
arteriogenesis is an inflammation-driven process, we hypothesized that PCAF acts 
as multifactorial regulator of arteriogenesis. 
After induction of hind limb ischemia (HLI), blood flow recovery was impaired in 
both PCAF-/- mice and healthy wild type (WT) mice treated with the pharmacological 
PCAF inhibitor Garcinol, demonstrating an important role for PCAF in arteriogenesis. 
PCAF deficiency reduced the in vitro inflammatory response in leukocytes and vas-
cular cells involved in arteriogenesis. In vivo gene expression profiling revealed that 
PCAF deficiency results in differential expression of 3505 genes during arteriogene-
sis and, more specifically, in impaired induction of multiple pro-inflammatory genes. 
Additionally, recruitment from the bone marrow of inflammatory cells, in particular 
“pro-inflammatory” Ly6Chi monocytes, was severely impaired in PCAF-/- mice. 
These findings indicate that PCAF acts as master switch in the inflammatory proces-








Peripheral arterial occlusive disease is a leading cause of morbidity and mortality. 
Blood flow to ischemic tissues in the affected limb can be restored by distinct proces-
ses (van Oostrom et al, 2008), namely vasculogenesis, angiogenesis and arterio-
genesis, of which arteriogenesis, the remodeling of pre-existing collateral arterioles 
into larger arteries, has the greatest impact (Heil & Schaper, 2004).
Effective arteriogenesis requires coordination of multiple events. Arteriogenesis is 
triggered by an increase in fluid shear stress across pre-existing collaterals cross-
connecting adjacent arterial trees, which is caused by a pressure gradient created 
by occlusion or atherosclerotic stenosis of one of the trees. This leads to activation 
of the endothelial cells and adjacent vascular smooth muscle cells (VSMCs) of the 
collateral wall. Induction of adhesion molecules, cytokines and chemokines then 
follows as the first step of an inflammatory cascade essential for arteriogenesis. Re-
cruitment of leukocytes from blood and bone marrow follows, in particular monocytes 
(Bergmann et al, 2006; Heil et al, 2002; Schaper et al, 1976; Voskuil et al, 2004) 
but also CD4+, CD8+ and regulatory T cells and natural killer cells (Hellingman et 
al, 2012; Stabile et al, 2003; Stabile et al, 2006; van Weel et al, 2007; Zouggari et 
al, 2009). These cells infiltrate into the perivascular space around collaterals and 
release additional paracrine signaling molecules and growth factors. Subsequent 
degradation and reorganization of the extracellular matrix by released matrix metal-
loproteases (MMPs), including MMP2 and MMP9, creates space required for expan-
sive remodeling of the pre-existing collaterals.  Proliferation of collateral endothelial 
cells, VSMCs and fibroblasts is stimulated, resulting in an increased anatomic lumen 
diameter. All of the steps described above underline the crucial role of inflammation 
in effective arteriogenesis. 
Although stimulation of collateral remodeling is regarded as a promising therapeu-
tic alternative to surgical interventions, clinical trials aimed at modulating individual 
growth factors or cytokines have thus far not been as successful as anticipated 
(Schirmer et al, 2009). We now know that the coordinated inflammatory and immune 
modulatory processes driving collateral growth are multifactorial and too complex to 
be modulated by therapeutics that target a single gene or pathway. In contrast, mo-
dulation of a factor that acts as a master switch for multiple relevant gene programs 
may be a more effective strategy to augment arteriogenesis. 
A recently described protein with such master switch potential is P300/CBP-Associ-
ated Factor (PCAF), a transcriptional co-activator with intrinsic histone acetyltrans-
ferase activity. PCAF acetylates histones H3 and H4, but there is also increasing evi-
dence that PCAF modulates non-histone proteins (Imhof et al, 1997; Itoh et al, 2000; 
Liu et al, 1999; Sartorelli et al, 1999), including hypoxia-inducible factor 1α (Hif-1α) 
(Lim et al, 2010) and Notch (Guarani et al, 2011). Furthermore, the histone acetyla-
ting activity of PCAF is essential for NF-κB-mediated gene transcription (Sheppard 
et al, 1999) and facilitates inflammatory gene regulation (Miao et al, 2004). Since 
arteriogenesis is an inflammatory-like process, we hypothesized that PCAF acts as 
master switch that stimulates multiple inflammatory processes important for colla-
teral remodeling.
Recently, it was shown in a large patient population study (>3000 individuals) (Mon-
raats et al, 2005) that a variation in the promoter region of PCAF is associated with 
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coronary heart disease-related mortality (Pons et al, 2011). In support of this obser-
vation, we recently demonstrated a role for PCAF in vascular remodeling in a mouse 
model for reactive stenosis. However, whether PCAF participates in arteriogenesis 
has not yet been investigated.
In the present study, we investigated the contribution of PCAF to post-ischemic neo-
vascularization in a hind limb ischemia (HLI) model, using PCAF deficient (PCAF-/-) 
mice. When studying arteriogenesis in a knockout model, it is possible that the gene 
deletion may affect vascular development in the embryo, including collaterogenesis, 
thus affecting the number of collaterals available for remodeling after an occlusive 
event in the adult. To investigate whether observed effects were caused by differen-
ces in arteriogenesis, in the native collateral circulation or a combination of both, we 
examined the pre-existing collateral density as well as the effect of administration of 
the PCAF inhibitor Garcinol to wild type (WT) mice after induction of HLI. We also 
studied gene expression and leukocyte recruitment in PCAF-/- and WT mice after 





Experiments were approved by the committee on animal welfare of the Leiden 
University Medical Center (Leiden, The Netherlands). Male C57BL/6 mice were 
purchased from Charles River (France). The generation of PCAF-/- mice (C57BL/6 
background) has previously been described (Duclot et al, 2010; Yamauchi et al, 
2000) and the animals were kindly provided by Dr. C. Gongora (Montpellier, France). 
All animals received regular chow diet and water ad libitum.
Induction of hind limb ischemia
Mice were anesthetized by intraperitoneal (i.p.) injection of midazolam (8 mg/kg, 
Roche Diagnostics), medetomidine (0.4 mg/kg, Orion) and fentanyl (0.08 mg/kg, 
Janssen Pharmaceutica). Unilateral HLI was induced by electrocoagulation of the 
left femoral artery proximal to the superficial epigastric arteries alone, or combined 
with electrocoagulation of the distal femoral artery proximal to the bifurcation of the 
popliteal and saphenous artery (Hellingman et al, 2010). After surgery, anesthesia 
was antagonized with flumazenil (0.7 mg/kg, Fresenius Kabi), atipamezole (3.3 mg/
kg, Orion) and buprenorphine (0.2 mg/kg, MSD Animal Health). For pharmacological 
PCAF inhibition in WT mice, 20 µl 40% pluronic gel (Sigma-Aldrich) with or without 
25 mg/ml Garcinol (Santa Cruz Biotechnology) was applied topically to the adductor 
muscle before skin closure.
Laser Doppler perfusion imaging
Hind limb perfusion was measured with laser Doppler perfusion imaging (LDPI) 
(Moor Instruments) after intraperitoneal injection of midazolam (8 mg/kg) and me-
detomidine (0.4 mg/kg). The regions of interest analyzed consisted of the foot distal 
to the base of the first digit. Perfusion was expressed as the ratio of ligated to non-
ligated foot. After measurement, anesthesia was antagonized with flumazenil (0.7 








Pre-existing collateral density in the pial circulation of the dorsal cerebral cortex 
predicts collateral density in skeletal muscle and other vascular beds (Chalothorn 
et al, 2010; Wang et al, 2010; Zhang et al, 2010). However, unlike in other tissues 
where arterial trees are arranged three-dimensionally and difficult to image with fi-
delity, all cerebral collaterals are contained within the pia and can thus be directly 
identified and counted. Methods for measurement of collateral density between the 
anterior cerebral artery (ACA), middle cerebral artery (MCA), and posterior cerebral 
artery (PCA) were described elsewhere (Chalothorn et al, 2010; Wang et al, 2010; 
Zhang et al, 2010). Briefly, animals were heparinized systemically and anesthetized 
with ketamine (100 mg/kg) and xylazine (10 mg/kg) prior to vascular casting. Maxi-
mal dilation was accomplished by cannulation of the thoracic aorta and infusion of 
sodium-nitroprusside (30 μg/ml) and papaverine (40 μg/ml) in PBS at 100 mmHg 
for 3 minutes. Yellow Microfil™ (Flow Tech Inc.) with viscosity adjusted to prevent 
capillary and venous filling was infused under a stereomicroscope after craniotomy. 
The dorsal cerebral circulation was fixed with topical application of 4% paraformal-
dehyde to prevent any reduction in vessel dimensions after Microfil injection. Brains 
were incubated in Evans Blue (2 μg/ml) for several days to improve contrast for 
visualization of the vasculature. Digital images were obtained at 13X (Leica) of the 
dorsal brain surface and processed with ImageJ software (NIH). Collateral density 
was calculated by determining the total number of pial collaterals between the ACA-
MCA, ACA-PCA and MCA-PCA and dividing by the dorsal surface area of the cere-
bral hemispheres. Areas that sustained damage, were incompletely filled, or were 
otherwise uncountable were excluded from analysis.
Immunostaining and analysis
Mice were sacrificed and the adductor muscle group medial to the femur was excised 
en bloc. Tissues were snap frozen in liquid nitrogen or fixed in 3.7% formaldehyde. 
Serial 5-μm-thick paraffin-embedded sections were used for histological analysis of 
collateral artery number and size. Vessels at the midpoint of the adductor muscle 
group, stained using anti-smooth muscle α-actin (αSMA) (DAKO), are likely com-
posed of collaterals but may also include arterioles of the opposing tree. Randomly 
photographed images through the central part of the adductor muscle group were 
used to quantify the number and lumen diameter of αSMA+ vessels using ImageJ 
software (total of 9 images of 3 sections per mouse). To correct for non-perpendicu-
larly cut sections, the circular lumen area of αSMA+ vessels was calculated from the 
lumen diameter measured at the narrowest point.
Frozen 5-μm-thick sections were fixed in ice-cold acetone and stained with anti-
PCAF (Abcam) and Cy3 conjugated anti-αSMA (Sigma-Aldrich). PCAF was visu-
alized using Alexa 488 conjugated secondary antibody (Invitrogen). Nuclei were 
stained using Vectashield with DAPI (Vector Laboratories). Fluorescent images were 
taken on a LSM700 microscope (Carl Zeiss) and contrast-stretched using Zen 2009 
software (Carl Zeiss). Collaterals were detected with Cy3 conjugated anti-αSMA, 
and perivascular monocytes with anti-MOMA-2 (Millipore), visualized using Alexa 
488 conjugated secondary antibody (Invitrogen). Monocytes were quantified from at 
least six consecutive sections per mouse and expressed as the number of MOMA-2 
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positive cells in the perivascular space of αSMA+ vessels.
In vitro immune response
Whole blood
Blood was collected from the tail vein of PCAF-/- and WT mice and diluted 1:25 
with RPMI 1640 (Invitrogen) supplemented with non-essential amino acids (PAA La-
boratories) and glutamax (Invitrogen). Blood was incubated overnight at 37ºC, 5% 
CO2, in the presence of lipopolysaccharide (LPS) (0-500 ng/ml) from Escherichia 
coli K-235 (Sigma-Aldrich). Cell-free supernatant was collected and TNFα level was 
measured by ELISA (BD Biosciences). 
Splenocytes
Spleens were isolated from PCAF-/- and WT mice, minced through a 40µm-cell strai-
ner (Biosciences) and, after erythrolysis with ammonium chloride solution, single cell 
suspensions were resuspended in DMEM (PAA Laboratories) supplemented with 
10% heat-inactivated FCS (Lonza). Splenocytes (1x106) from PCAF-/- and WT mice 
were plated and incubated for 24 hours with LPS (300 ng/ml) or control. Splenocytes 
of WT mice were also incubated with Garcinol (20 μM) in combination with LPS (300 
ng/ml) or control. MCP-1 level in the cell-free supernatant was measured by ELISA 
(BD Biosciences).
Vascular smooth muscle cells
VSMCs were isolated from abdominal aortas from PCAF-/- and WT mice. For stimu-
lation assays, cells (passage 2-4) were plated (5x103) and incubated for 24 hours 
with LPS (0.1 and 1 ng/ml) or control. VSMCs of WT mice were also incubated with 
Garcinol (15 μM) in combination with LPS (0.1 and 1 ng/ml) or control. MCP-1 level 
in the cell-free supernatant was measured by ELISA (BD Biosciences). RNA was iso-
lated from LPS stimulated (1 ng/ml) WT and PCAF-/- VSMCs (1x105) using RNeasy 
minikits (Qiagen). 
Whole-genome expression
The adductor muscle group of PCAF-/- and WT mice was harvested before (t0) and 
1 day after (t1) induction of HLI, and total RNA was extracted using RNeasy fibrous 
tissue minikit (Qiagen). RNA integrity was checked by NanoDrop 1000 Spectrop-
hotometer (NanoDrop Technologies) and 2100 Bioanalyzer (Agilent Technologies). 
For whole-genome expression profiling, amplified biotinylated RNA was generated 
using the Illumina TotalPrep RNA Amplification Kit. For array analysis, MouseWG-6 
v2.0 Expression Beadchips (Illumina), which contain more than 45,200 transcripts, 
were used. Expression levels were Log2-transformed and after quantile normaliza-
tion, transcripts showing background intensity, both at baseline and after induction of 
HLI, were removed from the analysis. Gene expression levels at t1 were expressed 
relative to average baseline levels generating t1/t0avg ratios for all 15,555 regulated 
genes, and compared between both mouse strains. To define the effect of PCAF on 
inflammatory gene transcription, gene descriptions, as provided by Illumina, contai-
ning any of these criteria (interleukin, chemokine, interferon, TGF, TNF, NF-κB) were 
selected and ratios were tested for significance. 
Real-time quantitative PCR







systems). Quantitative PCR was performed on the ABI 7500 Fast system, using 
commercially available TaqMan gene expression assays for HPRT1, MCP-1, MMP9, 
TNFα, CCL9, CXCL12 and IRF7 (Applied Biosystems).
Flow cytometry
Blood, spleen, bone marrow and non-draining lymph nodes were harvested before 
(t0) and 1 day after (t1) induction of HLI. Draining lymph nodes were dissected from 
the inguinal region. Total circulating leukocytes were measured using the KX-21N 
Hematology Analyzer (Sysmex). Tissues were minced through a 40µm-cell strai-
ner (BD Biosciences) to obtain single cell suspensions which were resuspended 
in IMDM (Lonza) with 2% FCS. For dendritic cell-specific cell surface staining, the 
spleen and lymph nodes were first perfused with collagenase (1mg/ml) and DNase 
(0.02mg/ml) for 10 minutes and minced. Erythrocytes were lysed and samples for 
intracellular staining were permeabilized. Fluorochrome-conjugated monoclonal an-
tibodies specific for CD3, CD4, CD8, CD11c, CD11b, CD19, CD25, CD86, CD115, 
FoxP3, Ly6C, Ly6G, B220, DX5 were used. Cells were measured on a LSRII flow 
cytometer (BD Biosciences) and data was analyzed using FlowJo software (Tree 
Star, Inc.).
Statistical analysis
All results are presented as mean ± standard error of the mean (SEM) or as scatter 
plot. Comparisons between groups were performed using Student’s T-test. All sta-
tistical analyses were performed using SPSS 17.0 software. P-values < 0.05 were 
considered statistically significant and are indicated with *; p-values < 0.01 and < 
0.001 are indicated by ** and ***, respectively. Statistical Analysis of Microarray data 
(SAM) (Tusher et al, 2001) was used for the analysis on t1/t0avg ratios in the whole-
genome expression array. A false discovery rate (expressed as q-values) of less 
than 5% was considered significant.
Results
PCAF contributes to collateral remodeling
PCAF-/- mice showed impaired blood flow recovery after HLI (Fig 1A-B). Postopera-
tive blood flow was decreased to approximately 6% of blood flow in the contralateral 
limb in both groups, with a trend towards reduced blood flow in PCAF-/- mice compa-
red to WT mice (Fig 1C, p=0.07). Thereafter, blood flow recovery in PCAF-/- mice was 
reduced and did not recover completely before termination at 28 days. Moreover, 
PCAF-/- mice showed significantly more necrotic toe nails than WT mice (PCAF-/- 2.9 
±0.6 vs WT 0.45±0.2, p<0.001) (Fig 1D). No auto-amputation of hind limb digits was 
observed in either group. The reduced blood flow recovery in PCAF-/- mice was con-
firmed by quantification of αSMA+ vessels in the adductor muscle group, 28 days 
after HLI (Fig 1E). Although the number of αSMA+ vessels was nearly similar (Fig 
1F), the size of αSMA+ vessels in PCAF-/- mice was significantly reduced, resulting in 
a reduced blood flow. The mean lumen area per αSMA+ vessel (PCAF-/- 139±15µm2 
vs WT 297±26µm2, p<0.001) and total lumen area per section (PCAF-/- 447±46µm2 
vs WT 1253±117µm2, p<0.001) were severely reduced in PCAF-/- mice (Fig 1G-H). 
Thus, PCAF deficiency leads to reduced arteriogenesis after induction of HLI.
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To assess whether the reduction in blood flow recovery in PCAF-/- mice was caused 
by reduced collateral remodeling or by fewer pre-existing collaterals, we performed 
Figure 1. Arteriogenesis in PCAF-/- mice. A. Representative LDPI images of paws from PCAF-/- and WT 
mice directly and 7 days after induction of HLI in the left limb. High blood flow is displayed in red. B. 
Quantification of LDPI measurements of PCAF-/- and WT mice over time. Data are calculated as the ratio 
of ligated over non-ligated paw. C. Quantification of LDPI measurements of PCAF-/- and WT mice directly 
after induction of HLI. Data are calculated as the ratio of ligated over non-ligated paw. D. Quantification of 
necrotic toe nails of the ligated limb in PCAF-/- and WT mice counted 28 days after HLI. E. Immunohisto-
chemical staining of paraffin-embedded adductor muscle group of PCAF-/- and WT mice 28 days after HLI 
using anti-αSMA (red) antibodies. Lumen diameter of αSMA+ vessels is indicated by black bars. Scale 
bars = 50 μm. F-H. Number, mean lumen area (μm2) and total lumen area per section (μm2 / section) of 
αSMA+ vessels, measured at the center of the adductor muscle group in ligated and non-ligated limbs of 







two additional experiments. First, we inhibited PCAF by pharmacological interven-
tion with Garcinol to rule out any effects on number of pre-existing collaterals in the 
PCAF-/- mice. In WT mice, local PCAF inhibition by Garcinol resulted in reduced 
blood flow restoration compared to the empty pluronic gel control group (Fig 2A-B). 
Secondly, the pre-existing vascular bed of PCAF-/- and WT mice was assessed in 
the pial circulation using an arterial vascular casting (Fig 3A). Pial collateral density 
in PCAF-/- mice was reduced by 11% compared to WT mice, reflecting a moderate 
but significant contribution of PCAF in determining the abundance of the native col-
lateral circulation (Fig 3B-C, p=0.02). This was in agreement with the trend towards 
decreased blood flow perfusion in PCAF-/- mice directly after HLI.
Figure 2. Arteriogenesis after pharmacological inhibition of PCAF. A. Representative LDPI images of 
paws directly and 7 days after induction of HLI in the left limb. In WT mice, pluronic gel with or without 
25 mg/ml Garcinol was applied topically to the adductor muscle before skin closure. High blood flow is 
displayed in red. B. Quantification of LDPI measurements of WT mice treated with Garcinol or control 
over time. Data are calculated as the ratio of ligated over non-ligated paw. All values are presented as the 
mean ± SEM. **P < 0.01, ***P < 0.001, Garcinol versus control. 
Figure 3. Pre-existing collateral bed in PCAF-/- mice. A. Representative images of the pial circulation in 
PCAF-/- and WT mice. White asterisks indicate collateral arteries between anterior, middle and posterior 
cerebral arteries (ACA, MCA and PCA, respectively). Following exsanguination and maximal dilation of 
the dorsal cerebral circulation, Microfil™ was used as a casting agent, after which the whole brain was 
fixated in 4% PFA. B. Pial collateral density was calculated in PCAF-/- and WT mice by dividing the sum of 
ACA to MCA, ACA to PCA and MCA to PCA by the surface area of the cerebral hemispheres. C. Region 
of the brain utilized for calculation of pial density. Areas were excluded when they were damaged, had 
poor filling with Microfil™, or were otherwise uncountable. NS = non-significant. All values are presented 
as the mean ± SEM. *P < 0.05, PCAF-/- versus WT. 
268
Chapter 11
PCAF is required for in vitro inflammatory response
We investigated the role of PCAF in the inflammatory response of multiple cell ty-
pes, given the above evidence for decreased collateral remodeling and the known 
involvement of these cells in arteriogenesis. Analysis of circulating cells in a whole 
blood LPS stimulation assay showed dose-dependent increase of TNFα in blood 
from WT mice, which was significantly reduced in blood from PCAF-/- mice (Fig 4A). 
Next, the splenic cell reservoir was subjected to LPS stimulation and pharmacolo-
gical PCAF inhibition with Garcinol. LPS (300 ng/ml)-stimulated MCP-1 levels of 
splenocytes from both PCAF-/- mice (63±32pg/ml) and WT splenocytes treated with 
20 μM Garcinol (195±35 pg/ml) were both significantly reduced in comparison to 
WT splenocytes (372±13 pg/ml, p=0.005 and p=0.04 respectively) (Fig 4B). Also the 
inflammatory phenotype of PCAF-/- VSMCs was assessed. Similar to the splenocyte 
stimulation, MCP-1 levels were markedly reduced after LPS (0.1 ng/ml) stimulation 
of PCAF-/- VSMCs (689±49 pg/ml) and WT VSMCs when exposed to 15μM Garcinol 
(3087±284 pg/ml) compared with untreated WT VSMCs (4175±264 pg/ml, p<0.001 
and p=0.049 respectively) (Fig 4C). In addition, upregulation of MCP-1 mRNA was 
significantly reduced by 53% in PCAF-/- VSMCs (Fig 4D, p=0.01). To exclude non-
specific effects of Garcinol, these experiments were repeated in WT VSMCs treated 
with siRNAs against PCAF mRNA instead of Garcinol. Transfection with siRNAs 
targeting PCAF mRNA efficiently decreased PCAF mRNA expression by 61% and, 
like Garcinol, inhibited MCP-1 production (Supporting Information Fig 1A-C).
Figure 4. The role of PCAF in in vitro inflammatory response. A. Inflammatory response of whole blood 
from PCAF-/- and WT mice was evaluated. Blood from tail vein was collected, diluted (1:25) and incuba-
ted 24 h with LPS (0-500 ng/ml). TNFα (pg/ml) level in cell-free supernatant was measured by ELISA. 
ND = non-detectable. B. Splenocytes of PCAF-/- and WT mice were cultured and incubated for 24 h 
with LPS (300 ng/ml) or control. Splenocytes of WT mice were also incubated with Garcinol (20 μM) in 
combination with LPS (300 ng/ml) or control. Cell-free supernatant MCP-1 (pg/ml) level was measured 
by ELISA. C. VSMCs of PCAF-/- and WT mice were cultured and incubated for 24 h with LPS (0.1 and 
1 ng/ml) or control. VSMCs of WT mice were also incubated with Garcinol (15 μM) in combination with 
LPS (0.1 and 1 ng/ml) or control. Cell-free supernatant MCP-1 (pg/ml) level was measured by ELISA. D 
Vascular smooth muscle cells (VSMCs) of PCAF-/- and WT mice were cultured and incubated for 24 h 
with LPS (1 ng/ml) or control. MCP-1 mRNA expression was measured by real-time quantitative PCR. 
Cts were normalized against Cts of HPRT1. All values are presented as the mean ± SEM of triplicates. 







PCAF modulates post-ischemic gene regulation
PCAF staining showed enhanced expression in cells of large developing collaterals 
in the adductor muscle group compared to surrounding skeletal muscle (Fig 5A). To 
study differential gene expression after HLI between PCAF-/- and WT mice, total RNA 
isolated from the adductor muscle group was used in a whole-genome expression 
analysis using Illumina Beadchips. Statistical analysis by SAM on t1/t0avg ratios 
identified 1963 genes with a significant lower ratio and 1542 genes with a higher ra-
tio in PCAF-/- relative to WT mice (q<5%), indicating that PCAF exhibits a large effect 
on gene transcription after HLI (Fig 5B).
Supporting Information Table 1 shows the top 50 genes with impaired upregulation 
in PCAF-/- mice compared to WT mice, including MMP9, critical in matrix degradation 
required for collateral artery expansion. Since PCAF has been shown to regulate 
inflammatory gene transcription, we selected inflammatory genes that were signi-
ficantly regulated (Supporting Information Table 2 and Supporting Information Fig 
2). Among the inflammatory genes showing a more pronounced induction in WT 
mice compared to PCAF-/- mice were genes encoding cytokines CXCL12, CCL9 and 
TNFα, chemokine receptor CXCR1, transcription factor IRF7, TNF receptor associ-
ated factors TRAF2 and TRAF3, TNF receptor associated protein TRAP1 and mem-
bers of the TNF receptor superfamily TNFRSF19 and TNFRSF11a (also known as 
RANK). The total of inflammatory genes with greater induction in PCAF-/- mice was 
much smaller than the number of genes more strongly induced in WT, and included 
inhibitors of the NF-κB pathway like NFKBIA and NKIRAS1. Aberrant regulation of 
several relevant regulated factors (MMP9, TNFα, CCL9, CXCL12, IRF7) were con-
firmed using real-time quantitative PCR (Fig 5C-G).
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PCAF deficiency alters leukocyte recruitment
We quantified leukocyte subtypes that are involved in arteriogenesis, including T 
cells (helper CD4+, cytotoxic CD8+ and regulatory T cells) and natural killer cells, 
and subtypes which have not been previously implicated in arteriogenesis, including 
B cells and dendritic cells. Blood samples from before (t0) and 1 day after (t1) HLI, 
were analyzed by FACS. PCAF deficiency had effects on most of the leukocyte sub-
types examined. Following HLI, circulatory T cells were significantly decreased in 
PCAF-/- mice compared to WT mice. This difference was caused mainly by a reduc-
tion in CD4+ T cells, especially by the fraction of activated CD4+ T cells, defined by 
the loss of CD62L (L-selectin), and regulatory T cells (CD4+CD25+FoxP3+ T cells). 
The number of circulatory CD8+ T cells did not differ between WT and PCAF-/- mice. 
Also counts of other leukocyte subtypes, including B cells and natural killer cells 
were decreased by PCAF deficiency.
To investigate the migratory behavior of the leukocyte subtypes, the spleen, bone 
marrow and lymph nodes were harvested from both mouse strains before (t0) and 1 
day after (t1) HLI. Compared to WT mice, we observed reduced numbers of dendritic 
cells in the draining inguinal lymph nodes of PCAF-/- mice after HLI. Accordingly, the 
fraction of dendritic cells expressing the co-stimulatory molecule CD86+ was smaller 
in the draining lymph nodes of PCAF-/- mice. Furthermore, nearly all tested leukocy-
tes subtypes were increased in the bone marrow of PCAF-/- mice compared to WT 
mice, including CD4+ and CD8+ T cells, natural killer cells and dendritic cells, sug-
gesting that these subpopulations are retained in the bone marrow of PCAF-/- mice 
during recovery after HLI (Supporting Information Fig 3A-I).
Because monocytes play a key role in arteriogenesis and are among the first leuko-
cytes recruited to remodeling collaterals, we evaluated different monocyte populati-
ons in blood, spleen and bone marrow. After HLI, the absolute number of circulating 
monocytes in WT mice was equal to baseline numbers, but monocytes in PCAF-
/- mice significantly decreased compared to baseline (PCAF-/- 0.13±0.05x106/mL vs 
WT 0.37±0.02x106/mL, p=0.002) (Fig 6A). In WT mice, the monocyte population 
increased in the spleen and decreased in the bone marrow after HLI. In contrast, 
bone marrow monocytes in PCAF-/- mice increased compared to baseline and were 
significantly higher after HLI compared to WT mice (Fig 6B-C). The differences in 
monocyte numbers were caused mainly by the specific subtype of “pro-inflammato-
ry” Ly6Chi monocytes (Fig 6D-F). The activation state of total and Ly6Chi monocytes 
did not differ between the two strains, measured by mean fluorescent intensity of the 
adhesion molecule CD11b (Fig 6G-H).
Figure 5. Gene regulation in PCAF-/- mice after HLI. A. Immunohistochemical staining on fresh frozen 
sections of WT adductor muscle 1 day after HLI, using anti-αSMA (red) and anti-PCAF (green) antibodies. 
Cell nuclei were stained with DAPI (blue). Scale bars = 50 μm. B. Heatmap of differentially regulated 
genes in whole-genome expression analysis, comparing PCAF-/- and WT mice. Included are genes that 
were significantly different between PCAF-/- and WT mice (q-value < 5). Data are presented as the fold 
change in expression between day 1 (t1) and average preoperative baseline levels (t0), generating t1/
t0avg ratios. Red indicates increased and green indicates reduced expression relative to average base-
line levels. The pie graph illustrates a significant decrease of 1963 genes (green) and increase of 1542 
(red) genes in PCAF-/- relative to WT mice. C-G. Microarray validation by real-time quantitative PCR of a 
selection of relevant regulated inflammatory factors MMP9, TNFα, CCL9, CXCL12 and IRF7. Cts were 








Finally, we assessed the number of monocytes/macrophages in the adductor muscle 
group by fluorescent staining with antibodies against MOMA-2 and smooth muscle 
α-actin (Fig 7A). Although PCAF-/- mice showed a significant increase in MOMA-
2-positive cells 24 hours after HLI, the increase in WT mice was significantly higher 
(PCAF-/- 3.2±0.35/section vs WT 6.0±0.43/section, p=0.001) (Fig 7B). Differences 
were most evident in the perivascular space of remodeling collaterals (PCAF-/- 
1.4±0.16/section vs WT 3.5±0.76/section, p=0.01) (Fig 7C).
 
Discussion
We demonstrate that blood flow recovery after induction of HLI is strongly impaired 
in PCAF-/- mice, in association with reduced expansive remodeling of collaterals. 
Furthermore, local PCAF inhibition by Garcinol in WT mice also reduces recovery, 
indicating that PCAF is directly required for normal arteriogenesis. PCAF gene de-
ficiency results in a repressed in vitro inflammatory response in many cell types 
known to be involved in arteriogenesis. One day after induction of HLI, 3505 genes 
are differentially regulated in the adductor muscle group of PCAF-/- mice compared to 
Figure 6. Monocyte recruitment in PCAF-/- mice after HLI. A-C. Flow cytometry analysis of monocytes be-
fore (t0) and 1 day after (t1) HLI in PCAF-/- and WT mice. Values are presented as total monocyte counts 
in blood (nx106/mL), spleen (% of total cells) and bone marrow (% of total cells). D-F. Flow cytometry 
analysis of “pro-inflammatory” Ly6Chi monocytes after HLI in PCAF-/- and WT mice. Values are presented 
as total Ly6Chi monocyte counts in blood (nx106/mL), spleen (% of total cells) and bone marrow (% of 
total cells). G-H. Activation state of monocytes and Ly6Chi monocytes measured by mean fluorescence 
intensity (MFI) of CD11b. *P < 0.05, **P < 0.01, ***P < 0.001.
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WT mice. Additionally, recruitment of different pro-arteriogenic leukocyte subtypes in 
PCAF-/- mice, in particular “inflammatory” monocytes, is significantly impaired at this 
time. Our data therefore demonstrate that PCAF plays a key role in post-ischemic 
arteriogenesis.
Compared to WT mice, PCAF-/- mice showed an impaired blood flow recovery af-
ter HLI. Our findings suggest that two deficiencies caused by a lack of PCAF are 
involved. First, the expansive remodeling of αSMA+ arterioles at the center of the 
adductor muscle group, of which most are collaterals, was reduced by 53% in PCAF-
/- mice compared to WT mice. Correspondingly, local application of PCAF inhibitor 
Garcinol in healthy WT mice also resulted in impaired blood flow recovery compared 
to control animals. Hence, PCAF has a major impact on arteriogenesis. Secondly, 
we observed that the density of native pre-existing collaterals in the pial circulation 
of PCAF-/- mice was reduced by 11%. Even changes of this magnitude have signifi-
cant effects on collateral-dependent perfusion of tissue downstream from an arterial 
obstruction (Chalothorn & Faber, 2010; Wang et al, 2010; Zhang et al, 2010).  Pre-
vious studies have shown that genetic-dependent variation in collateral number in 
the cerebral pial circulation is shared, at least qualitatively, by similar differences in 
collateral density in other tissues (Chalothorn et al, 2010; Wang et al, 2010; Zhang 
et al, 2010). Accordingly, we also observed a trend towards a decrease in blood flow 
directly after induction of HLI in PCAF-/- mice. In mice, the density of the native colla-
terals in tissues varies widely among strains from differences in genetic background 
(Chalothorn et al, 2010; Wang et al, 2010; Zhang et al, 2010). Hence, besides col-
lateral remodeling, genetic PCAF deficiency also contributes to reduced formation of 
Figure 7. Monocyte recruitment to collateral arteries in PCAF-/- mice after HLI. A. Immunohistochemical 
staining on fresh frozen sections of the adductor muscle group from PCAF-/- and WT mice 1 day after HLI, 
using anti-αSMA (red) and anti-MOMA-2 (green) antibodies. Cell nuclei were labeled with DAPI (blue). 
Scale bars = 100 μm. B-C. Quantification of MOMA-2 positive cells in the adductor muscle group of PCAF-
/- and WT before (t0) and 1 day after (t1) HLI. Monocytes were quantified from at least six consecutive sec-
tions per mouse and expressed as the number of MOMA-2 positive cells per section and as the number 







the collateral circulation which occurs during embryonic development.
In a clinical setting, the outcome after an ischemic event varies among individuals, 
and differences in abundance of the native collateral circulation have also been re-
ported in patients (Meier et al, 2007; Menon et al, 2012).  Moreover, a previous study 
found that the -2481G allele in the promoter region of the PCAF gene associates 
with an increased risk of mortality in patients with coronary heart disease (Pons et 
al, 2011), which further supports our findings that PCAF deficiency impairs collateral 
function.
In order for PCAF to serve as a master switch in collateral remodeling, it needs to 
impact multiple critical phases in the process, namely activation of the endothelium 
and vessel wall, leukocyte recruitment, matrix degradation and arteriolar expansion. 
We examined gene expression in the adductor muscle group containing remodeling 
collaterals in the initial phase after HLI. Over 3500 genes were differentially regu-
lated between PCAF-/- and WT mice. This suggests that PCAF impacts expression 
of a large number of genes activated in this setting. More specifically, PCAF-/- mice 
showed impaired induction of multiple pro-arteriogenic and pro-inflammatory genes, 
including matrix metalloproteinase (MMP) 9 and chemokines CXCL12 (SDF1) and 
CCL9.
MMP9 is critical in degradation and remodeling of the extracellular matrix allowing 
cell migration and outward expansion of the collaterals and thus effective arterio-
genesis (Huang et al, 2009). CXCL12 is elevated in ischemic skeletal muscle of 
patients with critical limb ischemia (Ho et al, 2010) and acts as chemoattractant for 
CXCR4+ cells, including leukocytes and progenitor cells. CXCL12-mediated recruit-
ment of bone marrow-derived cells to ischemic tissues results in enhanced neovas-
cularization (Hiasa et al, 2004; Shao et al, 2008). Also CCL9, which is a strong che-
moattractant for bone marrow derived cells (Yang & Odgren, 2005), is upregulated 
after muscle injury (Shireman, 2007).
In addition, PCAF-/- mice showed impaired induction of multiple factors related to the 
pro-inflammatory TNFα pathway (Silke & Brink, 2010). TNFα-/- mice have reduced 
collateral artery perfusion (Hoefer et al, 2002) and anti-TNFα therapy attenuates 
arteriogenesis (Grundmann et al, 2005). Thus, reduced TNFα expression in PCAF-
/- mice likely contributes to the impaired arteriogenesis in these mice. Our data sug-
gest that PCAF regulates many factors that have previously been described to play 
an important role in both inflammation and arteriogenesis (Lee et al, 2004).
It should be noted that RNA was isolated from the adductor muscle group as a whole 
(Lee et al, 2004) and not from the embedded collateral arteries alone, as was descri-
bed previously (Dai & Faber, 2010). In that report, a whole-genome microarray ana-
lysis was performed on collaterals microdissected from the gracilis muscle 24 hours 
after HLI. Here we found exceedingly more differentially expressed genes, then the 
404 genes that were found upregulated in gracilis collaterals of WT mice (Dai et al, 
2010). Using the entire adductor muscle group for microarray analysis, not only the 
collaterals but also infiltrating leukocytes and surrounding non-vascular tissues were 
included in these analyses.
As discussed in the introduction, an inflammatory-like process plays a role in all 
stages of arteriogenesis. To investigate the impact of PCAF on the inflammatory 
response of the different cell types involved in arteriogenesis, we studied circulating 
cells in whole blood, splenic leukocytes and VSMCs in vitro. PCAF is critical for 
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the regulation of transcription factor NF-κB, that consists of a p65 and p50 subunit 
bound to inhibitory proteins in the cytoplasm. Upon stimulation NF-κB is translocated 
to the nucleus and regulates the expression of multiple genes, including TNFα and 
MCP-1 (Lenardo & Baltimore, 1989; Miao et al, 2004). PCAF binds to the NF-κB 
p65 subunit and activates NF-κB-related inflammatory gene expression (Miao et al, 
2004; Sheppard et al, 1999). We clearly demonstrate that PCAF deficiency results 
in decreased production of pro-inflammatory cytokines by multiple cell types after 
stimulation with LPS. LPS stimulated whole blood from PCAF-/- mice produced less 
TNFα than blood from WT mice, indicating a reduced inflammatory phenotype of 
circulating cells. Also PCAF-/- cells isolated from the spleen, one of the major leuko-
cyte reservoirs, showed a reduced inflammatory response compared to splenocytes 
from WT mice. PCAF-/- VSMCs produced less MCP-1 than WT VSMCs in response 
to LPS, which would favor reduced monocyte recruitment and therefore reduced 
VSMC proliferation, which is essential for collateral remodeling. We obtained similar 
results using either Garcinol or PCAF-specific siRNA knockdown in WT VSMCs, 
thus excluding effects of any pre-existing differences in PCAF deficient cells. Our 
data correspond with a report that TNFα-induced NF-κB activity increases in human 
airway smooth muscle cells overexpressing PCAF (Clarke et al, 2008) and provide 
strong evidence for a wide effect of PCAF on inflammatory gene transcription.
The p65 subunit of NF-κB recruits co-activator PCAF and activates NF-κB-mediated 
gene transcription. In contrast, the NF-κB p50 subunit lacks the transcriptional acti-
vation domain and inhibits gene transcription (Driessler et al, 2004). Mice deficient of 
the NF-κB p50 subunit showed enhanced blood flow recovery after HLI as the result 
of increased monocyte recruitment to the perivascular space of collaterals (de Groot 
D. et al, 2010). Whereas arteriogenesis and monocyte recruitment is enhanced by 
NF-κB activation in NF-κB p50-/- mice, reduced regulation of the NF-κB p65 subunit 
in PCAF-/- mice could likely explain the impaired arteriogenesis by inhibition of mono-
cyte recruitment. In WT mice, the monocyte population increased in the spleen and 
decreased in the bone marrow after HLI. This is in line with earlier reports that mo-
nocytes are mobilized from the bone marrow after HLI (Cochain et al, 2010). In that 
report, the pro-arteriogenic potential of monocytes was described to originate from 
a specific “pro-inflammatory” subtype, which is characterized by high expression of 
Ly6C. These Ly6Chi monocytes are recruited in the early stage of collateral remode-
ling (Capoccia et al, 2008; Cochain et al, 2010) and our data confirm that they are 
mobilized from the bone marrow in WT mice. In contrast, recruitment of monocytes 
proved to be severely impaired in PCAF-/- mice. PCAF-/- mice showed reduced num-
bers of circulating monocytes following HLI, particularly reduced numbers of Ly6Chi 
monocytes. Whereas monocytes migrated away from the bone marrow in WT mice, 
PCAF-/- mice showed an increase in bone marrow monocytes, suggesting a defect 
in monocyte mobilization. Concomitantly, 24 hours after HLI fewer monocytes were 
recruited to the collaterals in PCAF-/- mice. Monocytes stimulate arteriogenesis by 
secretion of growth factors and degradation of extracellular matrix at the site of col-
lateral remodeling. Therefore, the lack of monocyte accumulation along collaterals 
likely contributes to the impaired arteriogenesis in PCAF-/- mice.
Besides monocytes, PCAF also affected numerous other leukocyte subtypes. In 
PCAF-/- mice, we demonstrated decreased numbers of circulating leukocytes in-







CD4+ T cells (Stabile et al, 2003; van Weel et al, 2007)), natural killer cells (van Weel 
et al, 2007) and regulatory T cells (Hellingman et al, 2012; Zouggari et al, 2009), 
and also in those cells that have not previously been implicated in arteriogenesis, 
including B cells. Furthermore, fewer dendritic cells were found in draining inguinal 
lymph nodes compared to WT mice, where the interaction between antigen-presen-
ting dendritic cells and T cells takes place. Interestingly, nearly all subtypes were 
increased in the bone marrow of PCAF-/- mice, after HLI. This indicates that PCAF 
deficiency interferes with recruitment of pro-arteriogenic leukocytes from the bone 
marrow reservoir (Meisner & Price, 2010).
In conclusion, PCAF-/- mice demonstrated impaired collateral remodeling after HLI, 
together with a reduction in the number of native pre-existing collaterals present 
before arterial obstruction. PCAF deficiency resulted in altered expression of a large 
number of genes, including those in immune and inflammatory pathways, and an 
attenuated inflammatory response in multiple cell types involved in arteriogenesis. 
These findings indicate that PCAF is a key regulator in post-ischemic blood flow re-
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Figure 1. PCAF knockdown by siRNA in vascular smooth muscle cells. A. Vascular smooth muscle cells 
(VMSCs) were transfected with nontarget fluorescent siGlow (Dharmacon) to test transfection efficiency, 
using Lipofectamine 2000 according to the manufacturer’s instructions. VSMCs were visualized on a 
Leica fluorescence microscope. B. VSMCs were plated and transfected with control short-interfering RNA 
(siRNA) or a combination of 4 siRNAs directed towards PCAF for 4 hours. Untransfected VMSCs were 
used as control.
VSMCs were incubated with LPS (1 ng/ml) for 24 hours. To confirm PCAF knockdown, PCAF mRNA 
was measured by real-time quantitative PCR. Levels were normalized against the expression of HPRT1. 
PCAF specific siRNA reduced PCAF expression with 61% in comparison to scrambled siRNA. C. Cell-
free supernatant of LPS stimulated VSMCs was collected for MCP-1 quantification, measured by ELISA. 
Transfection with PCAF specific siRNA inhibited MCP-1 production of VSMCs in comparison to scrambled 
siRNA. All samples were performed in triplicates. *P < .05, **P < .01, scrambled siRNA versus PCAF 
siRNA.
Figure 2. Differential inflammatory gene expression in PCAF-/- and WT mice. Heatmap of differentially 
expressed inflammatory genes in adductor muscle group of PCAF-/- and WT mice, 1 day after HLI. Gene 
definitions containing any of these criteria (interleukin, chemokine, interferon, TGF, TNF, NFKB) were 
selected. Included are genes that were significantly different between PCAF-/- and WT mice (q-value < 5). 
Data are presented as the fold change in expression between day 1 and average preoperative baseline 
levels, generating t1/t0avg ratios. Red indicates increased and green indicates reduced expression rela-









Figure 3. Leukocyte subtypes in PCAF-/- and WT mice after HLI. Flow cytometry analysis of lymphocytes 
in blood (nx103/mL), spleen and bone marrow (% of total cells). In succession, values are presented for 
(A) CD4+ T helper cells, (B) CD8+ cytotoxic T cells, (C) activated CD4+ T helper cells, (D) activated CD8+ 
cytotoxic T cells, (E) regulatory T cells (Treg), (F) Natural Killer (NK) cells and (G) B lymphocytes. (H) 
Dendritic cells (DCs) in spleen, bone marrow, nondraining and draining (inguinal) lymph nodes (LN). (I) 
Activated DCs in spleen, bone marrow, non-draining and draining (inguinal) lymph nodes.
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Table 1. List of differentially expressed genes in the adductor muscle group of PCAF-/- and WT mice. Data 
are presented as the log fold change in expression between day 1 after HLI and average preoperative 
baseline levels, generating t1/t0avg ratios. Listed are the top 50 genes which showed an impaired upre-








Table 2. List of significantly differentially expressed inflammatory genes in the adductor muscle group of 
PCAF-/- and WT mice. Data are presented as the log fold change in expression between day 1 after HLI 
and average preoperative baseline levels, generating t1/t0avg ratios. Gene definitions containing any of 
these criteria (interleukin, chemokine, interferon, TGF, TNF, NFKB) were selected. Q-values less than 5% 







Summary and general discussion
Cardiovascular diseases remain the major cause of death throughout the world and 
can be primarily attributed to atherosclerotic vascular disease leading to stroke and 
coronary heart disease (CHD). Improved primary prevention and the introduction 
and subsequent optimization of percutaneous coronary interventions (PCI) for myo-
cardial ischemia due to obstructive CHD have significantly improved patient out-
come and reduced morbidity and mortality. The insight into disease pathology has 
however expanded tremendously over the past decade and continuing research has 
shifted the focus of interest towards post-interventional accelerated atherosclerosis 
development due to a dysfunctional (auto) immune inflammatory response, respon-
sible for vascular remodeling, re-occlusion and recurrence of symptoms. 
The aim of this thesis therefore was to investigate the role of the immune system in 
this pathophysiological process that ultimately results in post-interventional athero-
sclerotic vascular remodeling and apply this insight for the development of new im-
mune-modulatory therapies in a preclinical setting. The important contribution of the 
various parts of the immune system involved in both clinical and preclinical vascular 
remodeling are described in chapter 1. Preclinical screening and testing of immune-
modulatory therapy effectiveness is a vital step towards clinical application of such 
interventions at the time of PCI or CABG-surgical procedures to prevent vascular 
re-occlusion and the necessity for re-interventions. Insight into the evoked immune 
responses, both in mouse and man, during these procedures lies at the basis for the 
discovery and application of new therapies with ultimate clinical potential.
Chapter 2 provides an overview of the immune reactions of the innate and adaptive 
immune systems that develop during native atherogenesis, as well as those which 
are evoked by vascular injury during revascularization strategies. Specific leukocyte 
receptors, ligands, co-stimulatory molecules and inflammatory cytokines are high-
lighted and are shown to be involved in disease initiation and lesion progression 
during inflammation. In addition, their association with disease severity is indepen-
dent of traditional risk factors such as smoking and hypertension and they could 
serve as helpful tools for biomarker-based risk stratification or and diagnosis. This 
includes diagnostic assessment of patients eligible for intensified treatment evalu-
ated clinicians performing target lesion revascularization interventions. Moreover, 
future biomarkers could be helpful in assessing treatment effectiveness in a way 
that traditional makers such as plasma lipoprotein levels or electrocardiographic do 
not provide adequate insight. Plasma measurements are above all strongly prefer-
red over diagnostic angioplasty procedures and local biomarkers in the arterial seg-
ments of interest could improve optimal disease severity assessment. The search for 
new biomarkers is therefore essential and markers of inflammation that are causally 
linked to post-interventional vascular remodeling could prove to be the most valua-
ble makers available to clinicians. 
Chapter 3 illustrates that investigational screening of the therapeutic effects of drug 
therapy on vascular remodeling and accelerated atherosclerosis development re-
quires preclinical models that optimally mimic the clinical situation of the vessel after 
intervention, not only in vascular anatomical aspects such as size, diameter and wall 
thickness, but also in features of disease stage aspects such as hypercholesterole-
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mia and other conventional risk factors for atherosclerosis. To this end, humanized 
animal models are discussed that have the best predictive value for the pathophy-
siological process in the development of restenosis, intimal hyperplasia and acce-
lerated atherosclerotic lesions. Various vascular interventions in transgenic mouse 
models are mentioned, with a strong focus on the mouse femoral artery cuff model. 
To study effects of (local) drug therapy, animals should be susceptible to the treat-
ment of interest, have similar metabolic levels, coagulatory phenotype and react in a 
human-like fashion. The use of humanized (transgenic) animal models has extensi-
vely increased the similarity between human and animal lesions and the translation 
of new therapies into the clinical setting. Furthermore, mechanistic and pathophy-
siological studies have shown that local vessel wall inflammation, proliferation and 
proteolysis are central in post-interventional vascular remodeling. It was therefore 
concluded that highly-reproducible animal models for post-interventional vascular 
remodeling are essential for studying the process of restenosis and the development 
of future anti-restenotic therapies. 
Specific stages of the immune response and their usefulness as target of immune-
directed interventions are discussed below. Vascular remodeling is originally initiated 
by endothelial damage and injury to the underlying plaque by balloon inflation, stent 
deployment or surgical harvesting and engraftment procedures during revasculari-
zation interventions. Exposure of thrombogenic tissue will evoke platelet adherence, 
activation and thrombosis formation and support the recruitment of leukocytes to the 
site of vascular injury. Platelet activation and binding is supported by the presence of 
phosphatidylserine (PS) on activated and apoptotic cells. Chapter 4 shows a thera-
peutic role for the PS-binding annexin A5 protein against vascular inflammation, re-
modeling and dysfunction in mouse models for accelerated atherosclerosis develop-
ment. It was demonstrated that annexin A5 injection resulted in a marked reduction 
in circulating plasma cytokine concentrations and early inflammatory cell recruitment 
to the vessel wall after injury, eventually leading to decreased intimal hyperplasia 
with less plaque instability features. Although the exact role through which annexin 
A5 led to these effects was not completely clarified, annexin A5 was shown to act 
through local platelet-supported leukocyte binding and prevention of the subsequent 
immune response, thus extending the role of annexin A5 as a regulator of inflam-
matory processes and demonstrated its potential therapeutic use in inflammation-
associated vascular disease.
In chapter 5 it is demonstrated that a strong association exists between genetic 
polymorphisms in the human annexin A5 gene and increased restenosis-risk in pa-
tients undergoing PCI enrolled in the GENDER study, composed of 866 patients of 
which 295 cases developed restenosis within 1 year following PCI and 571 controls 
were free of restenosis. Although association exists, this does not implicate a direct 
causal link between this polymorphism and clinical outcome. To this end, measure-
ment of patient plasma annexin A5 concentration could provide insight, since redu-
ced annexin A5 concentrations are linked to increased coronary stenosis severity, 
whilst increased concentrations occurs following myocardial infarction. Neverthe-
less, these results do suggest that annexin A5 genotype could function as a risk 
marker for restenosis. Together, these date indicate high diagnostic and therapeutic 
clinical potential for annexin A5 against post-PCI vascular remodeling.
Chapter 6 describes the process of optimization of a natural occurring protective 
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anti-phosphorylcholine (PC) T15/E06 IgM antibody into a recombinant chimeric IgG 
which was first evaluated for in vitro anti-inflammatory effectiveness. Remarkably, 
the inhibitory effects on oxidized low density lipoprotein (oxLDL) uptake by scaven-
ger receptor-bearing macrophages was lost after transition of the constant antibody 
region from an IgM to an IgG chain. Despite this loss, the recombinant anti-PC T15 
IgG was nevertheless effective in preventing monocyte chemotactic protein (MCP)-1 
expression by macrophages and passive immunization of cuffed hypercholestero-
lemic mice with this antibody prevented accelerated atherosclerosis development. 
These results suggest that although the chimeric antibody did not prevent oxLDL 
uptake, it did inhibit inflammatory responses towards oxLDL, possibly by masking 
the immunogenic epitope or by supporting its degradation and clearance from the 
circulation.
Using the Dyax library, phage display selection allowed identification of phosphoryl-
choline-specific phages that were converted to full IgGs and could still block oxLDL-
uptake by macrophages and subsequent MCP-1 expression. A selection of anti-
bodies was then tested in vivo and yielded potent fully human monoclonal anti-PC 
T15 IgG (M99-B05) antibodies that were effective in preventing intimal thickening in 
cuffed hypercholesterolemic animals. Codon optimization of M99-B05 produced the 
X19-A05 antibody with high specificity for PC and strong anti-inflammatory effects 
that could inhibit oxLDL uptake in vitro and vascular remodeling in vivo, even in low 
concentrations. This study, like those performed previously, showed that PC is a 
promising therapeutic target in the prevention and treatment of accelerated athe-
rosclerosis development in mice and anti-PC IgG antibodies can prevent vascular 
remodeling. However, the vital new aspect of this study is that it is the first to develop 
new fully human anti-PC IgG antibodies that are atheroprotective. Others used IgM 
antibodies passively in mice or induced anti-PC IgM and IgG through active immu-
nization. These techniques are promising, but not applicable in the clinical setting, 
since active immunization with a pneumococcal polysaccharide vaccine previously 
did not lead to adequate titers of oxLDL-recognizing anti-PC antibodies. We develo-
ped, screened and tested recombinant monoclonal anti-PC IgG antibodies that are 
suitable for passive therapeutic immunization in humans. By providing immediate 
and direct control of the patient’s immune response with restriction to a single im-
munogenic epitope, this immunization approach could prove to be an effective tre-
atment modality against post-interventional atherosclerotic vascular remodeling in 
patients undergoing PCI or CABG-surgery.
The important role of the innate immune system was confirmed in chapter 7, where 
a novel TLR7/9 dual antagonist was tested in a mouse restenosis model. Toll-like 
receptors are a vital part of the innate immune system and serve as pattern re-
cognition receptors (PRR) that recognize extracellular ligands that originate from 
bacteria or viruses (TLR2, 4 and 5), as well as intracellular ligand such as damaged 
or viral (double stranded) RNA (TLR3, 7 and 9). These endogenous ligands may 
be released after tissue damage or cell stress, processes that may be initiated by 
PCI. TLR7 or TLR9 presence occurred in vascular lesions at the location of ma-
crophage accumulation. In vitro, these cells responded to TLR7 or TLR9 activation 
by increased oxLDL uptake and TNFα production, which could be inhibited by the 
novel TLR7/9 dual antagonist. These effects led to reduced intimal thickening when 
applied in vivo. The magnitude of individual TLR signaling remains unknown, but 
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the therapeutic potential of targeting TLR7 and TLR9 to prevent restenosis and ac-
celerated atherosclerosis has been made clear. Since TLRs are easily accessible for 
circulating drugs (directly or after cellular infiltration) and form the first line of defense 
of the innate immune system, they are favorable as therapeutic targets in the acute 
phase of vascular injury and can be readily silenced or stimulated. Novel inhibitors 
can be designed to bear desired drug properties, whilst effectively targeting a TLR of 
great interest. Dual targeting of multiple receptors greatly increases drug effective-
ness, clearly demonstrated in this study.
In chapter 8, the contribution of the adaptive immune system to post-interventional 
atherosclerotic vascular remodeling was elucidated by investigating the role of CD4+ 
T-cells and CD28-CD80/86 co-stimulatory pathways. Post-interventional vascular re-
modeling was significantly attenuated in CD4-/- and CD80-/-CD86-/- mice compared to 
controls. To show that CTLA-4 is a key and vital regulator in this process, abatacept 
was injected in control mice that then failed to develop significant intimal thickening. 
Next, this was repeated in hypercholesterolemic ApoE3*Leiden mice, producing si-
milar striking results. Flow cytometry analysis of activated lymphocytes in spleen 
and draining lymph nodes revealed that abatacept prevented effector CD4+ T-cell 
activation and led to a reduced number of regulatory T-cells in the spleen, although 
without affecting Teff : Treg ratio. However, abatacept did not affect cellular activation 
status in draining lymph nodes. These findings were later linked to reduced plasma 
levels of interferon γ in abatacept-treated animals. The role of CTLA-4 co-inhibition 
in this process was finally confirmed by treating ApoE3*Leiden mice with hybridoma-
derived blocking anti-CTLA-4 IgG antibodies, which developed significantly larger 
lesions. 
Immune-mediated interventions directed towards therapeutically controlling the in-
flammatory T-cell response such as abatacept are widely applied in other immu-
ne (e.g. rheumatoid) disorders and could now be used in an early phase following 
vascular interventions to prevent subsequent vascular remodeling. Abatacept is a 
registered drug with an established efficacy and safety profile in patients, which 
can dramatically shorten the time necessary for bench-to-bedside translation for this 
specific drug. Although initial beneficial effects of abatacept were observed, these 
need to be reproduced in the prolonged treatment setting before they can be applied 
in the clinic. In addition, effects of abatacept treatment on other CD28-expressing 
cell types such as B-cells should be fully clear before application during vascular 
revascularization interventions. Nevertheless, this study clearly demonstrates the 
important role of CD4 T-cells and the CD28/CTLA-4-CD80/CD86 co-stimulatory pa-
thway in the inflammatory reaction as part of the adaptive immune system that oc-
curs after vascular intervention in vivo.
In chapter 9 it is showed in three large prospective studies that the -2481C allele 
in the PCAF promoter is associated with a significant survival advantage in elderly 
patients while also protecting against clinical and angiographic restenosis after PCI. 
It is suggested that the effect of this allele on these endpoints may be due to the 
well-known involvement of PCAF in inflammatory and proliferative processes. These 
results not shed light on a causal role of this polymorphism in the development of 
restenosis, but do promote the concept that epigenetic processes are under genetic 
control and that, other than environment, genetic variation in genes encoding KATs 
may also determine susceptibility to CHD outcomes and mortality. Until this point, 
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it remains to be established whether this SNP functionally affects transcriptional re-
gulation of P300/CBP-associated factor (PCAF). Provided that this SNP influences 
PCAF transcription and resulting protein levels, this could have a bearing on the cel-
lular portrait of expressed genes and might lead to a dramatic different outcome if the 
effects accumulate over years. Until this can be established, this SNP could serve 
as risk marker for both mortality and restenosis risk in patients undergoing PCI. 
Furthermore, it has provided insight into the association between PCAF and vascu-
lar remodeling, the exact role of which was further investigated in the next chapters. 
Chapter 10 describes the investigations performed into the causal role of PCAF in 
controlling the inflammatory response responsible for post-interventional atheroscle-
rotic vascular remodeling. It was found that PCAF regulates MHC class II, but not I, 
expression in macrophages through CIITA and is upregulated in the arterial wall in 
the early period following vascular injury at both mRNA and at protein level. It is de-
monstrated that post-interventional vascular remodeling is reduced in PCAF-/- mice 
and accelerated atherosclerosis development in hypercholesterolemic mice treated 
with the natural potent PCAF inhibitor garcinol. Furthermore, it was shown that this 
reduced remodeling was due to an attenuated inflammatory response, identified by 
reduced MCP-1 and TNF α-expression in vivo and in cultured SMCs and macropha-
ges in vitro. 
Although the role of PCAF in the regulation of inflammation is clear and was shown 
to affect macrophage recruitment, activation and cytokine expression, the specificity 
of garcinol for PCAF in this process needs to be further elucidated. Garcinol was 
shown to be extremely potent and can inactivate PCAF activity within 3 minutes in 
vitro, but also affects the expression of many other genes and is known to induce 
apoptosis in high concentrations. Indeed, the anti-inflammatory effects of short-term 
applied garcinol to inhibit PCAF expression at the time of vascular interventions was 
lost with prolonged garcinol application in high concentrations in the femoral drug-
eluting cuff model (unpublished data). This highlights the necessity of the search 
towards new and potent PCAF inhibitors that do not display as many or severe 
side-effects as garcinol does, before effective PCAF inhibition can be applied in 
the clinical setting. Nevertheless, the results highlight inflammation-regulation by the 
epigenetic factor in the acute setting as a causal factor in post-interventional vascu-
lar remodeling.
The role of PCAF in inflammation and vascular remodeling was further investigated 
in chapter 11, where PCAF-/- mice were shown to display impaired arteriogenesis 
capability following acute arterial occlusion. This process, a form of collateral artery 
growth from pre-existing arterioles to arterial occlusion, is initiated by flow and shear-
stress-increase and is highly dependent of the activation of circulating inflammatory 
cells. Using a hind-limb ischemia mouse model based upon surgically-induced acute 
femoral artery occlusion, PCAF was identified to be vital in this inflammatory pro-
cess. PCAF-/- animals were shown to display an impaired inflammatory response 
with functionally less activated dendritic cells, T-cells and reduced inflammatory cy-
tokine expression in vivo and following a LPS-challenge ex vivo. Although exactly 
which inflammatory genes and to what extent these are regulated by PCAF remains 
to be further investigated, it has been made clear that PCAF is causally involved in 
post-interventional vascular remodeling. 
PCAF regulation of inflammatory gene transcription was shown to occur in multiple 
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cell types involved in the innate and adaptive immune responses, including antigen-
presenting cells, lymphocytes and smooth muscle cells. By exerting a regulatory 
function in controlling acute inflammation, PCAF was shown to dominantly affect 
pro-inflammatory genes and by serving as central-regulating factor with intrinsic his-
tone acetyltransferase activity, it might provide clinicians with an interesting and con-
trollable epigenetic target for anti-inflammatory preventive therapy.
Therapy directed towards expression of such an epigenetic factor as PCAF might 
be more effective in preventing vascular remodeling than a single gene or single 
protein treatment approach, since a factor like PCAF can affect chromatin structure 
throughout the nucleus.
How do we proceed beyond our promising newly discovered therapies?
The aim of this thesis was to investigate the role of the immune system in the pa-
thophysiological process leading to the development of post-interventional athero-
sclerotic vascular remodeling. This research has yielded multiple new therapeutic 
applications that could be translated into the clinic within a varying range of time. Alt-
hough statements naming time units are mere predictions, it is wrong not to pursue 
such goals and leave promising drugs for what they are simply because investiga-
tions into their application might take a long time. Abatacept is already a registered 
drug treatment drug for rheumatoid arthritis and could be relatively quickly (<1 year) 
tested in a revascularization setting, once therapeutic effectiveness is confirmed in 
long-term animal studies. Annexin A5, recombinant monoclonal X19-A05 anti-PC 
IgG antibodies and our novel TLR7/9 antagonist have been tested and found effec-
tive in our animal models, but still require additional investigations into their efficacy 
and safety profiles, before clinical application could be initiated. This should be able 
to be performed within the foreseeable future (<2 years). Our PCAF results have 
identified a new factor involved in post-interventional vascular remodeling and still 
require more work before patients can receive their ‘anti-PCAF pill’ when undergoing 
PCI or CABG surgery. Specifically, the target genes other than CIITA and NFκB af-
fected by PCAF modulation need to be fully investigated, in order to provide insight 
into possible adverse effects. Once this is achieved, new PCAF modulators could be 
developed (e.g. using phage display selection) with the optimal drug characteristics 
of our desire (<3-4 years).
Nonetheless, this research was able for a large extent to fulfill the aim of this thesis 
stated in chapter 1. This has been clearly the result of fruitful collaboration between 
many departments within the LUMC and pharmaceutical partners and such joint ef-
forts should to be pursued continuously and vigorously to improve patient outcome 




Cardiovasculaire ziekten zijn verantwoordelijk voor het grootste aantal sterfgevallen 
wereldwijd en dit kan in het bijzonder worden toegeschreven aan atherosclerotische 
vaatziekten, die aanleiding geven tot beroertes of coronaire hartziekten. Verbeterde 
primaire preventie en de introductie en optimalisatie van percutane coronaire inter-
venties (PCI), dotteren, heeft sterk bijgedragen aan de verbeteringen van mortaliteit 
en morbiditeit ten gevolge van deze aandoeningen. Het inzicht in de ziektepathofy-
siologie is in het afgelopen decennium enorm toegenomen. Nieuw onderzoek naar 
het ontstaan van post-interventionele atherosclerotische vasculaire veranderingen 
heeft de focus gelegd op een disfunctionele (auto)immuun respons en ontstekings-
reactie. Ten gevolge hiervan ontstaan vaatwand verdikking, re-occlusie en de daar-
aan gerelateerde symptomen.
Het doel van dit promotieonderzoek was daarom gericht op het onderzoeken van de 
rol van het immuunsysteem in dit pathofysiologische proces, verantwoordelijk voor 
het optreden van vaatwandveranderingen. Deze nieuw verkregen inzichten werden 
toegepast bij de ontwikkeling van immuun modulerende therapieën in preklinische 
modellen. De belangrijke bijdragen van de verschillende delen van het immuunsys-
teem aan het ontstaan van vaatwandveranderingen in de klinische en preklinische 
situaties worden besproken in hoofdstuk 1. Het preklinisch screenen en testen van 
immuun modulerende therapie-effectiviteit is een belangrijke stap naar de klinische 
toepassing van dergelijke interventies ten tijde van PCI of coronaire arteriële bypass 
graft (CABG) operaties, om het ontstaan van vaatwand veranderingen en daarmee 
de noodzaak van re-interventies te voorkomen. Inzicht in de uitgelokte immuunre-
actie tijdens vasculaire ingrepen, zowel in de muis als in de mens, ligt aan de basis 
van de ontdekking en toepassing van nieuwe therapieën met de maximale klinische 
potentie. 
Hoofdstuk 2 biedt een overzicht van de immuunreacties van het aangeboren en 
verworven immuunsysteem die plaatsvinden tijdens het ontstaan van atheroscle-
rose en uitgelokt worden door revascularisatie procedures. Specifieke leukocyten 
receptoren, liganden, co-stimulatoire moleculen en ontstekingsmediatoren zoals 
cytokines, worden belicht. De nadruk ligt op hun rol bij het ontstaan en de progres-
sie van de ontstekingsreactie in de vaatwand. Bovendien wordt hun associatie met 
de ernst van het ziekteproces beschreven, onafhankelijk van de traditionele risico-
factoren zoals roken en hypertensie. Op basis hiervan zouden zij geschikt kunnen 
zijn om te dienen als biomarkers voor ziektestratificatie en diagnose. Hieronder valt 
hun geschiktheid om te dienen als markers voor patiënten die geïntensifieerde zorg 
behoeven, gericht op clinici die in deze patiëntengroep revascularisatie procedures 
uitoefenen. Daarnaast zouden dergelijke toekomstige biomarkers nuttig kunnen zijn 
voor het beoordelen van therapie-effectiviteit, hetgeen met de huidige meetbare risi-
cofactoren, zoals plasma lipoproteïnen, niet mogelijk is. Plasmametingen verdienen 
de voorkeur boven metingen uitgevoerd ter plaatse van en tijdens angioplastiek. 
Desondanks kunnen lokale markers in de vaatwand op dit punt ook additionele in-
formatie opleveren om de ernst van de laesies optimaal in te kunnen schatten. De 
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continue zoektocht naar nieuwe biomarkers is daarom essentieel. Met name mar-
kers van ontsteking, die causaal gerelateerd zijn met post-interventionele vasculaire 
veranderingen, bieden de meeste potentie en zijn van grote waarde voor clinici.
Hoofdstuk 3 illustreert dat het onderzoeksmatig screenen van therapeutische ef-
fectiviteit van medicamenteuze therapieën tegen vasculaire veranderingen en het 
optreden van versnelde atherosclerose niet mogelijk zou zijn zonder preklinische 
modellen. Zij bootsen de klinische situatie na vasculaire interventies optimaal na. 
Dit is niet slechts het geval op het gebied van anatomische aspecten van het vat 
zoals grootte, diameter en vaatwanddikte, maar ook in kenmerken van ziektestadia, 
conventionele risicofactoren en andere factoren voor atherosclerose. Voorts worden 
de gehumaniseerde muismodellen besproken die de pathofysiologische reactie, zo-
als deze optreedt ten tijde van restenose, alsmede de vasculaire veranderingen en 
versnelde atherosclerose het dichtst benaderen. Verscheidene vasculaire interven-
ties in transgene muismodellen worden belicht met de sterkste focus op het arteria 
femoralis cuff model. Om effecten van lokale medicamenteuze therapie te kunnen 
bestuderen dienen de dieren ontvankelijk te zijn voor de specifieke therapie, maar 
behoren zij daarnaast ook een vergelijkbare metabole status, coagulatoir fenotype 
en reactievermogen te hebben gelijk aan de mens. De toepassing van transgene 
muismodellen heeft de vergelijkbaarheid van humane en muislaesies sterk vergroot 
en daarmee de translatie van nieuwe therapieën richting de kliniek. Daarnaast heb-
ben mechanistische en pathofysiologische studies aangetoond dat lokale vaatwand 
ontsteking, proliferatie en proteolyse centraal staan in het optreden van post-inter-
ventionele vaatwand veranderingen. Om deze redenen werd geconcludeerd dat 
sterk reproduceerbare diermodellen voor post-interventionele vaatwand verande-
ringen essentieel zijn voor het bestuderen van het ontstaan van restenose en het 
vinden van nieuwe medicamenteuze therapieën. Specifieke onderdelen van het im-
muunsysteem en hun geschiktheid om te dienen als doel van immuunmodulerende 
therapie worden tevens besproken. Vasculaire veranderingen worden geïnitieerd 
door schade aan het endotheel en aan de onderliggende atherosclerotische plaque 
tijdens ballon inflatie, stent positioneringen of de chirurgische procedure tijdens het 
prepareren van het bypass vaatsegment. Blootstelling van onderliggend trombo-
geen materiaal aan circulerend bloed geeft plaatjesadhesie, activering en trombus-
vorming, wat voor aantrekking van leukocyten naar het beschadigde vaatsegment 
zorgt. Plaatjesactivering en binding wordt ondersteund door de aanwezigheid van 
phosphatidylserine (PS) op geactiveerde en apoptotische cellen.
Hoofdstuk 4 toont een therapeutische rol aan voor het PS-bindende annexine A5 
eiwit tegen vasculaire inflammatie, verdikkingen en dysfunctie in verschillende muis-
modellen voor versnelde atherosclerose. Aangetoond werd dat annexine A5 injec-
ties resulteren in een significante reductie van inflammatoire cytokine concentraties 
in plasma en daarmee de aantrekking van inflammatoire cellen naar de vaatwand 
na chirurgische interventie. Dit gaf uiteindelijk een verminderde intimale hyperplasie 
en ging gepaard met minder tekenen van plaque instabiliteit. Ondanks dat het niet 
volledig duidelijk werd waarom annexine A5 aanleiding gaf tot deze effecten, kon 
wel worden aangetoond dat annexine A5 functioneert via de aanhechting van leu-
kocyten aan gebonden trombocyten en dat het de hierop volgende inflammatoire 
respons kan voorkomen. Deze bevindingen breiden de rol van annexine A5 uit als 




In hoofdstuk 5 werd aangetoond dat er een sterke associatie bestaat tussen ge-
netische polymorfismen in het humane annexine A5 gen en een toegenomen risico 
op het ontwikkelen van restenose bij patiënten die PCI ondergaan. Deze associatie 
werd gevonden bij 866 patiënten uit de GENDER studie. Binnen één jaar na PCI 
ontwikkelde 295 patiënten hiervan restenose, terwijl 571 patiënten vrij bleven van 
herhaalde klachten. Ondanks dat een sterke associatie bestaat, is hiermee nog niet 
bewezen dat er een direct causaal verband bestaat tussen deze polymorfismen en 
klinische uitkomsten. Om het inzicht hierin te vergroten zouden plasmametingen uit-
gevoerd kunnen worden naar de concentratie van circulerend annexine A5 bij deze 
patiënten. Verlaagde annexine A5 concentraties zijn immers al eerder gerelateerd 
aan een toegenomen ernst van coronairsclerose, terwijl verhoogde plasma niveaus 
meetbaar zijn na een myocard infarct. Desalniettemin tonen deze resultaten wel aan 
dat het annexine A5 genotype zou kunnen dienen als risicomarker voor het ontstaan 
van restenose na PCI. Deze resultaten tonen een hoge diagnostische en therapeu-
tische potentiële waarde aan voor annexine A5 tegen PCI-geïnduceerde vaatwand 
veranderingen.
Hoofdstuk 6 beschrijft het proces van optimalisatie van het natuurlijk voorkomen-
de en beschermende anti-phosphorylcholine (PC) T15/E06 IgM antilichaam naar 
een recombinant chimeer IgG antilichaam. Opmerkelijk genoeg gingen de bescher-
mende effecten van het voorkomen van geoxideerd LDL (oxLDL) cholesterol op-
name door macrofagen met scavenger receptoren verloren na de transitie van een 
IgM naar een IgG antilichaam. Ondanks dit verlies was het recombinante anti-PC 
T15 IgG antilichaam effectief in het remmen van de monocyt-chemotactische eiwit 
(MCP)-1 expressie door macrofagen. Ook kon met passieve immunizatie van dit 
antilichaam versnelde atherosclerose vorming in gecuffde hypercholesterolemische 
muizen sterk geremd worden. Deze resultaten suggereren dat de inflammatoire re-
actie op oxLDL voorkomen wordt zonder dat het chimeer antilichaam een remming 
geeft van oxLDL opname. Wellicht komt dit door het maskeren van dit immunogene 
epitoop of door het stimuleren van de degradatie ervan en hiermee de verwijdering 
uit de circulatie. Volledig humane IgGs werden verkregen met behulp van phage 
display selectie van PC-specifieke fagen. Deze waren wel in staat om oxLDL opna-
me door macrofagen te blokkeren en de MCP-1 expressie te remmen. Een selecte 
groep antilichamen werd in vivo getest en dit leverde het potente volledige humane 
monoclonale anti-PC T15 IgG (M99-B05) antilichaam op, dat zeer effectief was in 
het voorkomen van intimale verdikking in gecuffde hypercholesterolemische muizen. 
Deze studie bevestigt de bevindingen uit eerdere studies dat PC als een veelbelo-
vende therapeutisch doel kan functioneren om versnelde atherosclerosevorming te 
voorkomen en te behandelen. Het unieke aan deze studie is echter dat er voor het 
eerst volledig humane anti-PC IgG antilichamen geproduceerd zijn die een atherop-
rotectieve functie hebben. Eerdere onderzoekers hebben anti-PC IgM antilichamen 
passief toegediend of muizen anti-PC IgM opgewekt via actieve immunizatie. Dit zijn 
veelbelovende technieken, maar zijn niet klinisch toepasbaar en eerdere actieve im-
munisatie met een pneumococcen-polysacharride vaccin gaf onvoldoende plasma 
titers van oxLDL-specifieke anti-PC antilichamen. In onze studie werden echter re-
combinante monoclonale anti-PC IgG antilichamen ontwikkeld, gescreend en getest 
welke geschikt zijn voor passieve therapeutische immunisatie in patiënten. Door 
295





het verzorgen van directe en acute controle over de immuunreactie van de patiënt, 
specifiek voor één enkel immunogeen epitoop, kan deze immunisatie aanpak als 
een effectieve therapie dienen tegen post-PCI atherosclerotische vasculaire veran-
deringen.
De belangrijke rol van het aangeboren immuunsysteem werd bevestigd in hoofd-
stuk 7. In dit hoofdstuk werd in het arteria femoralis cuff model een nieuw ont-
wikkelde duale toll-like receptor (TLR) 7 en 9 antagonist getest. TLRs vormen een 
zeer belangrijk onderdeel van het aangeboren immuunsysteem en functioneren als 
pathogene herkenningsreceptoren (PRRs). Zij herkennen in deze functie zowel ex-
tracellulaire liganden die voorkomen op bacteriën en virussen (TLR2, 4 en 5), als-
mede intracellulaire (endogene) liganden zoals beschadigd of viraal (dubbelstrengs) 
RNA (TLR3, 7 en 9). Deze endogene liganden kunnen vrijkomen na weefselschade 
of stress, zoals optreedt tijdens PCI procedures. Aanwezigheid van TLR7 en TLR9 
werd aangetoond in de gebieden met uitgesproken macrofagen accumulatie in vas-
culaire laesies. In vitro reageerden deze cellen op TLR7 of TLR9 stimulatie met een 
toegenomen opname van oxLDL en secretie van tumor necrosis factor (TNF) α, wat 
voorkomen werd door simultane incubatie met de nieuwe inhibitor. Na cuff plaatsing 
in vivo leidden deze effecten tot een afname van de intimale verdikking. De bijdrage 
van individuele TLR signalering is nog onduidelijk, maar de therapeutische potentie 
van het remmen van TLR7 en TLR9 om het ontstaan van restenose en versnelde 
atherosclerose te voorkomen is duidelijk aangetoond. Aangezien TLRs gemakkelijk 
benaderbaar zijn voor circulerende medicijnen (direct of na cellulaire opname) en 
de eerste verdedigingslinie vormen van het aangeboren immuunsysteem, zijn zij 
geschikte therapeutische doelen voor medicamenteuze inhibitie of stimulatie tijdens 
de acute fase van vaatwand beschadiging. Nieuwe inhibitoren kunnen zo ontwikkeld 
worden dat zij de gewenste eigenschappen bezitten, terwijl ze specifiek gericht zijn 
tegen de gewenste TLRs. Tevens kunnen zij ontwikkeld worden met specificiteit voor 
meerdere receptoren, waardoor hun effectiviteit sterk kan toenemen, zoals werd 
aangetoond in deze studie. 
In hoofdstuk 8 werd de bijdrage van het verworven immuunsysteem onderzocht bij 
het optreden van post-interventionele atherosclerotische vaatwand veranderingen, 
door de rol van CD4+ T lymfocyten en CD28-CD80/86 co-stimulatoire moleculen te 
onderzoeken. Post-interventionele vasculaire veranderingen waren significant ge-
remd in CD4-/- en CD80-/-CD86-/- muizen. Om aan te tonen dat cytotoxic T-lymphocy-
te antigen (CTLA)-4 een vitale factor is in de fysiologische co-stimulatie en betrok-
ken is bij de T cel reacties tijdens vaatwand veranderingen, ontvingen controledieren 
injecties met abatacept. Dit gaf aanleiding tot een verminderde intimale verdikking. 
Deze methode werd herhaald in hypercholesterolemische ApoE3*Leiden muizen en 
gaf vergelijkbare opmerkelijke resultaten. Flow cytometrie analyse van geactiveerde 
lymfocyten in de milt en drainerende lymfeknopen toonde aan dat door abatacept 
de activering van CD4+ T cellen voorkomen werd en dit leidde tot een afname van 
de hoeveelheid regulatoire T cellen in de milt. De ratio tussen effector en regulatoire 
T cellen werd echter niet veranderd ten opzichte van de controledieren. Abatacept 
gaf geen aanleiding tot verschillen in cellulaire activeringsstatus in de drainerende 
lymfeknopen, hetgeen voor een systemische werkzaamheid pleit. Deze bevindingen 
werden later gecorreleerd met afgenomen plasma concentraties van interferon γ 
in dieren die met abatacept waren behandeld. De rol van CTLA-4 co-inhibitie in dit 
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proces werd uiteindelijk bevestigd door de behandeling van ApoE3*Leiden muizen 
met blokkerende anti-CLTA-4 antilichamen, afkomstig uit hybridoma's, die daardoor 
significant grotere laesies ontwikkelden. Immuun-gemedieerde interventies gericht 
op het therapeutisch controleren van de inflammatoire T cel reactie, zoals met aba-
tacept, worden in een breed scala toegepast in andere immuunafwijkingen, waaron-
der rheumatische ziekten. Deze interventies kunnen nu ook toegepast worden in de 
acute fase na vasculaire interventies om hierop volgende vaatwandveranderingen 
te voorkomen. Abatacept is een geregistreerd medicijn met een bewezen effecti-
viteit en veiligheid in patiënten. Toepassing hiervan kan de benodigde tijd voor de 
translatie van bench-to-bedside sterk reduceren. Ondanks dat initiële positieve ef-
fecten geobserveerd zijn, moeten deze gereproduceerd worden op lange termijn na 
langdurige toepassing voordat abatacept klinisch toegepast zou kunnen worden. 
Daarnaast dienen de effecten op andere celtypen die CD28 tot expressie brengen, 
zoals B lymfocyten. Ondanks deze eisen heeft de huidige studie laten zien dat CD4 
T cellen en de CD28-CD80/86 co-stimulatie een belangrijke rol spelen bij de inflam-
matoire reactie die optreedt als onderdeel van het verworven immuunsysteem na 
vasculaire interventies in vivo. 
In hoofdstuk 9 laten drie grote individuele prospectieve studies zien dat een sig-
nificante associatie bestaat tussen het -2481C allel in de promoter regio van het 
P300/CBP-geassocieerde factor (PCAF) gen en een toegenomen overleving na 
PCI vanwege minder restenose. Dit suggereert dat de effecten van dit allel op deze 
klinisch eindpunten het resultaat kunnen zijn van de betrokkenheid van PCAF bij 
het optreden van inflammatoire en proliferatieve processen. De resultaten bieden 
geen inzicht in de mogelijke causale rol van dit polymorfisme bij de ontwikkeling 
van restenose, maar ondersteunen wel het concept dat epigenetische processen 
onder genetische controle staan. Tevens suggereren deze studies dat, anders dan 
de effecten van het milieu, genetische variatie in genen (die coderen voor K lysine 
acetyltransferasen (KATs)) mede het risico bepalen op het optreden van cardiovas-
culaire ziekten en sterfte. Het blijft tot op dit moment onduidelijk of de gevonden SNP 
functionele invloed heeft op de transcriptie en regulatie van PCAF. Op voorwaarde 
dat deze SNP een effect heeft op PCAF transcriptie of resulterende eiwit niveaus, 
zou dit een sterk effect kunnen betekenen op de cellulaire expressie van genen, 
welke geaccumuleerd over vele jaren een verschil kan opleveren in uitkomst op 
cardiovasculair gebied. Tot het moment waarop dit bevestigd kan worden, kan deze 
SNP dienen als risicomarker voor mortaliteit en restenoserisico in patiënten die PCI 
ondergaan. Daarnaast biedt de SNP inzicht in de betrokkenheid tussen PCAF en 
vasculaire veranderingen, waarvan de exacte rol verder onderzocht werd in de vol-
gende hoofdstukken. 
Hoofdstuk 10 beschrijft het onderzoek dat uitgevoerd is naar de causale rol van 
PCAF bij de regulatie van de inflammatoire reactie, die leidt tot post-interventionele 
atherosclerotische vasculaire veranderingen. In het onderzoek komt naar voren dat 
PCAF de expressie van MHC klasse II, maar niet I, door macrofagen reguleert via 
klasse II-transactivator (CIITA) en in toegenomen mate tot expressie komt in de vaat-
wand in de vroege periode na vasculaire beschadigingen op zowel mRNA als eiwit 
niveau. Voorts werd aangetoond dat post-interventionele vasculaire veranderingen 
sterk verminderd waren in PCAF-/- muizen, evenals de vorming van versnelde athe-
rosclerose in hypercholesterolemische muizen die behandeld werden met de na-
297





tuurlijke PCAF-remmer garcinol. Daarnaast kwam naar voren dat een verminderde 
inflammatoire reactie, ten gevolge van kortdurende garcinol therapie, ten grondslag 
lag aan deze afgenomen intimale verdikking. Dit kwam mogelijk doordat garcinol 
de expressie van MCP-1 en TNF α, geproduceerd door inflammatoir gestimuleerde 
SMCs en macrofagen, sterk deed verminderen. Ondanks dat de rol van PCAF in 
de regulatie van inflammatie duidelijk is en dat PCAF betrokken is bij macrofagen 
aantrekking, activering en cytokine expressie, dient de specificiteit van garcinol voor 
PCAF in dit proces verder verduidelijkt te worden. Garcinol is uiterst potent en kan 
de activiteit van PCAF binnen 3 minuten inactiveren in vitro, maar beïnvloedt ook de 
expressie van andere genen en kan in hoge concentraties apoptose veroorzaken. 
Dit volgde ook uit andere (ongepubliceerde) experimenten in het arteria femoralis 
drug-eluting cuff model, waarbij de anti-inflammatoire effecten van kortdurige gar-
cinol toepassing om PCAF te remmen verloren ging bij langdurige blootstelling van 
de vaatwand aan garcinol. Dit benadrukt de noodzaak van verder onderzoek naar 
nieuwe en potente PCAF remmers die niet zoveel, of niet in een dergelijke ernstige 
mate, bijwerkingen geven als garcinol. Pas dan kan PCAF inhibitie effectief worden 
toegepast in de kliniek. Desalniettemin tonen deze resultaten een regulatie aan van 
de inflammatoire reactie door een epigenetische factor in de acute fase volgend na 
interventie en belichten PCAF als een causale factor in dit proces.
De rol van PCAF in inflammatie en vasculaire verandering is verder onderzocht in 
hoofdstuk 11, waar PCAF-/- muizen een verminderde mate van arteriogenese lieten 
zien na acute arteriële occlusie. Dit proces, een vorm van collaterale arteriegroei uit 
pre-existente arteriolen van een geoccludeerde arterie, wordt geïnduceerd door een 
toename in flow en shear-stress en is erg afhankelijk van de activering van circu-
lerende inflammatoire cellen. Met behulp van een achterpoot ischemie muismodel, 
gebaseerd op een chirurgisch geïnduceerde acute arteria femoralis occlusie, werd 
de vitale betrokkenheid van PCAF in dit proces aangetoond. PCAF-/- muizen lieten 
een verminderde inflammatoire reactie zien met afname van geactiveerde dendriti-
sche cellen, T cellen en cytokine expressie in vivo. Dit was ook het geval na een gift 
lipopolysaccharide ex vivo. Ondanks dat verder onderzocht dient te worden welke 
inflammatoire genen en in welke mate deze door PCAF gereguleerd worden, is aan-
getoond dat PCAF causaal betrokken is bij post-interventionele vaatwand verande-
ringen. PCAF regulatie van inflammatoire gen transcriptie vindt plaats in meerdere 
cel types van zowel het aangeboren als verworven immuunsysteem, inclusief an-
tigeen presenterende cellen, lymfocyten en gladde spiercellen. Door een regule-
rende functie uit te oefenen in de acute inflammatoire reactie beïnvloedt PCAF met 
name pro-inflammatoire genen. PCAF functioneert hierbij als centrale factor met 
intrinsieke histon acetyltransferase activiteit. Dit kan clinici een interessante contro-
leerbare epigenetische factor bieden als doel voor anti-inflammatoire preventieve 
therapie. Behandeling gericht op expressie van een dergelijke epigenetische factor 
zoals PCAF zou daarom wellicht effectiever zijn in het voorkomen van vasculaire 
veranderingen dan therapie gericht op een enkel gen of eiwit. 
Hoe gaan we verder met deze nieuwe veelbelovende therapieën?
Het doel van dit promotieonderzoek was om de rol van het immuunsysteem in het 
pathofysiologische proces, wat leidt tot de ontwikkeling van post-interventionele 
atherosclerotische vaatwand veranderingen, te onderzoeken. Dit onderzoek heeft 
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meerdere nieuwe therapeutische toepassingen opgeleverd die vertaald kunnen wor-
den naar de kliniek binnen niet afzienbare tijd. Ondanks dat dergelijke tijdsindicaties 
per definitie speculatief zijn, is het onjuist om zich niet aan dergelijke voorspellingen 
te wagen. Daarnaast is het contraproductief om veelbelovende vindingen niet verder 
uit te zoeken, enkel omdat de translatie naar de kliniek mogelijk erg lang kan duren. 
Abatacept is een reeds geregistreerde medicamenteuze therapie voor de behan-
deling van rheumatoïde artritis en kan in een relatieve korte tijd (<1 jaar) getest 
worden tijdens revascularisatie technieken, op voorwaarde dat de therapeutische 
effectiviteit bevestigd wordt in langdurige dierstudies. Annexine A5, recombinante 
monoclonale X19-A05 anti-PC IgG antilichamen en onze nieuwe TLR7/9 antagonist 
zijn getest en effectief bevonden in onze diermodellen, maar voordat gestart kan 
worden met klinische toepassing behoeven zij extra onderzoek naar de effectiviteit 
en veiligheidsprofielen. Dit zou voltooid kunnen worden binnen de nabije toekomst 
(<2 jaar). De PCAF resultaten hebben een nieuwe factor geïdentificeerd die be-
trokken is bij post-interventionele vasculaire veranderingen en behoeft nog extra 
onderzoek voordat patiënten die PCI of CABG-chirurgie ondergaan een ‘anti-PCAF 
pil’ kunnen ontvangen. Om inzicht te geven in mogelijke bijwerkingen dienen in het 
bijzonder de genen onderzocht te worden die naast CIITA en NFκB door PCAF mo-
dulering beïnvloed worden. Wanneer dit voltooid is kunnen nieuwe PCAF modula-
toren worden ontwikkeld (bijvoorbeeld via phage display selectie) met de optimale 
en gewenste medicamenteuze eigenschappen (<3-4 jaar). Het promotieonderzoek 
heeft in grote mate voldaan aan de doelstellingen die gesteld werden in hoofdstuk 
1. Dit is te danken aan een goede samenwerking tussen vele afdelingen binnen het 
LUMC en farmaceutische partners. Dergelijke samenwerkingsprojecten dienen dan 
ook optimaal en continu nagestreefd te worden om patiëntresultaten te verbeteren 
en de morbiditeit en mortaliteit in klinieken wereldwijd te reduceren. 
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